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vii. SUMMARY 
G-protein coupled receptor 55 (GPR55) is a novel lipid sensing receptor activated by 
the endogenous lipid, lysophosphatidylinositol (LPI) and is reported as a putative 
cannabinoid receptor.   However GPR55 shares limited homology with the two cloned 
cannabinoid receptors (CB1 and CB2) but does exhibit some cannabinoid sensitivity.  
Recently a family of bioactive lipids, the N-acyl amino acids, are gaining interest due to 
their structural similarity to endocannabinoids (naturally occurring CB1 and CB2 
agonists).  N-acyl amino acids have little or no affinity for either CB1 or CB2 and many 
have no known biological target at present. 
 
This study used a subset of N-acyl amino acids; possessing either a serine or glycine 
head group attached to varying fatty acid chains; to assess these novel lipids as potential 
GPR55 ligands.   Three cell lines were utilised, a stably transfected HEK293 cell line 
that overexpresses 3xHA N-terminus tagged hGPR55 (hGPR55-HEK293 cells) and 
control HEK293 cells.  In addition, the DU145 a prostate cancer cell line which is 
reported to endogenously express GPR55 was investigated.  N-acyl amino acid 
challenge activated GPR55 to promote Ca2+ mobilisation, CREB phosphorylation, actin 
cytoskeletal reorganisation and elongation of focal adhesions.  Furthermore GPR55-
mediated downstream signalling effectors were studied comparing LPI to the orphan 
lipid; N oleoyl-L-serine (NOSer).   
 
This study highlights that N-acyl amino acids act as GPR55 agonist/partial agonists in 
hGPR55-HEK293 cells.  Both LPI and NOSer exert effects in prostate cancer cells 
(DU145s) which are GPR55 mediated.  GPR55 may exhibit ligand bias as LPI was 
more efficacious in Ca2+ mobilisation.  However in the pCREB assay NOSer was more 
efficacious than LPI.  A similar efficacy and potency to either LPI or NOSer was 
observed in the other assays in both hGPR55-HEK293 and DU145 cells.  Furthermore 
this study is the first where a named GPCR can be assigned for responses that are 
mediated by NOSer.   
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viii. ABBREVIATIONS 
µM  micromolar 
2-AG    2-arachidonoyl glycerol 
2-APB    2-Aminoethoxydiphenylborane 
AA    arachidonic acid 
ABDH4   α/β domain containing hydrolase 4 
Abn-CBD   abnormal cannabidiol 
ACEA    N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide 
AEA    N-arachidonoylethanolamide 
AJA    ajulemic acid 
AM251 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-     
piperidinyl-1H-pyrazole-3-carboxamide 
ANOVA analysis of variance 
AR4-2J pancreatic tumoral cell line  
Arp2/3 actin-related protein-2/3  
ATF activating transcription factor 
AtT-20 pituitary adenoma cell line 
BAPTA-AM 1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic  
acid tetrakis(acetoxymethyl ester) 
BKCa large conductance Ca2+-activated K+ channels 
BLAST basic local alignment search tool 
Bmx bone marrow kinase on chromosome X  
BV-2 murine microglial cell line 
bZIP basic region leucine zipper 
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Ca2+ calcium 
[Ca2+]i    intracellular calcium 
CaMKII calcium/calmodulin-dependent kinase II 
cAMP cyclic adenosine monophosphate 
CB1 cannabinoid receptor type 1 
CB2 cannabinoid receptor type 2 
CBD cannabidiol 
CBP CREB binding protein 
CF-HBS Ca2+ free HEPES buffered saline supplemented with 100 
µM EDTA 
CHI closed head injury 
CHO Chinese hamster ovary cells 
CID16020046 4-[4,6-Dihydro-4-(3-hydroxyphenyl)-3-(4-methylphenyl)-
6-oxopyrrolo[3,4-c]pyrazol-5(1H)-yl]benzoic acid 
CO2 carbon dioxide 
COX cyclooxygenase  
CP 55,940 (-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-
trans-4-(3-hydroxypropyl)cyclohexanol 
cPLA2 cytosolic phospholipase A2 
CRE cyclic-AMP response element 
CREB cyclic-AMP response element-binding protein 
CREM cyclic-AMP response element modulator 
CTCF corrected total cell-area fluorescence 
CTNF corrected total nuclear fluoresence 
DAG diacylglycerol 
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DAGL diacylglycerol lipase  
DALN deasacetyllevonantradol 
DDHD1 DDHD domain containing 1 
DMEM/F12 Dulbecco’s modified eagle medium: Nutrient mixture F-
12 
DMSO dimethyl sulfoxide 
DRG dorsal root ganglion neurons 
DU145 human prostatic carcinoma cell line 
EA.hy926 human vascular endothelial cell line 
EAE experimental autoimmune encephalomyelitis 
ECM extracellular matrix 
Edg endothelial cell differentiation gene 
EDTA ethylenediaminetetraacetic acid 
ER endoplasmic reticulum 
ERK1/2 extracellular signal-regulated kinase 1/2 
FA focal adhesion 
FAAH fatty acid amide hydrolase 
FCA Freund’s complete adjuvant 
FFA free fatty acid 
fMLP N-formyl-peptide receptor ligand 
Fura 2-AM 2-[6-[bis[2-[(Acetyloxy)methoxy]-2-oxoethyl]amino]-5-
[2-[2-[bis[2-[(acetyloxy)methoxy]-2-oxoethyl]amino]-5-
methylphenoxy]ethoxy]-2-benzofuranyl]-5-
oxazolecarboxylic acid (acetyloxy)methyl ester 
GDE glycerophosphodiesterase 
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GDP guanosine diphosphate 
GEF guanine exchange factor 
Gö6980 3-[1-[3-(Dimethylamino) propyl]-5-methoxy-1H-indol-3-
yl]-4-(1H-indol-3-yl)-1H-pyrrole-2, 5-dione 
GPCR G protein-coupled receptor 
GPR119 G protein-coupled receptor 119 
GPR120 G protein-coupled receptor 120 
GPR18 G protein-coupled receptor 18 
GPR23 G protein-coupled receptor 23 
GPR35   G protein-coupled receptor 35 
GPR40 G protein-coupled receptor 40 
GPR41 G protein-coupled receptor 41 
GPR43 G protein-coupled receptor 43 
GPR55 G protein-coupled receptor 55 
GPR92 G protein-coupled receptor 92 
G-protein guanine nucleotide-binding protein 
GRKs G-protein receptor kinases 
GTP guanosine triphosphate 
GTPγS guanosine 5'-O-[gamma-thio] triphosphate  
H+ hydrogen 
H1152 dihydrochloride (S)-(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl) sulfonyl]-
hexahydro-1H-1,4-diazepine dihydrochloride 
HA tag haemagglutinin tag  
HBS HEPES buffered saline 
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HEK293 cells human embryonic kidney 293 cell line 
HeLa cells cervical adenocarcinoma cell line 
HEPES  2-[4-(2-hydroxyethyl) piperazin-1-yl] ethanesulfonic acid 
hGPR55-HEK293 cells HEK293 cell line stably overexpressing recombinant 
human GPR55 protein 
HL-60 human promyelocytic leukemia cell line 
HMC-1 human mast cell leukaemic cell line 
HMVEC human dermal microvascular endothelial cells 
HU-210 (6aR)-trans-3-(1,1-Dimethylheptyl)-6a,7,10,10a-
tetrahydro-1-hydroxy-6,6-dimethyl-6H-
dibenzo[b,d]pyran-9-methanol 
HUVEC human umbilical vein endothelial cells 
ICRAC calcium-release-activated Ca2+ channel 
IFNγ interferon gamma 
IL-2 interleukin 2 
IM9 EBV-transformed human B lymphoblastoid cell line 
IP3 inositol 1, 4, 5-triphosphate 
IP3R inositol 1, 4, 5-triphosphate receptor 
JNK c-JUN-N-terminal kinase 
JWH015 (2-Methyl-1-propyl-1H-indol-3-yl)-1-
naphthalenylmethanone 
JWH133 (6aR,10aR)-3-(1,1-Dimethylbutyl)-6a,7,10,10a-
tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran 
KID kinase inducible domain 
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KN-62 4-[(2S)-2-[(5-isoquinolinylsulfonyl) methylamino]-3-oxo-
3-(4-phenyl-1-piperazinyl) propyl] phenyl 
isoquinolinesulfonic acid ester 
LGCC ligand gated Ca2+ channel 
LOX lipoxegenase 
LPA lysophosphatidic acid 
LPI L-α-lysophosphatidylinositol 
LPI-PLC lysophophatidylinositol-phospholipase C 
LPS lipopolysaccharide 
LY294002 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 
hydrochloride 
MAGL monoacylglycerol lipase 
MAPK mitogen activated protein kinase 
MCF-7 human breast adenocarcinoma cell line  
MDA-MB-231 human breast adenocarcinoma cell line 
mDia mammalian diaphanous 
MEF mouse embryonic fibroblasts 
MEK1 mitogen-activated protein kinase kinase 1 
MEKK1 mitogen-activated protein kinase kinase kinase 1 
mEPSC mini excitatory postsynaptic currents 
min minute 
ML-141 4-[4, 5-Dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-
pyrazol-1-yl] benzenesulfonamide 
mM millimolar 
mTOR mammalian target of rapamycin 
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N18TG2 murine neuroblastoma cell line 
Na+ sodium 
NADA N-arachidonoyl dopamine 
NAGly N-arachidonoyl glycine 
NAPE N-arachidonoyl-phosphatidylethanolamine 
NAPE-PLD NAPE-hydrolysing phospholipase D 
NASer    N-arachidonoyl-L-serine 
NAT    N-acyltransferase 
NFAT    nuclear activated factor of T-cells 
NG108-15   neuroblastoma x glioma hybrid cell line 
nM    nanomolar 
NOGly N-oleoyl glycine 
NOSer N-oleoyl-L-serine 
NPGly N-palmitoyl glycine 
NPSer N-palmitoyl-L-serine 
O-1602 5-Methyl-4-[(1R,6R)-3-methyl-6-(1-cyclohexen-1-yl]-1,3-
benzenediol 
OEA N-oleoylethanolamide 
oGPCRs orphan G-protein coupled receptor 
OHSC organotypic hippocampal slice cultures 
Orai1 calcium release-activated calcium channel protein 1 
P2Y5 lysophosphatidic acid receptor 6 
pAKT phosphorylated AKT 
PBS phosphate buffered solution 
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PC12 cell line derived from a phaeochromocytoma of the rat 
adrenal medulla  
PC3 human prostatic carcinoma cell line 
pCREB phosphorylated CREB 
PD98059   2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 
PEA    palmitoylethanolamide 
PFA  paraformaldehyde 
PI phosphatidylinositol 
PI-3 kinase phosphoinositide 3-kinase 
PIP2 phosphatidylinositol 4, 5-bisphosphate 
PKA protein kinase A 
PKB protein kinase B 
PKC protein kinase C 
PLA1 phospholipase A1 
PLA2 phospholipase A2 
PLC phospholipase C 
PLD phospholipase D 
PMCA plasma membrane Ca2+ ATPase 
PPAR peroxisome proliferator-activated receptor 
PTEN  phosphatase and tensin homolog deleted on chromosome 
10 
PTPN22 protein tyrosine phosphatase non-receptor type 22 
PTX pertussis toxin 
PWR plasmon waveguide resonance 
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RAW264.7  murine leukaemic monocyte macrophage cell line 
RGS regulators of G-protein signalling 
Rho A ras homolog gene, family member A 
RIN m5F rat insulinoma cell line 
ROCK Rho associated protein kinase 
RyR ryanodine receptor 
S1P sphingosine 1-phosphate 
sec second 
SEM standard error of the mean 
SERCA sarcoplasmic/endoplasmic reticulum calcium ATPase 
SH-SY5Y human neuroblastoma cell line 
siRNA short interfering ribonucleic acid 
SOC store operated Ca2+  
SOCE store operated Ca2+ entry 
SR141617A N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide 
hydrochloride 
SR144528 5-(4-chloro-3-methylphenyl)-1-[(4-
methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-
trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-
carboxamide 
STIM-1 stromal interacting molecule-1 
Syk spleen tyrosine kinase 
TM transmembrane 
TNF-α tumour necrosis factor-α  
30 
 
TPA 12-O-Tetradecanoylphorbol-13-acetate 
Triton™ x-100 4-(1, 1, 3, 3-Tetramethylbutyl) phenyl-polyethylene 
glycol 
TRP transient receptor potential 
TRPC5 transient receptor potential cation channel, subfamily C, 
member 5 
TRPM6 transient receptor potential cation channel, subfamily M, 
member 6 
TRPM7 transient receptor potential cation channel, subfamily M, 
member 7 
TRPM8 transient receptor potential cation channel, subfamily M, 
member 8 
TRPV1 transient receptor potential vanilloid 1 
TRPV2 transient receptor potential vanilloid 2 
TRPV3 transient receptor potential vanilloid 3 
TRPV6 transient receptor potential vanilloid 6 
U1026 1, 4-Diamino-2, 3-dicyano-1, 4-bis [2-aminophenylthio] 
butadiene 
U73122 1-[6-[[(17β)-3-Methoxyestra-1, 3, 5(10)-trien-17-yl] 
amino] hexyl]-1H-pyrrole-2, 5-Dione 
U87 human glioblastoma-astrocytoma, epithelial-like cell line 
VGCC voltage gated Ca2+ channel 
vGLUT1 vesicular glutamate transporter 1 
WIN 55, 212-2  (R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-
yl]-1-naphthalenylmethanone mesylate 
31 
 
Y-27632 dihydrochloride trans-4-[(1R)-1-Aminoethyl]-N-4-
pyridinylcyclohexanecarboxamide dihydrochloride 
Δ9-THC    Δ9-tetrahydrocannabinol  
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1.  INTRODUCTION 
1.1. G-protein coupled receptors 
Seven transmembrane receptors (7TM) also known as G protein-coupled receptors 
(GPCRs) constitute a large and diverse family of membrane receptors with around 800 
genes encoding GPCRs in the human genome (Fredriksson et al., 2003; Civelli et al., 
2013).  GPCRs are classified into 5 different groups – Glutamate, Rhodopsin, Adhesion, 
Frizzled and Secretin (GRAFS) (Fredriksson et al., 2003; Jacoby et al., 2006).  The 
majority of GPCRs are members of the Rhodopsin family which is further subdivided 
into α, β, γ and δ groups (Fredriksson et al., 2003; Civelli et al., 2013).  Over 100 
GPCRs are known as orphan GPCRs (oGPCRs) as they have no known ligand 
(Klabunde and Hessler, 2002; Jacoby et al., 2006).  GPCRs allow a plethora of 
extracellular stimuli, such as lipids, proteins and peptides, biogenic amines, amino acids 
or ions, to interact with intracellular signalling effectors (Marinissen and Gutkind, 
2001).  Thereby, allowing cells to interact with their surrounding extracellular 
environment to promote physiological homeostasis (Dorsam and Gutkind, 2007).     
GPCRs are known to be important in pathophysiological conditions such as obesity, 
cardiovascular disease, type II diabetes, Alzheimer’s disease, multiple sclerosis and 
cancer (Marinissen and Gutkind, 2001; Radhika and Dhanasekaran, 2001; Heng et al., 
2013).  GPCRs are the most important protein family for drug discovery where ~50% of 
pharmaceuticals target GPCRs either as agonists or antagonists (Klabunde and Hessler, 
2002; Rask-Andersen et al., 2011; Garland, 2013). 
 
Many physiological responses that are now known to be mediated by GPCRs were 
revealed before the receptors eliciting the responses had been discovered.  Earl 
Sutherland’s work with cyclic adenosine monophosphate (cAMP); the first second 
messenger to be characterised (Sutherland and Wosilait, 1955; Sutherland, 1972); and 
the discovery that guanine nucleotides mediate adenylyl cyclase activation through the 
action of glucagon on a hormone receptor (Rodbell et al., 1971) were carried out at time 
when it was not known that GPCRs were the signal transducers.  Furthermore several 
pharmaceuticals were developed and used in the clinic, such as β-blockers and analgesic 
opiates (now known to act on the β–adrenoceptors and morphine receptors respectively) 
but the GPCRs involved were still to be isolated (Jacoby et al., 2006).  However 
coupled with the knowledge of ligands such as isoproterenol and adrenaline the β–
adrenoceptor was purified through affinity chromatography (Caron et al., 1979; Jacoby 
et al., 2006) but the structure remained to be determined.  In the interim 
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bacteriorhodopsin and subsequently bovine rhodopsin amino acid sequences were 
determined and using hydrophobicity plots the proteins were suggested to have similar 
topologies – the presence of 7TM spanning domains (Ovchinnikov, 1982).  Interestingly 
the structural homology of the β–adrenoceptor was found to have the same 7TM 
domains and similarities were noted in TM V-VII to the previously elucidated 
rhodopsin receptor (Dixon et al., 1986).   Moreover functional similarities of both 
receptors highlighted activation of guanine nucleotide exchange factors (Dixon et al., 
1986).  Rhodopsin was the first GPCR to have its crystal structure determined and this 
confirmed the presence of 7TM domains (Palczewski et al., 2000).  In the last decade 
crystallography has elucidated a total of 13 GPCR structures from rhodopsin 
(Palczewski et al., 2000) to the most recent the neurotensin receptor (White et al., 
2012).  GPCRs share a common topology of seven hydrophobic trans-membrane α-
helices, each around 20-30 amino acids in length. Three intracellular and three 
extracellular loops of hydrophilic amino acid chains link the helices together (Oldham 
and Hamm, 2008).  GPCRs also possess an extracellular amino terminus and a 
cytoplasmic carboxy terminus (Stadel et al., 1997).   
 
1.1.1. GPCRs, G-proteins and signal transduction 
Extracellular stimulation of a GPCR requires heterotrimeric guanine nucleotide-binding 
proteins (G-proteins) to act as molecular switches to allow the initiation of intracellular 
signalling (Oldham and Hamm, 2008).  G-proteins consist of Gα- and Gβγ-subunits 
which elicit effects on downstream effectors.  There are 16 genes encoding the 21 Gα-
subunits, 5 genes encode the 6 Gβ-subunits and 14 genes encode the 14 Gγ-subunits 
(Milligan and Kostenis, 2006; Oldham and Hamm, 2006). When the Gα-subunit of the 
G-protein has guanosine diphosphate (GDP) bound it associates with an inactive GPCR 
and the Gβγ-subunit.   The Gα-subunit alone can interact with inactive GPCRs however, 
when the Gβγ-subunit is present the association with the inactive GPCR is stronger 
(Neer, 1994).  Upon ligand binding a conformational change occurs within the 
transmembrane α–helices of the GPCR leading to a change in the cytoplasmic domains 
(Oldham and Hamm, 2008).   This lowers the affinity of the Gα-subunits to bind to GDP 
and increases their affinity for GTP.  In essence the GPCR acts as a guanine nucleotide 
exchange factor (GEF) hastened by the higher concentration of GTP compared to GDP 
in the cells (Milligan and Kostenis, 2006).  The binding of GTP to the α-subunit leads to 
a conformational change in that subunit which allows the dissociation of the Gα–subunit 
from both the GPCR and the Gβγ-subunits (Neer, 1994; Oldham and Hamm, 2006).  
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Both the Gα-subunit and the Gβγ-subunits can then interact with effectors to initiate 
signalling within the cell (Neer, 1994).  Moreover the Gα-subunit possesses intrinsic 
GTPase activity which hydrolyses the terminal γ-phosphate producing GDP.  This Gα-
GDP-subunit now has a high affinity for associating with the Gβγ-subunit producing an 
inactive heterotrimeric G-protein (Svoboda et al., 2004).  Furthermore the early 
biochemical studies of purified Gα-subunits found that the rate of the GTPase 
hydrolysis of GTP to GDP was slower than the rapid turnover seen with physiological 
processes.  This led to the discovery of regulators of G-protein signalling (RGS) 
proteins. RGS proteins increase the rate of GTPase hydrolysis of the Gα-subunits at a 
faster more physiological rate (Hollinger and Hepler, 2002; Milligan and Kostenis, 
2006).   
 
Due to their homological and functional similarities heterotrimeric Gα proteins exist as 
members of four groups Gαs, Gαi, Gαq and Gα12/13 (Oldham and Hamm, 2008).  The Gαs 
group consist of four subtypes Gαs(S), Gαs(L), Gαs(XL) and Gαolf (Milligan and Kostenis, 
2006). The Gαs subtypes are ubiquitously expressed whereas Gαolf is expressed in the 
digestive and urogenital tract and in the CNS in olfactory neurons (Milligan and 
Kostenis, 2006).  Gαs stimulates the production of cyclic AMP (cAMP) through the 
activation of adenylyl cyclase (Kostenis et al., 2005), activates large conductance Ca2+ -
activated K+ channels (BKCa), tubulin GTPase and c-Src (Milligan and Kostenis, 2006).  
Furthermore the increase in cAMP activates a small GTPase Rap1 which links Gαs 
activation to the mitogen activated protein kinase (MAPK) pathway (Neves et al., 
2002).   
 
The Gαi/o family consists of eight subtypes; Gαo1, Gαo2, Gαi1, Gαi2, Gαi3, Gαz, Gαt1/2 and 
Gαgust (Milligan and Kostenis, 2006).  Gαi/o proteins are expressed for example in 
neurons, adrenal chromaffin cells, the heart and taste buds (Milligan and Kostenis, 
2006).  The Gαi family inhibit adenylyl cyclase and therefore inhibit the production of 
cAMP (Neves et al., 2002).  Gαi/o proteins also activate K+ channels, inhibit Ca2+ 
channels, activate Rap1 mediated MAPK activation and increase tubulin GTPases 
(Milligan and Kostenis, 2006).   
 
There are five members of the Gαq group; Gαq, Gα11, Gα14, Gα15 and Gα16 (Milligan and 
Kostenis, 2006).   Gαq proteins are ubiquitously expressed however Gα15/16 are 
expressed in haematopoietic cells (Milligan and Kostenis, 2006).  Gαq proteins activate 
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phospholipase C-β (PLC-β) which hydrolyses PIP2 into IP3 and DAG.  IP3 then acts 
upon IP3 receptors on the endoplasmic reticulum to release Ca2+ from this Ca2+ store 
(Neves et al., 2002; Clapham, 2007).  Gαq can also activate phospholipase D (PLD) 
through the activation of protein kinase C (PKC) (Neves et al., 2002).  Moreover Gαq 
can inhibit two pore K+ channels (Veale et al., 2007; Shrestha et al., 2010), activate 
Bruton’s tyrosine kinase  (Bence et al., 1997; Milligan and Kostenis, 2006) and p63-
RhoGEF (Lutz et al., 2005; Milligan and Kostenis, 2006). 
 
Finally members of the Gα12/13 family consist of two members Gα12 and Gα13 and are 
ubiquitously expressed (Milligan and Kostenis, 2006).  Gα12/13 proteins activate 
p115RhoGEF (Kozasa et al., 1998), leukaemia-associated RhoGEF (LARG; Suzuki et 
al., 2003), PLCε (Kelley et al., 2004; Hains et al., 2006), PLD (Ziembicki et al., 2005) 
and the membrane-cytoskeletal protein, radixin (Vaiskunaite et al., 2000).  However the 
Gα-subunits are not the only way effectors are activated when GPCRs are stimulated 
(figure 1.1).   
 
 
Figure 1.1:  Examples of the diverse signalling of seven trans-membrane receptors.  Lipids 
are one type of ligand that can bind to GPCRs and initiate amplification signalling pathways 
which result in stimulation of the appropriate effector to regulate physiological homeostasis.  
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Gαi proteins reduce the level of cAMP as well as exerting effects on ion channels such as Ca2+ 
and K+ channels.  Gαq proteins lead to the formation of DAG and IP3 and then the subsequent 
release of Ca2+.  Gαs increases cAMP and Gα12/13 signals through the small GTPase Rho.  
GPCRs were classically known to bind to G-proteins but recent evidence highlights they can 
also activate β–arrestins to initiate signalling through MAP kinase.  GRK, G-protein receptor 
kinase; MAPK, mitogen activated protein kinase; JNK, c-Jun N-terminal kinase; GDP, guanine 
diphosphate; PI3K, phosphatidylinositol-3-kinase; PLC, phospholipase C; GTP, guanine 
triphosphate; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; GEF, guanine 
exchange factor.  Adapted from Dorsam and Gutkind, 2007; Galandrin et al., 2007. 
 
Originally the Gβγ subunit was thought to only interact with the inactive Gα-subunit to 
inhibit constitutive signalling, and due to its hydrophobicity, to act as an anchor for the 
heterotrimeric G-protein with the cell membrane (Milligan and Kostenis, 2006).  
However this hypothesis was contested when muscarinic GPCRs in the heart which 
activate K+ channels were found to require Gβγ-subunits to promote single channel 
conductance (Logothetis et al., 1987).  Further evidence found Gβγ-subunits are also 
required for breast cancer (MD-MBA-231) cell proliferation and migration towards 
serum (Tang et al., 2011).  Serum-induced growth of MD-MBA-231 breast cancer cells 
decreased when the Gβγ-subunits were inhibited.  However proliferation of a non-
tumorigenic breast epithelial cell line (MCF10A) was unaffected by Gβγ-subunit 
activation suggesting that the effects on proliferation by Gβγ occur only in tumour cells 
(Tang et al., 2011).  Furthermore inhibiting Gβγ-subunits reduced lung metastasis and 
tumour formation in vivo where MDA-MB-231 cells had been injected into the tail vein 
of mice.  Angiogenesis and leukocyte infiltration were also inhibited in primary breast 
tumours when Gβγ dimers were blocked (Tang et al., 2011).  Gβγ-subunits from the Gαi-
subunit are also important for chemoattractant neutrophil chemotaxis mediated by 
phosphoinositide-3 kinase (PI-3 kinase) activation (Lehmann et al., 2008).  Furthermore 
Gβγ-subunits can activate PLC (Boyer et al., 1992), Tsk and Btk tyrosine kinase 
(Langhans-Rajasekaran et al., 1995) and MAPK (Faure et al., 1994).  Therefore Gβγ-
subunits are also important signalling mediators. 
 
Finally, recent research suggests signalling through GPCRs can also occur 
independently of G-proteins.  β-arrestins are now recognised as playing a role in GPCR 
signalling.  There are four β-arrestin subtypes expressed in mammals; β-arrestin1, β-
arrestin2 and two visual arrestins – rod-arrestin and cone-arrestin (Coffa et al., 2011).  
Classically β-arrestins were merely considered to terminate GPCR-mediated signalling 
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by desensitisation, sequestration and downregulation of the activated GPCR (Luttrell 
and Lefkowitz, 2002).  To initiate β-arrestin’s role in desensitisation G-protein coupled 
receptor kinases (GRKs) are activated after docking with a ligand bound GPCR 
(Gurevich et al., 2012).  GRKs then phosphorylate serine and threonine residues on the 
carboxyl terminus of an activated GPCR thereby increasing the affinity of GPCR to 
interact with β-arrestins in a process known as homologous desensitisation (Luttrell and 
Lefkowitz, 2002; Gurevich et al., 2012).  Additionally second messengers can 
phosphorylate other protein kinases such as protein kinase A (PKA) and protein kinase 
C (PKC) which can also phosphorylate the cytoplasmic loops and/or serine and 
threonine resides on the GPCR carboxy terminus also leading to a subsequent 
interaction with β-arrestins (Luttrell and Lefkowitz, 2002).  Unlike GRK 
phosphorylation which requires an agonist to be bound to the targeted GPCR, PKA and 
PKC can also phosphorylate unoccupied GPCRs in a process known as heterologous 
desensitisation (Luttrell and Lefkowitz, 2002).  The presence of the β–arrestin disrupts 
G-protein coupling with the GPCR therefore desensitising the receptor.  The GPCR-β-
arrestin complex can now interact with 2-AP an adaptor protein which links the GPCR-
β-arrestin complex with clathrin (Luttrell and Lefkowitz, 2002).  Clathrin is a structural 
protein component of clathrin-coated pits which promote endocytosis of the ligand 
bound GPCR (Goodman et al., 1996; Gagnon et al., 1998; Luttrell and Lefkowitz, 
2002).  Finally the presence of dynamin at the neck of the invaginated membrane allows 
the clathrin-coated pit to be ‘pinched off’ where it then internalises promoting GPCR 
sequestration (Damke et al., 1994; Rappoport et al., 2008; Delom and Fessart, 2011).  
In studies where a mutant inactive dynamin is present AP-2 still associates with clathrin 
coated pits however they remain at the cell membrane (Damke et al., 1994).  GPCR 
downregulation occurs when sequestered GPCRs are either targeted into early 
endosomes for recycling back into the cell membrane or targeted to acidic lysosomes 
for degradation (Gagnon et al., 1998; Luttrell and Lefkowitz, 2002).  Previously β-
arrestins from β-adrenoceptors have been reported to dissociate close to the membrane 
allowing the receptors to recycle quickly.  However the vasopressin receptors which 
recycle slowly were found to remain associated with β-arrestins in endosomes.  
Furthermore when the c-termini of each receptor type was exchanged the β-
adrenoceptors were then targeted to endosomes and the vasopressin receptors were 
found to dissociate from β-arrestins at the cell membrane (Oakley et al., 1999).  
Therefore the resensitisation of the activated GPCRs may be dictated by the interaction 
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between the c-termini of a receptor and the recruited β-arrestin (Oakley et al., 1999; 
Luttrell and Lefkowitz, 2002). 
 
Recent evidence however suggests that β-arrestins can also initiate signalling through 
MAPK (Daaka et al., 1998; Shenoy et al., 2006; Yang et al., 2012), JNK (McDonald et 
al., 2000; Marinissen and Gutkind, 2001), p38 MAPK (Yang et al., 2012) and AKT 
(Beaulieu et al., 2005; Yang et al., 2012).  HEK293 cells transfected with mutant forms 
of β-arrestin and dynamin inhibited isoproterenol activated β-adrenoceptor ERK1/2 
phosphorylation suggesting that endocytosis of the β–adrenoceptors is necessary to 
initiate MAPK signalling (Daaka et al., 1998).  Immunocytochemical studies revealed 
angiotensin II stimulated the angiotensin II type 1A (AT1A) receptors which promoted 
β-arrestin2 to act as a scaffold protein for Raf1 and MEK1 in COS-7 cells.  Therefore 
protein complexes consisting of AT1A receptor, β-arrestin2, Raf1, MEK1 and ERK2 
were recruited to endosomes (Luttrell et al., 2001).  The retention of β-arrestin-ERK1/2 
in endosomes increases the cytosolic whilst lowering the nuclear concentration of 
phosphorylated ERK1/2 mediated by AT1A receptor activation (Tohgo et al., 2002).   A 
subsequent study highlighted that angiotensin II stimulation of AT1A receptor promoted 
β-arrestin mediated phosphorylation of ERK1/2.  This led to the initiation of protein 
synthesis therefore providing evidence that β-arrestins can mediate transcriptional 
regulation (DeWire et al., 2008).  However the phosphorylation of eukaryotic 
translation initiation factor 4E (eIF4E) was not directly via ERK1/2 but by the 
downstream Mnk1 protein (DeWire et al., 2008).   
 
G-protein and β-arrestin dependent signalling  may act synergistically as AT1A 
receptors treated with angiotensin II require both activation of Gαq and β-arrestin1 to 
promote the formation of stress fibres which are Rho mediated (Barnes et al., 2005).  
Gαq or β-arrestin1 alone could not activate RhoA and only when both signalling 
mediators were activated was an increase in RhoA-mediated stress fibres observed 
(Barnes et al., 2005).  Therefore cell signalling has come a long way from the canonical 
the concept of one GPCR-one signalling pathway, to the possibility that GPCRs activate 
multiple signalling pathways which may be G-protein dependent or independent 
therefore allowing for the possibility of “ligand bias”, where different ligands can 
promote distinct signalling events. 
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1.1.2.  Ligand bias 
Traditional receptor theory dictated that an agonist bound GPCR signals via one 
pathway leading to a known outcome regardless of the agonist (Clarke and Bond, 1998; 
Kenakin et al., 2012).  Therefore intrinsic efficacy (sometimes referred to as intrinsic 
activity) is a measure of the effect induced by agonist-receptor activation which was the 
same for all agonists of a given receptor (Clarke and Bond, 1998).  Furthermore full 
agonists are defined as having a high intrinsic efficacy where maximal responses to the 
ligand are produced (Urban et al., 2007).  Partial agonists have a lower intrinsic efficacy 
which leads to submaximal responses being produced.  Inverse agonists act on 
constitutive signalling to reduce the intrinsic efficacy.  A neutral antagonist whilst 
having affinity (the ability to bind to the receptor) blocks the effect of agonists but has 
no intrinsic efficacy (Urban et al., 2007).  However evidence disputes the simplicity of 
this model as GPCRs have the ability to initiate multiple signalling pathways and 
different agonists can promote activation of these with differing intrinsic efficacies, a 
phenomenon known as functional selectivity or ligand bias (Clarke and Bond, 1998; 
Kenakin et al., 2012).   Ligand bias leads to GPCRs adopting altered conformations 
dependent on the particular ligand that is bound to the GPCR.  Stabilised 
conformational changes in the cannabinoid receptor type 1 (CB1) were observed with 
plasmon waveguide resonance (PWR) spectroscopy.  It was observed that both WIN 
55,212-2 and CP 55,940 bind to CB1 producing altered PWR spectra suggesting that the 
CB1 had adopted different structural conformations with these ligands.  Moreover Gαi1 
binding to the receptor promoted different affinities and efficacies (WIN 55,212-2 being 
lower than CP 55,940) depending on the ligand that was bound to the receptor 
suggesting that ligand bias of the Gαi1 protein could occur (Georgieva et al., 2008).  It is 
also known that ligand bias can lead to the recruitment of not only various G-proteins 
but also β-arrestins (Kenakin, 2011; Wacker et al., 2013).  Another study has also 
reported that CB1 activated by either CP 55,940 or HU210 promoted differences in gene 
transcription mediated by AP-1 activation.  Each ligand could differentially stabilise the 
receptor, therefore recruiting different Gα-proteins, leading to divergence in the 
associated signalling and consequent differential promotion of AP-1 activation (Bosier 
et al., 2008).  To this end it is important to consider more than one signalling outcome 
when testing GPCR ligands.  The ligand may be inactive in one signalling pathway but 
may be potent in a different signalling pathway (Urban et al., 2007).  Initially many 
studies were carried out in recombinant systems overexpressing a receptor of interest 
and the promiscuity of signalling was thought to be due to the increased receptor 
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number (Kenakin, 2011).  However there is growing evidence in endogenously 
expressing systems that ligand bias occurs. Furthermore it may be that a ligand can act 
as an agonist and antagonist at the same GPCR.  The somatostatin sst2A receptor can be 
activated by the synthetic ligands SOM230 or KE108 in endogenously expressing 
pancreatic cells (AR4-2J) to inhibit adenylyl cyclase, whilst at the same time acts as an 
antagonist of Ca2+ mobilisation and ERK1/2 phosphorylation (Cescato et al., 2010), 
highlighting the importance of testing novel ligands in different signalling pathways.  
Furthermore in this study the synthetic ligands promoted effects that varied from the 
endogenous agonist where the natural ligand SS-14 activated ERK1/2 by two separate 
pathways (Gαi and Gα14) where Gα14 was antagonised by SOM230 and KE108 (Cescato 
et al., 2010) therefore differences in ligand bias may occur between endogenous and 
synthetic ligands in similar cells activating the same receptor (Kenakin et al., 2012).    
The responses elicited by a GPCR may also be dependent on the cellular environment 
for example the composition of the membrane, the extracellular and intracellular 
environments and other GPCRs and proteins that may exert an influence (Clarke and 
Bond, 1998; Bosier et al., 2010).  Therefore agonist activity may differ depending on 
the cell type that the receptor is present in (Kenakin et al., 2012).   
 
Allosteric modulators can also influence the signalling by GPCRs.  These are binding 
sites distinct from the orthosteric (primary) binding site.  Receptor conformation will be 
altered when a ligand binds to the allosteric site therefore changing the affinity and 
efficacy of the ligand that binds to the orthosteric site and the subsequent G-protein that 
is recruited (Bosier and Hermans, 2007).  CB1 receptors when a ligand is bound to the 
allosteric site are noted as having a higher affinity for a ligand at the orthosteric site 
however the efficacy is lowered (Price et al., 2005).  Furthermore ligand binding in the 
allosteric site may alter the GPCR signalling even if a ligand is not present in the 
orthosteric site (Bosier et al., 2010).  Therefore allosteric ligands may influence GPCR 
signalling in their own right or by modulating the effects of the orthosteric ligand. 
 
An understanding of the intricate signalling of the receptor of interest should lead to 
more specific therapeutics which can act on the pathway responsible without affecting 
other signalling pathways.  Therefore this could lead to the development of novel and 
more specific ligands.  In the long term this coupled with testing at orphan receptors can 
only enhance modern drug discovery. 
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1.1.3. Orphan GPCRs 
Early studies had led to the characterisation of the first second messenger; cyclic 
adenosine monophosphate (cAMP) linking the effects from receptor activation to 
intracellular effectors (Jacoby et al., 2006).  There was great success in the clinic with 
therapeutics in areas of cardiovascular disease, asthma, allergy, pain and epilepsy even 
though the isolation and sequencing of GPCRs had not taken place (Jacoby et al., 2006).  
In 1979 the β2 adrenoceptor was purified and was found to be functional allowing for 
the characterisation of GPCRs (Jacoby et al., 2006).  As molecular techniques 
advanced,  methods based on hybridisation probes (Bunzow et al., 1988)  or degenerate 
polymerase chain reaction (Libert et al., 1989) proved to be highly successful and led to 
the discovery of numerous orphan G-protein coupled receptors (oGPCRs).  Orphan 
GPCRs have no cognate endogenous ligand assigned to them and therefore still require 
characterisation.  Of the 701 receptors that make up the human Rhodopsin GPCR 
family around 100 of them remain oGPCRs which present potential for future drug 
targets by pharmaceutical companies (Stadel et al., 1997; Schlyer and Horuk, 2006; 
Civelli et al., 2013).   
 
In an attempt to find the endogenous ligands for the growing number of oGPCRs 
reverse pharmacology was adopted.  This technique required the oGPCR to be 
transfected into a host cell where it is known that there is no endogenous expression of 
the target receptor.  Tissue fractions from regions adjacent to where the receptor is 
expressed or libraries of endogenous ligands would then be tested on the transfected 
cells in a variety of signalling assays (Stadel et al., 1997).  The deorphanisation of the 
HT1A serotonin receptor (Fargin et al., 1988) and a D2 dopamine receptor (Bunzow et 
al., 1988) were the first to be achieved using reverse pharmacology.  Now high 
throughput screening assays can test numerous ligands from libraries with oGPCRs 
leading to faster ligand-GPCR pairings.  However it is important that more than one 
signalling assay is tested as ligand bias may occur and potential ligands could be missed 
in high throughput screening (Southern et al., 2013). 
 
Interestingly, in 1992 the cannabinoid receptor type 1 (CB1), although not technically 
an oGPCR, was used to bait fractions from porcine brain whereby anandamide (AEA), a 
fatty acid amide, was found to displace a radiolabelled cannabinoid probe; [3H]HU-243 
(Devane et al., 1992).  Therefore, AEA was not only the first mammalian natural 
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cannabinoid (endocannabinoid) to be discovered but was also the first lipid mediator to 
be identified using reverse pharmacology (Civelli et al., 2013).   
 
1.2. Overview of the endocannabinoid system 
The first medicinal use of the marijuana plant Cannabis sativa occurred in China around 
5000 years ago.  Emperor Shen Nung prescribed C. sativa to his subjects for ailments 
such as rheumatism, absent mindedness and dysmenorrhoea (Hanus, 2009).  C. sativa 
was recorded in the first Chinese pharmacopeia; Shen Nung pen ts’ao ching (Divine 
Husbandman’s Materia Medica), with a warning that consuming too many seeds would 
lead to seeing demons (Zuardi, 2006; Hanus, 2009) pertaining to the psychoactive 
effects of cannabis.  The effects of cannabis were also noted as “Protracted taking may 
make one fat, strong and never senile.” (Russo, 2007).  Therefore, suggesting a role for 
cannabinoids in obesity, immune function and neuroprotection.  However it was not 
until the latter decades of the 20th Century that the most intense research on the 
molecular mechanisms and chemical structures of phytocannabinoids, 
endocannabinoids, synthetic analogues and cannabinoid receptors have taken place. 
 
1.2.1. Cannabinoid receptors  
The discovery in the mid-1960s of the main active constituent of C. sativa, the 
phytocannabinoid Δ9-tetrahydrocannabinol (Δ9-THC), was to open the field of 
cannabinoid research (Gaoni and Mechoulam, 1964).  The lipophilic nature of Δ9-THC 
was initially thought to exert effects by disrupting the cell membrane however, by the 
end of the decade stereoisomers of Δ9-THC led to the hypothesis that Δ9-THC was 
acting upon a target in the cell membrane (Mechoulam and Gaoni, 1967).  It would be 
another twenty years before the discovery and cloning of the first cannabinoid receptor.  
Cannabinoid receptor type 1 (CB1) was elucidated from rat brain (Devane et al., 1988) 
and autoradiography with a labelled cannabinoid ligand ([3H]CP 55,940) further 
confirmed the location of CB1 in the brain (Herkenham et al., 1990).  CB1 is 
predominantly localised in the cerebellum, cerebral cortex, hippocampus, 
hypothalamus, limbic system and basal ganglia (Moldrich and Wenger, 2000).  CB1 is 
the most abundantly expressed GPCR in the mammalian brain at the mRNA level and is 
responsible for the ‘high’ associated with cannabis use (Herkenham et al., 1990; Begg 
et al., 2005).  The lack of toxicity of cannabinoids may be attributed to absence of CB1 
from the brain stem (Iversen, 2003).  Furthermore CB1 is also expressed in the 
periphery, including skeletal muscle (Cavuoto et al., 2007), immune system (Galiègue 
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et al., 1995; Small-Howard et al., 2005), gastrointestinal tract (Pertwee et al., 1996), 
placenta (Park et al., 2003), cardiovascular system (Liu et al., 2000), testis (Gerard et 
al., 1991) and prostate (Ruiz-Llorente et al., 2003).  A second cannabinoid receptor 
(CB2) was elucidated from macrophages in the marginal zone of the spleen (Munro et 
al., 1993).  The two cannabinoid receptors share a 44% homology with each other and a 
68% similarity in the transmembrane region (Munro et al., 1993).  Whereas CB1 is 
localised mainly in the central nervous system, CB2 is predominantly localised in the 
periphery such as in the spleen (Lee et al., 2001) and in different types of immune cells.  
CB1 receptors are also expressed in immune cells but are between 10 to 100 times lower 
than seen for CB2 receptors (Galiègue et al., 1995). It was found that levels of CB2  
mRNA were B cells > natural killer cells > monocytes > neutrophils > cluster of 
differentiation CD8+ cells > CD4+ cells (Galiègue et al., 1995; Lee et al., 2001).  
However there is also growing evidence of CB2 expression in the central nervous 
system, including microglia in the human cerebellum (Núñez et al., 2004), the rat 
cerebellum, brainstem and modest levels in the cortex (van Sickle et al., 2005), 
vasculature of both human cerebral endothelial cells (Golech et al., 2004) and rat 
Purkinje cells (Ashton et al., 2006).  The initial discovery of cannabinoid receptors in 
mammals promoted the question; do endogenous ligands exist that can activate these 
receptors? 
 
1.2.2. Endocannabinoids, endogenous CB1 and CB2 ligands 
Δ9-THC being lipophilic suggested that an endogenous ligand for the cannabinoid 
receptors might also be a lipid.  In 1992, the first endogenous cannabinoid ligand 
(endocannabinoid) was isolated from porcine brain, this was a fatty acid amide and 
named anandamide (AEA) after the Sanskrit word “ananda”, meaning “inner bliss” 
(Devane et al., 1992).  AEA binds to CB1 (Devane et al., 1992) and CB2 (as a partial 
agonist at both receptors) (Bayewitch et al., 1995; Howlett et al., 2002) and also to the 
transient receptor potential vanilloid 1 cation channel; TRPV1 (Zygmunt et al., 1999; 
Smart et al., 2000).  Within three years a second endocannabinoid, 2-arachidonoyl-
glycerol (2-AG) was isolated from canine gut (Mechoulam et al., 1995) and a 
subsequent study in the same year isolated 2-AG in rat brain (Sugiura et al., 1995).  2-
AG is suggested to be the more important endocannabinoid as lower levels of AEA are 
reported in the brain suggesting that it may not be as physiologically important as 2-AG 
(Sugiura et al., 2000).  Indeed the abundance of 2-AG in rat brains is suggested to be 
170 times higher than AEA (Stella et al., 1997).  2-AG acts as an agonist of both CB1 
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(Mechoulam et al., 1995) and CB2 (Mechoulam et al., 1995; Gonsiorek et al., 2000).  
Other endocannabinoids, all derivatives of arachidonic acid, have since been discovered 
and include; N-arachidonoyl dopamine (NADA) a CB1 > CB2 agonist (Bisogno et al., 
2000; Huang et al., 2002), the ester of ethanolamine and arachidonic acid, O-
arachidonoyl ethanolamine (virodhamine) a CB1 partial agonist/antagonist and CB2 
agonist (Porter et al., 2002) and the 2-AG analogue, 2-arachindonoyl glycerol ether 
(noladin ether) a CB1 (Hanus et al., 2001) and CB2 agonist (Shoemaker et al., 2005).  
There is some controversy as to whether noladin ether is a true central nervous system 
(CNS) endocannabinoid with some groups reporting this lipid in the brain (Hanus et al., 
2001; Fezza et al., 2002) however, this is disputed by other groups. Upon testing of 
various mammalian brain regions the presence of noladin ether was not found (Oka et 
al., 2003; Richardson et al., 2007). 
 
The endocannabinoids are synthesised on demand when intracellular Ca2+ is elevated, 
either by depolarisation or the action of phospholipase C (PLC) promoting the 
subsequent release of Ca2+ from stores (Kano et al., 2009).  The endocannabinoids AEA 
and 2-AG, whilst sharing a similar structure, are synthesised by different enzymes 
(Iversen, 2003).  AEA is synthesised from the phospholipid precursor N-arachidonoyl-
phosphatidylethanolamine (NAPE).  N-acyltransferase (NAT) is Ca2+-dependent 
enzyme which transfers arachidonic acid from phosphatidylcholine to the headgroup of 
phosphatidylethanolamine to produce NAPE (Cadas et al., 1996).  The requirement of 
Ca2+ is thought to be a rate limiting factor in the synthesis of NAPE and therefore AEA 
(Jin et al., 2007).  The increase in Ca2+ activates a D-type phosphodiesterase; NAPE-
hydrolyzing phospholipase D (NAPE-PLD) which hydrolyses NAPE to form AEA and 
phosphatidic acid (Di Marzo et al., 1994; Cadas et al., 1997).  Recently a Ca2+ 
independent NAT (rat LRAT-like protein; RLP-1) has been discovered and is expressed 
in the testis (Jin et al., 2007).  The physiological significance of the Ca2+ independent 
NAT is unknown at present but the localisation in the testis suggest that it may be 
important for AEA synthesis in that tissue (Okamoto et al., 2007).   The generation of 
NAPE-PLD(-/-) mice challenged whether the NAPE-PLD enzymatic pathway is required 
for AEA synthesis.  NAPE-PLD(-/-) mice have AEA concentrations that are  similar to 
wild-type littermates suggesting alternative biosynthesising enzymes must exist (Leung 
et al., 2006).  Another AEA synthesising pathway has been described starting with 
NAPE as the precursor.  The two-step AEA synthesising pathway begins with the 
double-O-deacylation of NAPE by α/β domain containing hydrolase 4(ABDH4) to form 
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glycerophospho-AEA.  This glycerophospho-AEA is then acted upon by 
glycerophosphodiesterase (GDE1) to generate AEA (Simon and Cravatt, 2008).  A 
subsequent study using double knockout NAPE-PLD(-/-)/GDE(-/-) mice partially 
disrupted AEA formation suggesting yet another synthesising pathway must exist for 
the generation of AEA (Simon and Cravatt, 2010).  In brain and macrophage 
RAW264.7 cells AEA synthesis occurs from the precursor NAPE in a two-step process.  
This pathway requires the activation of phospholipase C (PLC) to generate phospho-
AEA followed by subsequent activation of protein tyrosine phosphatase non-receptor 
type 22 (PTPN22) to generate AEA.  However some less AEA was observed in the 
brain extracts from PTPN22(-/-) mice compared to wild type littermates therefore 
suggesting that other phosphatases may exist for the conversion of phospho-AEA to 
AEA (Liu et al., 2006).  AEA can be either transported across the membrane by 
diffusion through the membrane leaflet or through a membrane based transporter.  
There is still controversy as to the exact mechanism of AEA release and cellular uptake 
(Fowler, 2013).   
 
Rapid termination of signalling occurs by degradation of AEA through the activation of 
the membrane bound enzyme, fatty acid amide hydrolase (FAAH) (Dainese et al., 
2014).  FAAH can degrade AEA into arachidonic acid and ethanolamine (Di Marzo et 
al., 1994).   FAAH(-/-) mice have higher levels of AEA in the brain than wild type 
littermates suggesting that this enzyme is degrading the endocannabinoid (Cravatt and 
Lichtman, 2002).  AEA can also be metabolised by cyclooxygenase-2 (COX-2) and 
lipoxygenase (LOX) enzymes in particular 12-LOX and 15-LOX  (Woodward et al., 
2008; Yates and Barker, 2009).   
 
As with AEA an increase in intracellular Ca2+ is required for 2-AG synthesis (Stella et 
al., 1997).  2-AG is synthesised from phospholipid precursors through the hydrolysis of 
PIP2 by PLC to produce diacylglycerol (DAG; Stella et al., 1997).  Diacylglycerol 
lipase (DAGL) α and DAGLβ are the enzymes which hydrolyse DAG at the sn-1 
position to produce 2-AG (Stella et al., 1997; Bisogno et al., 2003).  Moreover in mice 
lacking either DAGLα or DAGLβ the concentration of 2-AG in the brain is decreased 
by ~80% and ~50% respectively and is decreased by ~90% in the liver of DAGLβ(-/-) 
(Gao et al., 2010).  Furthermore a specific lysophosphatidylinositol-phospholipase C 
(LPI-PLC) present in porcine platelets and rat brain can also metabolise LPI (2-
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arachidonoyl LPI) into the endocannabinoid 2-AG (Tsutsumi et al., 1994; Kobayashi et 
al., 1996).   
 
2-AG metabolism can occur with FAAH but is thought to be less important as studies in 
FAAH(-/-) mice had increased AEA levels but 2-AG concentrations remained the same 
(Lichtman et al., 2002).  Alternatively 2-AG is a substrate for the serine hydrolase 
monoacylglycerol lipase (MAGL).  In vivo studies in rats found that 2-AG is 
metabolised by MAGL into arachidonic acid and glycerol (Dinh et al., 2002).  
Importantly MAGL in the brain is expressed in similar regions to CB1 (Dinh et al., 
2002).  When MAGL was overexpressed in neurons which were stimulated with 
NMDA/carbachol the synthesis of both AEA and 2-AG increased, however 2-AG levels 
were decreased in the neurons overexpressing MAGL.  Moreover AEA levels in HeLa 
cells were similar to the levels in neurons transfected with the vector alone (Dinh et al., 
2002).  However adenoviral vector-mediated gene transfer of MAGL into HeLa cells 
did not hydrolyse AEA or palmitoylethanolamine (PEA); a structural analogue of AEA 
(Dinh et al., 2002).  2-AG is also a substrate for leukocyte-type 12-lipoxygenase (LOX; 
Kozak et al., 2002) and for cyclooxygenases (COX), in particular COX-2 (Kozak et al., 
2000).   
 
Figure 1.2:  Overview of the endocannabinoid system.  Two cloned cannabinoid receptors; 
CB1 and CB2 along with the endogenous lipids, the endocannabinoids, which are produced on 
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demand and enzymes for the synthesis and degradation of the endocannabinoids.  Furthermore 
there is growing evidence of potential novel cannabinoid receptors such as GPR55 and GPR18. 
 
1.2.3. Cannabinoid receptor signalling 
The classical cannabinoid receptors are members of the GPCR Rhodopsin class A α-
group (Civelli et al., 2013) and therefore recruit G-proteins.  CB1 can inhibit adenylyl 
cyclase and therefore lower the concentration of the second messenger, cAMP (Howlett 
and Fleming, 1984).  Four isoforms of adenylyl cyclase (I, V, VI and VIII) are reported 
to be inhibited by CB1 signalling via Gαi/o (Rhee et al., 1998).  In contrast, CB1 
activation can stimulate three isoforms of adenylyl cyclase (II, IV and VII) which the 
authors suggest is mediated by Gβγ subunits from the Gαi/o protein (Rhee et al., 1998). 
 
There is some controversy as to whether CB1 receptors can promote Ca2+ mobilisation 
and this may depend on the cellular environment.  2-AG applied to CB1 receptors is 
reported to promote Ca2+ mobilisation in two neuronal cell lines, NG108-15 cells and 
N18TG2 cells (Sugiura et al., 1997).  In contrast 2-AG does not induce Ca2+ 
mobilisation in the CB1-HEK293 cells.  However the synthetic cannabinoid WIN 
55,212-2 can promote Ca2+ mobilisation which is Gαq mediated in CB1-HEK293 cells 
(Lauckner et al., 2005).  A subsequent study in rat insulinoma β-cells (RIN m5F) 
showed that the CB1 agonist arachidonoyl-chloro-ethanolamide (ACEA) can promote 
Ca2+ mobilisation, which may be Gαq mediated (De Petrocellis et al., 2007). 
 
Cannabinoid receptors are also reported to signal via kinase signalling pathways.  CB1, 
like many GPCRs, can promote activation of MAPK (Bouaboula et al., 1995; Galve-
Roperh et al., 2002).  Application of CP-55940 to the human astrocytoma cell line U373 
MG which endogenously expresses CB1 receptors and CHO-CB1 cells promotes the 
phosphorylation of ERK1/2 (Bouaboula et al., 1995).  Furthermore CB1 stably 
transfected HEK293 cells demonstrate ERK1/2 phosphorylation when challenged with 
either AEA or HU-210 (Liu et al., 2000).  Endothelial cells (ECV304) which 
endogenously express CB1 when treated with HU-210 and AEA were also found to 
promote the phosphorylation of ERK1/2 (Liu et al., 2000)  Other members of the 
MAPK family are activated by CB1, including p38 MAPK (Galve-Roperh et al., 2002) 
and c-JUN-N-terminal kinase (JNK; Liu et al., 2000; Rueda et al., 2000).  CB1 also 
promotes the phosphorylation of AKT in stably transfected CHO cells or U373 MG 
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cells (Gómez del Pulgar et al., 2000).  Signalling to AKT through CB1 was dependent 
on Gαi/o proteins and PI-3-kinase (Gómez del Pulgar et al., 2000). 
 
N-type Ca2+ channels can be inhibited in the neuroblastoma-glioma cell line (NG108-
15) that have been challenged with WIN 55,212-2 (Mackie and Hille, 1992).  N and P/Q 
type Ca2+ channels are inhibited in cultured rat hippocampal neurons through CB1 
(Twitchell et al., 1997).  Also in AtT-20 cells stably expressing CB1, AEA inhibits Q-
type Ca2+ channels.  These effects were sensitive to PTX and are therefore likely to be 
mediated by Gαi/o proteins (Mackie et al., 1995).  Furthermore CB1 receptors located in 
cat cerebral arterial smooth muscle cells stimulated with either WIN 55,212-2 or AEA 
can inhibit L-type Ca2+ channels.  The modulation of the Ca2+ channels can be promoted 
through the activation of Gαi/o proteins (Gebremedhin et al., 1999).  L-type Ca2+ 
channels are also activated in N18TG2 neuroblastoma cells challenged with the 
cannabinoid agonist, deasacetyllevonantradol (DALN) which was sensitive to 
SR141716A a CB1 antagonist (Rubovitch et al., 2002).  Furthermore inwardly 
rectifying K+ channels were activated in AtT-20 cells that were transfected with CB1 
receptors (Felder et al., 1995; Mackie et al., 1995).   
 
As with CB1, activation of CB2 receptors can inhibit adenylyl cyclase and this effect is 
sensitive to PTX application suggesting that Gαi/o proteins are involved (Bayewitch et 
al., 1995).  Also forskolin induced cAMP accumulation was inhibited in CHO cells 
stably transfected with CB2 receptors and mediated by Gαi/o proteins (Felder et al., 
1995).  However CB2 receptor activation does not couple to ion channels as reported for 
CB1.  WIN 55,212-2 applied to CHO cells stably expressing CB2 receptors did not 
affect K+ currents (Felder et al., 1995).  PLA2, PLC and PLD activation along with Ca2+ 
mobilisation did not occur in CHO-CB2 cells these cells (Felder et al., 1995).  
Furthermore in AtT-20 cells stably expressing CB2 receptors treatment with WIN 
55,212-2 did not inhibit the Ca2+ current (Felder et al., 1995).  In contrast some cell 
lines do exhibit CB2 receptor-mediated Ca2+ mobilisation; RIN m5F cells challenged 
with JWH133 demonstrate CB2 receptor-mediated Ca2+ mobilisation (De Petrocellis et 
al., 2007).  Furthermore 2-AG promoted Ca2+ mobilisation in HL-60 cells which was 
attenuated by application of the CB2 antagonist, SR144528 and sensitive to PTX 
(Sugiura et al., 2000).  CB2 activation can also lead to changes in gene transcription, 
CP-55940 applied to the human pro-myelomonocytic cell line, HL60 promoted 
activation of ERK1/2 and subsequent immediate early gene Krox-24 expression 
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(Bouaboula et al., 1996).  Activation of CB2 receptors in HL-60 cells did not promote 
the phosphorylation of AKT (Gómez del Pulgar et al., 2000).  However recent studies 
dispute this and CB2 receptors in human prostatic carcinoma PC3 cells activate AKT 
(Sánchez et al., 2003).  Therefore CB2 receptor-mediated AKT phosphorylation may be 
cell type specific. 
 
1.2.4. Non CB1/CB2 cannabinoid sensitive receptors 
1.2.4.1. Transient receptor potential vanilloid 1 
The transient receptor potential vanilloid 1 (TRPV1) is a non-selective cation channel, 
but has a preference for Ca2+ over other cations (Vriens et al., 2009).  Originally TRPV1 
was found to be activated by capsaicin, noxious heat ( > 43oC) and protons (pH < 5.9) 
(Caterina et al., 1997; Tominaga et al., 1998; Vriens et al., 2009) and is localised to 
small and medium primary sensory neurons (Caterina et al., 1997).  Interestingly 
TRPV1 and CB1 receptors are co-localised in cultured dorsal root ganglion neurons 
(Ahluwalia et al., 2000), cholinergic myenteric neurons (Coutts et al., 2002; Anavi-
Goffer and Coutts, 2003) and several brain regions such as the basal ganglia and 
hippocampus (Cristino et al., 2006).  Previously it was shown with capsacin that the 
TRPV1 binding site is located intracellularly  (Jung et al., 1999).  AEA has also been 
shown to act intracellularly to activate TRPV1 (De Petrocellis et al., 2001).  
Endogenous ligands that have activity at vanilloid receptors are known as 
endovanilloids (Starowicz et al., 2007).  AEA acting at TRPV1 was first observed in 
patch clamp experiments in either whole cell or isolated membranes of HEK293 cells 
transfected with rat TRPV1.  AEA, acting as a partial agonist, induced an inward current 
which was sensitive to the TRPV1 antagonist, capzaspine (Zygmunt et al., 1999).  AEA 
sensitivity at TRPV1 was further confirmed when screening ~1000 bioactive 
compounds for TRPV1 activity  in the FLIPR Ca2+ assay (Smart et al., 2000).  Smart et 
al., (2000) also observed AEA acting as a partial agonist, similarly to that reported by 
Zygmunt et al., (1999), inducing inward currents in HEK293 cells transfected with 
human TRPV1.   Whilst AEA can activate both CB1 and TRPV1 it is reported that 2-10 
fold higher concentrations of AEA are required to activate TRPV1 compared to 
concentrations required to mediated CB1 responses (Starowicz et al., 2007).  Also the 
endocannabinoid NADA activates both rat and human TRPV1 expressed in HEK293 
cells.  Furthermore the release of substance P and calcitonin gene-related peptide in 
dorsal root ganglion (DRG) cells is attributed to NADA activating TRPV1 (Huang et 
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al., 2002).  However the endocannabinoid 2-AG does not activate TRPV1 (Zygmunt et 
al., 1999). 
 
1.2.4.2. Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors are nuclear receptor transcription factors of 
which there are three subtypes PPAR-α, -γ and -δ/β.  Activated PPARs heterodimerise 
with nuclear retinoid X receptors and bind to PPAR response elements to promote gene 
transcription (O’Sullivan, 2007). PPARs have a diverse range of functions such as lipid 
metabolism, cell differentiation and survival and inflammatory responses (Michalik et 
al., 2006).  PPARs can be activated by a various ligands; free fatty acids, eicosanoids 
and prostaglandins (Berger and Moller, 2002).  There is also growing evidence that 
PPARs can be activated by cannabinoids (O’Sullivan, 2007).  
  
1.2.4.3. Novel cannabinoid receptors 
Evidence suggests that there are at least three additional cannabinoid receptors; in the 
brain (Di Marzo et al., 2000; Breivogel et al., 2001; Begg et al., 2005), in the 
cardiovascular system (Járai et al., 1999; Begg et al., 2005) and the immune system 
(Rao and Kaminski, 2006).  Both AEA and WIN55212-12 applied to CB1(-/-) mouse 
brain were observed to stimulate [35S]GTPγS binding mediated by an unknown GPCR 
which did not bind Δ9THC (Breivogel et al., 2001).  Moreover structural analogues of 
AEA were ineffective at promoting [35S]GTPγS binding in brain membranes derived 
from CB1(-/-) mice (Breivogel et al., 2001).  The effects of AEA induced [35S]GTPγS 
binding in CB1(-/-) brain membranes were unaffected by CB1 (SR141716A) or CB2 
(SR144528) antagonists (Di Marzo et al., 2000).  The localisation of the WIN 55,212-2 
sensitive receptor only partially overlaps with regions where CB1 is found (Breivogel et 
al., 2001).  This suggests that the WIN 55,212-2 sensitive receptor has a divergent 
pharmacology and physiological role when compared to CB1 and CB2 receptors. 
 
Vasodilatation of the mesenteric arteries has been observed with Abn-CBD and may act 
on a novel anadamide receptor which is distinct from CB1 and CB2 (Offertáler et al., 
2003).  The existence of this novel anadamide receptor was further confirmed with 
physiological studies in CB1(-/-)/CB2(-/-) mice where Abn-CBD could still exert 
vasodilation of the mesenteric arteries (Járai et al., 1999).  The hypothesis at the time 
was that an orphan GPCR could be responsible for the effects and attention turned to the 
G protein-coupled receptor 55 (GPR55).  However when Abn-CBD was applied to 
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GPR55(-/-) mice and compared to wild type littermates it was discovered that the effect 
remained suggesting that GPR55 was not responsible (Johns et al., 2007).  More 
recently another oGPCR has been suggested as the Abn-CBD receptor, G protein-
coupled receptor 18 (GPR18) (McHugh et al., 2010).  Interestingly, GPR18 and GPR55 
share some pharmacology (Ross, 2009).   
 
Cannabinoid receptors may have a role in the suppression of the immune response in T-
cells derived from the spleen (Brown, 2007).  Splenocytes derived from double 
knockout mice (CB1(-/-)/CB2(-/-)) treated with Δ9THC, cannabinol, and HU-210 show 
increases in intracellular Ca2+ ([Ca2+]i) when compared to wild-type littermates.  
Furthermore mobilisation of Ca2+ was sensitive to CB1 and CB2 antagonists but was 
CB1 and CB2 independent suggesting a novel target for these cannabinoid ligands is 
present in splenocytes (Rao and Kaminski, 2006).  In addition, the phytocannabinoid 
cannabidiol (CBD) is able to suppress the production of pro-inflammatory cytokines 
interleukin 2 (IL-2) and IFN-γ.  Interestingly this effect is also seen in spleens derived 
from CB1(-/-)/CB2(-/-) mice suggesting that a novel cannabinoid receptor may mediate the 
effects.  The authors propose that there may be a role for GPR55 (Kaplan et al., 2008) 
which is interesting as high levels of GPR55 mRNA have been detected in the spleen 
(Baker et al., 2006; Ryberg et al., 2007; Oka, et al., 2010).  This provides further 
evidence that GPR55 may have a role in immune function. 
 
1.3. G-protein coupled receptor 55 
In 1999 the orphan G-protein coupled receptor 55 (GPR55) was discovered in silico, 
and subsequently cloned, through the use of homology searches of previously 
discovered GPCRs using BLAST (basic local alignment search tool) of the expressed 
sequence tags database (Sawzdargo et al., 1999).  GPR55 is a 7TM spanning receptor 
containing 319 amino acids and the gene is mapped to chromosome 2q37 (Sawzdargo et 
al., 1999).  GPR55 has attracted much recent attention as it is thought to be sensitive to 
certain cannabinoid ligands and has been proposed to be a novel cannabinoid receptor 
(Pertwee et al., 2010). 
 
1.3.1. GPR55 pharmacology 
Cannabinoid activation of GPR55 was first described in two industrial patents (Brown 
and Wise, 2001; Drmota et al., 2004).  In the first patent from GlaxoSmithKline a yeast 
based assay highlighted that reporter gene activity is increased in the presence of 
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AM251 when GPR55 is expressed (Brown and Wise, 2001).  The second patent from 
AstraZeneca further confirmed that GPR55 was sensitive to synthetic cannabinoid 
ligands, phytocannabinoids and the endocannabinoids AEA, 2-AG, and virodhamine.  
Furthermore some N-acyl amides were reported to activate GPR55 in GTPγS assays 
(Drmota et al., 2004).  AstraZeneca confirmed their findings in a key publication in the 
British Journal of Pharmacology suggesting that GPR55 is a novel cannabinoid receptor 
(Ryberg et al., 2007).  However, controversy remains as to whether endocannabinoids, 
such as AEA, 2-AG and virodhamine can activate GPR55.  Some research groups report 
that endocannabinoids can activate GPR55 (Ryberg et al., 2007; Lauckner et al., 2008; 
Sharir et al., 2012), however, other groups do not reiterate these findings (Oka et al., 
2007; Henstridge et al., 2009).  A beta-arrestin study also highlighted that 
endocannabinoids only weakly activated GPR55 (Yin et al., 2009).  Finally there is also 
controversy as to whether palmitoylethanolamine (PEA), a structural analogue of AEA, 
activates GPR55.  Some groups find that low nanomolar potencies of PEA activate 
GPR55 (Ryberg et al., 2007),  whilst others found no difference when PEA was applied 
to hGPR55-HEK293 cells and compared to control HEK293 cells (Oka et al., 2007; 
Lauckner et al., 2008).  Furthermore GPR55 does not possess the classic cannabinoid 
binding pocket (Petitet et al., 2006).  Therefore the binding sites for the same ligand 
will be different between CB1/CB2 and GPR55 (Garland, 2013).  However, emerging 
data suggests that the endogenous lipid, L-α-lysophosphatidylinoisitol (LPI) is the 
natural ligand for GPR55.  In 2007 a Japanese group first revealed that LPI could 
activate GPR55 (Oka et al., 2007).  Interestingly a subsequent publication from the 
same group demonstrated that LPI containing an arachidonic fatty acid chain was the 
most biologically active LPI species in GPR55-mediated Ca2+ mobilisation and ERK1/2 
phosphorylation assays (Oka et al., 2009).  The activity of LPI at GPR55 has now been 
confirmed by a number of groups (Henstridge et al., 2009; Kapur et al., 2009; Yin et 
al., 2009). 
 
The synthetic cannabinoid ligand, O-1602 is also a putative GPR55 ligand.  It was first 
noted as a GPR55 agonist when tested in a [35S]GTPγS binding assay where it activated 
the receptor in a concentration dependent manner (Drmota et al., 2004; Johns et al., 
2007).  However it remains controversial as to whether O-1602 activates GPR55.  O-
1602 activation does not promote ERK1/2 phosphorylation or Ca2+ mobilisation assays 
in hGPR55-HEK293 cells (Oka et al., 2009).  Furthermore O-1602 does not effect β-
arrestin redistribution (Kapur et al., 2009).  However O-1602 can promote GPR55-
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mediated inhibition of osteoclastogenesis, an effect that was not observed in GPR55(-/-) 
mice (Whyte et al., 2012).  Also O-1602 decreases the contractility of colonic strips 
which is blocked in GPR55(-/-) mice when compared to control wild-type littermates 
(Ross et al., 2012).  These data suggest that O-1602 exhibits varying effects on GPR55 
depending on the cell type being studied.   
 
Cannabidiol (CBD) is an antagonist for GPR55 and many researchers find that CBD can 
antagonise GPR55 responses to LPI (Ryberg et al., 2007; Whyte et al., 2009).  However 
CBD is known to act at various targets; CBD has affinity for the Abn-CBD receptor in 
the vasculature (Járai et al., 1999) therefore suggesting that it may also be an antagonist 
for GPR18 (McHugh et al., 2010).  CBD is also reported to be a CB1 and CB2 
antagonist in [35S]GTPγS binding assays in vitro suggesting that in vivo CBD may 
effect more than just GPR55 (Thomas et al., 2007).  However this is contrary to 
previous data which ruled out CBD-induced activation of cannabinoid receptors in 
glioma (U87) cell migration (Vaccani et al., 2005).  CBD may also act at TRPV1 to 
promote antihyperalgesic effects (Costa et al., 2004) and CBD activates PPARγ 
promoting 3T3-L1 differentiation into adipocytes (O’Sullivan and Kendall, 2010).  
Therefore the development of more GPR55 specific antagonists is required to help 
clarify the role of GPR55 in normal and pathological states.  Recently CID16020046 
was identified in a high throughput screen and discovered to be a selective GPR55 
antagonist against LPI induced Ca2+ mobilisation, ERK1/2 phosphorylation and 
transcription factor activation in HEK293 cells stably transfected with GPR55.  These 
effects were not observed in CB1 and CB2 transfected HEK293 cells.  Furthermore 
CID16020046 also was effective in endogenous GPR55 expressing cells with similar 
potencies to that noted in the recombinant cells (Kargl et al., 2013).  The generation of 
more specific antagonists like CID16020046 will help the research field gain a better 
understanding of the physiological role of GPR55. 
 
1.3.2. Localisation of GPR55 
GPR55, when compared to the two classical cannabinoid receptors, shares only 13.5% 
and 14.5% homology with CB1 and CB2 respectively (Oka et al., 2007).   
Phylogenetically CB1 and CB2 are members of the Rhodopsin class A α-group whereas 
GPR55 is a member of the class A δ-group (Civelli et al., 2013).  Furthermore, when 
GPR55 was subjected to a homology search using the GenBank database it highlighted 
that GPR55 shared a higher level of homology with GPCRs which are members of the 
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rhodopsin Class A δ-group purinoreceptors; GPR35 (37%), GPR92 (30%), P2Y5 (30%), 
GPR23 (29%) (Baker et al., 2006).  Interestingly the endogenous lipid lysoposphatidic 
acid (LPA) has been reported to activate GPR35 (Oka, et al., 2010), GPR92 (Kotarsky 
et al., 2006; Lee et al., 2006), P2Y5 (Pasternack et al., 2008; Lee et al., 2009) and 
GPR23 (Noguchi et al., 2003; Lee et al., 2007) but does not activate GPR55 (Oka et al., 
2007; Henstridge et al., 2009).  Furthermore other lysophospholipids; 
lysophsophatidylserine, lysophosophatidylcholine and lysophsophatidylethanolamine do 
not induce GPR55-mediated ERK1/2 phosphorylation (Oka et al., 2007).  Interestingly, 
other notable members of  the rhodopsin Class A δ-group are the free fatty acid 
receptors; GPR40 (Briscoe et al., 2003) which is sensitive to medium to longer chain 
fatty acids, GPR41 and GPR43 (Brown et al., 2003), which are sensitive to shorter 
chain fatty acids with 6 or less carbons.  Also the putative Abn-CBD receptor which 
also is activated by the lipid N-arachidonoyl glycine (NAGly), GPR18 (McHugh et al., 
2010) is located within the δ-group (Civelli et al., 2013).  Therefore GPR55 is clustered 
in phylogenetic proximity to a number of novel lipid sensing receptors.  
 
GPR55 mRNA is expressed in various brain regions, including caudate, putamen 
(Sawzdargo et al., 1999), hippocampus, frontal cortex, cerebellum, striatum, 
hypothalamus and brain stem (Ryberg et al., 2007).  GPR55 mRNA was also detected 
in the adrenal glands, spleen, jejunum and ileum (Ryberg et al., 2007).  There is 
evidence of GPR55 mRNA in microglia (Pietr et al., 2009), large diameter dorsal root 
ganglion (Lauckner et al., 2008), bone (Whyte et al., 2009) and in metastatic cancer 
cells (Ford et al., 2010; Andradas et al., 2011) including the prostate cancer cell line; 
DU145 (Piñeiro et al., 2011).   
 
1.3.3. GPR55 signal transduction  
There is a great deal of controversy as to whether cannabinoids activate GPR55.  
However there is consensus that the membrane derived lipid lysophosphatidylinositol 
(LPI) is an endogenous ligand for GPR55.  Originally LPI was found to activate 
ERK1/2 in a screening assay that had also looked at several cannabinoid ligands (Oka et 
al., 2007).  Whilst the cannabinoid ligands had shown no difference when compared to 
control HEK293 cells, HEK293 cells transiently transfected with human GPR55 were 
found to increase the phosphorylation of ERK1/2 when LPI was applied (Oka et al., 
2007).   
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Around the same time, Ca2+ mobilisation and the activation of the transcription factor, 
nuclear factor of activated T-cells (NFAT) had been studied and the signalling pathway 
elucidated, further confirming the effects of LPI activation on GPR55 (Henstridge et al., 
2009).  As mentioned previously LPI with an arachidonic fatty acid chain induced the 
most potent effects on  Ca2+ mobilisation and ERK1/2 phosphorylation (Oka et al., 
2009). Two heterotrimeric G-proteins have been implicated in GPR55-mediated 
signalling (Lauckner et al., 2008; Henstridge et al., 2009).  GPR55-mediated activation 
of Gα13 was first reported in the GlaxoSmithKline patent application (Brown and Wise, 
2001).  The second G-protein associated with GPR55 is Gαq which is involved in the 
mobilisation of Ca2+ (Lauckner et al., 2008; Obara et al., 2011).  In endothelial cells 
AEA promoted GPR55-mediated Ca2+ mobilisation is distinct requiring the activation of 
PI3K-Bmx-PLCγ signalling.  Moreover integrin clustering is necessary to release the 
inhibition of GPR55 Ca2+ signalling, mediated by CB1 activation (Waldeck-Weiermair 
et al., 2008).  It remains to be determined if Gα13 or Gαq are required for Ca2+ 
mobilisation in endothelial cells. 
 
GPR55 can also act on several kinase signalling pathways such as MAPK, PI-3-kinase 
and AKT.  Initially LPI was found to promote GPR55-mediated ERK1/2 
phosphorylation but several cannabinoids tested at the same time had no effect (Oka et 
al., 2007).  Recently evidence reported that certain cannabinoid ligands phosphorylate 
ERK1/2 by activating GPR55 (Henstridge et al., 2010; Anavi-Goffer et al., 2012).  
Furthermore Anavi-Goffer et al., (2012) report that SR141716A can both activate and 
inhibit GPR55-mediated ERK1/2 phosphorylation.  They describe for the first time that 
there may be an orthosteric and allosteric binding site present on GPR55.  Previously 
AM251 and SR141716A, CB1 antagonists are reported as agonists of GPR55 (Kapur et 
al., 2009; Yin et al., 2009; Henstridge et al., 2010).  However SR141716A can also act 
as a GPR55 antagonist (Lauckner et al., 2008; Piñeiro et al., 2011).  The discovery of a 
potential allosteric site on GPR55 may help to explain the discrepancies with 
SR141716A (Anavi-Goffer et al., 2012).  The aforementioned studies were carried out 
in recombinant GPR55 over-expressing systems however ERK1/2 phosphorylation is 
also reported in cell-types endogenously expressing GPR55.  Murine BV2 microglia 
cells treated with interferon γ (INFγ) produced a concentration-dependent increases in 
LPI induced ERK1/2 phosphorylation (Pietr et al., 2009).  ERK phosphorylation is also 
reported in some cancer cells treated with LPI (Andradas et al., 2011; Piñeiro et al., 
2011).  Another kinase thought to be downstream of GPR55 is AKT.  Modulation of 
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GPR55 expression in breast and glioblastoma cancer cells did not alter AKT 
phosphorylation suggesting it is not required for the proliferation of these cancer cell 
types (Andradas et al., 2011).  However when LPI was applied to prostate cancer cells 
GPR55 mediated AKT phosphorylation was observed (Piñeiro et al., 2011).  Overall 
GPR55 has the ability to influence multiple signalling pathways when activated.  These 
include signalling to transcription factors such as NFAT (Henstridge et al., 2009), 
CREB and NFκB (Henstridge et al., 2010) suggesting GPR55 may be important for 
transcription of genes such as c-Fos (Andradas et al., 2011).   
 
1.3.4. (Patho)physiology of GPR55 
The pathophysiological role of GPR55 has still to be fully elucidated.  Several studies 
are now highlighting pathologies where GPR55 may be important.  GPR55 is thought to 
have a role in cancer (Ford et al., 2010; Andradas et al., 2011; Piñeiro et al., 2011), 
immune regulation (Pietr et al., 2009; Balenga et al., 2011), pain modulation (Staton et 
al., 2008; Schuelert and McDougall, 2011), diabetes, obesity (Moreno-Navarrete et al., 
2012) and osteoarthritis (Whyte et al., 2009).   The lack of GPR55-specific antagonists 
has made deciphering GPR55 pathophysiology difficult at the present time.  To 
overcome this problem the use of siRNA targeting GPR55 has helped to decipher the 
effects that are mediated by GPR55.  This has been successful in studies with prostate 
cancer cells where increases in AKT and ERK1/2 phosphorylation and 
Ca2+ mobilisation are all mediated by GPR55 (Piñeiro et al., 2011).  However siRNA 
applied to breast cancer cells did not lower the endogenous level of GPR55 in the cells 
however when the cells were transiently transfected with GPR55 and then siRNA was 
applied the GPR55 level lowered suggesting that the siRNA was lowering the 
expression of the  transfected GPR55 (Ford et al., 2010).  Many other studies have 
employed GPR55 siRNA to gain an understanding of the effect GPR55 has in areas as 
diverse as neuroprotection (Kallendrusch et al., 2013), breast and brain cancer 
proliferation (Andradas et al., 2011) and Ca2+ mobilisation in endothelial cells 
(Waldeck-Weiermair et al., 2008).  Another method for deciphering GPR55 mediated 
effects is to use GPR55(-/-) mice.  GPR55(-/-) mice were generated and have allowed 
assessment of inflammatory pain (Staton et al., 2008).  The knockout mice have also 
highlighted that GPR55 is necessary for regulating increases in bone mass (Whyte et al., 
2009).  These mice are valuable tools in understanding the physiological processes 
mediated by GPR55 and allow an understanding of the effects GPR55 has on human 
physiology (Hall et al., 2009). 
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1.3.4.1. GPR55 and cancer 
GPR55 is expressed in several types of cancer derived from the brain, cervix, pancreas 
(Andradas et al., 2011), breast (Ford et al., 2010; Andradas et al., 2011), skin (Andradas 
et al., 2011; Pérez-Gómez et al., 2013), blood (Oka et al., 2010), ovaries and prostate  
(Piñeiro et al., 2011).  GPR55-mediated cancer cell proliferation is induced by LPI with 
the MAPK pathway playing an important role especially in aggressive cancer (Andradas 
et al., 2011).  Early studies with LPI reported that the lipid was synthesised by PLA2 in 
k-ras oncogene transformed fibroblasts where the concentration rose to three times that 
observed in normal fibroblasts (Falasca and Corda, 1993).  A subsequent study 
highlighted that k-ras oncogene transformed rat thyroid cells were also found to have an 
accumulation of LPI due to the increased activity of PLA2 (Falasca and Corda, 1994).  
Moreover LPI accumulated in the extracellular medium of neoplastic fibroblasts and 
was found to promote the proliferation of these cells an effect that was not observed in 
normal fibroblasts (Falasca, et al., 1998).  LPI was also found to accumulate in the 
ascites of women with ovarian cancer (Xiao et al., 2001; Sutphen et al., 2004).  Late 
stage and recurrent ovarian cancer samples were found to have higher concentrations of 
unsaturated LPI (Shen et al., 2001).  These results suggested that LPI is being released 
from cancer cells into the tumour microenvironment and then could promote effects in 
an autocrine manner on at the time an unknown membrane target.  Therefore late stage 
ovarian cancer cells that have GPR55 present may have exacerbated effects, such as 
proliferation, due to their tumour microenvironments (ascites) containing the more 
biologically active LPI species which could then act upon GPR55 present in the cells 
that are releasing LPI.  Furthermore the prostate cancer cell line, DU145 confirmed LPI 
was generated in cancer cells through the activation of cytosolic PLA2 (cPLA2).  
Application of cPLA2-siRNA decreased the proliferation of PC3 prostate cells, using an 
anchorage independent assay, when compared to scrambled cPLA2-siRNA but could be 
recovered by exogenous application of LPI.  Furthermore [3H]-LPI when applied to PC3 
cells accumulated in the extracellular medium and further experiments concluded that 
the ABCC1 transporter was involved in the release of LPI from the cytosol as 
knockdown of ABCC1 inhibited the accumulation of [3H]-LPI in the extracellular 
medium.  Therefore LPI is thought to act in an autocrine manner to augment the effects 
of LPI on the PC3 prostate cancer cells (Piñeiro et al., 2011).  Proliferation mediated by 
GPR55 has also been observed in breast cancer and glioblastoma cell lines and 
correlated with an increase in the percentage of cells exhibiting the proliferation marker, 
Ki67 (Andradas et al., 2011).  Indeed this effect was also observed in vivo where there 
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was an increase in proliferation of cells in a xenograft glioblastoma assay (Andradas et 
al., 2011).  Overall the presence of GPR55 increased the proliferative effect in several 
cancer cell types and this was reversed with GPR55 knockdown.  However one study 
has reported contradictory effects where application of O-1602 and AEA-induced 
GPR55 activation which was anti-proliferative in cholangiocarcinoma both in vitro and 
in vivo (Huang et al., 2011).  The effects were found to require Gα12, JNK, lipid rafts 
and the FAS receptor suggesting that either the discrepancies may be due to the effects 
being cell type specific or may be due to  ligand biased signalling via GPR55 in this cell 
type. 
 
Furthermore two breast cancer cell lines; MCF-7 and MDA-MB-231 were found to 
express GPR55 mRNA.  Higher GPR55 mRNA expression was found in the MDA-MB-
231 cells which are known to have a higher metastatic capability than the MCF-7 cells 
(Ford et al., 2010).  The authors observed the MCF-7 cells did not migrate towards 
serum and LPI had no effect in a Boyden chamber assay.  However increasing the 
expression of GPR55 by transiently transfecting GPR55 cDNA into MCF-7 cells led to 
the development of a migratory phenotype more typical of the MDA-MB-231 cells, 
whereby the cells could now migrate towards the serum an effect which was enhanced 
when LPI was present.  Furthermore the invasiveness of MCF-7 cells was greater when 
GPR55 expression was increased by prior transient transfection of GPR55.  The MDA-
MB-231 cells also exhibited an elongated phenotype which exhibited polarity when 
plated on grooved substrata.  These results suggest GPR55 is important for polarity, 
migration and invasion in breast cancer cells (Ford et al., 2010).   
 
1.3.4.2. GPR55 and the immune system 
Staton et al. (2008) studied neuropathic and inflammatory pain using GPR55 knockout 
mice and wild type controls.  Levels of both pro-inflammatory and anti-inflammatory 
cytokines were found to increase in GPR55(-/-) when compared to GPR55(+/+).  These 
results suggest that GPR55 has a role in the regulation of the production of certain 
cytokines (Staton et al., 2008).  Mast cells are mediators of inflammatory events and as 
such are important in inflammatory mediated angiogenesis.  Mast cells activated by the 
phorbol ester; 12-O-Tetradecanoylphorbol-13-acetate (TPA) promoted the release of 
nerve growth factor.  This concentration of TPA induced nerve growth factor was lower 
when cannabinoid like ligand palmitoylethanolamine (PEA) was applied to human 
mastocytic cells (HMC-1).  However neither CB1 or CB2 were expressed in HMC-1 
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cells (Cantarella et al., 2011).  Previously PEA has been reported to be a GPR55 agonist 
(Ryberg et al., 2007).  Application of GPR55 siRNA did not lower the TPA induced 
concentration of nerve growth factor in HMC-1 cells challenged with PEA suggesting 
that PEA induced GPR55 activation promotes an anti-inflammatory effect by inhibiting 
the release of nerve growth factor in HMC-1 cells (Cantarella et al., 2011).   
 
Recent studies utilising western blotting techniques have shown that p38 mitogen 
activated protein kinase (p38 MAPK) and activating transcription factor 2 (ATF2) are 
both phosphorylated when treated with 1 μM LPI.  The study utilised stably transfected 
hGPR55-HEK293 cells and IM9 lymphoblastoid cells.  The IM9 cells are derived from 
B-cells which are immune cells found in the spleen and that the group found to 
endogenously express GPR55 mRNA (Oka, et al., 2010).  Treatment with GPR55 
siRNA reduced the level of p38 MAPK and ATF2 phosphorylation in these cells 
suggesting that the phosphorylation is dependent on GPR55 (Oka, et al., 2010).   
 
GPR55 expression is also found in human neutrophil (HL60) cells.  To allow effective 
neutrophil migration GPR55 and CB2 are reported to act in a synergistic manner in the 
HL60 cells.  Application of both AM251 (GPR55 agonist) and 2-AG (CB2 agonist) 
increased the migration observed with HL60 cells compared to either agonist alone.  
Moreover an elongated migratory phenotype was only observed when both agonists 
were applied together.  The migration was sensitive to both GPR55 and CB2 
antagonism.  Furthermore the two receptors also promote cross talk to inhibit the 
formation of reactive oxygen species and neutrophil degranulation.  Moreover the 
crosstalk between GPR55 and CB2 is mediated by the small Rho GTPases (Balenga et 
al., 2011).   
 
Recently GPR55 is suggested to possibly play a role in multiple sclerosis.  
GPR55(+/+) and GPR55(-/-) mice with a C57BL/6 genetic background were immunised 
with myelin oligodendrocyte glycoprotein 35-55 peptide (MOG35-55) to promote 
experimental autoimmune encephalomyelitis (EAE); a model of multiple sclerosis.  The 
GPR55(-/-) mice were less susceptible to the development of EAE than wild type 
littermates.  The development of EAE was lower in female GPR55(-/-) mice when 
compared to both wild type littermates and male GPR55(-/-) mice.  The authors also 
report that changing the genetic background can influence the disease severity.  The 
ABH genetic background for GPR55(-/-) mice followed the trend of female mice having 
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a lower severity of EAE but this was not as prominent as had been seen with the mice of 
with a C57BL/6 genetic background (Sisay et al., 2013). 
 
1.3.4.3. GPR55 and pain 
GPR55 has been highlighted to play a role in mediating sensitivity to pain.  
Hyperalgesia to mechanical stimuli after the application of Freund’s complete adjuvant 
(FCA) was not observed for two weeks after the injection of FCA in male GPR55(-/-) 
mice.  Moreover partial ligation of the sciatic nerve in both male and female GPR55(-/-) 
mice did not promote hyperalgesia to mechanical stimuli for four weeks.  Furthermore 
GPR55 knockout animals displayed a resistance to inflammatory and neuropathic pain 
(Staton et al., 2008).  GPR55 is a suggested target inducing pro-nociception in a rat 
chronic constriction injury (CCI) model. Application of O-1602 was found to increase 
the pain sensitivity of the rat paw in this neuropathic pain model (Breen et al., 2012).  
Furthermore in a rat model of arthritis, application of O-1602 decreased nociception of 
the knee joint (Schuelert and McDougall, 2011).  The O-1602 anti-nociceptive effects 
were mediated by un-myelinated C-fibres and were unaffected by application of the 
antagonists to CB1 and CB2; AM281 and AM630 respectively. Moreover, application 
of O-1918 the Abn-CBD antagonist prior to application of O-1602 increased the 
sensitivity to pain suggesting that a novel target is mediating the effect with one 
possibility being GPR55 (Schuelert and McDougall, 2011).  However a caveat of the 
study is that O-1602 can also target the Abn-CBD receptor and therefore the effects may 
be mediated by GPR18 (McHugh et al., 2010).  Therefore further work using GPR55 
knockout animals would be required to confirm if GPR55 plays a role in these pain 
models.  
 
Recent evidence reports that GPR55 has a pro-nociceptive effect in peripheral sensory 
neurons in vivo (Gangadharan et al., 2013).  LPI challenge in Gα13(-/-) and Gαq(-/-) mice 
highlighted these G-proteins were important for the LPI induced mechanical 
hypersensitivity.  However the loss of mechanical hypersensitivity was greater in these 
mice than observed in the GPR55(-/-) mice suggesting that the LPI-induced sensitivity to 
pain in sensory neurons are only partially mediated by GPR55.  Moreover LPI partially 
lowered cancer associated pain in GPR55(-/-) mice (Gangadharan et al., 2013).  
Interestingly GPR55 can be extruded from cancer cells into the tumour 
microenvironment therefore sensory neurons in the vicinity of the tumour could 
potentially be activated by this increase in LPI concentration (Piñeiro et al., 2011).   
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Finally in contrast to the previous reports of GPR55 mediated pro-nociception, a recent 
study highlights that anti-nociception in mice treated with PEA and AM251 followed by 
an injection of formalin may be attributed to GPR55, however knockout mice would be 
required to substantiate this (Naderi et al., 2012).   
 
1.3.4.4. GPR55  and bone 
GPR55 mRNA is expressed in osteoclasts (bone resorption) and osteoblasts (bone 
formation) cells derived from humans or mice (Whyte et al., 2009).  GPR55 mediated 
the inhibition of O-1602-induced osteoclastogenesis as this effect was not observed in 
GPR55(-/-) mice.  LPI and O-1602 promoted osteoclast polarisation and bone resorption 
by GPR55 activating Rho and ERK1/2 signalling.  The activation of Rho and ERK1/2 
was not observed in osteoclasts derived from GPR55 knockout mice.  There were subtle 
differences as LPI induced ERK1/2 phosphorylation which was decreased in cells pre-
treated with cannabidiol (CBD).  However the CBD decrease in ERK1/2 
phosphorylation was not significant.  Furthermore Rho activation was increased with O-
1602 and LPI however prior treatment with CBD was found to significantly lower the 
O-1602 induced Rho activation.  In contrast the LPI increased Rho activation but was 
not significantly lowered with CBD pre-treatment.  The authors noted that ligand bias 
may promote these signalling differences (Whyte et al., 2009).  O-1602 and LPI-
induced Rho activation was mediated through GPR55 as osteoclasts derived from 
GPR55(-/-) mice exhibited Rho levels that were decreased compared to wild type 
osteoclasts (Whyte et al., 2009).  Furthermore bone volume was increased due to a 
decrease in bone resorption in male GPR55(-/-) mice. The authors noted that there was an 
increase in the number of osteoclasts but they were found to be inactive.  Interestingly 
these effects are present in an osteopetrotic phenotype.   GPR55 may therefore have a 
role in osteoporosis, arthritis and bone cancer pain (Ross, 2011).   
 
1.3.4.5. GPR55 and the cardiovascular system 
Originally, as mentioned before, studies with mesenteric arteries had highlighted that 
Abn-CBD could activate a novel cannabinoid receptor to promote vasodilatation as 
these effects remained in double knockout mice CB1(-/-)/CB2(-/-) (Járai et al., 1999; 
Offertáler et al., 2003).  This novel receptor was primarily considered to be GPR55 but 
was then discounted as the vasodilatation remained in GPR55(-/-) mice (Johns et al., 
2007).  GPR55 has since been visualised in mesenteric arterial smooth muscle cells 
through the use of T1117 a fluorescent tetramethylrhodamine attached to AM251 (Daly 
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et al., 2010).  Whilst AM251 is an antagonist of CB1 receptors (Pertwee, 2006) it is also 
an agonist of GPR55 (Henstridge et al., 2010).  Ca2+ mobilisation occurred when T1117 
was applied to hGPR55-HEK293 cells an effect that was attenuated in control HEK293 
cells.  However T1117 was found to be inactive at CB1 receptors (Daly et al., 2010).  
Furthermore application of O-1602 prior to application of T1117 reduced the 
fluorescence observed suggesting that O-1602 had internalised GPR55 before T1117 
was applied.  GPR55 was found to be localised to the three layers of the arteries; the 
tunica media, adventitia and endothelium (Daly et al., 2010). 
 
In human umbilical vein endothelial cells (HUVEC), GPR55 is reported to mediate Ca2+ 
mobilisation.  However the GPR55 mediated Ca2+ mobilisation in HUVEC cells 
depends on the configuration of integrins in the cell membrane.  When integrins were 
clustered GPR55 mediated Ca2+ mobilisation was seen as the inhibition that had 
previously been exerted by the CB1 receptor was diminished (Waldeck-Weiermair et 
al., 2008).  AEA applied in the presence of extracellular Ca2+ was found to initiate 
signalling through CB1 which activated spleen tyrosine kinase (Syk) which then inhibits 
PI-3-kinase; which is required for GPR55 signalling to occur.  It is the action of integrin 
clustering which then negatively regulates Syk promoting the uncoupling of CB1 and 
the β1 integrin thereby allowing AEA-induced GPR55 mediated Ca2+ mobilisation to 
occur in the HUVEC cells (Waldeck-Weiermair et al., 2008).  Furthermore LPI applied 
to HUVEC cells promoted the mobilisation of Ca2+ and membrane hyperpolarisation 
which was augmented when GPR55 expression was increased by transient transfection 
and was diminished when GPR55-siRNA was present (Bondarenko et al., 2010).  
Previously LPI was found to be increased in bradykinin stimulated endothelial cells 
through the activation of PLA2 (Kaya et al., 1989).  This could allow LPI to act in an 
autocrine manner on targets in the endothelial cells.  Moreover the depolarising current 
in endothelial cells was GPR55-independent.  LPI can exert direct effects by acting on 
ion channels and therefore may have a role in membrane potential.  LPI triggered the 
hyperpolarisation of endothelial cells by acting directly on intermediate conductance 
Ca2+ activated K+ (IKCa) channels (Bondarenko et al., 2011).  Furthermore LPI can also 
act on endothelial large-conductance Ca2+ and voltage-gated K+ (BKCa) channels 
suggesting that LPI effects in endothelial cells are partially mediated by GPR55 with 
LPI induced ion channel activation also playing a role (Bondarenko et al., 2011). 
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More recently GPR55 mRNA was expressed in rat neonatal ventricular cardiomyocytes 
and divergent signalling events were dependent on GPR55 localisation.  Application of 
LPI extracellularly to GPR55 located at the cell membrane promotes depolarisation that 
is Ca2+ independent.  However application of LPI to intracellular GPR55 hyperpolarises 
the cardiomyocyte membrane and was found to be Ca2+ dependent.  The effects of LPI 
were antagonised by the application of a novel GPR55 antagonist ML-193 (Kotsikorou 
et al., 2013; Yu et al., 2013; Zhao and Abood, 2013). 
 
Angiogenesis may also be GPR55-mediated by a novel N-acyl amino acid; N-
arachidonoyl-L-serine, an ‘endocannabinoid-like’ lipid (Zhang et al., 2010).   Migration 
of endothelial cells was partially reduced when GPR55-siRNA was present and the tube 
formation was also partially inhibited with GPR55 knockdown (Zhang et al., 2010).  
Application of O-1918 inhibited the tube formation when GPR55 was present but had 
no effect when GPR55 was knocked down (Zhang et al., 2010).  O-1918 has previously 
been reported as inhibiting the effects of the Abn-CBD receptor in endothelial cells 
(Offertáler et al., 2003).  However, it remains to be determined if O-1918 is a GPR55 
antagonist. 
 
1.3.4.6. GPR55 and the nervous system 
The role of GPR55 in the brain is still in its infancy at the present time.  However 
research is beginning to reveal pathologies where GPR55 may be of importance.  
GPR55 mRNA is expressed in the central nervous system (high to low abundance) in 
the frontal cortex, striatum, hypothalamus, brain stem, hippocampus, cerebellum and 
spinal cord and is localised in regions where CB1 was also present (Ryberg et al., 2007).  
Whereas another study reported GPR55 mRNA in the striatum >  hippocampus > 
forebrain > cortex > cerebellum (Wu et al., 2013).  Furthermore LPI is present in brain 
(37.5 nmol/g tissue).  Furthermore the second most common LPI composition in the rat 
brain contains the arachidonic fatty acid which is reported as the most potent form to 
activate GPR55  (Oka et al., 2009).   Recently GPR55 expression was reported to be co-
localised with vesicular glutamate transporter 1 (vGLUT1), the synaptic vesicle protein 
in the CA1 region of the hippocampus.  Acute hippocampal slices when treated with 
LPI were found to increase miniature excitatory postsynaptic currents (mEPSCs) in 
neurons in CA1 pyramidal cells and was sensitive to the GPR55 antagonist CBD 
(Sylantyev et al., 2013).  Moreover presynaptic Ca2+ mobilisation was required for the 
mEPSCs as store depletion abolished the responses.  GPR55 activation associated with 
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neurotransmitter release and did not affect Ca2+ mobilisation postsynaptically 
(Sylantyev et al., 2013).  This emerging data suggests that GPR55 may be important in 
synaptic plasticity. 
 
Microglia are the macrophages of the brain and are known to express cannabinoid 
receptors (Walter et al., 2003).  Quantitative real time polymerase chain reaction 
(qPCR) was employed by Pietr et al., (2009) to compare the levels of CB1, CB2 and 
GPR55 mRNA in both primary mouse microglial and in BV-2 cells.  A low level of 
expression of CB1 receptors were found in the BV-2 cells, (Pietr et al., 2009) which 
correlates with the low expression of CB1 previously seen in primary microglial (Walter 
et al., 2003).  There were higher levels of expression of both CB2 and GPR55 receptors 
in both types of cells.   It was found that when the BV-2 cells were treated with INF-γ to 
produce ‘primed’ cells there was an increase in the level of GPR55 mRNA expression. 
However, this was not seen in the primary microglial cells (Pietr et al., 2009).  The BV-
2 cell line when treated with LPS (‘activated’ cells) lead to both the CB2 and GPR55 
mRNA expression levels being lowered (Pietr et al., 2009).  Therefore this is in 
agreement with previous studies where the expression of CB2 mRNA is dependent on 
the activation state of microglia (Lee et al., 2001; Carlisle et al., 2002).  In a recent 
study conditioned media from LPS activated BV-2 cells was applied to SH-SY5Y 
neuroblastoma cells.  Application of Abn-CBD and O-1602 to these SH-SY5Y cells 
promoted protection against microglial induced neurotoxicity however it remains to be 
determined if this protection is mediated by GPR55 (Janefjord et al., 2013).   
 
Immunohistochemical studies report that GPR55 is also expressed in large diameter 
(>35 µm) dorsal root ganglion (DRG) neurons.  Application of LPI promoted the 
mobilisation of Ca2+ in the large DRG neurons.  Furthermore activation of GPR55 
inhibits the M-current suggesting that GPR55 may have a role in promoting neuronal 
excitability (Marrion, 1997; Lauckner et al., 2008).  In a model of neurodegeneration 
using rat organotypic hippocampal slice cultures (OHSC) GPR55 activated by LPI was 
found to protect the dentate gyrus cells and decrease the number of activated microglia 
(Kallendrusch et al., 2013).  Immunocytochemical labelling of degenerating neurons 
and activated microglia were found to be decreased in OHSC which had been lesioned 
with NMDA prior to application of LPI when compared to NMDA lesion alone.  
Moreover higher concentrations of LPI decreased the microglial numbers whereas lower 
concentrations were found to protect the neurons with little or no effect on the number 
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of microglia present (Kallendrusch et al., 2013).  GPR55 is reported to be important for 
motor co-ordination as GPR55(-/-) mice did not perform as well as wild type littermates 
in a rotarod test. Also GPR55(-/-) mice were found to produce more footslips when 
walking on parallel rods (Wu et al., 2013).  However GPR55(-/-) mice retained the ability 
to learn and therefore improved in the rotarod test with training.  Both knockout mice 
and wild type littermates did not exert differences in anxiety/depression, grip strength, 
fear conditioning or auditory function each of which could have affected the rotarod test 
highlighting that motor co-ordination was affected but was not due to lack of grip 
strength or vestibular disturbance (Wu et al., 2013).  Furthermore LPI was found to 
promote [35S]GTPγS binding in the prefrontal cortex and the hippocampus.  The 
receptor that LPI binds to in this study was not determined however the authors 
speculate that it may be GPR55 due to the presence of GPR55 mRNA in the brain (Rojo 
et al., 2012).  Therefore further studies with GPR55(-/-) animals would help to confirm 
this hypothesis. 
 
1.3.4.7. GPR55 and the gastrointestinal system 
GPR55 mRNA was found in regions of the gastrointestinal (GI) tract; the ileum (Ryberg 
et al., 2007; Lin et al., 2011; Li et al., 2013), jejunum (Ryberg et al., 2007), duodenum 
(Lin et al., 2011) and colon (Lin et al., 2011; Li et al., 2013).  GPR55 was localised to 
the mesenteric neurons of the colon (Li et al., 2013).  GPR55 expression was higher in 
the ileum and to a lesser extent in the colon and duodenum when the gut had been 
subjected to lipopolysaccharide (LPS) to induce inflammation of the gut (Lin et al., 
2011).  In one study O-1602 was applied to neutrophils derived from wild type mice 
and was observed to inhibit the neutrophil chemotaxis.  When O-1602 was applied to 
neutrophils derived from GPR55(-/-) mice the inhibition of neutrophil chemotaxis to the 
bacterial peptide N-formyl-peptide receptor ligand (fMLP) remained suggesting that the 
effect was not mediated by GPR55 (Schicho et al., 2011) but through an unknown 
target possibly GPR18 (McHugh et al., 2012).  However in studies looking at 
contraction of the gut GPR55 mediated effects were found.  Using electric field 
stimulation to induce neurogenic effects in colonic strips derived from GPR55(-/-) mice 
O-1602 was found to decrease contractility  compared to  colonic strips derived from 
either double CB1(-/-)/CB2(-/-) mice or wild type controls (Ross et al., 2012).  Therefore 
GPR55 mediated neurogenic activity slowed gut contractions in colonic strips when 
challenged with O-1602 (Ross et al., 2012).  A subsequent study also confirmed that O-
1602 slowed the gut transit times and led to a slower rate of peristaltic expulsion in wild 
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type mice.   Therefore suggesting that the slowing of gut motility are GPR55-mediated 
as GPR55(-/-) mice had a shorter transit time and peristaltic expulsion was faster (Li et 
al., 2013).   
 
1.3.4.8. GPR55 in energy metabolism 
Plasma LPI levels are found to be higher in obese patients when compared to lean 
patients.  Moreover GPR55 expression is higher in the visceral and subcutaneous 
adipose tissue from the obese patients.  Studies on Type II diabetics also highlighted 
that GPR55 expression is increased in visceral adipose tissue (Moreno-Navarrete et al., 
2012).  Visceral adipose tissue is correlated with the development of insulin resistance 
which then leads to Type II diabetes, cardiovascular disease, obesity which ultimately 
lead to metabolic syndrome (Lebovitz and Banerji, 2005).  Furthermore GPR55 protein 
is expressed in pancreatic β-cells, the insulin secreting cells.  GPR55 however is not 
expressed in pancreatic α and δ-cells (Romero-Zerbo et al., 2011).  Activation of 
GPR55 with both synthetic and endogenous agonists promotes the release of insulin in 
clonal pancreatic β (BRIN-BD11) cells which was dependent on Ca2+ mobilisation and 
partially via cAMP with increased insulin release when glucose was also present 
(glucose stimulated insulin secretion).  Abn-CBD was found to be the most potent and 
selective for GPR55.  However AM251, O-1602 and the N-acyl amides; OEA and PEA 
also stimulated insulin release by activating GPR55 but these effects were less GPR55 
specific suggesting that other targets are also present in the BRIN-BD11 cells 
(McKillop et al., 2013).  Moreover a previous study also reported that O-1602 promoted 
insulin release in pancreatic β-cells stimulated with glucose.  The authors confirmed that 
Abn-CBD also activated GPR55 in murine derived pancreatic islet cells which 
decreased glucose concentrations and increased insulin release.  The insulin release was 
lowered in GPR55(-/-) mice suggesting that GPR55 mediated the increases in insulin 
secretion (Romero-Zerbo et al., 2011).  Another set of researchers found that lipid 
storage induced by O-1602 was GPR55 independent as GPR55(-/-) mice exhibited a 
higher food intake when compared to wild type littermates (Díaz-Arteaga et al., 2012).  
More specific GPR55 agonists would be of benefit in better understanding GPR55 and 
energy metabolism.  However GPR55 is a promising target for type II diabetes research. 
 
1.4. Lipid signalling 
Originally lipids were described as structural components of the lipid bilayer of cells 
(Singer and Nicolson, 1971).  Lipids are hydrophobic molecules that play an important 
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role in biological membranes providing a barrier between external environments and the 
internal cytosolic region of cells (Singer and Nicolson, 1972; Piomelli et al., 2007).  It is 
now acknowledged that membrane lipids are also important precursors for the synthesis 
of bioactive lipids.  Bioactive lipids have the ability to  activate signalling pathways by, 
for example, lipid binding and subsequent activation of GPCRs (Wenk, 2005).  
Imbalances in bioactive lipids have consequences in the progression of several diseases 
such as autoimmunity, inflammation, obesity and cancer to name but a few (Wymann 
and Schneiter, 2008; Hu et al., 2009).  Lysophospholipids are thought to have the 
potential as biomarkers for the diagnosis of certain gynaecological cancers (Xiao et al., 
2001; Sutphen et al., 2004).  Interestingly, LPA/LPI species that contain unsaturated 
fatty acid chains are more prominent in women with late stage or a re-occurrence of 
ovarian cancer (Shen et al., 2001).  Indeed, both lysophosphatidic acid (LPA) and L-α-
lysophospatidylinositol (LPI) occur at elevated levels in the ascites of women with 
ovarian cancer when compared to healthy controls (Sutphen et al., 2004).  However, 
more recent studies have started to uncover a role for bioactive lipids in cell signalling.  
Several bioactive lipids are known to act upon GPCRs to initiate intracellular signalling. 
 
1.4.1. Sphingosine-1-phosphate 
Sphingosine 1-phosphate (S1P) is a bioactive lipid which is synthesised intracellularly 
from phosphorylation of sphingosine by sphingosine kinases; sphingosine kinase 1 and 
2 (Spiegel and Milstien, 2003).  S1P is then pumped out of the cell through ABCC 
transporters where it can then act in an autocrine or paracrine manner on receptors in the 
membrane in a process known as ‘inside-out signalling’ (Kunkel et al., 2013).  
Degradation of S1P requires the actions of  S1P lysase or S1P phophatases (Ishii et al., 
2004; Kunkel et al., 2013).  S1P is stored at high concentrations in platelets and 
released when they are activated (Yatomi et al., 1995; Moolenaar, 1999; Ishii et al., 
2004).  The concentration of S1P in blood ranges from 200 nM - 800 nM and it is bound 
to serum albumin and lipoproteins (Ishii et al., 2004).  Originally S1P had been 
observed to cell growth by an as yet unknown target (Zhang et al., 1991).  However Lee 
et al., (1998) transfected the clone of endothelial cell differentiation gene (Edg) 1 into 
HEK293 cells as these cells do not endogenously express Edg1.  Several lipids from 
serum such as LPA and LPI were then tested and only S1P was found to induce changes 
in morphology in Edg1 transfected HEK293 cells (Lee et al., 1998).  This study 
deorphanised the Edg1 receptor and highlighted S1P as a bioactive lipid (Lee et al., 
1998).   Subsequent studies led to the discovery of another four orphan S1P receptors all 
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of which belong to the subset of Edg GPCRs.  To date a total of five S1P receptors 
exist, S1P1-5 (Spiegel and Milstien, 2003).  Three other receptors are part of the Edg 
family of receptors but are not activated by S1P, rather by another bioactive lipid known 
as lysophosphatidic acid; LPA (Meyer zu Heringdorf and Jakobs, 2007). 
 
1.4.2. Lysophsophatidic acid 
LPA is a mitogenic bioactive lipid which acts on GPCRs (Ishii et al., 2009).  LPA is 
known to act extracellularly on at least 6 GPCRs.  The first three LPA receptors are 
similar sharing a homology of 50-57%  (Noguchi et al., 2003; Ishii et al., 2009).  LPA1-
3 are members of the Edg group of GPCRs and as such are phylogenetically related to 
the S1P receptors.  Activation of LPA1-3 induces signalling that promotes activation of 
MAPK, mobilisation of Ca2+ and inhibition of cyclic AMP (Noguchi et al., 2003).   
Studies on LPA1(-/-) and LPA2(-/-) revealed that other LPA receptors must exist.  This led 
through reverse pharmacological approaches to the discovery and subsequent cloning of 
LPA4/GPR23 (Noguchi et al., 2003); LPA5/GPR92 (Lee et al., 2006) and LPA6/P2Y5 
(Pasternack et al., 2008).  These receptors are structurally distinct from LPA1-3 
receptors, being more related to the purinergic GPCR cluster.  Activated platelets, 
adipocytes and neurons produce LPA (Ishii et al., 2004).  LPA is derived from the 
biosynthesis of membrane phospholipids by three synthesis pathways; the 
phospholipase A1 (PLA1) and secretory PLA2 deacylating phosphatidic acid, lyso-PLD 
or autotaxin catalysis of lysophosphatidylcholine or by phosphorylation of 2-AG by 
acylglycerol kinase (Meyer zu Heringdorf and Jakobs, 2007).  Metabolism of LPA is 
via dephosphorylation with a lipid phosphate phosphatase (Brindley and Pilquil, 2009).  
LPA plays a role in several biological processes such as neurite retraction (Lee et al., 
2007; Yanagida et al., 2007), cell survival, wound healing (Ishii et al., 2004) and cancer 
progression (Mukherjee et al., 2012).  LPA in the blood is bound to serum albumin and 
lipoproteins (Ishii et al., 2004).  Physiologically LPA in serum ranges between 100 nM 
and 25 µM (Tigyi and Miledi, 1992; Ishii et al., 2004).  Furthermore LPA is present at 
higher levels in the ascites and serum of ovarian cancer patients when compared to 
control patients (Sedláková et al., 2011).  It was found that 90% of patients with early 
stage I ovarian cancer had elevated levels of LPA.  LPA2 and LPA3 were found to be 
up-regulated in ovarian cancer patients and were absent in control individuals 
(Sedláková et al., 2011).  Interestingly LPA acts on the non-EDG receptors GPR23, 
GPR92 and P2Y5 which are phylogenetically closest to GPR55 (Fredriksson et al., 
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2003; Baker et al., 2006).   Furthermore LPA is structurally similar to LPI however, 
unlike LPI it does not activate GPR55 (Oka et al., 2007; Henstridge et al., 2009).  
 
1.4.3. L-α-lysophosphatidylinositol 
LPI is a product from the hydrolysis of cell membrane-derived phosphatidylinositol (PI) 
where a free fatty acid is released resulting in the generation of LPI (Yamashita et al., 
2013).  In the 1960s the acylation of LPI by acyl CoA to form PI was described 
(Keenan and Hokin, 1964).  By the early 1980s activated platelets were found to 
generate LPI by PI deacylation through the actions of phospholipase A2; PLA2 (Billah 
and Lapetina, 1982).  PLA hydrolyses the acyl bond of the membrane derived lipid, 
phosphatidylinositol at either the sn-1 or sn-2 position to generate a free fatty acid and 
LPI (Bonventre, 1992).  With PLA1 or PLA2 cleaving the fatty acid chains at either the 
sn-1 or sn-2 position respectively.  PLA1 is localised both extracellularly and 
intracellularly.  An increase in Ca2+ is required to stimulate the PLA1 DDHD domain 
containing 1 (DDHD1) which in turn hydrolyses PI forming LPI and its activity can be 
modulated by phospholipase D acting on phophatidic acid (Yamashita et al., 2010).  
Arachidonic acid being polyunsaturated is in general found at the sn-2 position as would 
other polyunsaturated fatty acids (Yamashita et al., 1997).  Therefore as 2-arachidonyl 
LPI is the most potent LPI species to act on GPR55 and it is thought to be generated by 
hydrolysis of the fatty acid chain at the sn-1 position by intracellular PLA1 (Yamashita 
et al., 2010).  Cytosolic PLA2α isoform may also be responsible for the formation of 
LPI species (Mariggiò et al., 2006; Piñeiro et al., 2011).  Once LPI has been generated 
the lipid can be further metabolised.  LPI can be acylated to form PI via 1 acyl- or 2 
acyl-LPI acyltransferase.  Furthermore a specific LPI-PLC present in porcine platelets 
and rat brain can also metabolise LPI (2-arachidonoyl LPI) into the endocannabinoid 2-
AG (Tsutsumi et al., 1994; Kobayashi et al., 1996).  LPI can also be metabolised by 
phospholipase D (autotaxin) to form LPA in activated platelets (Aoki et al., 2002; 
Piñeiro and Falasca, 2012; Yamashita et al., 2013). 
 
LPI as a signalling mediator was first observed in pancreatic islets where application of 
LPI promoted insulin release (Metz, 1986).  Around the same time studies with 
macrophage RAW 264.7 cells treated with lipid X were found to accumulate LPI 
(Zoeller et al., 1987).  Also hepatocytes treated with 1,25-dihydroxyvitamin D 
displayed increases in cytosolic Ca2+ which was promoted by the deacylation of PI by 
PLA2 to form LPI.  When LPI was applied directly to hepatocytes Ca2+ mobilisation 
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was reported suggesting that LPI was mediating the 1,25-dihydroxyvitamin D induced 
Ca2+ mobilisation (Baran and Kelly, 1988).  LPI was also discovered to be synthesised 
by PLA2 in k-ras oncogene transformed fibroblasts where the concentration rose to 
three times of that observed in normal fibroblasts (Falasca and Corda, 1993).  A 
subsequent study highlighted that k-ras oncogene transformed rat thyroid cells were also 
found to have an accumulation of LPI due to the increased activity of PLA2 (Falasca 
and Corda, 1994).  Moreover LPI accumulated in the extracellular medium of neoplastic 
fibroblasts and was found to promote the proliferation of these cells an effect that was 
not observed in normal fibroblasts (Falasca et al., 1998).  It is now known that LPI 
concentrations from the plasma of healthy females is ~1.5 µM (Sutphen et al., 2004).  
Moreover the levels of LPI can increase significantly in late stage ovarian cancer 
patients or those with recurring ovarian cancer (Sutphen et al., 2004).  However the 
target for LPI was still unknown. 
 
The first study to uncover a molecular target for LPI was discovered when assessing the 
neuroprotective effect of lysophospholipids.  Application of LPI, 30 min before 
ischemia, promoted ~95% protection to hippocampal neurons in vivo in rats subjected to 
transient global forebrain ischemia.  Moreover in vitro glutamate induced neuronal cell 
death which was decreased in cultured cerebral granular cells treated with LPI.  The 
authors suggested that LPI may be acting upon 2 pore-domain K+ channels; TREK and 
TRAAK, to promote the neuroprotection (Blondeau et al., 2002) as LPI had been 
reported as a strong activator of TREK and TRAAK (Maingret, 2000).  LPI is also 
reported to activate members of the transient receptor potential family of cation 
channels.  Lysophospholipids including LPI induced Ca2+ mobilisation through the 
activation of TRPC5 (Flemming et al., 2006) and also modulates the temperature 
sensitivity required for TRPM8 (normally <25oC) activation to a physiological relevant 
37oC for channels expressed inside the body  (Andersson et al., 2007).  In the same year 
Ca2+ mobilisation and ERK1/2 phosphorylation were found to be induced by LPI 
through an oGPCR; GPR55 (Oka et al., 2007).  A plethora of papers followed; each 
confirming the effects of LPI on the activation of GPR55 not only in recombinant cell 
lines (Oka et al., 2007, 2009; Henstridge et al., 2009, 2010; Andradas et al., 2011) but 
also in cells that were shown to endogenously express GPR55 (Lauckner et al., 2008; 
Waldeck-Weiermair et al., 2008; Pietr et al., 2009; Whyte et al., 2009; Ford et al., 
2010; Andradas et al., 2011; Piñeiro et al., 2011; Pérez-Gómez et al., 2013).    
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1.4.4. Free fatty acids 
Free fatty acids (FFA) and lysophospholipids are the product of the action of PLA 
enzymes on the membrane derived lipids.  Evidence is growing that free fatty acids 
(FFA) can act on three FFA receptors; GPR40, GPR43 and GPR41 which were cloned 
in 1997 (Sawzdargo et al., 1997) and are now known as FFA1-3 respectively.  FFA1 is 
activated by medium and long chain FFAs; C6-22 (Briscoe et al., 2003; Stoddart et al., 
2008).  Whereas FFA2 and FFA3 are activated by short chain FFAs; C1-6 (Brown et al., 
2003; Stoddart et al., 2008).  FFA1 is expressed in pancreatic β-cells and when activated 
leads to insulin release.  Overstimulation can lead to β–cell dysfunction therefore FFA1 
is of interest as a therapeutic target pathologies such as obesity and type II diabetes 
(Costanzi et al., 2008).  FFA2 and FFA3 are expressed in pancreatic α- and β-cells 
moreover FFA2 is expressed in adipocytes and some immune cells.  FFA2 and FFA3 
may be a therapeutic target for metabolic syndrome and inflammatory bowel diseases 
however this is speculative as there is disparity in results from animal studies at the 
present time  (Offermanns, 2013).  Recently another two GPCRs can be activated by 
FFAs; GPR84 is activated by medium chain FFAs (C9-14) and GPR120 being activated 
by long chain FFAs (C14-22) however both these GPCRs share little homology with 
FFA1-3 (Stoddart et al., 2008).  GPR84 expression is up-regulated in tumour necrosis 
factor-α (TNF-α) stimulated adipocytes or in cultures where macrophages are present 
suggesting that GPR84 may be important in the development of inflammation induced 
insulin resistance in adipocytes (Nagasaki et al., 2012).  Recently mice lacking GPR120 
become obese and insulin resistant when fed a high fat diet.  Also a mutation of the 
GPR120 gene (p.R270H) within the European population predisposes those who 
express it to become obese.  Furthermore GPR120 is up-regulated in obese individuals 
(Ichimura et al., 2012).  Overall the FFA receptors are an emerging research field that 
offer potential novel therapeutic targets for metabolic disorders such as obesity and type 
II diabetes. 
 
1.4.5. N-acyl amino acids 
There is a growing interest in the ‘endocannabinoid-like’ N-acyl amino acids.  They are 
a family of more than 70 endogenous lipids and have a molecular structure that is 
similar to the two major endocannabinoids; AEA and 2-AG (figure 1.3;  Bradshaw et 
al., 2009).  The N-acyl amino acids despite being structurally similar to the 
endocannabinoids are found to have little or no affinity for cannabinoid receptors or 
TRPV1 (Sheskin et al., 1997; Milman et al., 2006; Smoum et al., 2010).  N-acyl amino 
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acids possess a fatty acid chain that is saturated, mono-saturated or unsaturated  
conjugated to an amino acid head group (Bradshaw et al., 2009; Tan et al., 2010).  
Furthermore many of the N-acyl amino acids remain orphans where the biological target 
and therefore their physiological function remains to be determined (Bradshaw et al., 
2009).  These lipids are of particular interest as they may be important endogenous 
activators of as yet unknown oGPCRs. 
 
 
Figure 1.3:  Endocannabinoids and structurally related N-acyl amino acids.  Chemical 
structures of the following families are A, endocannabinoids; B, N-acyl serines; C, N-acyl 
glycines.  Note that the structure of the endocannabinoids is similar to the N-acyl amino acids. 
  
1.4.5.1. N-arachidonoyl glycine 
The most studied N-acyl amino acid is N-arachidonoyl glycine (NAGly).  Originally 
synthetic NAGly was generated in the laboratory as a structural analogue of AEA and 
was found to have little affinity for CB1 or CB2 (Sheskin et al., 1997; Huang et al., 
2001).  However NAGly is  reported to activate several GPCRs; GPR18 (Kohno et al., 
2006; Yin et al., 2009; McHugh et al., 2010, 2012; Caldwell et al., 2013), GPR72 
(Hannedouche and Roy, 2010) and as a GPR92 partial agonist (Oh et al., 2008).  
NAGly does not activate TRPV1 as Ca2+ influx was not observed in TRPV1-HEK293 
N-arachidonoyl-L-serine
O-arachidonoylethanolamide
N-oleoyl-L-serine
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C
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cells (Huang et al., 2001) Endogenous NAGly was extracted from bovine brain (Huang 
et al., 2001).  Moreover NAGly was expressed in the following rat tissues; spinal cord > 
small intestine > kidney > glabrous skin > brain and lower expression in testes > lung > 
liver > blood > spleen and only modest expression in the heart (Huang et al., 2001).  
The widespread distribution of NAGly would suggest it may have a role in several 
physiological functions.   
 
At present most research on NAGly has been focused on pain and inflammation.  
Recent evidence highlights NAGly as having a role in pain and inflammation which is 
independent of cannabinoid receptors.  NAGly was found to inhibit formalin induced 
pain in rats and to lower inflammation (Huang et al., 2001).  Also a rat model of 
inflammatory pain; where Freund's complete adjuvant (FCA) was injected into the paw 
and reported to reduce mechanical allodynia and thermal hyperalgesia when the rats 
were treated with NAGly. This decrease in pain sensitivity was insensitive to 
cannabinoid antagonists (Succar et al., 2007).  Furthermore neuropathic pain is 
alleviated in rats with partial sciatic nerve ligation when NAGly is present highlighting 
an analgesic action.  Both arachidonic acid and glycine the metabolic products of 
NAGly did not affect mechanical allodynia.  The decrease in NAGly-induced 
mechanical allodynia was not sensitive to cannabinoid antagonists (Vuong et al., 2008).  
Recent evidence suggests that NAGly treatment in an in vivo model of peritonitis 
decreases the migration of leukocytes to sites of inflammation.   NAGly was also 
reported to increase the production of prostaglandin J and lipoxin A4 in vitro therefore 
NAGly may contribute to the resolution of inflammation (Burstein et al., 2011).   
 
Three biosynthesising pathways have been suggested for NAGly.  The first in situ 
NAGly synthesis occurs in rat brain from the precursors of arachidonic acid (AA) and 
glycine in a two-step process.  The enzyme arachidonyl-CoA synthetase is localised to 
brain, platelets and the aorta and is specific for AA conversion into arachidonyl-
coenzymeA (arachidonoyl-CoA).  The conjugation of glycine to arachidonyl-CoA 
requires a second enzyme; acyl-coenzyme A: glycine N-acyltransferase  (Huang et al., 
2001).  The second pathway involves the oxidation of AEA.  In a two-step enzymatic 
process alcohol dehydrogenases which oxidises ethanolamine of AEA to produce N-
arachidonoyl glycinal, an aldehyde intermediate which is then oxidised by an aldehyde 
dehydrogenase to form NAGly (Burstein et al., 2000).  Recent evidence suggests that 
FAAH may be part of the NAGly biosynthesis pathway through the hydrolysis of AEA 
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which generates arachidonic acid.  This arachidonic acid can then be conjugated glycine 
to produce NAGly.  Applying a FAAH inhibitor (URB 597) or using FAAH(-/-) mice 
promoted an increase in AEA but decreased NAG levels suggesting that FAAH is 
required for the biosynthesis of NAGly in vivo through the degradation of AEA 
(Bradshaw et al., 2009). 
 
1.4.5.2. N-arachidonoyl-L-serine 
Other arachidonic acid derived N-acyl amino acids have been extracted from the 
mammalian brain including N-arachidonoyl GABA, N-arachidonoyl alanine (Huang et 
al., 2001) and N-arachidonoyl serine (Milman et al., 2006).  N-arachidonoyl-L-serine 
(NASer) was isolated from bovine brain and found to have a structure similar to AEA 
differing only in the head group, a serine instead of an ethanolamine (Milman et al., 
2006).  In vitro, NASer can activate large conductance Ca2+ potassium channels (BKCa) 
(Godlewski et al., 2009) and N-type Ca2+ channels in sympathetic neurons (Guo et al., 
2008).  However there is some controversy as to whether NASer activates cannabinoid 
receptors and TRPV1.  Originally NASer was found to bind weakly to CB1 with a 
dissociation constant greater than 10 µM which was less than 1% of the response 
produced by the structural analogue AEA.  Additionally concentrations up to 30 µM 
NASer had no effect in displacing radioligand binding to rat CB2 or TRPV1 receptors 
(Milman et al., 2006).  However recent studies report that a decrease in oedema and 
lesion volume in mice treated with NASer after a closed head injury (CHI) are mediated 
by CB2, TRPV1 and partially mediated by BKCa (Cohen-Yeshurun et al., 2011).  The 
NASer mediated neuroprotection after CHI required phosphorylation of ERK1/2 and 
AKT and a subsequent increase in the anti-apoptotic protein BCL-xL (possibly 
mediated by CB2 and TRPV1).  Moreover CB2 activation by NASer decreased the pro-
apoptotic protein caspase-3 (Cohen-Yeshurun et al., 2011).  Furthermore a subsequent 
study highlights that NASer promoted the proliferation of neural progenitor cells in 
vitro which was mediated by CB1, CB2 and TRPV1.  Also the authors note that 96 hr 
after NASer treatment there is an increase in the expression of both CB1 and CB2 
suggesting NASer may mediate the initiation of cannabinoid gene transcription (Cohen-
Yeshurun et al., 2013). 
 
NASer applied to rat isolated mesenteric arteries and abdominal aorta promoted 
vasodilatation (Milman et al., 2006) similar to that previously seen with Abn-CBD 
(Offertáler et al., 2003).  The similarity of effects seen between NAS and Abn-CBD 
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suggest a similar, as yet unknown, target may induce these effects (Milman et al., 
2006).  Furthermore the endocannabinoid virodhamine (which is structurally similar to 
NASer) also exerts actions at the Abn-CBD endothelial receptor (Porter et al., 2002).   
Interestingly NASer is reported as the first endogenous ligand that acts selectively on 
the Abn-CBD receptor (Milman et al., 2006).  It is therefore suggested that NASer may 
play a role in vascular protection and homeostasis that is independent of CB1 and CB2 
(Milman et al., 2006).  The stereoselectivity of NASer (L-enantiomer is active) suggests 
that it is mediated via a receptor in the membrane (Milman et al., 2006).  Furthermore 
vasodilatation of the aorta is sensitive to pertussis toxin (PTX), an effect that is not 
observed in the mesenteric arteries, suggesting that a Gαi/Gαo linked receptor influences 
the aortic relaxation.   
 
NASer may also have a role in lowering inflammation as it can inhibit the formation of 
TNF-α promoted by lipopolysaccharide (LPS) in CB1(-/-) and CB2(-/-) knockout mice and 
in primary murine macrophages (Milman et al., 2006).  Moreover zymosan treatment 
promoted reactive oxygen intermediates which were suppressed in RAW264.7 cells 
treated with NASer - albeit at a high concentration (76.6 µM; Milman et al., 2006).  
Furthermore a Boyden chamber assay reported that NASer antagonised the AEA, 
virodhamine and Abn CBD-induced migration of human neutrophils at a non CB1/CB2 
target possibly by the Abn-CBD receptor, GPR18 (McHugh et al., 2008).   
 
There is also controversy as to whether NASer activates GPR55.  Previous research 
reports NASer promotes endothelial migration and in vitro tube formation which were 
partially attributed to GPR55 activation.  Application of NASer to GPR55 siRNA 
treated human dermal microvascular endothelial cells (HMVEC) lowered 
phosphorylation of ERK1/2 and Akt compared to control cells (Zhang et al., 2010).  As 
siRNA knockdown is never 100% efficient the remaining responses seen could be either 
due to incomplete knockdown of all the GPR55 present or may be due to NASer acting 
on another as yet unknown target in these cells.  For example NASer could act on a 
GPCR which is sensitive to PTX as was observed in the aorta  (Milman et al., 2006).  In 
another study however, utilising hGPR55-HEK293 cells in a GTPγS assay it was 
reported that NASer did not exert agonist or antagonist effects (Cohen-Yeshurun et al., 
2011).   
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1.4.5.3. N oleoyl-L-serine 
N-oleoyl-L-serine (NOSer) is similar in structure to NASer with the exception of the 
fatty acid chain being oleic rather than the arachidonic.  NOSer is an orphan lipid that is 
suggested to act through a Gαi/o protein-coupled receptor.  It is present in murine bone 
and the lipid acts to phosphorylate ERK1/2 (Smoum et al., 2010).  The lipid was also 
found in other mouse tissues such as the brain and the spleen and was found to be 10 
fold greater and 10 fold less respectively than seen in distal femoral metaphysis.  
Concentrations of 10 µM were unable to bind to either CB1 or CB2 in experiments 
using rat brain synaptosomal membranes or in transfected cells.  This was further 
confirmed in osteoblast cells that were deficient of CB1 and CB2.  NOSer may have a 
role in osteoporosis as ovariectomised mice treated with NOSer exhibited recovery of 
bone loss via increases in bone formation and inhibiting bone loss (Smoum et al., 2010). 
 
1.4.5.4. N-oleoyl glycine 
N-oleoyl glycine (NOGly) was originally thought to be an intermediate in the N-acyl 
amide, oleamide, synthesis pathway.  When either oleamide or NOGly was 
administered to rats the concentration of oleamide was found to increase in the animals 
treated with oleamide.  However rats treated with NOGly did not have increased 
concentrations of oleamide suggesting that NOGly is not required to produce oleamide. 
Furthermore when oleamide and NOGly were administered to rats both compounds 
were found to promote hypothermia and to decrease locomotion suggesting that NOGly 
is also a bioactive lipid (Chaturvedi and Driscoll, 2006).  NOGly is reported to be 
synthesised by the conjugation of oleoyl-CoA and glycine through the action of 
mitochondrial protein cytochrome c in the presence of hydrogen peroxide (Mueller and 
Driscoll, 2007).  Cytochrome c is also required for the synthesis of NAGly and NASer 
with arachidonoyl-CoA and either glycine or serine as substrates.  These studies 
highlight a potential in vivo biosynthesis for certain N-acyl amino acids (McCue et al., 
2008, 2009).   
 
1.5. Ca2+ signalling 
1.5.1. Overview of Ca2+ signalling 
In the late 19th Century Sydney Ringer serendipitously discovered that extracellular 
Ca2+ played a role in the contraction of an isolated heart (Ringer, 1883).  Ca2+ research 
did not progress a great deal until ~1940’s when Heilbrunn developed the hypothesis 
that Ca2+ acted as an intracellular messenger whereby Ca2+ was released from an 
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unknown internal store that he referred to as the “rigid cortex”.  However it was 
dismissed as unconventional by the scientific community at the time (Petersen et al., 
2005). Today it is widely acknowledged that Ca2+ is an important intracellular second 
messenger (Petersen et al., 2005).  Ca2+ concentration in quiescent cells is ~0.1 µM but 
increasing to ~1 µM in activated cells.  The range in concentration coupled with spatial 
(location of Ca2+ transients) and temporal (frequency of oscillatory Ca2+ transient) 
aspects of the Ca2+ signal generated allow diversity in Ca2+-mediated cellular processes.  
Ca2+ plays a role in many physiological processes such as fertilisation, muscle 
contraction, neuronal signalling, gene transcription, proliferation and apoptosis 
(Berridge et al., 1998).  To ensure Ca2+ homeostasis, cells have developed Ca2+ 
signalling that is both dynamic and meticulously regulated (Berridge et al., 1998). 
 
1.5.2. Regulation of Ca2+ signalling 
Ca2+ must be regulated as high concentrations are toxic to the cell (Berridge et al., 
1998).  Therefore cells regulate Ca2+ signalling by producing transient responses 
whereby Ca2+ is released from intracellular stores and then quickly sequestered back 
again (Berridge et al., 1998).  Agonist binding of GPCRs or tyrosine receptor kinases 
leads to the activation of phospholipase C (PLC) isoforms:  PLCβ and PLCγ 
respectively (Berridge et al., 2003; Clapham, 2007).  PLC cleaves phosphatidylinositol 
4, 5-bisphosphate (PIP2) to produce inositol 1, 4, 5-triphosphate (IP3) and 
diacylglycerol (DAG), whereby IP3 translocates through the cytosol and binds to IP3 
receptors located on the membrane of the endoplasmic reticulum (ER) leading to the 
subsequent release of Ca2+ (Clapham, 2007).  Also localised to the ER are ryanodine 
receptors (RyR).  Ca2+, as a natural ligand of RyR, promotes Ca2+  induced Ca2+  release 
(CICR) allowing Ca2+ to be released from the lumen of the ER (Clapham, 2007).  
Paradoxically, high concentrations of Ca2+ negatively feedback on IP3 and RyR closing 
the channels (Clapham, 2007).  Plasma membrane Ca2+ ATPases (PMCA) channel and 
the Na+ /Ca2+ exchanger localised in the cell membrane removes the Ca2+ from the cell 
(Bootman et al., 2001).  However the stores that are depleted must be replenished and 
cells use a mechanism known as store operated calcium entry (SOCE) to achieve this 
(Berridge et al., 1998; Bugaj et al., 2005). Depletion of the ER Ca2+ store induces 
signals to initiate store operated Ca2+ entry (SOCE) through store operated Ca2+ (SOC) 
channels located on the plasma membrane (Cheng et al., 2011).  The Ca2+ release-
activating current (ICRAC) is a member of the SOC family of Ca2+ entry channels (Cheng 
et al., 2011) and is highly selective for Ca2+ over other divalent cations (Yeromin et al., 
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2004).  ICRAC is activated by a decrease in ER luminal Ca2+ and is unaffected by the 
increases in cytosolic Ca2+ levels.  Therefore a Ca2+ sensor must exist to regulate ICRAC.   
 
Initially stromal interacting molecules (STIM) were identified in Drosophilia 
melanogaster and then subsequently in HeLa cells (Clapham, 2007).  RNA interference 
of STIM 1 was found to influence the ICRAC in HEK293 cells. The authors noted that 
the influence on ICRAC in HEK293 cells overexpressing STIM 1 generated only 17% 
increase in the SOC current therefore they suggest that STIM 1 while having a role in 
SOCE was not the Ca2+ channel (Roos et al., 2005).  Subsequent evidence observed that 
STIM are proteins located on the inside of the ER to act as Ca2+ sensors (Roos et al., 
2005; Zhang et al., 2005).  Depletion of Ca2+ from the ER leads to STIM translocating 
to a region of the ER which is situated close to the plasma membrane (Zhang et al., 
2005; Wu et al., 2006; Park et al., 2009).  Orai1 is a protein localised to the plasma 
membrane and was identified as being important in ICRAC and SOCE (Feske et al., 
2006).  Subsequent studies identified Orai1 as the pore subunit of CRAC (Prakriya et 
al., 2006).  Depletion of Ca2+ from the ER leads to the translocation of Orai1 to a 
plasma membrane at junctions with the ER (Park et al., 2009).  This allows STIM to 
bind and activate the Orai1 channels (Park et al., 2009).  The Ca2+ influx from the 
extracellular environment must be sequestered back into the stores.   
Sarcoplasmic/endoplasmic reticulum Ca2+ ATPases (SERCA) pumps this free cytosolic 
Ca2+ back into the ER (Clapham, 2007).  The stores are predominately in the 
endoplasmic reticulum but Ca2+ can also be stored in the mitochondria and nucleus 
(figure 1.4; Bootman et al., 2001; Clapham, 2007).   
 
LPI was reported to activate GPR55 to promote Ca2+ mobilisation in hGPR55-HEK293 
cells, an effect that was ablated in control HEK293 cells  (Oka et al., 2007).  A plethora 
of papers was to follow confirming GPR55-mediated elevation of intracellular Ca2+ in a 
variety of cell types; either recombinant GPR55-overexpressing cells or endogenously 
expressing cells.  These include hGPR55-HEK293 cells  (Oka et al., 2007; Lauckner et 
al., 2008; Henstridge et al., 2009, 2010), human umbilical vein derived endothelial cell 
(HUVEC) line; EA.hy926 (Waldeck-Weiermair et al., 2008) the neuronal cell line; 
PC12 cells (Obara et al., 2011), prostate cancer cell line; PC-3 (Piñeiro et al., 2011) and 
in cardiomyocytes (Yu et al., 2013).  Furthermore some cannabinoid ligands; Δ9THC, 
JWH015, AM251 and SR141716A are also reported to activate GPR55 to promote Ca2+ 
mobilisation (Lauckner et al., 2008; Henstridge et al., 2010).   
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Figure 1.4:  Summary of homeostatic regulation of cellular Ca2+.   Ca2+ homeostasis is 
essential for the survival of the cell.  Ca2+ can enter the cell through Ca2+ channels in the cell 
membrane such as voltage activated channels and the ligand activated channels.  Activated 
GPCRs lead to the formation of IP3 through PLC hydrolysis of PIP2.  IP3 acts on the IP3 
receptors in the ER and releases Ca2+.  This leads to a Ca2+ hotspot which attracts 
mitochondria whereby the uniport channel sequesters the Ca2+.  Removal of Ca2+ also occurs 
through the PMCA and the Na+/Ca2+ exchanger in the cell membrane.  ER replenishment 
occurs when STIM and Orai bind leading to SOCE.  The increase in Ca2+ is sequestered into 
the ER through the SERCA pump.  Ca2+ can also enter the nucleus via the nuclear pores where 
it can be stored.  Ca2+ is also bound to parvalbumin a Ca2+ binding protein.  Release of Ca2+ 
can also occur by a Na+/Ca2+ and H+/Ca2+ exchanger in mitochondria.  Each of these events 
ensures that intracellular Ca2+ remains low compared to the extracellular concentration.  Ca2+, 
calcium; Na+, sodium; H+, hydrogen; PMCA, plasma membrane Ca2+ ATPase; LGCC, ligand 
gated Ca2+ channel; VGCC, voltage gated Ca2+ channel; GPCR, G-protein coupled receptor; 
Orai, Ca2+ release-activated calcium channel protein 1; STIM, stromal interaction molecule; 
PLC, phospholipase C; IP3, inositol trisphosphate; RyR, ryanodine receptor; SERCA, 
sarcoendoplasmic reticulum calcium transport ATPase.  Modified from Carafoli, 2003. 
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1.6. Cyclic AMP response element binding protein 
CREB is a 43 kDa transcription factor that binds to a cyclic AMP response element 
(CRE) conserved (5’-TGACGTCA-3’) region on the promoter of genes to regulate their 
transcription (Kwok et al., 1994; Johannessen et al., 2004; Carlezon et al., 2005).  
CREB is a member of the basic region leucine zippers (bZIPs) family of transcription 
factors and is a closely related to cyclic AMP response element modulator (CREM) and 
activating transcription factor; ATF1 (Sands and Palmer, 2008).  CREB is found to exist 
as either monomers or dimers with the latter being required to initiate transcription 
(Yamamoto et al., 1988).  CREB can form either homo- or heterodimers with other 
members of the bZIPs (the leucine rich region unzips to allow dimerisation).  CREB 
phosphorylation increases the number of dimers in the cell thereby improving 
transcription efficiency (Yamamoto et al., 1988).   The basic region is important for 
CREB to bind to DNA and phosphorylation of serine 133 (Gonzalez and Montminy, 
1989) in the kinase inducible domain; KID (Sands and Palmer, 2008) recruits CREB 
binding protein (CBP) a co-transcriptional regulator and the CBP paralogue p300 
(Chrivia et al., 1993; Kwok et al., 1994; Cha-Molstad et al., 2004) allowing 
transcriptional regulation to occur.   
 
1.6.1. Signalling associated with CREB phosphorylation 
Multiple signalling pathways have been implicated where extracellular stimuli such as 
stress signals, neurotransmitters, lipids and fluxes of ions act upon cell surface channels 
or receptors and promote the phosphorylation of CREB (residue serine 133) in the 
nucleus to initiate gene expression (Euskirchen et al., 2004).  These signalling pathways 
include PKA (Dash et al., 1991), mitogen activated protein kinase (MAPK) (Impey et 
al., 1998), Ca2+/CaMKII (Sheng et al., 1990; Impey et al., 1998) and AKT/PKB (Du 
and Montminy, 1998).  Therefore multiple signalling pathways may converge and 
ultimately lead to CREB phosphorylation and subsequent regulation of gene 
transcription.  GPR55-mediated CREB phosphorylation has been reported in hGPR55-
HEK293 cells treated with the CB1 inverse agonist/antagonists; AM251 and 
SR141716A and LPI (Henstridge et al., 2010). 
 
1.6.2. Kinases and phosphatases - key players in phosphorylation signal 
transduction events 
The most common form of post-translational modification in eukaryotic signal 
transduction is phosphorylation (Ubersax and Ferrell, 2007).  Phosphorylation is a 
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reversible process where substrates have a phosphate group added by kinases.   A 
second group of enzymes known as phosphatases act in an opposing manner to kinases 
(by removing phosphate groups) to regulate signal transduction therefore, allowing 
phosphorylation to act as a molecular switch (Hunter, 1995; Bononi et al., 2011).   
 
CREB is phosphorylated on serine 133 and is then activated where it leads to regulation 
of transcription of genes (Arias et al., 1994).   Therefore after CREB has been 
phosphorylated it must be regulated this occurs through the action of phosphatases.  
Two nuclear localised protein serine/threonine phosphatases; PP1 (Hagiwara et al., 
1992) and PP2A (Wadzinski et al., 1993) are reported to dephosphorylate CREB.  
Using okadaic acid at concentrations above 10 nM the Hagiwara study highlights that 
PP1 was required to dephosphorylate pCREB in forskolin-stimulated PC12 cells (Cohen 
et al., 1989; Hagiwara et al., 1992).  However a subsequent study reports that PP2A is 
the dominant phosphatase required to dephosphorylate pCREB (Wadzinski et al., 1993).  
Using rat liver nuclear extracts which were PKA stimulated, the presence of okadaic 
acid inhibited the dephosphorylation of CREB and enhanced the transcription mediated 
by the phosphoenolpyruvate carboxykinase (PEPCK) promoter.  Furthermore a specific 
inhibitor for PP1, heat-stable protein inhibitor-2, when applied to the rat liver nuclear 
extracts had no effect on gene transcription mediated PEPCK.  Therefore in rat liver 
cells, PP2A is the phosphatase required to dephosphorylate pCREB (Wadzinski et al., 
1993).  These data suggest that the phosphatase required to dephosphorylate CREB may 
be cell-type specific.   
 
Additionally a recent study highlights that phosphate and tensin homolog deleted on 
chromosome 10 (PTEN) phosphatase has been found to be co-localised with CREB in 
HeLa and mouse embryonic fibroblasts (Gu et al., 2011).  The group reported a direct 
interaction between CREB and PTEN phosphatase and found that deletion of PTEN in 
PTEN(-/-) MEF cells led to c-Myc and Bcl2 gene expression both of which require 
CREB activation for transcription.  This was reversed in PTEN(+/+) MEFs where these 
cell survival genes had lower expression in quantitative PCR when compared to PTEN(-
/-) MEFs (Gu et al., 2011).   
 
CREB activation can also be regulated by phosphatases acting upon kinase upstream of 
the transcription factor.  As mentioned one of the main kinase signalling pathway 
required for CREB phosphorylation is MAPK (Impey et al., 1998).  MAPK (ERK1/2) is 
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a serine/threonine kinase where MAPK kinase (MEK1/2) phosphorylates both a 
threonine and tyrosine to activate the protein (Pouysségur et al., 2002).  Therefore, if 
either one of the phosphates or both are removed this renders ERK1/2 inactive.  Either 
tyrosine specific, serine/threonine specific phosphatases (such as PP2A) have the ability 
to remove one of the phosphate groups (Alessi et al., 1995).  Furthermore dual 
specificity protein phosphatases can also remove both of the phosphate groups on the 
ERK1/2 protein subsequently inactivating the protein and inhibiting the signalling via 
that pathway (Keyse, 2000; Kondoh and Nishida, 2007).   
 
PP2A is also implicated in the regulation of AKT by dephosphorylating the active 
protein (Bononi et al., 2011).  Therefore this protein phosphatase can regulate CREB 
both directly and indirectly.  
 
1.7. Focal adhesion proteins and the actin cytoskeleton 
Cell movement is important from our conception, throughout life and in some cases 
hastens our death.  The ability for cells to migrate is important in many cellular 
processes.  These include the movement of cells in gastrulation to sites where they 
differentiate into tissues and organs in the developing embryo, fibroblasts migrating to a 
wound where they migrate to each other to initiate the healing, immune cells infiltrating 
sites of inflammation and infection.  However aberrant migration of cells can lead to 
certain pathologies such as metastasis of cancer cells (Ridley et al., 2003).  The actin 
cytoskeleton is required for not only the shape of the cell but is essential for cell 
motility, cytokinesis and phagocytosis and also has a role in the movement of 
intracellular components (Nobes and Hall, 1995).  Migration of cells is a highly 
dynamic process where the leading edge of the cell is characterised by the formation of 
lamellipodia and filopodia, which contain focal adhesions and stress fibres.  Focal 
adhesions are complexes of more than 50 proteins (Zamir and Geiger, 2001; Zaidel-Bar 
et al., 2003).  Assembly and disassembly of focal adhesions is important at the leading 
and retracting edge of cells respectively.  These events lead to the polarity of the cell to 
allow directed migration (Zaidel-Bar et al., 2003).  Furthermore polymerisation of the 
actin cytoskeleton is also required (Machesky and Hall, 1997). 
 
1.7.1. Vinculin, a focal adhesion protein 
Focal adhesions (FAs), areas where the cell binds to the ECM were first visualised by 
electron microscopy (Abercrombie et al., 1971).    FAs tend to form just behind the 
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leading edge in motile cells although they are also prominent in stationary cells 
(Burridge and Chrzanowska-Wodnicka, 1996; Smilenov, 1999).  FAs are only a few 
microns long and attach the actin cytoskeleton to the extracellular matrix (ECM) (Zamir 
and Geiger, 2001).  Vinculin is 117 kDalton focal adhesion protein which intracellularly 
associates with the ECM-integrins and with cadherin cell-cell interactions (Ziegler et 
al., 2006).  However vinculin should not just be considered a linker protein as there are 
many binding sites for other proteins within vinculin (Ziegler et al., 2006).  These 
include Arp2/3 required for actin polymerisation in lamellipodia and is important in cell 
spreading, the Diaphanous-related formin mDia, and the actin regulatory proteins 
Ena/VASP suggested to be responsible for growth of stress fibres at the FAs (Endlich et 
al., 2007).  Another vinculin binding protein is zyxin which is suggested to be 
responsible for the retraction dependent formation of FAs from focal complexes at 
migrating edge of the lamellipodia (Zaidel-Bar et al., 2003).  Furthermore PIP2 can bind 
to vinculin where it crosslinks vinculin to other proteins such as paxillin to promote the 
formation of focal contacts (Zamir and Geiger, 2001).  Cell migration begins with the 
formation of small adhesions known as focal complexes which are dot-like structure.  
These then mature into focal adhesions which are elongated in appearance (Carisey and 
Ballestrem, 2011). Both focal complexes and FAs contain vinculin (Zaidel-Bar et al., 
2003).  Vinculin when activated has an open conformation which allows the binding of 
the actin cytoskeleton to the vinculin tail and talin to the vinculin head.  Talin binds and 
activates the integrins which form into clusters which leads to the enlargement of the 
FA (Humphries et al., 2007).   It is reported that mouse embryonic fibroblasts from 
vinculin(-/-) mice are smaller and less adhesive than wild type littermates.  Moreover the 
fibroblasts from the knockout animals also migrate faster than wild type littermates 
however re-introduction of vinculin reversed these effects (Carisey and Ballestrem, 
2011).   
 
Contraction of stress fibres generates force which acts on FAs leading to their 
elongation (Kaverina et al., 2002; Endlich et al., 2007).  Focal complexes are mediated 
by rac1 and cdc42 and mature into FAs when Rho is activated (Kaverina et al., 2002).  
Also mechanical cues from the extracellular environment lead to the control of the 
spatiotemporal aspects of FA assembly, disassembly and reorganisation which is 
mediated by vinculin to control the polarity of the migrating cell (Carisey et al., 2013).  
Therefore vinculin is at the fore-front of focal adhesion regulation (Carisey and 
Ballestrem, 2011). 
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1.7.2. Rho signalling and the actin cytoskeleton 
The actin cytoskeleton shows directionality in the way it is polymerised which is 
important for migration and cell movement in response to chemical stimuli as would be 
seen with cancer metastasis and immune cells moving to sites of inflammation 
(Machesky and Hall, 1997).  Stress fibres are highly organised bundles of polymerised 
F-actin (by the action of actin bundling proteins; α-actinin) to form the actin-myosin 
contractile system  (Katoh et al., 2001, 2007).  Stress fibres terminate in focal adhesions 
where the fibre interacts with the vinculin tail (Humphries et al., 2007).  α-actinin also 
interact with vinculin therefore regulating not only stress fibres but also FAs (Katoh et 
al., 2007).   
 
The small Rho GTPases such as Rho, rac and cdc42 have specific roles in the migration 
of cells (figure 1.5).  Rac activation promotes the formation of lamellipodia by actin 
polymerisation.  Actin stress fibres within the lamellipodia have a uniform polarity and 
the barbed (growing) end is at the leading edge of the lamellipodia (Cramer et al., 
1997).  In a process known as “treadmilling” actin monomers of G-actin are 
polymerised at the barbed end at the cell periphery with subsequent release of G-actin 
monomers from the interior end of the actin fibre (Wehrle-Haller and Imhof, 2003).  
The small Rho GTPase, cdc42, is responsible for filopodia formation (Small et al., 
1999).  Filopodia have stress fibres which are parallel to each other (Ridley et al., 
2003).  The bundling of the actin cytoskeleton that leads to the formation of stress fibres 
is well documented as being mediated by Rho (Machesky and Hall, 1997).  Rho is also 
reported to be required for the formation of focal adhesion complexes (Ridley and Hall, 
1992; Nobes and Hall, 1995).  Nobes and Hall (1995), state that two distinct pathways, 
each signalling through Rho, exist for either the formation of stress fibres or for the 
creation of focal adhesion complexes.  Previous studies have reported that increases in 
the stress fibres were observed in fibroblasts treated with LPA (Ridley and Hall, 1992; 
Amano et al., 1997).  The authors also noted that focal adhesion proteins were increased 
in cells treated with LPA (Ridley and Hall, 1992).  One set of researchers injected an 
inactive catalytic domain of the Rho binding domain and attenuated the formation of 
stress fibres and blocked the creation of focal adhesion complexes suggesting that Rho 
and ROCK are important in mediating the formation of stress fibres and focal adhesion 
complexes (Amano et al., 1997).  As GPR55 activates Rho, rac and cdc42 (Ryberg et 
al., 2007) it suggests that GPR55 may be important for both cytoskeletal reorganisation 
and FA formation.  Recently breast cancer cells have a migratory phenotype that is 
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mediated by GPR55 although the exact Rho GTPases remain to be determined (Ford et 
al., 2010). Furthermore GPR55 mediated polarisation of neutrophils required signalling 
via Rho (Balenga et al., 2011).  Therefore GPR55 may mediate the generation of 
cytoskeletal components required for the migration of cells. 
 
 
Figure 1.5:  Rho GTPases play important roles in cell migration.  Differing Rho GTPase 
family members (Rac1, Cdc42 and Rho) induce varying effects in cells that lead to cell 
polarisation and subsequent migration.  Bundles of actin filaments make up stress fibres and 
attach to focal adhesion complexes allowing the attachment of the cell to the extracellular 
matrix.  
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1.8. Project aims 
The main aims of this study were: 
• To assess a novel group of lipids, the N-acyl amino acids, in a recombinant 
stably overexpress human GPR55 cell line (hGPR55-HEK293 cells) in a variety 
of signalling assays; Ca2+ mobilisation, CREB phosphorylation, cytoskeletal 
reorganisation and changes in FAs. 
 
• To evaluate the signalling induced by GPR55 activation by either LPI or NOSer 
by the use of pharmacological inhibitors in the signalling assays above to 
attempt to elucidate the signalling pathways involved. 
 
• To assess GPR55 signalling in an endogenous setting when activated by either 
LPI or NOSer utilising the previously characterised endogenously GPR55 
expressing prostate cancer cell line, DU145.  Furthermore using 
pharmacological inhibitors to assess the signalling pathways mediated by 
GPR55 in DU145 cells. 
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2.1.  MATERIALS 
2.1.1.  Cell culture:  Plasticware and general reagents 
Bioquote Limited, York, UK.  
• Cell Permeable Rho Inhibitor  
 
cDNA Resource Center, Missouri University of Science and Technology USA. 
• Plasmids encoding Gα13 (Q226L/D294N) 
 
Fisher Scientific, Loughborough, UK. 
• Parafilm 
• Falcon™ Bacteriological Petri Dishes with Lid; 30 mm 
 
Greiner bio-one, Stonehouse, UK. 
• 25cm² TC treated flask with filter cap (T25 TC flask) 
• 75cm² TC treated flask with filter cap 
• Culture dish, Tissue culture treated, 35mm 
• Culture dish, Tissue culture treated, 60mm 
• 24 well Tissue culture treated plate with lid, sterile  
• Cryo.s™, 2 ml, polypropylene, round bottom, internal thread, sterile  
• Serological pipette PS, 5ml, ST, 1/10 GRADS 
• Pipette tips; 10 µl, 200 µl, 1000 µl 
• Sample container 25x90mm, 30ml, Conical skirted bottom 
• 15ml polypropylene centrifuge tube with conical base 
 
Life Technologies, Paisley, UK. 
• Dulbecco Modified Eagle Medium / F-12  
• Phosphate Buffered Solution 
• Lipofectamine™ 2000 
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• Opti-MEM® Reduced Serum Medium, no Phenol Red 
 
Merck Millipore Darmstadt, Germany. 
• Millex-GP, 0.22 µm, polyethersulfone, 33 mm, gamma sterilized  
 
Roche Diagnostics Limited, West Sussex, UK. 
• G418 solution 
 
Sera Labs International, West Sussex, UK. 
• Heat inactivated foetal bovine serum South American origin 
 
Sigma Aldrich, Dorset, UK. 
• Trypsin EDTA solution 
•  L-glutamine solution  
• Poly-D-lysine 
• Sodium hydroxide 
• HEPES  
• EDTA 
• Paraformaldehyde 
• Dimethyl sulphoxide 
• Serum replacement 2 
• Triton™ x-100 
• Dow Corning® high-vacuum silicone grease 
• Phorbol 12-myristate 13-acetate 
 
Thermo Fisher Scientific, Waltham, MA, USA. 
• Nalgene™ Cryo 1oC freezing container cat no 5100-0001 
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Tocris Bioscience, Bristol, UK. 
• Fura-2-AM  
 
VWR, Lutterworth, Leicestershire, UK. 
• Sucrose 
• Glucose 
• Sodium Chloride 
• Potassium Chloride  
• Calcium Chloride 
• Magnesium Chloride 
• Coverglasses, round, 9 mm 
• Ethanol 
 
 
2.1.2.  Cell lines 
• Human Embryonic Kidney 293-AD (HEK293) cells; Life Technologies, Paisley, 
UK. 
• Stable cell line over-expressing human 3xHA-GPR55 (hGPR55-HEK293 cells); 
Advantagen, Dundee, UK. 
• DU145 prostate cancer cell line; Division of Cancer Research, University of 
Dundee, Dundee, UK. 
 
 
2.1.3.  siRNA 
Dharmacon Thermo Scientific, Loughborough, UK. 
• DharmaFECT 1 Transfection Reagent 
• siGENOME ON TARGET plus SMARTpool duplex siRNA fragments.  The 
siRNA consisted of four individual targeted fragments (21 nucleotides) as 
follows: 
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Human GPR55-siRNA 
GCUACUACUUUGUCAUCAA 
AAGAACAGGUGGCCCGAUU 
GAGAAACAGCUUUAUCGUA 
GAAUUCCGCAUGAACAUCA 
 
 
2.1.4.  Antibodies 
Antibody Supplier  Dilution 
Mouse anti-HA 
 
Covance Inc., Alnwick  
Northumberland, UK. 
 
1:1000 
 
Mouse anti-phosphoCREB 
(serine 133) clone 10E9 
 
Millipore, Upstate, Billerica, MA, USA. 1:250 
 
Mouse anti-vinculin  
 
 
Sigma Aldrich, Dorset, UK. 
 
1:500 
 
Alexa fluor® 546-conjugated 
phalloidin 
 
 
Molecular Probes®, Life technologies, 
Paisley, UK. 
 
1:250 
 
Alexa Fluor® 488 donkey 
anti-mouse 
 
 
Molecular Probes®, Life technologies, 
Paisley, UK. 
 
1:500 
 
Cy 3 donkey anti-mouse 
 
Jackson Immunoresearch Laboratories 
Incorporated, West Grove, PA, USA. 1:500 
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2.1.5.  Lipids and other ligands 
 
Generic name 
Chemical name 
Chemical Structure 
 
Supplier 
 
 
AM251 
 
1-(2,4-Dichlorophenyl)-5-(4-
iodophenyl)-4-methyl-N-1-
piperidinyl-1H-pyrazole-3-
carboxamide 
 
 
 
Abcam 
biochemicals
® 
Cambridge, 
UK. 
 
 
L-α-
Lysophosphatidylinositol 
sodium salt from Glycine 
max (soybean) 
 
1-Acyl-sn-glycero-3-phospho-
(1-D-myo-inositol) 
 
 
Sigma 
Aldrich, 
Dorset, UK 
 
 
 
N- arachidonoyl-L-
serine 
 
1-(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-L-serine, 
 
(S)-3-hydroxy-2-
(5Z,8Z,11Z,14Z)-
eicosatetraenamidopropanoate, 
 
(S)-3-hydroxy-2-
arachidonamidopropanoate 
 
 
 
Avanti Polar 
Lipids, 
Alabaster, 
AL, USA 
 
 
N-oleoyl L-serine 
 
1-(9Z-octadecenoyl)-L-serine 
(S)-3-hydroxy-2-(9Z)- 
octadecenamidopropanoate 
(S)-3-hydroxy-2-
oleoamidopropanoate 
 
 
 
Avanti Polar 
Lipids, 
Alabaster, 
AL, USA 
 
 
 
I
NH
NO
N
N
Cl
Cl
O O
P
O
OH
O
O
OH
OH
OH
OH
OH
OH
COOH
OH
N
O
H
COOH
OH
N
O
H
98 
 
Generic name 
Chemical name Chemical Structure 
 
Supplier 
 
 
N-palmitoyl L-serine 
 
1-hexadecanoyl-L-serine, (S)-3-
hydroxy-2-
hexadecanamidopropanoate 
 
(S)-3-hydroxy-2-
palmitamidopropanoate 
 
 
 
Avanti Polar 
Lipids, 
Alabaster, 
AL, USA 
 
 
N arachidonoyl glycine 
 
N-[1-oxo-5Z,8Z,11Z,14Z-
eicosatetraenyl]-glycine 
 
 
 
 
Avanti Polar 
Lipids, 
Alabaster, 
AL, USA 
 
 
 
N oleoyl glycine 
 
N-(9Z-octadecenoyl)-glycine 
 
 
 
 
 
 
Avanti Polar 
Lipids, 
Alabaster, 
AL, USA 
 
 
N palmitoyl glycine 
 
N-(1-oxohexadecyl)-glycine   
 
Avanti Polar 
Lipids, 
Alabaster, 
AL, USA 
 
 
12-O-
Tetradecanoylphorbol 
13-acetate  
 
Phorbol 12-myristate 
13-acetate; 4β,9α,12β,13α,20-
Pentahydroxytiglia-1,6-dien-3-
one 12-tetradecanoate 13-
acetate 
 
  
Sigma 
Aldrich, 
Dorset, UK 
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2.1.6. Inhibitors 
Generic name 
Chemical name Chemical Structure 
 
Supplier 
 
 
2-APB 
 
(2-Aminoethoxydiphenylborane) 
 
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK. 
 
 
 
 
BAPTA-AM 
 
1,2-Bis(2-aminophenoxy)ethane-
N,N,N',N'-tetraacetic acid 
tetrakis(acetoxymethyl ester) 
 
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK. 
 
 
Gö6980 
 
2-[1-(3-Dimethylaminopropyl)-5-
methoxyindol-3-yl]-3-(1H-indol-3-yl) 
maleimide 
 
 
 
 
 
Calbiochem, 
Merck 
Chemicals, 
Nottingham, 
UK 
 
 
H1152 dihydrochloride 
 
(S)-(+)-2-Methyl-1-[(4-methyl-5-
isoquinolinyl)sulfonyl]-hexahydro-1H-
1,4-diazepine dihydrochloride 
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK. 
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Generic name 
Chemical name Chemical Structure 
 
Supplier 
 
 
KN-62 
 
4-[(2S)-2-[(5-isoquinolinylsulfonyl) 
methylamino]-3-oxo-3-(4-phenyl-
1piperazinyl) propyl] phenyl 
isoquinolinesulfonic acid ester 
 
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK. 
 
 
LY294002 hydrochloride 
 
2-(4-Morpholinyl)-8-phenyl-4H-1-ben-
zopyran-4-one hydrochloride 
 
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK. 
 
 
ML-141 
4-[4,5-Dihydro-5-(4-methoxyphenyl)-3-
phenyl-1H-pyrazol-1-
yl]benzenesulfonamide 
 
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK. 
 
 
PD98059 
 
2-(2-Amino-3-methoxyphenyl)-4H-1-
benzopyran-4-one  
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK. 
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Generic name 
Chemical name Chemical Structure 
 
Supplier 
 
 
 
Rapamycin 
 
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19-
E,21S,23S,26R,27R,34aS)-
9,10,12,13,14,21,22,23,24,25, 
26,27,32,33,34,34a-Hexadecahydro-
9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-
4-hydroxy-3-methoxycyclohexyl]-1-
methylethyl]-10,21-dimethoxy-
6,8,12,14,20,26-hexamethyl-23,27-
epoxy-3H-pyrido[2,1-c][1,4]oxaazacy-
clohentriacontine-
1,5,11,28,29(4H,6H,31H)-pentone 
 
 
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK 
 
 
Thapsigargin 
 
(3S,3aR,4S,6S,6AR,7S,8S,9bS)-6- 
(Acetyloxy)-2,3,3a,4,5,6,6a,7,8,9b-
decahydro-3,3a-dihydroxy-3,6,9-
trimethyl-8-[[(2Z)-2-methyl-1-oxo-2-
butenyl]oxy]-2-oxo-4-(1-oxobutoxy)
azuleno[4,5-b]furan-7-yl octanoate 
 
 
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK 
 
 
 
 
U0126 
 
1,4-Diamino-2,3-dicyano-1,4-bis[2-a-
minophenylthio]butadiene 
 
 
 
 
 
Calbiochem, 
Merck 
Chemicals, 
Nottingham, 
UK 
 
 
 
U0124 
 
1,4-Diamino-2,3-dicyano-1,4-bis[2-
methylthio]butadiene 
 
 
 
 
 
Calbiochem, 
Merck 
Chemicals, 
Nottingham, 
UK 
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Generic name 
Chemical name Chemical Structure 
 
Supplier 
 
 
U73122 
 
1-[6-[[(17β)-3-Methoxyestra-1,3,5(10)-
trien-17-yl]amino]hexyl]-1H-pyrrole-
2,5-dione 
  
 
Tocris 
Bioscience, 
Bristol, UK 
 
 
Wortmannin 
 
(1S,6bR,9aS,11R,11bR) 11-(Acetyloxy)-
1,6b,7,8,9a,10,11,11b-octahydro-1-
(methoxymethyl)-9a,11b-dimethyl-3H-f-
uro[4,3,2-de]indeno[4,5,-h]-2-h]-2-
benzopyran-3,6,9-trione 
 
 
 
 
 
 
Calbiochem, 
Merck 
Chemicals, 
Nottingham, 
UK 
 
 
 
 
Y27632 dihydrochloride 
 
trans-4-[(1R)-1-Aminoethyl]-N-4-
pyridinylcyclohexanecarboxamide 
dihydrochloride 
 
 
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK 
 
 
 
 
YM-254890 
 
 
 
 
 
Astellas 
Pharma Inc 
Osaka, Japan 
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2.1.7.  Antagonist 
Generic name 
Chemical name Chemical Structure 
 
Supplier 
 
 
 
(-)-Cannabidiol 
 
2-[(1R,6R)-3-Methyl-6-(1-methylethe-
nyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-
benzenediol 
 
 
 
 
 
Tocris 
Bioscience, 
Bristol, UK 
 
 
2.2.  METHODS 
2.2.1.  Cell Culture Protocols 
2.2.1.1.  Resuscitation of frozen cells 
HEK293, the stable cell line over-expressing human 3xHA-GPR55 (hGPR55-HEK293 
cells) and DU145 cells were stored in the -80oC freezer until required.  All cell culture 
products were filtered using Millex-GP, 0.22 µm, polyethersulfone, 33 mm, gamma 
sterilized filters.  DMEM medium containing 10% heat inactivated foetal bovine serum 
and 2 mM L-glutamine was warmed in a humidified incubator, 37oC and 5% CO2, prior 
to cells being resuscitated.  Next, 7 ml of serum-containing medium was filtered into a 
T25 tissue culture flask at the same time the cells were quickly warmed (to avoid 
damage to the cells).  The cells were then put into the medium in the flask and left to 
settle for around 2 hr.  The medium was removed at this point and fresh serum-
containing medium was added to the settled cells to reduce the amount of DMSO 
present in the flask.  Cells were then left to grow; if necessary media were changed 
every 2-3 days until the cells reached 80-90% confluency. 
 
2.2.1.2.  Cell maintenance 
HEK293 and DU145 cells were maintained in DMEM supplemented with 10% heat 
inactivated foetal bovine serum and 2 mM L-glutamine.  They were kept in a 
humidified atmosphere of 5% CO2 and 37oC.  hGPR55-HEK293 cells were selected for 
using the neomycin antibiotic; G418 (500 µg/ml).  Cells were passaged once they 
reached around 80-90% confluency.  Initially, they were washed once with phosphate 
buffer solution (PBS) to remove serum.  The cells were then incubated with 0.5 ml 
trypsin until they detached from the base of the flask.   The flasks were checked under a 
OH
OH
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light microscope to ensure that the cells were detached and the flask was gently tapped 
on the side to release any that were still attached.  Finally 3 ml of serum-containing 
medium was added to the flask; the presence of the serum inactivates the trypsin 
stopping its protease effects from further damaging the cells.  Two sterile T25 tissue 
culture flasks had 4 ml of serum-containing medium added and then 1 ml of the 
passaged cells was added to these flasks and kept in a humidified atmosphere of 5% 
CO2 and 37oC. 
 
Borosilicate glass coverslips (9 mm; ~200) were placed in a 30 ml sample container and 
70% ethanol was added until the coverslips were covered.  They were gently mixed (5 
min) to allow the ethanol to sterilise all the coverslips.  The ethanol was then aspirated 
and dH20 was filtered onto the coverslips where they were gently mixed then the dH2O 
was aspirated.  This washing process was carried out twice to ensure the removal of all 
the ethanol.   Poly-D-lysine (20 µg/ml) was added to filtered dH20 (20 ml) in the sample 
container with the coverslips.  The coverslips were then rotated for 1 hr to ensure even 
coating prior to the poly-D-lysine solution being aspirated.  The coverslips were then 
rinsed and stored in sterile water for up to a week.  Poly-D-lysine coated coverslips 
were dried and placed in petri dishes ~ 20 coverslips in a culture dish (60 mm); serum-
containing medium (4 ml) was added to the dishes prior to the addition of passaged cells 
(1 ml) which were left to settle for 24 hr in a humidified atmosphere of 5% CO2 and 
37oC.   The cells were then serum-starved for 12-16 hr before the commencement of 
experiments.  
 
2.2.1.3.  Freezing down cells 
Cells were grown to 80-90% confluency and then washed with PBS which was then 
aspirated.  Next, cells were treated with 0.5 ml of trypsin until they had detached from 
the bottom of the flask after which 4 ml of serum containing medium was added.  Each 
flask of detached cells was then transferred to a centrifuge tube (15 ml) and spun down 
at 1000 rpm for 5 min.  The supernatant was aspirated and the pellet was re-suspended 
in 0.75 ml of filtered serum-containing medium which was supplemented with 10% 
DMSO.  Cryotubes containing the re-suspended cells were then placed in the Nalgene™ 
Cryo 1oC freezing container to allow a slow freezing process to occur (to limit any 
damage occurring to the cells) and was placed in the -80oC freezer.  After 24 hr the 
cryotubes were removed from the freezing container and kept in the -80oC freezer until 
required.  
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2.2.1.4.  Preparation of transient transfections 
24 hr prior to the transient transfection – cells were plated as above onto poly-D-lysine 
coated coverslips.  They were placed in a humidified environment for 24 hr to settle and 
were ~ 70% confluent.  On the transfection day; 2 µl of Lipofectamine™ 2000 (2 
mg/ml) was added to 98 µl of OptiMEM® in one Eppendorf tube.  In a second 
Eppendorf tube 2 µl of cDNA (1 mg/ml) was added to 98 µl of OptiMEM.  Both 
Eppendorf tubes were mixed by gently pipetting the mixture up and down several times.  
They were left for 5 min.  After which the cDNA mix was added to the 
Lipofectamine™ 2000 mix and again gently pipetted up and down 4-5 times to mix 
well.  This was left for 20 min (to allow time for cDNA-liposome complexes to form) 
prior to the cDNA-liposome complexes being added dropwise to the coverslips (which 
were now in 0.8 ml of serum-free medium).  The cells/cDNA mix were then placed in a 
humidified environment and left for 15-20 hr before the commencement of experiments. 
 
2.2.1.5.  Preparation of siRNA transient transfection 
3 µl of Dharmafect1 was added to an Eppendorf tube and 97 µl of serum-free was added 
and gently pipetted up and down five times.  In another Eppendorf tube 5 µl of the 
required siRNA (20 µM) was added and then 95 µl of serum-free medium was gently 
pipetted up and down five times to ensure even distribution.  These Eppendorf tubes 
were then left for 15 min.  The contents of the siRNA eppendorf tubes was then added 
to the Dharmafect1 containing Eppendorf tubes and these were then gently pipetted up 
and down five times ensuring that no bubbles were present.  These tubes were then left 
for a further 20 min.  0.8 ml of serum-free medium that contained 1:50 of serum 
replacement 2 was added to the dishes.  Each set of siRNA mix was added to the 
coverslips in a drop wise manner onto each coverslip before gently moving the dish 
from side to side to allow good dispersal of the mix.  The final concentration of 100 nM 
of siRNA was achieved.  Cells were placed in a humidified atmosphere for between 60-
72 hr before commencement of experiments.   
 
2.2.2.  Experimental Protocols 
2.2.2.1.  Calcium (Ca2+) imaging 
Variations in intracellular calcium [Ca2+]i concentration were measured using a digital 
epifluorescence imaging system (Perkin Elmer, Emeryville, CA, USA) mounted on an 
Olympus BX50WI microscope (Olympus, Tokyo, Japan).  Cells plated on poly-D-
lysine coverslips were placed in serum-free medium overnight.  These cells were loaded 
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with a ratiometric dye, Fura-2-AM (6 µM) for 60 min before the commencement of 
experiments.  Cells were then washed in HEPES buffered saline (HBS in mM:  NaCl 
135; KCl 5; MgCl2 1; CaCl2 1; HEPES 10; Glucose 10; pH 7.4).  A coverslip 
containing loaded cells was then placed in a Falcon™ Petri dish (30 mm) attached with 
high vacuum grease to ensure stability during perfusion with HBS.  Typically ligands 
were perfused for a 5 min period at a rate of 2 ml/min.  Ratiometric images pairs (350 
nm and 380 nm excitation) were acquired at 2-5 sec intervals.  Effects of ligands on the 
F350/F380 ratio, which is proportional to the [Ca2+]i , were determined for individual 
cells in a given field.  
 
 
Figure 2.1:  Example Ca2+ trace of single cell recording.  The highest peak response ratio 
value within 15 min of ligand application is measured (red arrow) along with a baseline ratio 
value (blue arrow) which is subtracted to give the response height.   
 
For analysis, baseline ratio values obtained prior to drug addition were subtracted from 
peak responses.  Raw data was analysed with Metafluor® offline (Molecular Devices 
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(UK) Ltd, Wokingham, UK) software whereby background recordings were removed.  
Traces were then transferred to Origin 7 software (OriginLab Corporation, Stoke 
Mandeville, UK) where mean peak response data was measured within 15 min of 
ligands being applied (5 min ligand application and 10 min wash).  The response height 
measured the highest point reached in the 15 min stated above.  The baseline height was 
measured as the mean value within 5 min before the application of ligands (figure 2.1).   
 
Peak response measurements were made in Origin.  Having transferred the Metafluor 
data with the background removed into Origin as a single ASCII (in file tab) make the 
graph by plotting the line graph.  When this is minimised the raw data table can be seen 
(figure 2.2A).  From this data table highlight all the cells from time of ligand application 
until 15 min later - this accounts for the 5 min ligand application and 10 min washout 
(figure 2.2B).  Highlight the Statistic tab and click on descriptive statistics and then 
click on statistics on columns.  In the cell column delete any cells which have shown 
constitutive activity and then moving to the right find the Max(Y) column and copy and 
paste this into Excel (figure 2.2C).  Now going back to the raw data highlight 5 min of 
data prior to the application of the ligand and work out the average – this corresponds to 
the baseline value.  Ensure that any cell removed previously is also removed from the 
baseline values. 
 
The following calculation was used: 
 
Peak response = response height - baseline height. 
 
Peak response data was analysed using GraphPad Prism 4, (GraphPad Software, Inc., 
La Jolla, CA, USA) to generate both sigmoidal concentration response curves and 
histograms.   
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Figure 2.2:  Ca2+ analysis with Origin.  The Ca2+ data is analysed in Metafluor with the 
background removed and then imported as a single ASCII into Origin and a graph produced.  
A, when the graph is minimised the raw data values are revealed.  B, Raw data is highlighted 
from time when drug applied to 10 mins into wash.  Using the statistics button the descriptive 
statistics on columns is plotted.  C, Descriptive statistics for each cell and the Max(Y) column 
highlighted. 
 
2.2.2.2. Confocal microscopy 
2.2.2.2.1.  Phosphorylation of cAMP Response Element Binding Protein (pCREB) 
HEK293, hGPR55-HEK293 and DU145 cells were plated on poly-D-lysine coated 
coverslips and placed overnight in serum-free medium in a humidified incubator (37oC; 
5% CO2).  Cells were treated with ligands diluted in HBS and placed a dry incubator 
(37oC) for 25 min.  In experiments where inhibitors were applied, the cells were treated 
Individual 
cells
C
Maximum response in the 15 
min analysis time
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with the inhibitor for 30 min prior to co-application of the inhibitor and ligand for a 
further 25 min.  Cells were fixed and permeabilised with ice cold methanol, in a -20 oC 
freezer for 10 min.  Fat-free powdered milk was dissolved in HBS to a final 
concentration of 5% and was then applied to the cells and left at room temperature for 
20 min.  After which the cells were washed 3 times with HBS to ensure all the milk 
solution is removed.   Mouse anti-phosphoCREB diluted in HBS (1:250) was applied 
for 60 min.  The cells were then washed 3 times with HBS.  The secondary antibody 
Alexa fluor® 488 donkey anti-mouse diluted in HBS (1:500) was then applied for 30 
min.  Cells were washed as above and maintained in glucose-free HBS. Images were 
acquired and processed using a laser scanning confocal imaging system (Zeiss LSM510; 
Carl Zeiss Microscopy Ltd, Cambridge, UK) which incorporates an upright Axioskop 
FS2 microscope (Carl Zeiss, Oberkochen, Germany) using a 40x water immersion 
objective. 
 
Nuclear fluorescence measurements were performed with Image J freeware 
(http://imagej.nih.gov/ij/). To allow the measurements to be made ensure that the 
analyse tab is open and the set measurements box visible. Ensure that the following 
boxes are ticked area, min & max gray values, integrated density, mean gray value and 
add to overlay (figure 2.3).   
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Figure 2.3:  Measurement settings in Image J freeware.  Open the analyse tab and click on set 
measurements.  Ensure that the area, min & max gray values, integrated density, mean gray 
value and add to overlay are all ticked then click on OK. 
 
The analysis was carried out on the raw data image acquired from using Zeiss LSM 510 
Laser-sharp software. For each image, defined nuclei were traced using a bright-field 
image - use > key to visualise the bright-field, to highlight the nuclear membrane and 
then the measurement recorded with the fluorescent image present - use < key to 
visualise the fluorescent image.  To record the results press the ‘m’ key.  Three 
background regions devoid of cells were also analysed to allow a mean background 
reading to be calculated (figure 2.4).   
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Figure 2.4:  Analysis of nuclear phosphorylated CREB using Image J.  Click on the irregular 
icon and using the brightfield image draw either in a background region void of cells or round 
the nuclear membrane.  Change to the fluorescent image and press ‘m’ to record the results. 
Click on the irregular shape icon
Integrated 
density 
values
Region of 
interest area 
(eg nucleus)
Mean 
fluorescence 
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Measurements were derived from fluorescent image where the corrected Total Nuclear 
Fluorescence (CTNF) for individual nuclei was calculated as follows: 
 
CTNF = Integrated Density - (Area of the nucleus x mean background reading).   
 
Where, the integrated density is the product of the area of the nuclei and the mean grey 
level intensity value. The latter value is the sum of all the pixels in the region divided by 
the number of pixels that are present in the selected area giving a value for the 
fluorescence intensity within the nucleus.  The area of the nuclei x mean background 
reading is therefore equivalent to the background integrated density value (or 
background fluorescence intensity).  Thus, CTNF is fluorescence intensity within a 
nucleus minus background fluorescence intensity (Gavet & Pines, 2010; Potapova et al., 
2011).   For the compilation of concentration-response curves each point was calculated 
by CTNF minus the mean DMSO CTNF value from 25 nuclei per experiment then 
normalised to 1 µM LPI for 2-3 experiments.  This data was then transferred to 
GraphPad Prism 4 to allow the compilation of concentration-response curves.  Data on 
the histograms was derived by calculation of the CTNF which was then normalised to 
that obtained with the 1 µM LPI mean CTNF value.  This data was transferred to 
GraphPad Prism 4 and histograms were compiled.   
 
2.2.2.2.2.  Cytoskeletal reorganisation assay  
Cells were plated on poly-D-lysine coated coverslips and placed overnight in serum-free 
medium in a humidified atmosphere (37oC; 5% CO2).  HEK293 cells, hGPR55-
HEK293 cells or DU145 cells were transferred into individual wells in 24 well plates 
with 1 ml of serum-free medium for 30 min and kept in a humidified atmosphere.  
Subsequently the ligands were added to the serum-free well at the appropriate final 
concentration for 30 or 60 min; HEK293 and hGPR55-HEK293 or DU145 respectively.  
In experiments where inhibitors were applied, the cells were treated with the inhibitor 
for 30 min prior to co-application of the inhibitor and ligand for a further 30 or 60 min; 
hGPR55-HEK293 and DU145 cells respectively.  Cells were fixed in 4% 
paraformaldyhyde (PFA) supplemented with 200 mM sucrose for 10 min, then 
permeabilised with 0.2% triton X-100 for 10 min.  F-actin was labelled using Alexa 
Fluor® 546-conjugated phalloidin which was diluted in HBS (1:500) and applied for 30 
min at room temperature.  Cells were then washed 3 times with HBS and maintained in 
glucose-free HBS.  Cells were examined using a laser scanning confocal microscope 
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(Zeiss LSM510) as described previously.  Changes in actin structure were not directly 
quantified, and are displayed as images (figure 2.5). 
 
Figure 2.5:  Example confocal microscopy images depicting cytoskeletal reorganisation.  
Confocal images highlighting A, Stress fibres which are depicted by the closed arrowheads and 
filopodia depicted by the open arrowheads.  B, Lamellipodia are depicted by the arrows. 
 
 
A
B
115 
 
2.2.2.2.3.  Focal adhesion (FA) protein assay 
Cells were plated on poly-D-lysine coated coverslips and placed overnight in serum-free 
medium in a humidified atmosphere (37oC; 5% CO2).  Cells were transferred into 1 ml 
of serum-free medium in individual wells of a 24 well plate for 30 min in a humidified 
atmosphere prior to commencement of experiments.  The ligands were then applied for 
30 or 60 min; HEK293 and hGPR55-HEK293 or DU145 respectively.  In experiments 
where inhibitors were applied, the cells were treated with the inhibitor for 30 min prior 
to co-application of the inhibitor and ligand for a further 30 or 60 min; hGPR55-
HEK293 and DU145 cells respectively.  Cells were fixed in 4% PFA supplemented 
with  200 mM sucrose for 10 min, then permeabilised with 0.2 % triton X-100 for 10 
min.  Mouse anti-vinculin diluted in HBS (1:500) was applied for 60 min.  The cells 
were then washed 3 times with HBS.  A fluorescently-conjugated secondary antibody, 
Alexa fluor® 488 donkey-anti mouse, was diluted in HBS (1:500) and then applied for 
30 min.  After which the cells were washed as above and stored in glucose-free HBS.   
Cells were then examined using a laser scanning confocal microscope (Zeiss LSM510) 
as described previously. 
 
FA lengths were measured using LSM 510 Laser-sharp software (Carl Zeiss 
Microscopy Ltd, Cambridge, UK).  A measure tool in the overlay tab was used to 
record µm lengths; using LSM 510 Laser-sharp software click on the overlay button 
then click on the ruler icon and then the line icon.  Now drag over the FA and record the 
measurement (figure 2.6).  This data was then transferred to GraphPad Prism 4 where 
either concentration response curves or histograms were compiled.  For concentration 
response curves the mean control (DMSO) value was removed from the lipid-induced 
FA length. 
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Figure 2.6:  Analysis of FA length.  Clicking on the overlay icon on the right of the screen 
leads to the opening of the window to reveal the ruler and line icons.  After clicking all three 
icons the mouse can be dragged over the FA and the length recorded. 
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2.2.2.2.4.  HA immunoreactivity 
hGPR55-HEK293 cells were fixed with 4% PFA containing 200 mM sucrose at room 
temperature for 10 min.  Cells were then incubated for 60 min with mouse anti-HA 
(1:1000) in HBS.  The cells were then washed 3 times with HBS, after which a 
conjugated secondary antibody, Alexa fluor® 488 anti-rabbit (1:500) was applied for 30 
min.  Cells were washed 3 times with HBS.  Cells were examined using a laser scanning 
confocal microscope (Zeiss LSM510) as described previously. 
 
Fluorescence measurements were performed with Image J freeware.  The analysis was 
carried out on the raw data image acquired from using Zeiss LSM 510 Laser-sharp 
software. For each image, the outline of the cell area was traced using a bright-field 
image as a guide (similar to pCREB analysis). Three background regions devoid of cells 
were also analysed.  Measurements were derived from fluorescent image where the 
Corrected Total Cell-area Fluorescence (CTCF) was calculated as follows: 
CTCF = Integrated Density - (Area of cell region x mean background reading).   
This data was then transferred to GraphPad Prism 4 to allow the compilation of 
histograms.  
  
2.2.3.  Statistical analysis 
2.2.3.1.  Ca2+ studies 
Histogram data was analysed with unpaired Student t-tests to compare the two data sets.  
P < 0.05 was considered significant. Data were typically obtained from 10 cells per field 
obtained from a minimum of two experiments unless otherwise stated. 
 
2.2.3.2.  pCREB studies 
Statistical analyses were performed using one-way ANOVA followed by a Bonferroni 
post hoc test for multiple comparisons.  P < 0.05 was considered significant.  Data were 
typically obtained from three experiments unless otherwise stated. 
 
2.2.3.3.  FA studies 
Statistical analyses were performed using either one-way ANOVA followed by a 
Bonferroni post hoc test for multiple comparisons or a two-way ANOVA followed by a 
Bonferroni post hoc test for multiple comparisons.  P < 0.05 was considered significant.  
hGPR55-HEK293 cells: Data was typically obtained from a minimum of at least two 
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experiments.  DU145 cells:  Data were typically obtained from a minimum of at least 
two experiments unless otherwise stated. 
 
2.2.3.4.  HA immunoreactivity 
Statistical analyses were performed using one-way ANOVA followed by a Bonferroni 
post hoc test for multiple comparisons.  P < 0.05 was considered significant.  Data were 
typically obtained from a minimum of at least three experiments. 
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3.1.  INTRODUCTION 
In 2007 the first report of LPI activating GPR55 to promote Ca2+ mobilisation in 
hGPR55-HEK293 cells, an effect that was not observed in control HEK293 cells, was 
published (Oka et al., 2007).  A plethora of papers were to follow confirming that 
GPR55can elevate intracellular Ca2+ levels in a variety of cell types; either recombinant 
GPR55-overexpressing cells or endogenously expressing cells.  These include hGPR55-
HEK293 cells  (Oka et al., 2007; Lauckner et al., 2008; Henstridge et al., 2009, 2010), 
human umbilical vein derived endothelial cell (HUVEC) line; EA.hy926 (Waldeck-
Weiermair et al., 2008) the neuronal cell line; PC12 cells (Obara et al., 2011), prostate 
cancer cell line; PC-3 (Piñeiro et al., 2011) and in cardiomyocytes (Yu et al., 2013).  
Furthermore some cannabinoid ligands; Δ9THC, JWH015, AM251 and SR141716A are 
also reported to stimulate GPR55-mediated Ca2+ mobilisation (Lauckner et al., 2008; 
Henstridge et al., 2010).   
 
In HEK293 cells transiently expressing recombinant GPR55, JWH015 and Δ9THC 
induced GPR55 mediated Ca2+ mobilisation required Gα12 and Rho (Lauckner et al., 
2008).  The requirement for Gα12 family of G-proteins and Rho was confirmed in a 
separate study where signalling via the Gα13-Rho-ROCK axis was associated with 
GPR55-mediated Ca2+ mobilisation (Henstridge et al., 2009).  However in prostate 
cancer cells (PC-3) Ca2+ mobilisation mediated by GPR55 did not require ROCK 
signalling (Piñeiro et al., 2011).  Furthermore it was also reported that PLC, and 
Ca2+ release form stores was involved in GPR55-mediated Ca2+ mobilisation (Lauckner 
et al., 2008; Henstridge et al., 2009) and there was a requirement for an intact actin 
cytoskeleton (Lauckner et al., 2008).  Additionally the presence of extracellular Ca2+ 
was also found to be necessary to promote the formation of GPR55-mediated oscillatory 
Ca2+ transients in hGPR55-HEK293 cells (Henstridge et al., 2009).  A second G-
protein; Gαq was also reported for GPR55-promoted Ca2+ mobilisation in both hGPR55-
HEK293 cells and phaeochromocytoma (PC12) cells (Lauckner et al., 2008; Obara et 
al., 2011).  In endothelial cells AEA can promote GPR55-mediated Ca2+ mobilisation, 
but this is a distinct system, requiring the activation of PI3K-Bmx-PLCγ signalling for 
this effect.  Moreover, integrin clustering mediated by CB1 activation is necessary to 
release the inhibition of GPR55 Ca2+ signalling (Waldeck-Weiermair et al., 2008).  It 
remains to be determined if Gα13 or Gαq are required for Ca2+ mobilisation in endothelial 
cells.  A more recent study revealed that application of LPI to cardiomyocytes promoted 
increases in intracellular Ca2+ which were sensitive to the GPR55 novel antagonist ML-
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193.  The authors also reported that the localisation of GPR55 in cardiomyocytes 
influenced the signalling required for Ca2+ mobilisation.  GPR55 localised at the plasma 
membrane acted to release Ca2+ from stores via IP3 receptors and this was further 
augmented by Ca2+ induced Ca2+ release promoted by the activation of ryanodine 
receptors.  However GPR55 located on cardiomyocyte lysosomal membranes increased 
intracellular Ca2+ by activating acidic-like Ca2+ stores via the endo-lysosomal NAADP-
sensitive two-pore Ca2+-permeable ion channels followed by subsequent activation of 
ryanodine receptors (Yu et al., 2013). 
 
In this study a novel set of ‘endocannabinoid-like’ lipids were tested for their effects on 
intracellular Ca2+ homeostasis and their ability to activate GPR55. Such 
‘endocannabinoid-like’ lipids, including N-acyl amino acids, are of interest as whilst 
they have an endocannabinoid structure they are unable to activate the classical 
cannabinoid receptors (CB1 and CB2), but have interesting biological actions.  Many of 
these lipids remain orphans at the present time, with no known molecular target.  To 
investigate whether these lipids can activate GPR55, their actions were compared in 
hGPR55-HEK293 cells and control HEK293 cells.  Subsequent experiments utilised 
pharmacological inhibitors to study the signalling pathways underlying their effects on 
Ca2+ signalling. 
 
3.2.  RESULTS 
3.2.1. L-α-Lysophophatidylinositol promotes Ca2+mobilisation in hGPR55-
HEK293 cells. 
Firstly, the endogenous GPR55 ligand LPI was tested to allow for validation of the Ca2+ 
assay (Oka et al., 2007; Henstridge et al., 2009).  Several different cell types with either 
recombinant or native expression of GPR55 have been observed to induce Ca2+ 
mobilisation when challenged with LPI (Lauckner et al., 2008; Waldeck-Weiermair et 
al., 2008; Henstridge et al., 2009; Obara et al., 2011).    
 
hGPR55-HEK293 cells were loaded with Fura 2-AM (6 µM) for 60 min prior to being 
placed on a digital epifluorescent imaging system at 30-34oC.  Treatment with 100 nM, 
300 nM or 1 µM LPI (5 min) led to the generation of oscillatory Ca2+ transients (figure 
3.1Ai-iii), whereby the frequency and number of Ca2+ transients, along with the number 
of responsive cells, increased with higher LPI concentrations.  In hGPR55-HEK293 
cells the mean LPI-mediated peak response was concentration-dependent (figure 3.1B) 
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with an EC50 of 183 ± 8 nM (95% confidence limits).  Little or no response to LPI (1 
µM) was observed in control HEK293 cells (figure 3.1Aiv) in comparison with 
hGPR55-HEK293 cells (mean, peak LPI response in hGPR55-HEK293 cells = 0.77 ± 
0.059 ratio units, HEK293 cells = 0.031 ± 0.022 ratio units, n = 32 cells, P < 0.001, 
figure 3.2C).    These data suggest that LPI induced Ca2+ mobilisation is mediated by 
GPR55. 
 
Figure 3.1:  Treatment of hGPR55-HEK293 cells with LPI promotes oscillatory Ca2+ 
transients.  Ligands were perfused over the cells at a rate of 2 ml/min for 5 min.  Ai, 
representative Ca2+ trace from an hGPR55-HEK293 cell treated with 100 nM LPI; Aii, 
representative Ca2+ trace from an hGPR55-HEK293 cell treated with 300 nM LPI; note 
oscillatory Ca2+ transients are formed which are concentration dependent.  Aiii,   representative 
Ca2+ trace from an hGPR55-HEK293 cell treated with 1 µM LPI; Aiv,   representative 
Ca2+ trace from a HEK293 cell treated with 1 µM LPI; note that Ca2+ transients were not 
observed.  B, LPI concentration response curve in hGPR55-HEK293 cells. Data are the mean, 
peak response ± SEM derived from 32 cells, from 3 independent experiments.     C, histogram 
comparing responses in hGPR55-HEK293 cells and control HEK293 cells.   Note the responses 
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are ablated in HEK293 cells.  Data are the mean, peak response ± SEM of 32 cells from 3 
independent experiments.  Student’s unpaired two-tailed t-test; ***P < 0.001. 
 
3.2.2.  N-acyl serines induce Ca2+ mobilisation in hGPR55-HEK293 cells. 
Having validated the Ca2+ assay with LPI, the next experiments were to test if three 
novel N-acyl serine lipids could induce Ca2+ mobilisation in hGPR55-HEK293 cells.  
Three lipids were chosen each with a serine head group but with varying fatty acid 
chain saturation and length; NASer (C20:4; polyunsaturated), NOSer (C18:1; 
monounsaturated) and NPSer (C16:0; saturated).    
 
Various concentrations of NASer, up to a maximum concentration of 10 µM, were 
perfused over hGPR55-HEK293 cells at a rate of 2 ml/min over a 5 min period.  NASer 
(100 nM) when applied to hGPR55-HEK293 cells induced just a single Ca2+ transient 
(figure 3.2Ai).   However when NASer (1 µM) challenged hGPR55-HEK293 cells it 
was observed to increase both the height of the peak response and the number of 
oscillatory Ca2+ transients produced (figure 3.2Aii).  The mean, peak Ca2+ response was 
concentration-dependent with an EC50 of 256 ± 18 nM (95% confidence limits) (figure 
3.3B).  To test if these results were GPR55-mediated NASer (3 µM) was first applied to 
hGPR55-HEK293 cells where robust oscillatory Ca2+ transients were produced (figure 
3.2Aiii).  Next NASer (3 µM) was applied to HEK293 cells where no effect was 
observed (responses to NASer (3 µM) hGPR55-HEK293 cells = 0.771 ± 0.037 ratio 
units, HEK293 cells = 0.024 ± 0.024 ratio units, n = 32 cells, P < 0.001, figure 3.2C).    
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Figure 3.2:  NASer-mediated Ca2+ responses in hGPR55-HEK293 cells.  Ai, representative 
Ca2+ trace from an hGPR55-HEK293 cell treated with 100 nM NASer; note a small delay in 
response and the formation of a single Ca2+ transient when NASer was perfused over the cells 
at 2 ml/min for 5 min. Aii, representative Ca2+ trace from an hGPR55-HEK293 cell treated with 
1 μM NASer; note oscillatory Ca2+ transients when NASer was perfused over the cells.  Aiii, 
representative Ca2+ trace from an hGPR55-HEK293 cell treated with 3 µM NASer; note the 
increased frequency of oscillatory Ca2+ transients.  Aiv, representative Ca2+ trace from a 
HEK293 cell treated with 3 µM NASer; note, Ca2+ responses were ablated.  B, concentration-
response response curve for NASer illustrating the mean, peak Ca2+ response in hGPR55-
HEK293 cells. Data are the mean, peak response ± SEM derived from 32 cells, from 3 
independent experiments. C, histogram of mean peak Ca2+ responses in hGPR55-HEK293 cells 
and HEK293 cells challenged with 3 µM NASer.  Data are the mean peak response ± SEM of 32 
cells from 3 independent experiments.  Student’s unpaired two-tailed t-test; ***P < 0.001.   
 
Next we investigated the effects of NOSer.  Treatment of hGPR55-HEK293 cells with 
NOSer (100 nM) also induced Ca2+ transients that were oscillatory (figure 3.3Ai).  
Higher NOSer concentrations (1-10 µM) promoted a greater peak response and 
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increased the frequency of oscillations (figure 3.3Aii and iii).   NOSer-induced Ca2+ 
responses were concentration-dependent with an EC50 of 253 ± 4 nM (95% confidence 
limits) (figure 3.3B).  HEK293 cells when challenged with NOSer (10 µM) did not 
produce Ca2+ transients but rather a small ‘bump-like’ increase in the Ca2+ ratio 
(hGPR55-HEK293 cells = 0.767 ± 0.066 ratio units, HEK293 cells = 0.13 ± 0.021 ratio 
units, n = 32 cells, P < 0.001; figure 3.3C). 
 
Figure 3.3:  NOSer promotes oscillatory Ca2+ transients in hGPR55-HEK293 cells.  Ai, 
representative Ca2+ trace from an hGPR55-HEK293 cell treated with 100 nM NOSer; note the 
formation of small oscillatory Ca2+ transient when NOSer was perfused over the cells at 2 
ml/min for 5 min.  Aii, representative Ca2+ trace from an hGPR55-HEK293 cell treated with 1 
μM NOSer; note oscillatory Ca2+ transients when NOSer was perfused over the cells.  Aiii, 
representative Ca2+ trace from an hGPR55-HEK293 cell treated with 10 µM NOSer.  Aiv, 
representative Ca2+ trace from a HEK293 cell treated with 10 µM NOSer; note, transient Ca2+ 
responses were ablated but a small bump-like response is observed.  B, concentration-response 
response curve for NOSer illustrating the mean, peak Ca2+ response in hGPR55-HEK293 cells. 
Data are the mean, peak response ± SEM derived from 32 cells, from 3 independent 
experiments.  C, histogram of mean peak Ca2+ responses in hGPR55-HEK293 cells and 
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HEK293 cells challenged with 10 µM NOSer.  Data are the mean peak response ± SEM of 32 
cells from 3 independent experiments.  Student’s unpaired two-tailed t-test; ***P < 0.001.   
 
Next hGPR55-HEK293 cells were challenged with NPSer (100 nM).   Ca2+ responses to 
NPSer were single Ca2+ transients with a delayed initiation (figure 3.4Ai).  Increasing 
the concentration of NPSer (1-10 µM) led to faster responses, an increase in the peak 
response and the appearance of Ca2+ oscillations (figure 3.4Aii and iii).    NPSer-
mediated Ca2+ responses were concentration-dependent with an EC50 of 314 ± 12 nM 
(95% confidence limits) (figure 3.5B).  To determine whether these responses were 
likely to be mediated by GPR55 responses to a high concentration of NPSer (10 µM) 
were compared between hGPR55-HEK293 cells and control, HEK293 cells (figure 
3.4Aiii and iv).  Responses in the latter cells were not observed (hGPR55-HEK293 cells 
= 0.647 ± 0.045 ratio units, HEK293 cells = 0.036 ± 0.023 ratio units, n = 32 cells, P < 
0.001, figure 3.4C).   
 
Figure 3.4:  Oscillatory Ca2+ transients are promoted when NPSer is applied to hGPR55-
HEK293 cells.  Ai, representative Ca2+ trace from an hGPR55-HEK293 cell treated with 100 
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nM NPSer; note a delay in response and the formation of a single Ca2+ transient when NPSer 
was perfused over the cells at 2 ml/min for 5 min.  Aii, representative Ca2+ trace from an 
hGPR55-HEK293 cell treated with 1 μM NPSer; note faster initiation of Ca2+ transients when 
NPSer was perfused over the cells.  Aiii, representative Ca2+ trace from an hGPR55-HEK293 
cell treated with 10 µM NPSer; note the increased frequency of oscillatory Ca2+ transients.  
Aiv, representative Ca2+ trace from a HEK293 cell treated with 10 µM NPSer; note, transient 
Ca2+ responses were ablated.  B, concentration-response response curve for NPSer illustrating 
the mean peak Ca2+ response in hGPR55-HEK293 cells. Data are the mean, peak response ± 
SEM derived from 32 cells, from 3 independent experiments.  C, histogram of mean peak Ca2+ 
responses in hGPR55-HEK293 cells and HEK293 cells challenged with 10 µM NPSer.  Data 
are the mean peak response ± SEM of 32 cells from 3 independent experiments.  Student’s 
unpaired two-tailed t-test; ***P < 0.001.   
 
3.2.3.  N-acyl glycines induce a more modest Ca2+ response in hGPR55-HEK293 
cells. 
These experiments were to investigate if a different amino acid head group influenced   
N-acyl amino acid -mediated Ca2+ mobilisation in hGPR55-HEK293 cells.  Three novel 
N-acyl glycines with either an arachidonic, oleic or palmitic fatty acid chain were 
studied.   
 
Treatment of hGPR55-HEK293 cells with NAGly (300 nM) promoted a single, delayed 
Ca2+ transient (figure 3.5Ai).  Higher concentrations of NAGly (3-10µM) promoted a 
faster onset Ca2+ response that was also oscillatory (figure 3.5Aii and iii).  Ca2+ 
responses were concentration-dependent with an EC50 of 908 ± 63 nM (figure 3.5B).  
No response to NAGly (10 µM) was observed in control HEK293 cells (response to 10 
µM NAGly in hGPR55-HEK293 cells = 0.551 ± 0.059 ratio units, HEK293 cells = 
0.003 ± 0.003 ratio units, n = 32 cells, P < 0.001, figure 3.5Aiv and C). 
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Figure 3.5:  NAGly induces oscillatory Ca2+ transients in hGPR55-HEK293 cells.  NAGly was 
perfused over hGPR55-HEK293 cells are a rate of 2 ml/min.  Ai, representative Ca2+ trace from 
an hGPR55-HEK293 cell treated with 300 nM NAGly; note a small delay in response and the 
formation of a single Ca2+ transient.  Aii, representative Ca2+ trace from an hGPR55-HEK293 
cell treated with 3 μM NAGly; note oscillatory Ca2+ transients when NAGly was perfused over 
the cells.  Aiii, representative Ca2+ trace from an hGPR55-HEK293 cell treated with 10 µM 
NAGly; note the increased frequency of oscillatory Ca2+ transients which is concentration 
dependent.   Aiv, representative Ca2+ trace from a HEK293 cell treated with 10 µM NAGly; 
note, Ca2+ responses were ablated.  B, concentration-response response curve for NAGly 
illustrating the mean, peak Ca2+ response in hGPR55-HEK293 cells. Data are the mean, peak 
response ± SEM derived from 32 cells, from 3 independent experiments.  C, histogram of mean, 
peak Ca2+ responses in hGPR55-HEK293 cells and HEK293 cells challenged with 10 µM 
NAGly.  Data are the mean, peak response ± SEM of 32 cells from 3 independent experiments.  
Student’s unpaired two-tailed t-test; ***P < 0.001.   
 
Exposure of hGPR55-HEK293 to NOGly (300 nM) produced modest, delayed Ca2+ 
transients (figure 3.6Ai).  Increasing NOGly concentrations (1-3µM) promoted larger, 
Ai
Aii Aiv
B C
10 µM NAGly
Aiii
 hGPR55-HEK293 HEK293 
0.0
0.2
0.4
0.6
0.8
1.0
***
m
ea
n 
pe
ak
 r
es
po
ns
e
5 min
0.
2 
un
its
300 nM NAGly
5 min
0.
2 
un
its
3 μM NAGly
10 μM NAGly
5 min
0.
2 
un
its
10 μM NAGly
5 min
0.
2 
un
its
-10 -9 -8 -7 -6 -5
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Log [NAGly] M
m
ea
n 
pe
ak
 r
es
po
ns
e
130 
 
more oscillatory Ca2+ transients (EC50 of 347 ± 12 nM (95% confidence limits); figure 
3.6Aii, iii and B), although the effects were smaller than those seen with the other lipids 
at equivalent concentrations.  NOGly (3 µM) applied to HEK293 generated a very small 
Ca2+ elevation (response to NOGly (3 µM) in hGPR55-HEK293 cells = 0.372 ± 0.051 
ratio units, HEK293 cells = 0.072 ± 0.028 ratio units, n = 32 cells, P < 0.001; figure 
3.6Aiv and C).  The small ‘bump-like’ response profile in HEK293 cells was similar to 
that seen with NOSer suggesting that the oleic acid tail may interact with an unknown 
target in HEK293 cells.   
 
Figure 3.6:  Oscillatory Ca2+ transients are promoted when NOGly is applied to hGPR55-
HEK293 cells.  NOGly was perfused over hGPR55-HEK293 cells are a rate of 2 ml/min.  Ai, 
representative Ca2+ trace from an hGPR55-HEK293 cell treated with 300 nM NOGly; note a 
small delay in response and the formation of a single Ca2+ transient. Aii, representative Ca2+ 
trace from an hGPR55-HEK293 cell treated with 1 μM NOGly; note oscillatory Ca2+ transients 
when NOG was perfused over the cells.  Aiii, representative Ca2+ trace from an hGPR55-
HEK293 cell treated with 3 µM NOGly; note the increased peak response of the oscillatory 
Ca2+ transients which is concentration dependent.   Aiv, representative Ca2+ trace from a 
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HEK293 cell treated with 3 µM NOGly; note, Ca2+ responses were ablated but a small bump-
like response is observed.  B, concentration-response response curve for NOGly illustrating the 
mean, peak Ca2+ response in hGPR55-HEK293 cells.  Data are the mean, peak response ± SEM 
derived from 32 cells, from 3 independent experiments. C, histogram of mean, peak Ca2+ 
responses in hGPR55-HEK293 cells and HEK293 cells challenged with 3 µM NOGly.  Data are 
the mean, peak response ± SEM of 32 cells from 3 independent experiments.  Student’s unpaired 
two-tailed t-test; ***P < 0.001.   
 
Finally hGPR55-HEK293 cells challenged with NPGly (300 nM) displayed very little 
effect with the majority of cells producing no response (figure 3.7Ai).  Higher 
concentrations of NPGly (3-10 µM) generated small Ca2+ transients in cells (figure 
3.7Aii-iii) with a lower maximal response in relation to the other lipids (figure 3.7B).    
NPGly (10 µM) did not induce Ca2+ responses in control HEK293 cells (response to 
NPGly (10 µM) in hGPR55-HEK293 cells = 0.064 ± 0.027 ratio units, HEK293 cells = 
0.004 ± 0.004 ratio units, n = 32 cells, P < 0.05, figure 3.7Aiv and C).  These data 
suggest that whilst the NPGly induced Ca2+ responses in hGPR55-HEK293 cells were 
small they may be GPR55-mediated. 
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Figure 3.7:  Ca2+ transients are promoted when NPGly is applied to hGPR55-HEK293 cells.  
Ai, representative Ca2+ trace from an hGPR55-HEK293 cell treated with 300 nM NPGly, 
showing no response.  Aii, representative Ca2+ trace from an hGPR55-HEK293 cell treated 
with 3 μM NPGly; note a slightly delayed and small Ca2+ transient when NPGly was perfused 
over the cells.  Aiii, representative Ca2+ trace from an hGPR55-HEK293 cell treated with 10 
µM NPGly; note a similarly delayed and small Ca2+ transient when NPGly was perfused over 
the cells.  Aiv, representative Ca2+ trace from a HEK293 cell treated with 10 µM NPGly; note, 
transient Ca2+ responses were ablated.  B, concentration-response response curve for NPGly 
illustrating the mean, peak Ca2+ response in hGPR55-HEK293 cells. Data are the mean, peak 
response ± SEM derived from 32 cells, from 3 independent experiments.  C, histogram of mean 
peak Ca2+ responses in hGPR55-HEK293 cells and HEK293 cells challenged with 10 µM 
NPGly.  Data are the mean, peak response ± SEM of 32 cells from 3 independent experiments.  
Student’s unpaired two-tailed t-test; *P < 0.05.   
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LPI remains the most potent and efficacious lipid when compared to the N-acyl amino 
acids.  NASer and NOSer produced a similar Emax which was ~20 % lower than that 
seen with LPI (figure 3.8A).  NASer and NOSer had similar EC50 values and were the 
most potent of all the N-acyl amino acids studied (table 3.1).  NPSer had the lowest 
potency and efficacy of the three N-acyl serines.  Presence of a glycine head group 
resulted in a reduced efficacy when compared to either LPI or the N-acyl serines.  The 
lower Emax produced by NAGly and NOGly suggests they may be partial agonists of 
GPR55 (figure 3.8B).  NAGly was found to be the least potent of the N-acyl amino 
acids studied (table 3.1).  NOGly whilst having a similar potency was found to be less 
efficacious than NPSer.  NOGly was ~50% less efficacious than either NASer or 
NOSer.  NPGly promoted a small increase in [Ca2+]i  at 3 and 10 µM concentrations but 
lower concentrations were found to have no effect in  hGPR55-HEK293 cells.  Overall 
these data suggest that the presence of the serine head group increases the potency and 
efficacy of the mean Ca2+ peak responses in hGPR55-HEK293 cells when compared to 
lipids with a glycine head group.  The lower efficacy of the N-acyl glycines suggests 
that these lipids act as partial agonists at GPR55 in the Ca2+ assay. 
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Figure 3.8:  Pooled concentration-response data for Ca2+ responses to lipids in hGPR55-
HEK293 cells.  LPI is depicted in red on all graphs.  A, comparison of the lipids that contain a 
serine head group.  B, comparison of lipids that contain a glycine head group.  C, N-acyl amino 
acids with an arachidonic (C20:4) fatty acid chain.  D, N-acyl amino acids that contain an oleic 
(C18:1) fatty acid chain.  E, N-acyl amino acids that have a palmitic (C16:0) fatty acid chain.  
Data are the mean, peak response ± SEM of 32 cells from 3 independent experiments.  
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Ligand EC50 (nM) 
LPI 183 ± 8 
NASer 256 ± 18 
NOSer 253 ± 4 
NPSer 314 ± 12 
NAGly 908 ± 63 
NOGly 347 ± 12 
NPGly nd 
 
Table 3.1:  Relative potencies of the N-acyl amino acids compared to LPI.  Results derived 
from three independent experiments.   nd  = not determined.  EC50 values (95% confidence 
limits). 
 
3.2.4.  Ca2+ signalling in hGPR55-HEK293 cells. 
As NOSer was the most potent and efficacious of the N-acyl amino acids it was used to 
elucidate the cell signalling events that underlie the oscillatory Ca2+ responses in 
hGPR55-HEK293 cells.   In particular we studied the origin of the NOSer-mediated 
Ca2+ response in hGPR55-HEK293 cells.  BAPTA-AM is a membrane permeable Ca2+ 
chelator which is preferentially selective for Ca2+ over other divalent cations.  In control 
experiments, NOSer induced oscillatory Ca2+ transients in hGPR55-HEK293 (figure 
3.9Ai).  However, when BAPTA-AM (50 µM) was applied for 20 min prior to co-
application with NOSer for a further 5 min, responses were inhibited by 87.1 ± 4.83% 
(control NOSer = 0.547 ± 0.043 ratio units, BAPTA-AM + NOSer = 0.073 ± 0.009 ratio 
units, n = 30 cells, P < 0.001, figure 3.9B and C).  These results suggest that free 
cytosolic Ca2+ is required for NOSer-induced Ca2+ responses in hGPR55-HEK293 cells. 
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Figure 3.9:  Chelation of Ca2+ reduces the mobilisation of Ca2+ in hGPR55-HEK293 cells.  
The membrane permeant Ca2+ chelator, BAPTA-AM was applied for 20 min prior to the co-
application of NOSer.  A, representative Ca2+ trace from an hGPR55-HEK293 cell challenged 
with 1 µM NOSer.  B, representative Ca2+ trace from an hGPR55-HEK293 cell treated with 50 
µM BAPTA (20 min) prior to co-application with 1 µM NOSer (5 min); note the loss of Ca2+ 
transients.  C, histogram of pooled mean Ca2+ responses of hGPR55-HEK293 cells treated 
either with NOSer alone or in the presence of BAPTA-AM.  Data are the mean, peak response ± 
SEM; n = 30 cells derived from two independent experiments.  Student’s unpaired two-tailed t-
test; ***P < 0.001. 
 
GPCR-mediated Ca2+ signalling often requires a release of Ca2+ from intracellular stores 
associated with Ca2+ influx through channels located in the plasma membrane (SOCE).  
Re-uptake of Ca2+ into stores is via the ATP driven SERCA pump  (Clapham, 2007).  
The plant alkaloid thapsigargin can inhibit irreversibly the SERCA pump (Thastrup et 
al., 1990; Lytton et al., 1991), which leads to the depletion of Ca2+ from the ER. This is 
associated with the influx of Ca2+ across the cell membrane by ATP driven PMCA or 
Na+/Ca2+ exchanger (Bootman et al., 2001).  Therefore the effects of thapsigargin (2 
µM) on NOSer responses in hGPR55-HEK293 cells were investigated.  In control cells, 
NOSer (1 µM) promoted Ca2+ transients in hGPR55-HEK293 cells (figure 3.10Ai).    
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Treatment with thapsigargin induced an elevation in [Ca2+]i followed by a slow 
decrease which did not return to baseline levels even after thapsigargin was washed out.  
Subsequent addition of NOSer after a 20 min wash did not induce any Ca2+ response in 
hGPR55-HEK293 cells (figure 3.10Aii).   
 
Oscillatory activity requires a release of Ca2+ from an intracellular Ca2+ store and SOCE 
to promote influx of Ca2+ across the plasma membrane which is sequestered back into 
the store whereby it can be released in the next wave of Ca2+ release (Uhlén and Fritz, 
2010).   Responses to NOSer in the absence of extracellular Ca2+ exhibited a single Ca2+ 
transient with no oscillatory activity.  Subsequent addition of HBS supplemented with 
Ca2+ (1.8 mM) promoted the reinstatement of Ca2+ oscillations suggesting that Ca2+ 
influx through SOC channels located in the plasma membrane is required for this 
activity (figure 3.10B) .  These data suggest that Ca2+ responses to NOSer in hGPR55-
HEK293 cells involve Ca2+ release from the ER and influx of extracellular Ca2+.   
 
Figure 3.10:  Role of Ca2+ stores and extracellular Ca2+ in NOSer-mediated responses.  The 
source of Ca2+ mobilisation in hGPR55-HEK293 cells was investigated.  Thapsigargin was 
applied to deplete Ca2+ from stores.  Ai,  representative Ca2+ trace from an hGPR55-HEK293 
cell challenged with 1 µM NOSer; note Ca2+ transients were produced.  Aii,  representative 
Ca2+ trace from an hGPR55-HEK293 cell treated with 2 µM thapsigargin and 1 µM NOSer; 
note the formation of a single Ca2+ transient suggesting Ca2+ release from the ER.  Ca2+ 
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remained elevated and subsequent application of NOSer did not induce Ca2+ transients.  B,  
representative Ca2+ trace from an hGPR55-HEK293 cell perfused with Ca2+ free HBS 
supplemented with 100 µM EDTA for 5 min prior to addition of  1 µM NOSer; a single Ca2+ 
transient was formed.  Readdition of HBS containing 1.8 mM Ca2+ promoted oscillatory Ca2+ 
transients.  
 
Having ascertained that Ca2+ release from the ER was important for the intracellular 
Ca2+ response the upstream mediators ROCK and PLC were studied.  Previous work by 
Henstridge and colleagues suggest that both ROCK and PLC activation are necessary 
for the mobilisation of intracellular Ca2+ in hGPR55-HEK293 cells challenged with LPI 
(Henstridge et al., 2009).  ROCK has two isoforms; therefore both isoforms were 
studied in their ability to mobilise Ca2+ in hGPR55-HEK293 cells when challenged with 
NOSer (1 µM).  ROCK I and II are targeted by the use of Y-27632 dihydrochloride 
(Ishizaki et al., 2000; Tamura et al., 2005) and ROCK II by the use of H1152 
dihydrochloride (Tamura et al., 2005).  Pre-treatment of hGPR55-HEK293 cells with 
the ROCK I and ROCK II inhibitor, Y-27632 (10 µM; 20 min) prior to co-application 
with NOSer (1 µM; 5 min) reduced the peak Ca2+ response by 53.9 ± 19.2% relative to 
that observed with NOSer alone (NOSer = 0.458 ± 0.061 ratio units, Y-27632 + NOSer 
= 0.245 ± 0.05 ratio units, n = 30 cells, P < 0.01, figure 3.11Ai-iii).  The role of the 
ROCK II isoform was tested by utilising the selective ROCK II inhibitor, H1152.  
H1152 (1 µM; 20 min) was applied to hGPR55-HEK293 cells prior to the co-
application of NOSer (1 µM; 5 min), subsequent responses were reduced in amplitude 
by 29.3 ± 9.5% relative to control (NOSer = 0.763 ± 0.063 ratio units, H1152 + NOSer 
= 0.543 ± 0.064 ratio units, n = 30 cells, P < 0.05, figure 3.11Bi-iii).  These results 
highlight that ROCK signalling is important in hGPR55-HEK 293 cells treated with 
NOSer.  The inhibition of Ca2+ peak response appears more pronounced with cells 
treated with Y-27632 compared to H1152.  This may be due to Y-27632 blocking the 
two isoforms of ROCK whereas H1152 blocks the ROCK II isoform only.  
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Figure 3.11:  ROCK signalling is required for NOSer-induced Ca2+ mobilisation in hGPR55-
HEK293 cells.  Two different ROCK inhibitors were applied to hGPR55-HEK293 cells for 20 
min prior to co-application of the inhibitor with 1 µM NOSer.  Ai, representative Ca2+ trace 
from an hGPR55-HEK293 cell challenged with 1 µM NOSer. Aii, representative Ca2+ trace 
from an hGPR55-HEK293 cell treated with 10 µM Y-27632; ROCK I and II inhibitor (20 min) 
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prior to co-application with 1 µM NOSer (5 min); note the peak response is lowered in the 
presence of the Y-27632.  Aiii, histogram of mean, peak Ca2+ responses in hGPR55-HEK293 
cells treated with either NOSer alone or co-applied with Y-27632.  Bi, representative Ca2+ trace 
from an hGPR55-HEK293 cell challenged with 1 µM NOSer.  Bii, representative Ca2+ trace 
from an hGPR55-HEK293 cell treated with 1 µM H1152; ROCK II inhibitor (20 min) prior to 
co-application with 1 µM NOSer (5 min); note the  peak response is lowered in the presence of 
H1152.  Biii, histogram of pooled mean Ca2+ responses in hGPR55-HEK293 cells challenged 
with either NOSer alone or co-applied with H1152.  Data are the mean, peak response ± SEM; 
n = 30 cells derived from two independent experiments.  Student’s unpaired two-tailed t-test; *P 
< 0.05; **P < 0.01. 
 
PLC is required to catalyse the hydrolysis of PIP2 into IP3 and DAG.  IP3 then diffuses 
within the cytoplasm and activates IP3 receptors on the ER to promote the release of 
Ca2+ (Berridge et al., 2003).  Therefore NOSer was co-applied with the PLC inhibitor, 
U73122 (1 µM) after an initial 20 min application of U73122.  Responses to NOSer in 
the presence of U73122 had a lower peak Ca2+ response of 66.5% relative to control 
(NOSer = 0.879 ± 0.054 ratio units, U73122 + NOSer = 0.294 ± 0.062 ratio units, n = 
15 cells, P < 0.05, figure 3.12Bi-iii).    Also it was noted that fewer cells responded 
when U73122 was present.  These results suggest that NOSer-mediated 
Ca2+ mobilisation involves PLC activation in hGPR55-HEK293 cells.  Higher 
concentrations of U73122 (3-5 µM) generated direct effects on Ca2+ levels, thus could 
not be evaluated further. 
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Figure 3:12:  PLC is required for NOSer-mediated Ca2+ responses in hGPR55-HEK293 cells.  
Application of the PLC inhibitor, 1 µM U73122, lowered the Ca2+ responses.  A, representative 
Ca2+ trace from an hGPR55-HEK293 cell challenged with 1 µM NOSer.  B, representative Ca2+ 
trace from an hGPR55-HEK293 cell treated with 1 µM U73122 (20 min) prior to co-
application with 1 µM NOSer (5 min); note the lower peak response.  C, histogram of pooled 
mean Ca2+ responses of hGPR55-HEK293 cells treated either with NOSer alone or in the 
presence of the PLC inhibitor. Data are the mean, peak responses ± SEM; n = 15 cells derived 
from one experiment.  Student’s unpaired two-tailed t-test; *P < 0.05.  
 
3.3.  DISCUSSION 
3.3.1.  N-acyl amino acid and Ca2+ mobilisation in hGPR55-HEK293 cells. 
LPI-induced Ca2+ mobilisation is known to be mediated by GPR55 in various cell types 
and expression systems (Oka et al., 2007; Lauckner et al., 2008; Henstridge et al., 2009; 
Obara et al., 2011).  This study highlighted that all the N-acyl amino acids promoted the 
mobilisation of Ca2+ in hGPR55-HEK293 cells.  Little or no effect was observed in 
control HEK293 cells challenged with the N-acyl amino acids suggesting that Ca2+ 
mobilisation was GPR55-mediated.  LPI remains the most efficacious and potent ligand 
tested when compared to the N-acyl amino acids in this Ca2+ assay.  The N-acyl amino 
acids that contain a serine head group were found to be more efficacious and more 
potent than those that possess a glycine head group with the same fatty acid chain.  To 
date the N-acyl amino acids utilised in this study have not been characterised in relation 
their GPR55 activity with the exception of NASer and NAGly. 
 
This is the first study to highlight that NASer-induced Ca2+ mobilisation is GPR55-
mediated.  Previous research, however, has provided conflicting reports as to whether 
NASer activates GPR55.  Effects of NASer promoting endothelial migration and in 
vitro tube formation were attributed in part to GPR55.  Application of NASer (10 nM-
10 µM) to GPR55 siRNA treated human dermal microvascular endothelial cells 
(HMVEC) also lowered phosphorylation of ERK1/2 and Akt compared to control cells 
(Zhang et al., 2010).  As siRNA knockdown is never 100% efficient the remaining 
responses seen could be either due to incomplete silencing of GPR55 or may be due to 
NASer acting on another, as yet unknown, target in these cells.  In another study 
utilising hGPR55-HEK293 cells,  a GTPγS assay highlighted that NASer did not exert 
agonist or antagonist effects when binding to GPR55 (Cohen-Yeshurun et al., 2011).    
Such discrepancies could be due to different cell types being utilised and therefore 
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responses may be cell-type specific.  Also hGPR55-HEK293 cells may produce 
differing results due to variations in laboratory culturing methods or passage number. 
To date this is the first study to highlight that NAGly, acting as a partial GPR55 agonist, 
can induce Ca2+ mobilisation in hGPR55-HEK293 cells.  In contrast, two previous 
studies have observed that the effects of NAGly do not involve GPR55 activation.  In 
one study hGPR55-HEK293 cells were reported to promote weak migration when 
challenged with NAGly (0.1 nM–10 µM).  This was concentration-independent and 
similar effects were observed with the GPR55 agonist, LPI.  The authors however report 
that GPR18 mediated the NAGly-induced migration in the murine microglial cell line 
(BV2) and hGPR18-HEK293 cells (McHugh et al., 2010).   It should be noted that the 
cells in the McHugh study were not placed in serum free medium prior to the 
experiments which may explain why migratory responses were not seen (Marazzi et al., 
2011).  In another study the NAGly-induced lowering of intraocular pressure in a 
murine model of glaucoma was not GPR55-mediated, as GPR55 (-/-) mice exhibited 
similar results to wild type mice.  Interestingly, GPR18 was observed to mediate the 
NAGly-induced lowering of intraocular pressure (Caldwell et al., 2013).  Emerging 
evidence highlights that NAGly can activate several GPCRs; GPR18 (Kohno et al., 
2006; Yin et al., 2009; McHugh et al., 2010, 2012; Caldwell et al., 2013), GPR72 
(Hannedouche and Roy, 2010) and GPR92 as a partial agonist (Oh et al., 2008).  
However in two independent β–arrestin assays, NAGly was inactive at GPR18 (Yin et 
al., 2009; Southern et al., 2013).  This discrepancy may be due to the sensitivity of β–
arrestins assays being lower than that of signalling assays where amplification of signal 
occurs as the pathway is activated.  Another explanation may be that NAGly exerts a 
ligand bias where signalling via β-arrestins does not occur.  Therefore testing the ligand 
in other assays/cell types provides evidence that NAGly activates GPR18 (Caldwell et 
al., 2013).  This study however adds another GPCR to the repertoire of known GPCRs 
that are activated by NAGly.  
 
NOSer was found to promote concentration-dependent, oscillatory Ca2+ transients in 
hGPR55-HEK293 cells, but not in control HEK293 cells.  These data suggest that the 
Ca2+ responses in this study are likely to be GPR55-mediated.  This is the first study to 
assign a GPCR for the orphan lipid, NOSer.  A previous study of osteoblast 
proliferation reported NOSer effects to be sensitive to pertussis toxin (PTX) suggesting 
that it acts through an unknown Gαi/o sensitive GPCR (Smoum et al., 2010).  However, 
PTX treatment of GPR55-containing membranes was found to produce no effect in a 
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GTPγS binding assay when compared to untreated GPR55-containing membranes 
therefore suggesting that GPR55 does not signal through Gαi/o (Ryberg et al., 2007).   
These data suggest that NOSer induces effects through GPR55 however; there is also 
another as yet unknown GPCR target for NOSer that is sensitive to Gαi/o proteins.  
 
The structurally similar NOGly was originally thought of as an intermediate in the 
production of the sleep-inducing lipid amide, oleamide (Merkler et al., 2004).  However 
recent evidence suggests that NOGly may also be a biologically active signalling 
molecule (Chaturvedi and Driscoll, 2006) but the target for this lipid remains unknown.   
This study observed weak activity at GPR55 suggesting that NOGly may be a GPR55 
partial agonist. 
 
NPSer promoted Ca2+ mobilisation in hGPR55-HEK293 cells.  Little is known about 
this lipid, eg synthesis and localisation, therefore further work will be required to 
elucidate a physiological role.  NPGly is structurally similar to NPSer and is known to 
act on an unknown PTX-sensitive GPCR in both primary cultured dorsal root ganglion 
cells and a hybrid neuroblastoma x dorsal root ganglion cell line; F-11 to promote Ca2+ 
mobilisation (Rimmerman et al., 2008).   NPGly was found to promote a small increase 
in [Ca2+]i in hGPR55-HEK293 cells with a threshold concentration of 3 µM.  The 
presence of the glycine head group conjugated to a palmitic fatty acid chain has 
diminished GPR55- activity when compared to NPSer.   
 
3.3.2. NOSer-induced formation of oscillatory Ca2+ transients requires PLC, 
ROCK, Ca2+ release from the ER and extracellular Ca2+. 
Activation of a GPCR can initiate the formation of IP3 and DAG from PLC-induced 
PIP2 hydrolysis. IP3 translocates and acts on IP3 receptors to promote the mobilisation 
of Ca2+ from the ER.  Released Ca2+ can then act upon SOCs in the plasma membrane 
allowing the opening of the channel and an influx of Ca2+ into the cell.  Ca2+ can act as 
an agonist of IP3 receptors therefore allowing high levels of Ca2+ to negatively feedback 
in the IP3 receptor to close the channel leading to the formation of a Ca2+ transient 
(Finch et al., 1991).  Ca2+ at low µM concentrations is reported to activate a second type 
of Ca2+ channel on the ER, the ryanodine receptor; RyR (Clapham, 2007).  Therefore 
the presence of a Ca2+ buffer would be expected to influence the Ca2+ induced activation 
of IP3 receptors (Dargan and Parker, 2003).  Application of BAPTA-AM, the 
membrane permeable Ca2+ chelator inhibited NOSer-induced oscillatory Ca2+ transients 
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in hGPR55-HEK293 cells.  One possibility is that the chelation of free cytosolic Ca2+ 
lowered the concentration of Ca2+ available to activate IP3 or RyR receptors or led to 
Ca2+ store depletion.  These data suggest that free cytosolic Ca2+ is important for Ca2+ 
mobilisation in NOSer challenged hGPR55-HEK293 cells. 
 
Previous studies highlighted a requirement for both Ca2+ release from stores (Lauckner 
et al., 2008; Henstridge et al., 2009) and extracellular Ca2+ influx for GPR55-mediated 
Ca2+ signalling (Henstridge et al., 2009).  Extracellular Ca2+ was not required for 
GPR55-mediated Ca2+ transients when hGPR55-HEK293 cells treated with cannabinoid 
ligands (Lauckner et al., 2008).  Cannabinoid ligands (Δ9THC and JWH015) were 
applied to hGPR55-HEK293 cells in either 0 or 2 mM Ca2+ Ringer’s solution Ca2+ 
responses were similar suggesting that extracellular Ca2+ was not required (Lauckner et 
al., 2008).  However, a subsequent study revealed that extracellular Ca2+ was required 
for LPI-induced oscillatory Ca2+ transients in hGPR55-HEK293 (Henstridge et al., 
2009).  A single Ca2+ transient occurred in the presence of Ca2+ free HBS supplemented 
with 100 µM EDTA but subsequent Ca2+ oscillations were ablated.  This suggests that 
intracellular Ca2+ stores are depleted and cannot refill when extracellular Ca2+ is absent 
(Bird and Putney, 2005).  Interestingly, the reintroduction of 1.8 mM Ca2+ containing 
HBS led to the reinstatement of oscillatory Ca2+ transients (Henstridge et al., 2009) 
suggesting that Ca2+ from the extracellular media is entering the cell and subsequently 
refilling the ER through the SERCA pump.  Indeed, application of thapsigargin, a 
selective inhibitor of SERCA (Thastrup et al., 1990; Lytton et al., 1991) promoted a 
sustained elevation of [Ca2+]i in hGPR55-HEK293 cells. Upon subsequent application 
of NOSer no responses were observed, suggesting that the oscillatory Ca2+ transients 
require refilling of the ER.   
 
GPR55 is reported to signal via the Gα13-Rho-ROCK pathway to promote Ca2+ 
mobilisation in hGPR55-HEK293 cells challenged with LPI (Henstridge et al., 2009).  
Recent evidence suggests that an intact actin cytoskeleton is necessary for Ca2+ 
signalling to occur in astrocytes (Sergeeva et al., 2000), fibroblasts (Ribeiro et al., 
1997) and hGPR55-HEK293 cells (Lauckner et al., 2008).  Rho-ROCK signalling is 
important for cytoskeletal reorganisation in cells (Amano et al., 1997; Hall, 1998; Katoh 
et al., 2001).  As with LPI, activation of ROCK was involved in NOSer-induced 
GPR55-mediated Ca2+ mobilisation in hGPR55-HEK293 cells.   
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In summary this study has identified novel N-acyl amino acids that promote oscillatory 
Ca2+ transients in hGPR55-HEK293 cells.  Ca2+ oscillations were absent in HEK293 
cells challenged with the N-acyl amino acids suggesting that Ca2+ mobilisation is 
GPR55-mediated.  Furthermore, the NOSer-induced mobilisation of Ca2+ required free 
cytosolic Ca2+, ROCK, PLC, Ca2+ release from the ER, and the presence extracellular 
Ca2+ (figure 3.13).  Together this study introduces a novel group of lipids that are 
structurally similar to the endocannabinoids which activate GPR55 to promote Ca2+ 
mobilisation.   
 
Figure 3.13:  Summary of signalling cascade required to promote Ca2+ mobilisation.  
hGPR55-HEK293 cells were challenged with NOSer.  Upon NOSer activation of GPR55 it is 
suggested that Gα13 is activated and leads to phosphorylation of the small GTPase RhoA.  
ROCK phosphorylation leads to the activation of PLC which metabolises membrane bound 
PIP2 into IP3 and DAG. IP3 translocates to act on IP3 receptors in ER membrane and promotes 
the release of Ca2+.  Increases in Ca2+ lead to Ca2+ induced Ca2+ release by opening SOC 
localised in the plasma membrane.  NOSer, N-oleoyl-L-serine; GPR55, G-protein coupled 
receptor 55; RhoA, Ras homolog gene, family member A; ROCK, Rho associated protein 
kinase; PLC, Phospholipase C; PIP2, phosphatidylinositol 4, 5-bisphosphate; DAG, 
diacylglycerol; IP3, inositol 1, 4, 5-triphosphate; Ca2+, calcium; ER, endoplasmic reticulum.  
Solid arrows = signalling effectors; dashed arrows = suggested effectors.  
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To provide further evidence that the N-acyl amino acids are GPR55 agonists other 
signalling assays were examined.  Ca2+ signalling is important in homeostatic regulation 
and plays a role in transcriptional activation (Dolmetsch et al., 1998; Chawla and 
Bading, 2001).  A transcription factor that can be activated by Ca2+ signalling is CREB 
(Chawla and Bading, 2001).  In the next chapter GPR55-mediated N-acyl amino acid- 
induced CREB signalling will be discussed.  
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Promoted by N-acyl Amino Acids in 
hGPR55-HEK293 Cells 
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4.1.  INTRODUCTION 
GPR55 is known to signal through a plethora of pathways in recombinant 
overexpressing cell lines or endogenously GPR55 expressing immortalised cells along 
with primary cell cultures.  These pathways include Ca2+ mobilisation (Oka et al., 2007; 
Lauckner et al., 2008; Henstridge et al., 2009; Obara et al., 2011), cytoskeletal 
reorganisation (Balenga et al., 2011), phosphorylation of ERK1/2 (Oka et al., 2007, 
2009; Anavi-Goffer et al., 2012) and p38 MAPK phosphorylation (Oka et al., 2010).  
Furthermore, subsequent downstream signalling occurs promoting the activation of 
transcription factors such as nuclear factor of activated T-cells (NFAT; Henstridge et 
al., 2009), Activating transcription factor 2 (ATF2; Oka et al., 2010) and 
phosphorylation of cyclic AMP response element binding protein (pCREB; Henstridge 
et al., 2010).  LPI can induce GPR55-mediated pCREB in a concentration dependent 
manner in hGPR55-HEK293 cells (Henstridge et al., 2010).  Both Ca2+ (Sheng et al., 
1991; Impey et al., 1998) and the MAPK pathway (Impey et al., 1998) can induce 
pCREB and as mentioned above these are signalling pathways associated with GPR55.  
However the precise role of these pathways in GPR55-mediated pCREB has not been 
elucidated.   
 
Many of the effectors that GPR55 can activate are also important for cytoskeletal 
reorganisation, such as members of Rho small GTPase family which includes RhoA, 
cdc42 and rac1 (Ryberg et al., 2007).  GPR55-mediated signalling through ROCK has 
also been implicated in cytoskeletal reorganisation (Balenga et al., 2011).  Furthermore 
the authors report that the Gα13/Rho/ROCK signalling axis is important for changes in 
F-actin (the polymerised form of actin) in hGPR55-HEK293 cells (Balenga et al., 
2011).  LPI is reported to promote GPR55-mediated cytoskeletal reorganisation in the 
breast cancer cell line; MDA-MB-231 (Ford et al., 2010), hGPR55-HEK293 cells and 
the neutrophil cell line; HL60 (Balenga et al., 2011). Furthermore the focal adhesion 
protein, vinculin is known to be activated by Gα13 (Buhl et al., 1995) and Rho (Nobes 
and Hall, 1995; Amano et al., 1997) and as such could potentially be regulated by 
GPR55-mediated signalling.   
 
This study began by utilising previously characterised GPR55 agonists and novel N-
acyl amino acids to examine the activation of pCREB in hGPR55-HEK293 cells.  To 
date, N-acyl amino acids have not been evaluated in a GPR55-mediated pCREB assay.  
As CREB is a transcription factor downstream of multiple signalling pathways; the 
150 
 
mechanisms by which LPI and NOSer promote pCREB in hGPR55-HEK293 cells were 
compared.  Finally to assess whether LPI or the N-acyl amino acid, NOSer display 
agonist bias a further two GPR55 assays; a cytoskeletal reorganisation assay and a novel 
focal adhesion protein assay whereby changes in length of vinculin-containing FAs 
were assessed.  To the best of our knowledge GPR55-mediated changes in FAs have not 
been previously reported.  The potential signalling pathways required for cytoskeletal 
reorganisation and FA changes were also studied. 
 
4.2.  RESULTS 
4.2.1.  Cyclic AMP response element binding protein 
Several studies have reported that the phosphorylation of ERK1/2 can be mediated via 
GPR55 activation with LPI as a ligand (Oka et al., 2007; Whyte et al., 2009; Obara et 
al., 2011; Anavi-Goffer et al., 2012).  Downstream of ERK1/2 signalling is the 
transcription factor CREB.  Previously an increase in pCREB was observed in western 
blot studies, where certain cannabinoid ligands activated GPR55 (Henstridge et al., 
2010).  It was observed that AM251, a CB1 antagonist, was the most efficacious ligand 
tested (Henstridge et al., 2010).  Here a novel approach was developed to evaluate this 
pathway, utilising pCREB immunolabelling and confocal microscopy which allowed 
the visualisation of increases in pCREB and their cellular location.   
 
4.2.1.1.  Application of the synthetic cannabinoid, AM251, promotes nuclear 
pCREB in hGPR55-HEK293 cells. 
Previous western blot studies in hGPR55-HEK293 cells have shown efficacious effects 
of the synthetic CB1 antagonist, AM251 on pCREB mediated by GPR55 (Henstridge et 
al., 2010).  Therefore, in order to validate the immunocytochemical pCREB assay for 
GPR55, AM251 was use as a test ligand.  In control hGPR55-HEK293 cells treated 
with DMSO, pCREB labelling was at low levels.  Furthermore, cells treated with the 
12-OTetradecanoylphorbol-13-acetate (TPA; 100 nM), a phorbol ester used as a 
positive control, had marked nuclear pCREB staining.  Application of low 
concentrations of AM251 (10 nM - 30 nM) did not induced pCREB labelling.  Higher 
concentrations of AM251 (100 nM - 10 µM) however promoted concentration-
dependent nuclear pCREB expression with an EC50 of 256 ± 51 nM (95% confidence 
limits) (figure 4.1 and B).  
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Figure 4.1: AM251 induces nuclear pCREB expression in hGPR55-HEK293 cells.  Varying 
concentrations of AM251 were applied to hGPR55-HEK293 cells for 25 min.  Cells were 
methanol-fixed and pCREB labelling was visualised using a mouse anti-pCREB (ser 133) 
primary antibody followed by an Alexa fluor® 488-conjugated secondary antibody.  A, 
representative confocal images of nuclear pCREB in hGPR55-HEK293 cells illustrating the 
effects of various concentrations of AM251.  Ligand treatments were as follows DMSO, vehicle 
control; 100 nM TPA, positive control; 10 nM AM251; 30 nM AM251; 100 nM AM251; 300 nM 
AM251; 1 µM AM251; 3 µM AM251; 10 µM AM251.  Scale bars = 20 µm; n = 3.  Note that as 
the concentration of AM251 increases there is an increase in the intensity of nuclear pCREB 
staining.  B, AM251 concentration-response curve depicting the effects of AM251 on nuclear 
pCREB fluorescence in hGPR55-HEK293 cells.  Note AM251 increases pCREB in a 
concentration-dependent manner.  Fluorescence intensity is the corrected total nuclear 
A
DMSO 100 nM TPA 10 nM AM251
100 nM AM251 300 nM AM25130 nM AM251
1 µM AM251 3 µM AM251 10 µM AM251
B
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fluorescence (CTNF) minus the mean DMSO value normalised to that observed with 1 µM LPI.  
Data are the means ± SEM; n = 3.   
 
4.2.1.2. LPI promotes nuclear pCREB in hGPR55-HEK293 cells. 
Next, the effect of LPI, the putative, endogenous ligand for GPR55, on pCREB was 
evaluated in hGPR55-HEK293 cells.  Treatment of hGPR55-HEK293 cells with low 
concentrations of LPI (10 nM - 30 nM) had little effect on pCREB labelling.  However, 
higher levels (100 nM - 10 µM) promoted concentration-dependent increases in nuclear 
pCREB with an EC50 of 262 ± 54 nM (95% confidence limits) (figure 4.2A and B). 
 
Figure 4.2:  LPI promotes nuclear pCREB expression in hGPR55-HEK293 cells. Various 
concentrations of LPI were applied to hGPR55-HEK293 cells for 25 min.  A,  representative 
laser scanning confocal images of nuclear pCREB in hGPR55-HEK293 cells illustrating the 
DMSO 100 nM TPA 10 nM LPI
100 nM LPI 300 nM LPI30 nM LPI
1 µM LPI 3 µM LPI 10 µM LPI
A
B
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effects of various ligands, including: DMSO, vehicle control; 100 nM TPA, positive control; 10 
nM LPI; 30 nM LPI; 100 nM LPI; 300 nM LPI; 1 µM LPI; 3 µM LPI; 10 µM LPI.    Scale bars 
= 20 µm. n = 3.  B, LPI concentration-response curve for nuclear pCREB responses in 
hGPR55-HEK293 cells. Fluorescence intensity is the corrected total nuclear fluorescence 
(CTNF) minus the mean DMSO value then normalised to 1 µM LPI.  Data are the means ± 
SEM; n = 3. 
 
4.2.1.3. Pharmacological characterisation of N-acyl serine-evoked pCREB in 
hGPR55-HEK293 cells. 
In the next series of experiments N-acyl amino acid activation of GPR55-pCREB 
signalling in hGPR55-HEK293 cells was investigated using the N-acyl serines NASer, 
NOSer and NPSer which have previously been tested in the Ca2+ assay.  At 
concentrations below 100 nM NASer had no clear effect on pCREB).  However, higher 
concentrations of NASer (300 nM - 3 µM) induced concentration-dependent increases 
in nuclear pCREB; the EC50 was not calculated as the pCREB response did not reach a 
maximum level (figure 4.3A and B).    
 
Next hGPR55-HEK293 cells were treated with NOSer (10 nM - 10 µM), which induced 
a concentration-dependent increase in nuclear pCREB, giving an EC50 of 95 ± 29 nM 
(95% confidence limits) (figure 4.4A and B). 
 
The next ligand tested was NPSer.  Treatment of hGRP55-HEK293 cells with NPSer 
within the range 10 nM - 100 nM produced little effect.  However, higher 
concentrations of NPSer (300 nM - 10 µM) generated pCREB responses which were 
lower than those previously observed with NAS and NOSer in hGPR55-HEK293 cells 
(figure 4.5A and B).   
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Figure 4.3:  NASer induces nuclear pCREB in hGPR55-HEK293 cells. Various 
concentrations of NASer were applied to hGPR55-HEK293 cells for 25 min.  A,  representative 
confocal images of nuclear pCREB in hGPR55-HEK293 cells illustrating the effects of 25 min 
treatment with the following ligands: DMSO, vehicle control; 100 nM TPA, positive control; 10 
nM NASer; 30 nM NASer; 100 nM NASer; 300 nM NASer; 1 µM NASer; 3 µM NASer; 10 µM 
NASer.  Scale bars = 20 µm; n = 3.  B.  NASer concentration-response curve for nuclear 
pCREB in hGPR55-HEK293 cells.  Fluorescence intensity is CTNF minus the mean DMSO 
value then normalised to 1 µM LPI.  Data are the means ± SEM; n = 3.   
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Figure 4.4:  NOSer treatment of hGPR55-HEK293 cells promotes the phosphorylation of 
nuclear CREB.  Various concentrations of NOSer were applied to hGPR55-HEK293 cells for 
25 min.  A, representative confocal images of nuclear pCREB in hGPR55-HEK293 cells 
illustrating the effects 25 min exposure to various ligands., including DMSO, vehicle control; 
100 nM TPA, positive control; 10 nM NOSer; 30 nM NOSer; 100 nM NOSer; 300 nM NOSer; 1 
µM NOSer; 3 µM NOSer; 10 µM NOSer.  Scale bars = 20 µm. n = 3.  B, NOSer concentration-
response curve for nuclear pCREB fluorescence in hGPR55-HEK293 cells.  Fluorescence 
intensity is CTNF minus the mean DMSO value.  Data are the means ± SEM; n = 3.   
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Figure 4.5:  NPSer induces nuclear CREB phosphorylation in hGPR55-HEK293 cells. 
Various concentrations of NPSer were applied to hGPR55-HEK293 cells for 25 min.  A, 
representative confocal images of nuclear pCREB labelling in hGPR55-HEK293 cells 
illustrating the effects of 25 min treatment with various ligands, including DMSO, vehicle 
control; 100 nM TPA, positive control; 10 nM NPSer; 30 nM NPSer; 100 nM NPSer; 300 nM 
NPSer; 1 µM NPSer; 3 µM NPSer;  10 µM NPSer.  Scale bars = 20 µm.  n = 3.  B, NPSer 
concentration-response curve for nuclear pCREB in hGPR55-HEK293 cells.  Fluorescence 
intensity is CTNF minus the mean DMSO value then normalised to 1 µM LPI.  Data are the 
means ± SEM; n = 3.   
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4.2.1.4. Pharmacological characterisation of N-acyl glycine-induced pCREB in 
hGPR55-HEK293 cells. 
In the next experiments a range of N-acyl glycine ligands were evaluated using the 
GPR55 pCREB assay.  Firstly, hGPR55-HEK293 cells were challenged with NAGly at 
varying concentrations.  At 30 nM, NAGly had no clear effects. However, slight 
increases in nuclear pCREB staining were observed with NAGly treatment between 100 
- 300 nM.  More marked effects were observed at high concentration (1 - 10 µM), 
giving an EC50 of 848 ± 153nM (95% confidence limits) (figure 4.6A and B).  
  
Secondly pCREB responses to NOGly in hGPR55-HEK293 cells were tested.  NOGly 
(30 nM - 10 µM) produced a concentration-dependent increased in pCREB with an 
EC50 of 1085 ± 264 nM (95% confidence limits) (figure 4.7A and B).  
 
Finally, NPGly was tested in the pCREB assay.  Whilst this ligand had little effect in 
the Ca2+ assay it was evaluated for pCREB activity to determine whether it might 
display agonist-biased signalling.  However, NPGly over the concentration range 30 nM 
- 10 µM generated little or no pCREB response (figure 4.8A and B). 
 
 
 
158 
 
 
Figure 4.6:  NAGly induces nuclear pCREB in hGPR55-HEK293 cells. A, representative 
confocal images of nuclear pCREB labelling in hGPR55-HEK293 cells treated for 25 min with 
various ligands, including DMSO, vehicle control; 100 nM TPA, positive control; 10 nM 
NAGly; 30 nM NAGly; 100 nM NAGly; 300 nM NAGly; 1 µM NAGly; 3 µM NAGly;  10 µM 
NAGly.  Scale bars = 20 µm.  n = 3.  B, NAGly concentration-response curve of nuclear 
pCREB fluorescence in hGPR55-HEK293 cells.  Fluorescence intensity is CTNF minus the 
mean DMSO value then normalised to 1 µM LPI.  Data are the means ± SEM; n = 3.   
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Figure 4.7: NOGly induces nuclear pCREB in hGPR55-HEK293 cells. Various 
concentrations of NOGly were applied to hGPR55-HEK293 cells for 25 min. A,  representative 
confocal images of nuclear pCREB in hGPR55-HEK293 cells illustrating the effects of 25 min 
treatment with the following ligands,  DMSO, vehicle control; 100 nM TPA, positive control; 10 
nM NOGly; 30 nM NOGly; 100 nM NOGly; 300 nM NOGly; 1 µM NOGly; 3 µM NOGly;  10 
µM NOGly.  Scale bars = 20 µm. n = 3.  B, NOGly concentration-response curve for nuclear 
pCREB labelling in hGPR55-HEK293 cells.  Fluorescence intensity is corrected total nuclear 
fluorescence minus the mean DMSO value then normalised to 1 µM LPI.  Data are the means ± 
SEM; n = 3. 
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Figure 4.8:  Effects of NPGly on nuclear pCREB in hGPR55-HEK293 cells. Various 
concentrations of NPGly were applied to hGPR55-HEK293 cells for 25 min.  A, representative 
confocal images of nuclear pCREB in hGPR55-HEK293 cells illustrating the effects of 25 min 
treatment with the following compounds, DMSO, vehicle control; 100 nM TPA, positive control; 
10 nM NPGly; 30 nM NPGly; 100 nM NPGly; 300 nM NPGly; 1 µM NPGly; 3 µM NPGly;  10 
µM NPGly.  Scale bars = 20 µm. n = 3.  B, NPGly concentration-response curve for nuclear 
pCREB fluorescence in hGPR55-HEK293 cells.  Fluorescence intensity is CTNF minus the 
mean DMSO value normalised to 1 µM LPI.  Data are the means ± SEM; n = 3.   
 
4.2.1.5. The relative potencies and efficacy of endogenous N-acyl amino acids-
evoked pCREB in hGPR55-HEK293 cells. 
AM251 was found to be more efficacious than LPI  (figure 4.9) which is in agreement 
with a previous western blot study using hGPR55-HEK293 cells (Henstridge et al., 
A
DMSO 100 nM TPA 10 nM NPGly
100 nM NPGly 300 nM NPGly30 nM NPGly
1 µM NPGly 3 µM NPGly 10 µM NPGly
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2010).  NOSer was also found to have a higher Emax than LPI.  Indeed NOSer was 
~30% more efficacious than LPI.  In contrast to the Ca2+ assay these data suggest that 
NOSer is more efficacious in the pCREB assay than in the Ca2+ mobilisation assay.  As 
noted in the Ca2+ assay the serine head group appears to increase the pCREB efficacies 
compared to the lipids with a glycine head group suggesting that there is no ligand bias 
with the N-acyl amino acids. 
 
 
Figure 4.9:  Pooled concentration-response data for pCREB responses to lipids in hGPR55-
HEK293 cells.  A, comparison of the lipids that contain a serine head group.  B, comparison of 
lipids that contain a glycine head group.  C, comparison of lipids with the arachidonic (C20:4) 
fatty acid chain.  D, comparison of lipids containing oleic (C18:1) fatty acid chain.  E, 
comparison of lipids containing palmitic (16:0) fatty acid chain.  Note the presence of a glycine 
head group increases the efficacy in the lipids with either arachidonic or oleic fatty acid chains.  
NASer and NOSer are more efficacious than LPI.  Data are the mean responses ± SEM; n = 3. 
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NOSer was found to be the most potent of the ligands tested in the pCREB assay (table 
4.1).  This was followed by AM251 and LPI; all with EC50 values in the low nanomolar 
range.  NOGly was found to have an EC50 value which was in the low micromolar 
range.  This was a little unexpected as this lipid had shown similar EC50 values in the 
Ca2+ assay to NOSer.  These data therefore suggest that NOGly may be exerting some 
agonist bias when acting on GPR55 in hGPR55-HEK293 cells.  NASer, NPSer and 
NPGly did not produce a clear maximal response within the concentration range tested 
therefore an EC50 could not be calculated.  NAGly in both the Ca2+ and pCREB assay 
was found to have an EC50 that was in the high nanomolar range.   
 
Ligand EC50 (nM) 
AM251 256 ± 51 
LPI 262 ± 54 
NASer nd 
NOSer 95 ± 29 
NPSer nd 
NAGly 848 ± 153 
NOGly 1085 ± 264 
NPGly nd 
 
Table 4.1:  Relative potencies of pCREB compared to LPI.  EC50 values for the ligands 
studied.  NASer, NPSer and NPGly were undetermined as their Emax values could not be 
determined.  Note the most potent ligands were NOSer, AM251 and LPI.  Results are derived 
from three independent experiments. nd = not determined.  EC50 values (95% confidence 
limits). 
 
4.2.1.6. Endogenous lipids do not promote pCREB signalling in control HEK293 
cells. 
The endogenous lipoamino acids were tested for pCREB activity in control HEK293 
cells.  None of the GPR55 lipid ligands generated pCREB responses in HEK293 cells.  
However, responses were observed with 100 nM TPA; a phorbol ester used as a positive 
control.  Responses to supra-maximal concentrations of GPR55 ligands were compared 
between hGPR55-HEK293 cells and HEK293 cells.  In hGPR55-HEK293 cells a one-
way ANOVA highlighted increases in pCREB were significant (F(17,36) = 12.17; P = 
0.0001).  Moreover Bonferroni post hoc analysis revealed that compared to DMSO, 
vehicle control, all lipids except 3 µM NOGly and 3 µM NPGly were significantly 
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different.  Furthermore 3 µM NPGly pCREB staining was similar to DMSO in 
hGPR55-HEK293 cells (figure 4.10A).  However, no significant effects of the ligands 
on pCREB were observed in HEK293 cells relative to DMSO control (figure 4.10A and 
B). These results suggest that the pCREB promoted by the endogenous lipids are 
GPR55-mediated. 
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Figure 4.10:  A comparison of pCREB responses to GPR55 ligands in hGPR55-HEK293 cells 
and control HEK293 cells.    Cells were treated with ligands for 25 min.  A, Representative 
confocal images of hGPR55-HEK293 cells and HEK293 cells exposed to the following 
treatments: DMSO; 100 nM TPA; 3 µM AM251; 3 µM LPI; 3 µM NASer; 3 µM NOSer;  3 µM 
NPSer; 3 µM NAGly; 3 µM NOGly; 3 µM NPGly.  B, histogram of pooled data depicting 
nuclear pCREB responses to various ligands in either hGPR55-HEK293 (black) or HEK293 
cells (grey).  Note that pCREB responses to GPR55 ligands are absent in HEK293 cells.  Data 
is CTNF normalised to 1 µM LPI.  Data are the means ± SEM; n = 3.  One-way ANOVA 
followed by a Bonferroni post hoc test; #P < 0.05; ##P < 0.01; ###P < 0.001; ns = not 
significant. 
 
4.2.1.7. Gα13, not Gαq, is required for the phosphorylation of nuclear CREB in 
hGPR55-HEK293 cells. 
Two heterotrimeric G-protein families have been suggested to be involved in GPR55 
signalling, including Gα12 and Gαq.  For example, the related G proteins Gα12 and Gα13 
have been implicated in the mobilisation of Ca2+ in hGPR55-HEK293 cells (Lauckner et 
al., 2008; Henstridge et al., 2009)   However, Gαq may also have a role in this pathway 
in recombinant hGPR55-HEK293 cells (Lauckner et al., 2008) and also the rat 
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phaeochromocytoma cell line and PC12 cells (Obara et al., 2011) treated with either 
THC (5 µM) or LPI (10 µM) respectively. 
 
Initially the effects of dominant negative Gα13(Q226L/D294N) on responses to LPI and 
NOSer were investigated.  One-way ANOVA highlighted that hGPR55-HEK293 cells 
transfected with Gα13(Q226L/D294N) promoted significant increases across the data set 
(F(5,6) = 17.11; P = 0.0017).   Bonferroni post hoc analysis revealed that LPI in the 
presence of Gα13(Q226L/D294N) generated a pCREB response which was significantly 
less than LPI alone.  Furthermore, the general trend was that Gα13(Q226L/D294N) 
transfected hGPR55-HEK293 cells treated with NOSer promoted pCREB responses that 
were lower than NOSer alone however, this was not significant.  Both LPI or NOSer in 
the presence of Gα13(Q226L/D294N) and Gα13(Q226L/D294N) alone produced pCREB 
staining that was similar to basal levels (figure 4.11A and B). 
 
The cyclic depsipeptide YM-254890 was derived from culture broth of the bacterium, 
Chromobacterium sp. QS3666 and had been observed to inhibit platelet aggregation 
(Taniguchi et al., 2003).  Ca2+ mobilisation was inhibited when known Gαq activated 
receptors were studied and the effect was found to mediated by YM-254890 inhibiting 
the exchange of GDP for GTP on Gαq following receptor activation (Takasaki et al., 
2004; Nishimura et al., 2010).   Furthermore LPI-induced Ca2+ mobilisation in PC12 
cells, which endogenously express GPR55, was inhibited by YM-254890 (Obara et al., 
2011).  Therefore the Gαq inhibitor YM-254890 (1 µM) was used to elucidate if the Gαq 
signalling is required for GPR55 to promote nuclear pCREB.  An one-way ANOVA 
highlighted a significant difference across the data set (F(5,12) = 17.65; P < 0.0001). Post 
hoc analysis revealed that LPI treated hGPR55-HEK293 cells when compared to other 
cells treated with LPI in the presence of YM-254890 there was very little difference 
observed (figure 4.12A and B).  Similarly, NOSer alone when compared to YM-254890 
co-applied with NOSer showed little difference in pCREB staining.  Finally treatment 
with YM254890 alone had no effect on pCREB levels, producing staining that was 
similar to that observed with DMSO.  
 
Taken together these data suggest that LPI requires Gα13 but not Gαq heterotrimeric G-
proteins to induce nuclear pCREB in hGPR55-HEK293 cells.  These data are in 
agreement with a previous Ca2+ signalling study in hGPR55-HEK293 cells where Gα13 
was important to promote the mobilisation of Ca2+ in cells treated with LPI (Henstridge 
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et al., 2009).  Moreover, NOSer induce pCREB is likely to be Gα13 dependent and Gαq 
independent. 
 
 
 
Figure 4.11:  Gα13 is required for GPR55-mediated CREB activation in hGPR55-HEK293 
cells.  Cells were transfected with a dominant negative Gα13 cDNA (Q226L/D294N) for 18 hr 
prior to application of the lipids.  A, representative confocal images of pCREB labelling in 
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hGPR55-HEK293 in response to the following treatments: DMSO; 1 µM LPI; 1 µM NOSer; 
Gα13(Q226L/D294N); Gα13(Q226L/D294N) + 1 µM LPI; Gα13(Q226L/D294N) + 1 µM NOSer.  
Scale bars = 20 µm; n = 2.  B, histogram of pooled data, showing the mean CTNF normalised 
to 1 µM LPI when hGPR55-HEK293 cells were challenged with either 1 µM LPI or 1 µM 
NOSer either with or without the presence of Gα13(Q226L/D294N).  Data are the means ± SEM; 
n = 2.  * = compared to vehicle control.  One-way ANOVA with a Bonferroni post hoc test; **P 
< 0.01; #P < 0.05; ns = not significant.  
 
4.2.1.8. The Rho-ROCK pathway is required for GPR55-mediated nuclear CREB 
phosphorylation.  
The next set of experiments was designed to study the effect inhibiting Rho had on 
GPR55-mediated pCREB.  Previous work reported that the small G-protein RhoA is 
downstream of GPR55-mediated signalling through activation of Gα12 and Gα13 
heterotrimeric G-proteins when challenged with either cannabinoid ligands, AEA or O-
1602 (Ryberg et al., 2007), or with LPI  (Henstridge et al., 2009).    Therefore, a 
membrane permeable Rho inhibitor, CT04 (1 µg/ml) was tested in hGPR55-HEK293 
cells to assess the effect of Rho in the promotion of nuclear pCREB.   Significant 
differences were highlighted when testing the data with a one-way ANOVA (F(5,12) = 
4.93; P = 0.011).  Post hoc analysis revealed that CT04 (1 µg/ml) had no effect by itself, 
relative to vehicle control (DMSO; 0.1%) on nuclear pCREB staining (figure 4.13A and 
B).  Moreover NOSer promoted a significant increase in nuclear pCREB.  However, 
CT04-treated hGPR55-HEK293 cells challenged with LPI exhibited 58.24 ± 22.93% 
reduced responses when compared to LPI alone.   Likewise, responses to NOSer were 
also inhibited by 48.94 ± 6.5% in the presence of CT04.  However the lowering of the 
lipids response in the presence of CT04 was not significant. 
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Figure 4.12:  Gαq is not required for GPR55-mediated CREB phosphorylation in hGPR55-
HEK293 cells.  Cells were treated for 30 min with a Gαq inhibitor (YM-254890; 1 µM) prior to 
co-application of inhibitor with LPI or NOSer.  A, representative confocal images of nuclear 
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pCREB labelling in hGPR55-HEK293 cells treated as follows: DMSO; 1 µM LPI; 1 µM 
NOSer; 1 µM YM-254890; 1 µM YM-254890 + 1 µM LPI; 1 µM YM-254890 + 1 µM NOSer. 
Scale bars = 20 µm; n = 3.    B, histogram of pooled data, revealing the mean CTNF 
normalised to 1 µM LPI of nuclear pCREB fluorescence when hGPR55-HEK293 cells were 
challenged with either 1 µM LPI or 1 µM NOSer either with or without 1 µM YM-254890.  C, 
chemical structure of YM-254890.  Note the presence of the Gαq inhibitor has no significant 
effect on the responses promoted by the lipids.  Data are the means ± SEM; n = 3.  * = 
compared to vehicle control.  One-way ANOVA with a Bonferroni post hoc test; *P < 0.05; 
***P < 0.001; ns = not significant.  
 
 
Figure 4.13:  Signalling through Rho small GTPases is required for GPR55-mediated 
pCREB signalling.  hGPR55-HEK293 were treated for 4 hr with a membrane permeant Rho 
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inhibitor (CT04; 1 µg/ml) prior to treatment with lipid ligands.  A, representative confocal 
images of nuclear pCREB in cells treated as follows: DMSO; 1 µM LPI; 1 µM NOSer; 1 µg/ml 
CT04; 1 µg/ml CT04 + 1 µM LPI; 1 µg/ml CT04 + 1 µM NOSer. Scale bars = 20 µm; n = 3.  
B, histogram of pooled data, revealing the mean CTNF normalised to 1 µM LPI of nuclear 
pCREB fluorescence of hGPR55-HEK293 cells challenged as stated.    Note NOSer-induced 
pCREB staining was more robust than LPI-induced pCREB staining.  Data are the means ± 
SEM; n = 3.  * = compared to vehicle control.   One-way ANOVA with a Bonferroni post hoc 
test; * < 0.05; ns = not significant.  
 
Next the effects of inhibition of Rho kinases (ROCK) I and II were investigated using 
the synthetic inhibitors; Y-27632 dihydrochloride which targets the catalytic site of 
ROCK I and ROCK II (Ishizaki et al., 2000; Tamura et al., 2005) or H1152 
dihydrochloride which blocks ROCK II (Tamura et al., 2005).  LPI and NOSer 
produced a robust increase in pCREB staining that is localised to the nucleus (figure 
4.14A). Furthermore an one-way ANOVA highlighted a significant difference across 
the experimental data (F(5,12) = 36.3; P < 0.0001).   Post hoc analysis revealed a very 
highly significant difference to either of the lipids when compared to the lipid in the 
presence of Y-27632.  Furthermore treatment with Y-27632 (10 µM) lowered nuclear 
pCREB to both LPI and NOSer by 68.44 ± 8.15% and 59.73 ± 7.92%.  Y-27632 + LPI 
and Y27632 + NOSer reduced the nuclear pCREB response to basal levels (figure 
4.14A). Moreover by itself, Y-27632 had no effect on pCREB levels (figure 4.14A and 
B). 
 
One-way ANOVA revealed significant differences within the ROCK II inhibitor data 
set (F(5,12) = 17.95; P < 0.0001).  Bonferroni post hoc analysis revealed a general trend 
whereby CREB phosphorylation was reduced when H1152 (100 nM) was co-applied 
with LPI by 86.0 ± 9.5% or NOSer by 34.8 ± 27.6% however these effects were not 
significant.  When tested by itself, H1152 alone had no effect on pCREB labelling 
(figure 4.14D and E).  Taken together these data suggest that ROCK I is required to 
promote nuclear pCREB in hGPR55-HEK293 cells treated with either of the lipids 
tested.  However it is likely that ROCK II is required in hGPR55-HEK293 cells 
challenged with LPI but may not be so important in cells treated with NOSer. 
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Figure 4.14:  A role for ROCK signalling in GPR55-mediated pCREB signalling.  hGPR55-
HEK293 cells were treated with ROCK inhibitors (either Y-27632 dihydrochloride; 10 µM or 
H1152 dihydrochloride; 100 nM) for 30 min prior to co-application of inhibitor and either 1 
µM LPI or 1 µM NOSer for a further 25 min.  A, representative confocal images of pCREB 
labelling in cells following treatment with: DMSO; 1 µM LPI; 1 µM NOSer; 10 µM Y-27632; 
10 µM Y-27632 + 1 µM LPI; 10 µM Y-27632 + 1 µM NOSer.  Scale bars = 20 µm; n = 3.  B, 
histogram of pooled data, showing the mean CTNF of pCREB normalised to 1 µM LPI, 
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hGPR55-HEK293 cells were challenged with either 1 µM LPI or 1 µM NOSer in the absence or 
presence of 10 µM Y-27632.  C, chemical structure of Y-27632 dihydrochloride.  D, 
representative confocal images of nuclear pCREB in hGPR55-HEK293 cells following 
treatment with:  DMSO; 1 µM LPI; 1 µM NOSer; 100 nM H1152; 100 nM H1152 + 1 µM LPI; 
100 nM H1152 + 1 µM NOSer.  Scale bars = 20 µm; n = 3.  E, histogram depicting pooled 
pCREB data, highlighting the mean CTNF normalised to 1 µM LPI for responses to 1 µM LPI 
or 1 µM NOSer in the presence or absence of 100 nM H1152.  F, chemical structure of H1152 
dihydrochloride.  Data are the means ± SEM; n = 3.  * = compared to vehicle control.  One-
way ANOVA with a Bonferroni post hoc test; **P < 0.01; ***P < 0.001; ###P < 0.001; ns = 
not significant.  
 
4.2.1.9. Does Ca2+ play a role in GPR55-mediated pCREB signalling in hGPR55-
HEK 293 cells? 
Mobilisation of Ca2+ is downstream of GPR55 in hGPR55-HEK293 cells treated with 
either LPI or NOSer.  Previous research has shown that Ca2+ plays a role in 
transcriptional regulation; where the amplitude and frequency of transient Ca2+ 
oscillations are important factors (Dolmetsch et al., 1998).  As GPR55-mediated Ca2+ 
mobilisation is oscillatory it suggests that Ca2+ may play an important role in pCREB in 
hGPR55-HEK293 cells treated with endogenous lipid ligands.  Therefore this next set 
of experiments was designed to assess if Ca2+ is involved in GPR55-mediated pCREB 
signalling.  To study if free cytosolic Ca2+ influences nuclear pCREB in hGPR55-
HEK293 cells the cell permeable Ca2+ chelator, BAPTA-AM (50 µM), was utilised. 
Treatment with BAPTA-AM (50 µM; 55 min) itself resulted in a small increase in 
nuclear pCREB labelling, however when applied 30 min before and then in the presence 
of either of the lipids there was a lowering of nuclear pCREB observed (F(5,6) = 9.512; P 
= 0.0081).  There is a general trend whereby both LPI and NOSer are inhibited by 
BAPTA-AM; 78.12 ± 5.46% and 84.90 ± 6.33% respectively. However Bonferroni post 
hoc analysis revealed no significant difference between hGPR55-HEK293 cells treated 
with lipid alone or in the presence of BAPTA-AM.  These data suggest that it is likely 
that chelation of intracellular Ca2+ exerts a small effect on pCREB responses in 
hGPR55-HEK293 cells treated with the endogenous lipids.  
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Figure 4.15: Intracellular Ca2+ chelation influences GPR55-mediated pCREB signalling.  
hGPR55-HEK293 cells were treated for 30 min with a Ca2+ chelator (BAPTA-AM; 50 µM) 
prior to co-application of chelator with lipid.  A, representative confocal images of nuclear 
pCREB labelling in cells following treatment with, DMSO; 1 µM LPI; 1 µM NOSer; 50 µM 
BAPTA-AM; 50 µM BAPTA-AM + 1 µM LPI; 50 µM BAPTA-AM + 1 µM NOSer.   Scale bars 
= 20 µm; n = 2.  B, histogram of pooled data, highlighting the mean CTNF normalised to 1 µM 
LPI for responses to either 1 µM LPI or 1 µM NOSer either in the absence or presence of 50 
µM BAPTA-AM.  Data are the means ± SEM; n = 2.  Note chelation of Ca2+ decreases the 
nuclear pCREB labelling of lipid treated hGPR55-HEK293 cells.  C, chemical structure of 
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BAPTA-AM.  * = compared to vehicle control.  One-way ANOVA with a Bonferroni post hoc 
test; *P < 0.05; ns = not significant.  
 
As oscillatory Ca2+ transients in hGPR55-HEK293 cells require extracellular Ca2+ 
(Henstridge et al., 2009) the effects of extracellular Ca2+ on GPR55-mediated pCREB 
activity was studied.  Thus hGPR55-HEK293 cells were pre-treated with Ca2+-free HBS 
supplemented with 100 µM EDTA (CF-HBS) for 5 min prior to application of lipids in 
CF-HBS for a further 25 min.  Analysis with a one-way ANOVA highlighted that there 
were significant differences across the CF-HBS experimental data (F(5,12) = 13.23; P = 
0.0002).  Treatment of cells with CF-HBS had no effect on basal pCREB activity 
(figure 4.16A and B).  However, it was noted that cells in CF-HBS had a tendency to 
become retracted with a rounded morphology during the experiment.  Responses to LPI 
in CF-HBS in hGPR55-HEK293 cells were markedly inhibited by 75.7 ±13.3% and 
were not significantly different from CF-HBS.   Interestingly, in the presence of CF-
HBS NOSer responses were inhibited to a lesser extent of 52.1 ±17.5% than observed 
with LPI.  However despite the general trend of CF-HBS inhibiting the lipids, 
Bonferroni post hoc analysis revealed the inhibition was not significant.  These data 
suggest that extracellular Ca2+ is likely to be involved in GPR55-mediated pCREB 
signalling in hGPR55-HEK293 cells treated with either of the lipids.  Therefore, 
extracellular Ca2+ may be important for responses to LPI than NOSer. 
 
PLC activation is reported to be required for GPR55-mediated Ca2+ mobilisation in 
hGPR55-HEK293 cells challenged with either cannabinoid ligands (Δ9THC; JWH015) 
or LPI (Lauckner et al., 2008; Henstridge et al., 2009).  The present study has also 
highlighted that PLC is required for NOSer-mediated Ca2+ mobilisation in hGPR55-
HEK293 cells.  Therefore the PLC inhibitor, U73122 (1 µM), was used to evaluate 
whether PLC is involved in GPR55-pCREB signalling in hGPR55-HEK293 cells. One-
way ANOVA revealed significant differences within the experimental data (F(5,12) = 
21.21; P < 0.0001).  Bonferroni post hoc analysis highlighted that treatment with 
U73122 itself (1 µM) did not significantly affect pCREB levels (figure 4.17A and B). 
However, responses to LPI and NOSer were inhibited in cells treated with co-
application of U73122 by 75.6 ±3.5% and 63.7 ±10.1% respectively compared to cells 
treated with lipid alone. These data suggest that PLC is involved in promoting pCREB 
in hGPR55-HEK293 cells treated with endogenous lipids.   
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Figure 4.16:  A role for extracellular Ca2+ in GPR55-mediated pCREB signalling.  hGPR55-
HEK293 cells were placed in normal extracellular Ca2+ or Ca2+ free HBS + 100 µM EDTA 
(CF-HBS) for 5 min prior to the addition of the appropriate lipid ligand.  A, representative 
confocal images of nuclear pCREB labelling in cells following treatment with: DMSO; 1 µM 
LPI; 1 µM NOSer; CF-HBS; CF-HBS + 1 µM LPI; CF-HBS + 1 µM NOSer.  Scale bars = 20 
µm; n = 3.  B, histogram of pooled data; depicting the mean CTNF normalised to 1 µM LPI of 
pCREB in hGPR55-HEK293 cells treated with either 1 µM LPI, 1 µM NOSer in HBS or with 
the lipid in CF-HBS.  Note extracellular Ca2+ is involved for GPR55-mediated nuclear pCREB 
activity in hGPR55-HEK293 cells.  * = data compared to vehicle control.  Data are the means 
± SEM; n = 3.  One-way ANOVA with a Bonferroni post hoc test; *P < 0.05; ***P < 0.001; ns 
= not significant.  
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CaMKII has been implicated in signalling to CREB (Zanassi et al., 2001) and can be 
activated by an increase in intracellular Ca2+.  Therefore the cell permeable CaMKII 
inhibitor KN-62 (Tokumitsu et al., 1990) was tested on the hGPR55-HEK293 cells.  
One-way ANOVA analysis highlighted significant differences within the CAMKII 
experimental data (F(5,12) = 11.79; P = 0.0003).  Further analysis with a Bonferroni post 
hoc test revealed that cells treated with the CaMKII inhibitor KN-62 (2 µM) alone did 
not significantly affect basal pCREB levels. However, although the general trend was 
one whereby lower pCREB responses was observed where the lipids were co-applied 
with KN-62 however this was not significantly different to lipid alone.   It is likely that 
CAMKII is required to promote nuclear pCREB responses in hGPR55-HEK293 cells 
challenged with either LPI or NOSer (figure 4.18A and B).   
 
PKC a kinase activated downstream of PLC or via increased Ca2+ has been implicated 
as a signalling mediator leading to CREB phosphorylation (Zanassi et al., 2001).  
Therefore Gö6983 (1 µM), a cell permeable, selective PKC inhibitor was tested on LPI 
and NOSer responses in hGPR55-HEK293 cells.  One-way ANOVA revealed 
significant differences across the experimental data (F(5,12) = 32.31; P < 0.0001).  
Therefore the data was subjected to a Bonferroni post hoc test where it highlighted that 
treatment with Gö6983 alone did not affect basal pCREB levels (figure 4.19A and B). 
However, LPI or NOSer when co-applied with Gö6983 exhibited reduced nuclear 
pCREB responses by 81.1 ± 3.5% and 60.3 ± 5.7% respectively.   
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Figure 4.17:  A role for PLC in GPR55-mediated nuclear pCREB signalling in hGPR55-
HEK293 cells treated with endogenous lipids.  Cells were treated for 30 min with a PLC 
inhibitor (U73122; 1 µM) prior to co-application of inhibitor with ligand.  A, representative 
confocal images of nuclear pCREB in hGPR55-HEK293 cells following treatment with: DMSO; 
1 µM LPI; 1 µM NOSer; 1 µM U73122; 1 µM U73122 + 1 µM LPI; 1 µM U73122 + 1 µM 
NOSer.   Scale bars = 20 µm.  n = 3.  B, histogram of pooled data, showing the mean CTNF 
normalised to 1 µM LPI of pCREB when hGPR55-HEK293 cells were challenged with either 1 
1 µM U73122
+ 1 µM NOSer
DMSO 1 µM LPI 1 µM NOSer
1 µM U73122 1 µM U73122
+ 1 µM LPI
A
D
M
SO
M
 L
PI
µ
1 
M
 L
PI
µ
M
 U
73
12
2+
1 
µ
1 
M
 N
O
Se
r
µ
1 
M
 N
O
Se
r
µ
M
 U
73
12
2+
1 
µ
1 
M
 U
73
12
2
µ
1 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
**
***
*
# ##
re
la
tiv
e
flu
or
es
ce
nc
e 
in
te
ns
ity
B
C
179 
 
µM LPI or 1 µM NOSer either with or without co-application of 1 µM U73122.  Note inhibition 
of PLC decreases the immunolabelling of lipid-induced nuclear pCREB.  C, structure of 
U73122.  Data are the means ± SEM; n = 3.  * = compared to vehicle control.  One-way 
ANOVA with a Bonferroni post hoc test; *P < 0.05; **P < 0.01; ***P < 0.001; #P < 0.05; ##P 
< 0.01.  
 
 
Figure 4.18:  CaMKII is involved in GPR55-mediated nuclear pCREB responses in hGPR55-
HEK293 cells treated with endogenous lipids.  Cells were treated for 30 min with a CaMKII 
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inhibitor (KN-62; 2 µM) prior to co-application of inhibitor with lipid ligands.  A, 
representative confocal images of pCREB in hGPR55-HEK293 cells treated as follows: DMSO; 
1 µM LPI; 1 µM NOSer; 2 µM KN-62; 2 µM KN-62 + 1 µM LPI; 2 µM KN-62 + 1 µM NOSer.   
Scale bars = 20 µm; n = 3.  B, histogram of pooled data, showing the mean pCREB CTNF 
normalised to 1 µM LPI when hGPR55-HEK293 cells were challenged with either 1 µM LPI or 
1 µM NOSer either in the absence or presence of 2 µM KN-62.  C, chemical structure of KN-62.    
Data are the means ± SEM; n = 75 cells derived from 3 independent experiments.  * = 
compared to vehicle control.   One-way ANOVA with a Bonferroni post hoc test; **P < 0.01; 
***P < 0.001; ns = not significant.  
 
4.2.1.10. Phosphoinositide-3 kinase and mammalian Target of Rapamycin (mTOR) 
promotes pCREB in hGPR55-HEK293 cells challenged with endogenous lipids.  
In HUVEC cells GPR55-mediated Ca2+ mobilisation requires PI-3 kinase which then 
activates PLCγ (Falasca et al., 1998; Waldeck-Weiermair et al., 2008).  As observed in 
the present study the broad spectrum PLC inhibitor decreased agonist-stimulated 
pCREB in hGPR55-HEK293 cells.  Although the PLC isoform is unknown it is possible 
that PI-3 kinase may influence PLC in these cells.  Furthermore, PI-3 kinase is an 
upstream mediator of AKT (Dugourd et al., 2003) and GPR55 is reported to activate 
AKT in PC3 and DU145 prostate cancer cells  (Piñeiro et al., 2011).  The AKT/PKB 
pathway can also promote pCREB (Du and Montminy, 1998; Das et al., 2005).      
Therefore these experiments were designed to study the effect that PI-3-kinase 
inhibitors exert on GPR55-mediated pCREB when applied to hGPR55-HEK293 cells. 
One-way ANOVA analysis highlighted significant differences across the data set (F(5,12) 
= 13.37; P = 0.0001).  Bonferroni post hoc analysis revealed that treatment of cells with 
LY294002 (3 µM) did not affect basal pCREB levels (figure 4.20A and B).  However, 
LPI (1 µM) pCREB responses were inhibited by 91.0 ± 10.3% when co-applied with 
LY294002 compared to LPI treatment alone but were not significant.  Likewise with 
NOSer (1 µM), responses were significantly inhibited by 74.6 ± 8.0% with LY294002.   
 
To further determine that PI-3 kinase is involved in GPR55-mediated nuclear pCREB 
signalling, wortmannin, a structurally distinct PI-3 kinase inhibitor was tested. There 
were significant differences within the experimental data highlighted with one-way 
ANOVA analysis (F(5,12) = 16.04; P < 0.0001).  Wortmannin alone did not affect basal 
pCREB levels (figure 4.20D and E).  However, when wortmannin treatment reduced 
pCREB responses to LPI or NOSer by 89.2 ± 7.2% and 84.9 ± 7.5% respectively 
compared with agonist treatments alone.  
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Figure 4.19:  PKC is involved in GPR55-mediated pCREB responses in hGPR55-HEK293 
cells treated with endogenous lipids.  Cells were treated for 30 min with a PKC inhibitor 
(Gö6983; 1 µM) prior to co-application of inhibitor with lipid ligands.  A, representative 
confocal images of nuclear pCREB in hGPR55-HEK293 cells treated as follows: DMSO; 1 µM 
LPI; 1 µM NOSer; 1 µM Gö6983; 1 µM Gö6983 + 1 µM LPI; 1 µM Gö6983 + 1 µM NOSer.   
Scale bars = 20 µm; n = 3.  B, histogram of pooled data, depicting the mean pCREB CTNF 
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normalised to 1 µM LPI for hGPR55-HEK293 cells were challenged with either 1 µM LPI or 1 
µM NOSer in the absence or presence of 1 µM Gö6983.  C, chemical structure of Gö6983.  
Data are the means ± SEM; n = 75 cells derived from 3 independent experiments.  * = 
compared to vehicle control.  One-way ANOVA with a Bonferroni post hoc test; **P < 0.01; 
***P < 0.001; # < 0.05; ##P < 0.01. 
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4.20:  PI-3 kinase is involved in NOSer induced GPR55-mediated pCREB signalling.  
hGPR55-HEK293 cells were treated for 30 min with PI-3 kinase inhibitors (LY294002; 3 µM or 
wortmannin; 50 nM) prior to co-application of inhibitor with a lipid.  A, representative 
confocal images of nuclear pCREB in cells following treatment with: DMSO; 1 µM LPI; 1 µM 
NOSer; 3 µM LY294002; 3 µM LY294002 + 1 µM LPI; 3 µM LY294002 + 1 µM NOSer.   Scale 
bars = 20 µm.  n = 3.  B, histogram of pooled data, showing the mean CTNF normalised to 1 
µM LPI of nuclear pCREB when hGPR55-HEK293 cells were challenged with either 1 µM LPI 
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or 1 µM NOSer either in the presence of absence of 3 µM LY294002.    C, chemical structure of 
LY294002.  D, representative confocal images of hGPR55-HEK293 cells following treatment 
with DMSO; 1 µM LPI; 1 µM NOSer; 50 nM wortmannin; 50 nM wortmannin + 1 µM LPI; 50 
nM wortmannin + 1 µM NOSer.  Scale bars = 20 µm; n = 3.   E,  histogram of pooled data, 
highlighting the mean CTNF normalised to 1 µM LPI of nuclear pCREB in hGPR55-HEK 293 
cells when treated with either 1 µM LPI or 1 µM NOSer alone or in the presence of 50 nM 
wortmannin.  F, chemical structure of wortmannin.  Note that two structurally distinct PI-3 
kinase inhibitors decreased the NOSer-induced nuclear pCREB in hGPR55-HEK293 cells.  
Data are the means ± SEM; n = 3.   * = compared to vehicle control.  One-way ANOVA with a 
Bonferroni post hoc test; *P < 0.05; ***P < 0.001; #P < 0.05; ##P < 0.01; ns = not 
significant.  
 
The kinase mTOR is downstream of PI-3 kinase activation and has the ability to 
regulate AKT phosphorylation and as such may influence pCREB (Vogt, 2001).  This is 
the first study to look at potential GPR55-mediated mTOR effects.  One-way ANOVA 
highlighted a significant difference within the experimental data (F(5,12) = 3.824; P = 
0.0265).  A Bonferroni post hoc test revealed that treatment of cells with rapamycin (50 
nM; 55 min) resulted in a slight elevation, but not significant, on pCREB staining 
relative to vehicle control, basal levels (figure 4.21A and B).  Treatment with rapamycin 
lowered the nuclear pCREB responses to both LPI and NOSer but was not significant. 
The increase in pCREB responses to the presence of rapamycin alone makes it difficult 
to decipher the inhibition that is occurring with each of the endogenous lipids.  Further 
experiments would be required to allow a better understanding.  However these data 
suggest that mTOR is not required for GPR55 ligand-induced nuclear pCREB in 
hGPR55-HEK293 cells.   
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Figure 4.21:  A role for mTOR in GPR55-pCREB signalling.  The mTOR inhibitor 
(rapamycin; 50 nM) was applied to hGPR55-HEK293 cells for 30 min prior to co-application 
with either of the lipids.  A, representative confocal images of nuclear pCREB labelling in cells 
following treatment with DMSO; 1 µM LPI; 1 µM NOSer; 50 nM rapamycin; 50 nM rapamycin 
+ 1 µM LPI; 50 nM rapamycin + 1 µM NOSer.  Scale bars = 20 µm; n = 2.  B, histogram of 
pooled data; depicting the mean CTNF normalised to 1 µM LPI of nuclear pCREB in hGPR55-
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HEK293 cells treated with either 1 µM LPI, 1 µM NOSer or either lipid co-applied with 50 nM 
rapamycin.  * = data compared to vehicle control.  Data are the means ±SEM; n = 2.  One-way 
ANOVA with a Bonferroni post hoc test; *P < 0.05; ns = not significant.  
 
4.2.1.11. The MAP kinase pathway contributes to GPR55-pCREB signalling in 
hGPR55-HEK293 cells.  
Ca2+ is one pathway that is associated with pCREB.  Other signalling pathways, 
however can induce pCREB, one of which is MAPK (Wade, 2003).  LPI acting via 
GPR55 can activate the MAP kinase pathway leading to phosphorylation of ERK1/2 
(Oka et al., 2007; Henstridge et al., 2010; Anavi-Goffer et al., 2012).  Therefore, 
MEK1/2 inhibitors (protein upstream of ERK1/2) were utilised to study a potential role 
for MAPK in GPR55-mediated nuclear pCREB signalling in hGPR55-HEK293 cells.  
A one-way ANOVA highlighted a significant difference within MAPK experimental 
data (F(8,18) = 7.025; P = 0.0003).  The MEK1/2 inhibitors PD98059 (25 µM) or U0126 
(5 µM) did not affect basal pCREB staining (figure 4.22A and B).  In the presence of 
PD98059 pCREB responses to LPI or NOSer were inhibited by 86.8 ± 7.2% and 76.2 ± 
11.8% respectively.  Furthermore the presence of U0126 inhibited pCREB responses to 
LPI or NOSer by 95.2 ± 3.5% and 68.6 ± 7.9% respectively.  These data highlight that 
LPI was significantly inhibited but in contrast NOSer effects were not significant 
However NOSer did exert a general trend of inhibiting pCREB when the MEK1/2 
inhibitors were present. 
 
To further confirm the MEK1/2 inhibitors results, U0124 (5 µM), an inactive analogue 
of U0126 was employed.  Analysis by one-way ANOVA highlighted significant 
differences within the experimental data (F(5,12) = 20.30; P < 0.0001).  Furthermore a 
subsequent Bonferroni post hoc test revealed that vehicle control produced basal levels 
of pCREB that was not localised to the nucleus.  U0124 by itself did not affect basal 
pCREB levels (figure 4.22D and E).  Responses to LPI and NOSer in the presence of 
U0124 were also not effected.  These results suggest that the MAPK pathway is 
involved in GPR55-pCREB signalling in hGPR55-HEK293 cells when challenged with 
LPI and is likely to be important in NOSer induced pCREB. 
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Figure 4.22:  MAPK is involved in GPR55-pCREB signalling in hGPR55-HEK293 cells 
treated with endogenous lipids.  Cells were treated for 30 min with MEK1/2 inhibitors 
(PD98059; 25 µM or U0126; 5 µM) prior to co-application of inhibitor with lipid ligands.  
Alternatively cells were treated for 30 min with an inactive form of MEK inhibitor (U0124; 5 
µM) prior to the lipids being co-applied.   A, representative confocal images of nuclear pCREB 
in hGPR55-HEK293 following treatment with DMSO; 25 µM PD98059; 5 µM U0126; 1 µM 
LPI;  25 µM PD98059 + 1 µM LPI; 5 µM U0126 + 1 µM LPI; 1 µM NOSer; 25 µM PD98059 
+ 1 µM NOSer; 5 µM U0126 + 1 µM NOSer.  Scale bars = 20 µm.  n = 3.  B, histogram of 
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pooled data, showing the mean CTNF normalised to 1 µM LPI of pCREB in hGPR55-HEK293 
cells which were challenged with either 1 µM LPI or 1 µM NOSer either with or without 
MEK1/2 inhibitors either 25 µM PD98059 or 5 µM U0126.    C, chemical structures of the 
MEK1/2 inhibitors are as follows i, PD98059; ii, U0126.  D, representative confocal images of 
hGPR55-HEK293 cells challenged as follows: DMSO; 1 µM LPI; 1 µM NOSer; 5 µM U0124; 5 
µM U0124 + 1 µM LPI; 5 µM U0124 + 1 µM NOSer.  Scale bars = 20 µm; n = 3.   E, 
histogram of pooled data, highlighting the CTNF normalised to 1 µM LPI of pCREB in 
hGPR55-HEK293 cells challenged with either 1 µM LPI or 1 µM NOSer either alone or in the 
presence of 5 µM U0124.  F, structure of U0124; an inactive analogue of U0126.  Data are the 
means ± SEM; n = 3.  * = compared to vehicle control.  One-way ANOVA with a Bonferroni 
post hoc test; *P < 0.05; **P < 0.01; ***P < 0.001; #P < 0.05; ##P < 0.01; ns = not 
significant.  
 
4.2.2. The actin cytoskeleton and the focal adhesion protein, vinculin. 
These final sets of experiments were carried out to study effects the endogenous lipids 
could exert on the actin cytoskeleton or vinculin, a focal adhesion protein.  Whilst 
previous studies have highlighted morphological changes in neutrophils; HL60, 
hGPR55-HEK293 (Balenga et al., 2011) and the breast cancer cell line; MDA-MB-231 
(Ford et al., 2010) when treated with LPI.  NOSer has not been studied in a GPR55-
mediated cytoskeletal assay.  This is also the first study using a novel FA assay to assess 
changes induced by the two endogenous lipids; LPI and NOSer.   
 
4.2.2.1. Endogenous lipids modulate the actin cytoskeleton and FA length in 
hGPR55-HEK293 cells. 
In order to investigate the effects of GPR55 ligands on the F-actin cytoskeleton, 
hGPR55-HEK293 cells were treated with Alexa fluor® 546 phalloidin following ligand 
exposure and subsequent fixation and permeabilisation.  Endogenous lipids were 
applied for various times.  Following 10 min ligand treatment, the cytoskeleton of LPI 
(1 µM) and NOSer (1 µM) challenged hGPR55-HEK293 cells were similar to vehicle 
control (DMSO) cells (figure 4.23).  It should be noted that at each of the time points 
the control cells had a cell morphology that was flat and spread out.  Application of the 
lipid ligands for 15 min promoted a modest cytoskeletal reorganisation with some stress 
fibres (depicted by arrowheads) being observed.  Longer treatments with either of the 
endogenous lipids promoted the formation of additional stress fibres (depicted by 
arrowheads) and morphological changes whereby lamellipodia (depicted by arrows) 
were observed.  These effects were pronounced at 60 min with more of the cells being 
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observed to have both lamellipodia and stress fibres present.  It was observed that as the 
time was increased the proportion of cells with cytoskeletal reorganisation was 
increased.  However due to the nature of phalloidin whereby it can dissociate with time, 
no quantitative analysis was carried out.  
 
 
Figure 4.23:  Time-dependence of actin cytoskeletal reorganisation in hGPR55-HEK293 cells 
following exposure to GPR55 ligands. To visualise the actin cytoskeleton cells were fixed, 
permeabilised and then incubated with Alexa fluor® 546 phalloidin.  DMSO treated cells at all 
DMSO – 10 min 1 µM LPI – 10 min 1 µM NOSer – 10 min
DMSO – 60 min 1 µM LPI – 60 min 1 µM NOSer – 60 min
DMSO – 25 min 1 µM LPI – 25 min 1 µM NOSer – 25 min
DMSO – 15 min 1 µM LPI – 15 min 1 µM NOSer – 15 min
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the time points have a flattened, spread out morphology.  Application of either LPI or NOSer 
for 15 min promoted a slight cytoskeletal reorganisation with some filopodia present.  At 25 min 
the effects were much more pronounced with the formation of lamellipodia, filopodia and some 
stress fibres.  Notably, stress fibres were more prominent in NOSer treated hGPR55-HEK293 
cells, with some lamellipodia are still present with 60 min lipid challenge.  Scale bars = 20 µm; 
n = 3; arrows = lamellipodia; open arrow head = filopodia; arrowheads = stress fibres. 
 
A similar temporal study was carried out investigating structural changes in the 
expression of the focal adhesion vinculin, assessed using vinculin immunostaining in 
hGPR55-HEK293 cells.  Changes in FA length were measured following treatment with 
LPI and NOSer (figure 4.24A and B).  To determine if there were temporal differences 
and if lipid presences promoted differences in the FA length a two-way ANOVA was 
used.  This highlighted that there was a significant difference dependant on the time the 
lipids were applied for (F(8,4) = 3.81; P = 0.0249).  Furthermore the presence of the 
lipids promoted FA length that was significantly different to vehicle control treated cells 
(F(8,2) = 6.92; P = 0.0074).  At 10 min LPI (1 µM) treatment, FA length was increased 
but not significantly relative to DMSO treated cells (DMSO = 2.62 ± 0.00 µm, LPI = 
2.81 ± 0.51 µm, n = 2, figure 4.24A and B).  NOSer had no effect FA length (DMSO = 
2.62 ± 0.00 µm, NOSer = 2.69 ± 0.01 µm).  At 15 min, both lipids were found to 
promote an increase in the FA length when compared to control cells (DMSO = 2.36 ± 
0.16 µm, LPI = 3.41 ± 0.06 µm, NOSer = 3.12 ± 0.37 µm).  An increase in FA length 
was also observed following 25 min ligand exposure (DMSO = 2.29 ± 0.09 µm, LPI = 
3.41 ± 0.43 µm, NOSer = 3.45 ± 0.69 µm).  However, at 60 min ligand exposure, FA 
length was similar to control cells (DMSO = 2.47 ± 0.14 µm, LPI = 2.70 ± 0.01 µm, 
NOSer = 2.55 ± 0.23 µm).  Interestingly at 120 min the lipid-mediated changes in FA 
length were observed again with both LPI and NOSer treated cells with longer FAs than 
control cells (DMSO = 1.87 ± 0.05 µm, LPI = 2.42 ± 0.24 µm, NOSer = 2.43 ± 0.07 
µm).  These data highlight the dynamic nature of FA turnover in hGPR55-HEK293 
cells. As both lipids produced good responses at 25 min to both cytoskeletal 
reorganisation and vinculin labelling this time was used for all subsequent experiments 
using hGPR55-HEK293 cells.   
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A DMSO – 10 min 1 µM LPI – 10 min 1 µM NOSer – 10 min
DMSO – 60 min 1 µM LPI – 60 min 1 µM NOSer – 60 min
DMSO – 25 min 1 µM LPI – 25 min 1 µM NOSer – 25 min
DMSO – 15 min 1 µM LPI – 15 min 1 µM NOSer – 15 min
DMSO – 120 min 1 µM LPI – 120 min 1 µM NOSer – 120 min
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Figure 4.24:  Time-course study of changes in vinculin-containing FA length in hGPR55-
HEK293 cells challenged with endogenous lipids.  Lipids were applied for times stated and 
then fixed and permeabilised prior to application of anti-vinculin for 60 min.  FA 
immunostaining was visualised using an anti-vinculin primary antibody followed by Alexa 
fluor® 488 conjugated secondary antibody. A, representative confocal images are DMSO 
(vehicle control), LPI or NOSer. Scale bars = 20 µm; n = 2.  B, histogram of pooled data, 
depicting vinculin-containing FA length in hGPR55-HEK293 cells treated with either LPI or 
NOSer.  Note FA length was dynamic initially increasing with time and then returning to basal 
levels at 60 min only to slightly increase again at 120 min.  Data are the means ± SEM; n = 2.  
Two-way ANOVA with a Bonferroni post hoc test. 
 
4.2.2.2. Endogenous lipid effects on the actin cytoskeleton in hGPR55-HEK293 
cells and HEK293 cells. 
Next various concentrations of LPI were applied to hGPR55-HEK293 cells.  DMSO-
treated cells (0.1%; 25 min) exhibited a flat, spread out morphology with some filopodia 
present.  Cells treated with LPI (10 and 30 nM) were also found to have a flat 
morphology with some filopodia (open arrowheads) and were similar to control cells.  
Cells treated with higher concentrations of LPI (100 and 300 nM) were retracted and 
were smaller than observed in control cells with filopodia, lamellipodia (arrows) and 
stress fibres (solid arrowheads) beginning to be formed.   High concentrations of LPI (1 
- 10 µM) also produced some stress fibres, filopodia and lamellipodia.  The cells were 
retracted and more rounded-up than the control cells (figure 4.25). 
B
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Figure 4.25:  LPI-induced F-actin cytoskeletal reorganisation in hGPR55-HEK293 cells.  
Cells were treated with LPI or DMSO for 25 min. Representative confocal images of phalloidin 
labelling are illustrated for DMSO; 10 nM LPI; 30 nM LPI;  100 nM LPI; 300 nM LPI; 1 µM 
DMSO 10 nM LPI
30 nM LPI
300 nM LPI
3 µM LPI 10 µM LPI
1 µM LPI
100 nM LPI
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LPI; 3 µM LPI; 10 µM LPI.  Scale bars = 20 µm; n = 3.  Note as the LPI concentration 
increased the morphology of the hGPR55-HEK293 cells were observed to become retracted and 
more rounded-up with lamellipodia, filopodia and some stress fibres being produced.  Filled 
arrow head = stress fibres; open arrow head = filopodia; arrows = lamellipodia. 
 
Various concentrations of LPI (10 nM - 10 µM) was applied to hGPR55-HEK293 cells 
for 25 min.  Vinculin-positive FAs were found predominately on the cell periphery. As 
the LPI concentration increased the number of FAs produced per cell was observed to 
increase (figure 4.26A).  Furthermore, FA length was found to increase with LPI 
treatment, in a concentration dependent manner with an EC50 of 72 ± 10 nM (95% 
confidence limits) (figure 4.26B). 
 
The next experiments were designed to study the effects of NOSer on both cytoskeletal 
reorganisation and vinculin-containing FAs.  Application of NOSer (10 nM) to 
hGPR55-HEK293 cells did not affect cell morphology relative to control cells treated 
with DMSO.  At higher concentrations, NOSer (30 nM) led to cytoskeletal 
reorganisation occurring whereby lamellipodia, some filopodia and stress fibres were 
observed.  As the NOSer concentration was increased (100 nM - 10 µM) the cells 
retracted and were more rounded than control cells.  There was an increase in the 
expression of lamellipodia, filopodia and stress fibres (figure 4.27).  However, the stress 
fibres were not noticeable at 10 µM. 
 
Next, NOSer (10 nM - 10 µM) was applied to the hGPR55-HEK293 cells to study the 
effect the lipid had on vinculin-containing FAs (figure 4.28A).  As had been observed 
with LPI the FAs were localised predominantly at the cell periphery.  The number of 
FAs per cell was also observed increase with NOSer concentration.  Additionally, the 
length of the FAs was found to increase in a concentration-dependent manner with an 
EC50 for NOSer of 65 ± 11 nM (95% confidence limits) (figure 4.28B).  These data 
taken together for both LPI and NOSer suggest that cytoskeletal reorganisation and 
vinculin-containing FA length is affected in a similar manner by both lipids.  NOSer 
was however slightly more potent in both assays.  
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Figure 4.26:  LPI modulates vinculin-containing FA length in hGPR55-HEK293 cells.  A, 
Representative confocal images of vinculin labelling illustrating the effect of: DMSO; 10 nM 
LPI; 30 nM LPI; 100 nM LPI; 300 nM LPI; 1 µM LPI; 3 µM LPI; 10 µM LPI.  Scale bars = 20 
µm; n = 3.  B, histogram of pooled data, depicting concentration-dependent increases in 
vinculin-containing FA length.  Note, the number of FAs per cell was also observed to increase 
in a concentration-dependent manner.  Data are the means ± SEM; n = 3.    
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Figure 4.27: NOSer exhibits concentration-dependent cytoskeletal reorganisation in 
hGPR55-HEK293 cells.  Cells were treated with NOSer or DMSO for 25 min.  Representative 
confocal images of phalloidin labelling are illustrated for:  DMSO; 10 nM NOSer; 30 nM 
DMSO 10 nM NOSer
30 nM NOSer
300 nM NOSer
3 µM NOSer 10 µM NOSer
1 µM NOSer
100 nM NOSer
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NOSer;  100 nM NOSer; 300 nM NOSer; 1 µM NOSer; 3 µM NOSer; 10 µM NOSer.  Note the 
NOSer-induced increase in cytoskeletal structures; including filopodia, stress fibres and 
lamellipodia is concentration-dependent.  Scale bars = 20 µm; n = 3.  Filled arrow head = 
stress fibres; open arrow head = filopodia; arrows = lamellipodia. 
 
 
Figure 4.28:  NOSer modulates vinculin-containing FAs in hGPR55-HEK293 cells.  A, 
representative confocal images of vinculin labelling illustrating the effect of: DMSO; 10 nM 
LPI; 30 nM LPI; 100 nM LPI; 300 nM LPI; 1 µM LPI; 3 µM LPI; 10 µM LPI.  Scale bars = 20 
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µm; n = 3.  B, histogram of pooled vinculin-containing FAs length data suggesting increases in 
NOSer-induced FA length are concentration dependent.  Note the number of FAs also increased 
in a concentration dependent manner.  Data are the means ± SEM; n = 3.   
 
4.2.2.3. Cytoskeletal reorganisation and differences in FA length are GPR55-
mediated. 
Next we investigated whether the cytoskeletal reorganisation and the differences to the 
FA length in hGPR55-HEK293 cells induced by LPI and NOSer were mediated by 
GPR55.  To test this hGPR55-HEK293 and HEK293 cells were treated with DMSO 
(0.1%) as a vehicle control, or submaximal concentrations of either LPI (1 µM) or 
NOSer (1 µM).  DMSO treated hGPR55-HEK293 cells had flattened spread out 
morphology.  LPI or NOSer applied to hGPR55-HEK293 cells exhibited typical 
cytoskeletal reorganisation with stress fibres, lamellipodia and filopodia being observed 
(figure 4.29Ai). HEK293 cells treated with DMSO, LPI or NOSer exhibited a cell 
morphology that was similar to the DMSO treated hGPR55-HEK293 cells (figure 
4.29Aii). Vinculin-containing FAs were observed in hGPR55-HEK293 cells treated 
with DMSO.  Application of either LPI or NOSer to hGPR55-HEK293 cells led to an 
increase in the number of FAs being observed (figure 4.29Bi).  However, HEK293 cells 
were found to have very few FAs present whether treated with DMSO, LPI or NOSer 
(figure 4.29Bii).  There may be some constitutive effects of GPR55 on FAs in hGPR55-
HEK293 as they were more prominent in control hGPR55-HEK293 cells than in the 
control HEK293 cells.  Nevertheless, these data suggest that the effects of LPI and 
NOSer are GPR55-mediated. 
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Figure 4.29:  Comparison of LPI and NOSer effects on cytoskeletal reorganisation and FAs 
in hGPR55-HEK293 cells and HEK293 cells.  Both hGPR55-HEK293 cells and HEK293 cells 
were treated with ligands for 25 min. Ai, representative confocal images of the actin 
cytoskeleton in hGPR55-HEK293 cells treated as follows:  DMSO; 1 µM LPI; 1 µM NOSer. 
Aii, representative confocal images of the actin cytoskeleton in HEK293 cells treated as 
follows:  DMSO; 1 µM LPI; 1 µM NOSer.  Bi, representative confocal images of vinculin-
containing FAs in hGPR55-HEK293 cells challenged with:  DMSO; 1 µM LPI; 1 µM NOSer. 
Bii, representative confocal images of vinculin-containing FAs in HEK293 cells challenged 
with:  DMSO; 1 µM LPI; 1 µM NOSer.  Note no clear effects of LPI and NOSer on stress fibres, 
Ai DMSO
DMSO
1 µM LPI 1 µM NOSer
1 µM LPIAii 1 µM NOSer
Bi
Bii
DMSO
DMSO
1 µM LPI 1 µM NOSer
1 µM LPI 1 µM NOSer
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lamellipodia or FAs were observed in HEK293 cells.  Arrow = lamellipodia; filled arrowheads 
= stress fibres; open arrow heads = filopodia.  Scale bars = 20 µm; n = 3. 
 
4.2.2.4. Gα13 but not Gαq mediate changes in the actin cytoskeleton and FAs in 
hGPR55-HEK293 cells. 
These next series of experiments were carried out to elucidate the signalling pathways 
required for cytoskeletal reorganisation and changes in vinculin-containing FAs.  Gα13 
(Henstridge et al., 2009) and Gαq (Lauckner et al., 2008) are reported to be required for 
Ca2+ mobilisation in hGPR55-HEK293 cells therefore both were tested to observe if 
they affected the actin cytoskeleton or vinculin-containing FAs.  Application of LPI (1 
µM) or NOSer (1 µM) promoted the formation of stress fibres that were not present in 
the control cells (figure 4.30).  Dominant negative Gα13(Q226L/D294N) cDNA 
transiently transfected into hGPR55-HEK293 cells for 18 hr prior to the commencement 
of experiments were found to have some stress fibres present and several cells had a 
retracted and rounded morphology.  This may be due to the protocol with the addition 
of ‘foreign’ DNA adding stress to the cells.  However this needs further investigation 
with a modification of the protocol to include a transfection control such as GFP, which 
would highlight if the transfection procedure itself was responsible for the cell 
rounding.  LPI challenged Gα13(Q226L/D294N) transfected cells were found to have 
very few stress fibres present similar to the control Gα13(Q226L/D294N) transfected 
hGPR55-HEK293 cells (figure 4.30E).  NOSer applied to Gα13(Q226L/D294N) 
transiently transfected hGPR55-HEK293 cells were found to have some stress fibres 
however they were found to be similar to Gα13(Q226L/D294N)-transfected hGPR55-
HEK293 cells.  There appeared to be a decrease in stress fibres present in lipid 
challenged Gα13(Q226L/D294N) transfected cells than in non-transfected hGPR55-
HEK293 cells; therefore, suggesting that Gα13(Q226L/D294N) activation is required for 
the observed cytoskeletal reorganisation which was either LPI or NOSer-mediated. 
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Figure 4.30:  Gα13 is required for GPR55-mediated cytoskeletal reorganisation.  hGPR55-
HEK293 cells were transiently transfected with Gα13 for 18 hr prior to the commencement of 
experiments. The F-actin cytoskeleton was visualised with Alexa Fluor® 546 phalloidin.   
Representative confocal images of the phalloidin labelling following treatment with: DMSO; 
Gα13(Q226L/D294N); 1 µM LPI; Gα13(Q226L/D294N) + 1 µM LPI; 1 µM NOSer; 
Gα13(Q226L/D294N) + 1 µM NOSer.  Note the presence of some stress fibres in the Gα13 
(Q226L/D294N) which were also observed in Gα13(Q226L/D294N) + NOSer treated cells.  
Overall LPI or NOSer was less effective at promoting stress fibres in Gα13(Q226L/D294N) 
transfected cells.  Arrowheads = stress fibres; Scale bars = 20 µm; n = 3. 
DMSO
1 µM LPI
1 µM NOSer
Gα13(Q226L/D294N)
Gα13(Q226L/D294N) 
+ 1 µM NOSer
Gα13(Q226L/D294N) 
+ 1 µM LPI
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Previous studies in Swiss 3T3 fibroblast cells have reported that Gα13 is required for 
vinculin-containing FA assembly (Buhl et al., 1995).  Gα13 activation is important for 
GPR55-mediated responses therefore Gα13(Q226L/D294N) was transiently transfected 
into hGPR55-HEK293 cells. One-way ANOVA highlighted significant differences 
between the data sets tested (F(5,12) = 26.74; P < 0.0001).  Bonferroni post hoc analysis 
revealed that application of LPI (1 µM) or NOSer (1 µM) to the hGPR55-HEK293 cells 
promoted vinculin-containing FA assembly with an increase in both the length of the 
FAs and the number present compared to control cells (DMSO = 2.09 ± 0.15 µm, LPI = 
3.09 ± 0.01 µm, NOSer = 3.19 ± 0.06 µm, n = 3; one-way ANOVA followed with a 
Bonferroni post hoc test, P < 0.001, figure 4.31A and B).  Transient transfection of 
Gα13(Q226L/D294N) into hGPR55-HEK293 cells did not affect FA length 
(untransfected DMSO = 2.09 ± 0.15 µm, Gα13(Q226L/D294N) = 2.15 ± 0.13 µm, P > 
0.05).  However, responses to LPI or NOSer were reduced, by 64.2 ± 11.6% and 58.4 ± 
7.9% respectively, in hGPR55-HEK293 cells transiently transfected with 
Gα13(Q226L/D294N) with shorter FAs than with ligand alone (LPI = 3.09 ± 0.01 µm, 
Gα13(Q226L/D294N) + LPI = 2.50 ± 0.15 µm, NOSer = 3.19 ± 0.06 µm, 
Gα13(Q226L/D294N) + NOSer = 2.61 ± 0.03 µm, P < 0.01). These data suggest that 
whilst the LPI and NOSer-mediated FAs were longer than seen in control cells the 
effects were dependent on Gα13 activation.   
 
Next we investigated the effects of Gαq inhibition on GPR55-mediated cytoskeletal 
changes. Application of the Gαq inhibitor YM-254890 (1 µM, 55 min) alone had little 
effect on the actin cytoskeleton in hGPR55-HEK293 cells and was similar to DMSO 
treatment (figure 4.32).   Treatment with Gαq inhibitor for 30 min prior to co-application 
with either LPI (1 µM) or NOSer (1 µM) did not affect responses to these ligands.  Thus 
cells exhibited a similar change in morphology to the lipid treated cells whereby 
filopodia, stress fibres and lamellipodia were observed.  These data suggest that Gαq 
activation is not required to promote the cytoskeletal changes observed in lipid 
challenged hGPR55-HEK293 cells. 
 
The effects of the Gαq inhibitor were assessed in the FA assay. One-way ANOVA 
analysis highlights a significant difference (F(5,12) = 18.2; P < 0.0001).  Gαq inhibition 
with YM-254890 (1 µM; 55 min) did not influence FA length (DMSO = 2.17 ± 0.13 
µm, YM-254890 = 2.24 ± 0.15 µm, n = 3, one-way ANOVA with a Bonferroni post hoc 
test, P > 0.05; figure 4.33A and B).  In addition, YM-254890 did not inhibit responses 
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to LPI (1 µM) and NOSer (1 µM) on FA length (LPI = 3.38 ± 0.13 µm, YM-254890 + 
LPI = 3.36 ± 0.13 µm, NOSer = 3.42 ± 0.17 µm, YM-254890+NOSer = 3.41 ± 0.15 
µm, n = 3, P > 0.05). These data suggest that lipid-induced increases in FA length in 
hGPR55-HEK293 cells are Gαq-independent.  
 
Figure 4.31: A role for Gα13 in GPR55-mediated effects on FA length.  A, representative 
confocal images of vinculin labelling in hGPR55-HEK293 cells illustrating the effect of: 
DMSO; 1 µM LPI; 1 µM NOSer; Gα13(Q226L/D294N); Gα13(Q226L/D294N) + 1 µM LPI; 
DMSO 1 µM LPI 1 µM NOSer
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Gα13(Q226L/D294N) + 1 µM NOSer.  Scale bars = 20 µm; n = 3.  B, histogram of pooled data 
depicting effects vinculin-containing FA length in hGPR55-HEK293 cells.  Note that the 
transient transfection of dominant negative Gα13(Q226L/D294N) decreases the length of the 
lipid-induced FAs when compared to non-transfected cells highlighting the importance of Gα13 
activation for increasing FA length.   * = data compared to vehicle control.  Data are the 
means ± SEM; n = 3.  One-way ANOVA with a Bonferroni post hoc test; *P < 0.05; ##P < 
0.01; ***P < 0.001. 
 
Figure 4.32:  Gαq does not influence cytoskeletal reorganisation in hGPR55-HEK293 cells 
treated with endogenous lipids.  The Gαq inhibitor (YM-254890; 1 µM) was applied for 30 min 
DMSO
1 µM LPI
1 µM NOSer
1 µM YM-298540
+ 1 µM LPI
1 µM YM-298540
+ 1 µM NOSer
1 µM YM-298540
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prior to co-application of inhibitor with lipid ligands.  The F-actin cytoskeleton was visualised 
with Alexa Fluor® 546 phalloidin.  Panels show representative confocal images of phalloidin 
labelling following treatment with: DMSO; 1 µM YM-254890; 1 µM LPI; 1 µM YM-254890 + 1 
µM LPI; 1 µM NOSer; 1 µM YM-254890 + 1 µM NOSer.  Note the formation of lamellipodia, 
filopodia and stress fibres in cells treated with either of the lipids.  These effects are also 
observed when the inhibitor is present with either of the lipids suggesting that the effects are not 
Gαq-mediated.  Scale bars = 20 µm; n = 3; arrows = lamellipodia; solid arrowheads = stress 
fibres; open arrowhead = filopodia. 
 
 
Figure 4.33:  GPR55-mediated changes in FA length are Gαq-independent in hGPR55-
HEK293 cells.  A, representative confocal images of vinculin labelling illustrating the effect of 
DMSO; 1 µM LPI; 1 µM NOSer; 1 µM YM-254890; 1 µM YM-254890 + 1 µM LPI; 1 µM YM-
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254890 + 1 µM NOSer.  Scale bars = 20 µm; n = 3.  Note there is an increase in the FA length 
and the number of FAs in lipid treated cells.   B, histogram of pooled data, depicting vinculin-
containing FA length in hGPR55-HEK293 cells.   Note Gαq activation is not required for 
increasing FA length in lipid challenged cells.   * = data compared to vehicle control.  Data are 
the means ± SEM; n = 3.  One-way ANOVA with a Bonferroni post hoc test; **P < 0.01; ***P 
< 0.001; ns = not significant. 
 
4.2.2.5. Rho-ROCK axis is required for the cytoskeletal reorganisation and FA 
changes in hGPR55-HEK293 cells. 
The Rho-ROCK axis lies downstream of Gα13 therefore the cell permeable Rho 
inhibitor (CT04; 1 µg/ml) was applied to the hGPR55-HEK293 cells for 4 hr prior to the 
commencement of experiments. Application of the Rho inhibitor for 4 hr had little or no 
effect on cytoskeletal structure with a cell morphology that was similar to control cells 
(figure 4.34).  Pre-treatment of hGPR55-HEK293 cells with the Rho inhibitor prior to 
the addition of LPI or NOSer did not prevent the cytoskeletal changes; the cells had 
retracted and were more rounded than seen with control cells.    Lamellipodia and stress 
fibres were observed in the Rho inhibitor treated cells but these appear to be less robust 
than seen in with cells treated with lipid alone.  These data suggest that the Rho 
inhibitor at the concentration used in this assay could only partially inhibit GPR55-
mediated cytoskeletal changes in hGPR55-HEK293 cells. 
 
Next, the Rho inhibitor (CT04; 1 µg/ml) was now tested in the GPR55-vinculin FA 
assay. One-way ANOVA analysis revealed a very high significant difference across the 
data set (F(5,12) = 29.33; P < 0.0001).  Rho inhibitor reduced the effects of LPI and 
NOSer on FA length by 95.1 ± 4.9% and 88.2 ± 5.5% respectively; (LPI = 3.19 ± 0.08 
µm, CT04 + LPI = 2.53 ± 0.05 µm, NOSer = 3.28 ± 0.07 µm, CT04 + NOSer = 2.75 ± 
0.06 µm, n = 3, one-way ANOVA with a Bonferroni post hoc test, P < 0.01, figure 
4.35A and B). These data suggest that signalling via Rho is required for the increases in 
the FA length mediated by the lipids.  The inhibition appears to be more robust in LPI 
treated than NOSer treated hGPR55-HEK293 cells.  As this is a general Rho inhibitor 
acting on Rho A, B and C further studies would be required to understand which of 
these isoforms mediates the effects seen in both the cytoskeletal reorganisation and the 
increases in vinculin-containing FA lengths. 
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Figure 4.34:  A role for Rho activation in GPR55-mediated cytoskeletal reorganisation.  The 
cell permeant Rho inhibitor CT04 was applied to hGPR55-HEK293 cells for 4 hr prior to 
addition of lipid ligands.  The F-actin cytoskeleton was visualised with Alexa Fluor® 546 
phalloidin.  Panels show representative confocal images of phalloidin labelling following 
treatment with: DMSO; 1 µg/ml CTO4; 1 µM LPI; 1 µg/ml CT04 + 1 µM LPI; 1 µM NOSer; 1 
µg/ml CT04 + 1 µM NOSer.  Note the lipid-induced cytoskeletal reorganisation is decreased in 
cells pre-treated with the Rho inhibitor.  Scale bars = 20 µm; n = 3.  Arrowhead = stress fibres; 
arrows = lamellipodia. 
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Figure 4.35:  Rho is involved in GPR55-mediated changes in FA length.  The Rho inhibitor 
(CT04) was applied to hGPR55-HEK293 cells 4 hr prior to the commencement of experiments.  
A, representative confocal images of vinculin labelling illustrating the effect of: DMSO; 1 µM 
LPI; 1 µM NOSer; 1 µg/ml CTO4; 1 µg/ml CT04 + 1 µM LPI; 1 µg/ml CT04 + 1 µM NOSer.  
Scale bars = 20 µm; n = 3.  B, histogram of pooled data highlighting lipid-mediated changes in 
FA length in hGPR55-HEK293 cells either in the presence or absence of the Rho inhibitor.  
Note Rho signalling is required for the formation of lipid-treated FAs.  * = data compared to 
vehicle control.  Data are the means ± SEM; n = 3.  One-way ANOVA with a Bonferroni post 
hoc test; **P < 0.01; ***P < 0.001; ##P < 0.01. 
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Next cdc42 was evaluated,  another member of the Rho small GTPase family, which 
can be activated by GPR55 (Ryberg et al., 2007).  Cdc42 is known to be important in 
the generation of filopodia in Swiss 3T3 fibroblasts (Nobes and Hall, 1995).  Therefore 
a novel cdc42 inhibitor (ML-141; 10 µM) was evaluated in hGPR55-HEK293 cells. 
Cells treated with the cdc42 inhibitor had a flat, spread out morphology similar to 
control cells.  Co-application of either LPI or NOSer with the cdc42 inhibitor had little 
effect on lipid-induced reorganisation of the cytoskeleton; the cells had a similar 
morphology to those treated with lipid alone (figure 4.36). These data suggest that the 
cdc42 inhibitor (ML-141) did not affect the lipid-induced changes in the F-actin 
cytoskeleton in hGPR55-HEK293 cells.  Filopodia were observed in all cells treated 
with the ML-141 suggesting that the inhibitor did not affect the filopodia formation in 
this assay.   
 
Cdc42 is implicated in the formation of vinculin-containing FAs in Swiss 3T3 
fibroblasts (Nobes and Hall, 1995) hence the cdc42 inhibitor was also tested in the 
vinculin assay. One-way ANOVA analysis highlights significant difference in the data 
set (F(5,12) = 11.2; P = 0.0003).  Furthermore Bonferroni post hoc analysis revealed in 
the presence of the cdc42 inhibitor ML-141 (10 µM), LPI (1 µM) or NOSer (1 µM) 
mediated FA lengthening was not significantly different with lipids alone (LPI = 3.31 ± 
0.08 µm, ML-141 + LPI = 2.99 ± 0.22 µm, NOSer = 3.30 ± 0.13 µm, ML-141 + NOSer 
= 2.98 ± 0.13 µm, n = 3, P > 0.05, figure 4.37A and B).  ML-141 (10 µM; 55 min) 
applied by itself did not significantly affect FA length (DMSO = 2.16 ± 0.12 µm, ML-
141 = 2.43 ± 0.13 µm, n = 3, P > 0.05).  These data suggest that cdc42 activation is not 
required for the formation of vinculin-containing FAs in hGPR55-HEK293 cells treated 
with the endogenous lipids. 
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Figure 4.36:  Cdc42 is not required for GPR55-mediated cytoskeletal remodelling.  The cdc42 
inhibitor (ML-141) was applied to hGPR55-HEK293 cells for 30 min prior to co-application 
with either of the lipids.  The F-actin cytoskeleton was visualised with Alexa Fluor® 546 
phalloidin.  Panels show representative confocal images of phalloidin labelling following 
treatment with: DMSO; 10 µM ML-141; 1 µM LPI; 10 µM ML-141 + 1 µM LPI; 1 µM NOSer; 
10 µM ML-141 + 1 µM NOSer.  Scale bars = 20 µm; n = 3; arrows = lamellipodia; 
arrowheads = stress fibres; open arrowheads = filopodia. 
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Figure 4.37:  GPR55-mediated FA elongation is not effected by cdc42 inhibition.  The cdc42 
inhibitor (ML-141; 10 µM) was applied to hGRP55-HEK293 cells for 30 min prior to the co-
application with either of the endogenous lipids.  A, representative confocal images of vinculin 
labelling illustrating the effect of: DMSO; 1 µM LPI; 1 µM NOSer; 10 µM ML-141; 10 µM 
ML-141 + 1 µM LPI; 10 µM ML-141 + 1 µM NOSer.  Scale bars = 20 µm; n = 3.  B, 
histogram of pooled data, highlighting lipid-mediated changes in FA length in hGPR55-
HEK293 cells.  Note that inhibition of cdc42 did not affect increases in FA length mediated by 
either of the lipids.  * = data compared to vehicle control.  Data are the means ± SEM; n = 3.  
One-way ANOVA with a Bonferroni post hoc test; *P < 0.05; **P < 0.01; ns = not significant. 
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Next the Rho-ROCK signalling axis was investigated as to whether the cytoskeletal 
reorganisation in hGPR55-HEK293 cells required ROCK signalling, using structurally 
different ROCK inhibitors.  Cells treated with the ROCK I and II inhibitor Y-27632 (10 
µM) were retracted and the cell membranes were jagged when compared to control cells 
(figure 4.38).  This was not observed with the ROCK II inhibitor H1152 (100 nM), 
where H1152 treated cells were similar to control.  Pre-treatment of hGPR55-HEK293 
cells with either Y-27632 or H1152 for 30 min prior to co-application of either lipid 
were found to inhibit the LPI and NOSer-induced formation of lamellipodia and stress 
fibres. 
 
ROCK activation by Rho is known to be an important factor in the formation of FAs 
(Amano et al., 1997).  Therefore the ROCK inhibitors; Y-27632 (10 µM) and H1152 
(100 nM) were applied to hGRP55-HEK293 cells for 30 min prior to the application of 
the lipids. There was a significant differences when the data was subjected to one-way 
ANOVA analysis (F(8,9) = 11.55; P = 0.0007).  Moreover post hoc analysis revealed that 
FA elongation in response to LPI was reduced in the presence of either Y-27632 or 
H1152 by 78.2 ± 5.0% and 82.6 ± 6.5% respectively, (LPI = 3.48 ± 0.13 µm, Y-27632 + 
LPI = 2.03 ± 0.21 µm, H1152 + LPI = 2.23 ± 0.09 µm, n = 3, P < 0.001, figure 4.39A 
and B).  Likewise with NOSer, FA elongation was reduced (Y-27632 = 79.2 ± 6.0%; 
H1152 = 80.2 ± 3.1%) in hGPR55-HEK293 cells that had been treated with the ROCK 
inhibitors prior to the co-application of lipid (NOSer = 3.42 ± 0.17 µm, Y-27632 + 
NOSer = 2.17 ± 0.06 µm, H1152 + NOSer = 2.53 ± 0.15 µm).  These data suggest that 
hGPR55-HEK293 cells treated with the endogenous lipids require ROCK activation to 
increase the FA length.  Furthermore increasing the ROCK II inhibitor concentration to 
1 µM ablates the vinculin-containing FAs (data not shown) however, at this 
concentration it can also inhibit CAMKII and cGMP-dependent protein kinase (PKG). 
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Figure 4.38:  Both ROCK I and II are required for GPR55-mediated F-actin cytoskeletal 
reorganisation.  Two structurally different ROCK inhibitors; the ROCK I and II inhibitor (Y-
27632; 10 µM) or the ROCK II inhibitor (H1152; 100 nM) were applied to hGPR55-HEK293 
cells for 30 min prior to co-application with the either LPI or NOSer.   The F-actin cytoskeleton 
was visualised with Alexa Fluor® 546 phalloidin.  Panels show representative confocal images 
of phalloidin labelling following treatment with: DMSO; 10 µM Y-27632; 100 nM H1152; 1 µM 
LPI; 10 µM Y-27632 + 1 µM LPI; 100 nM H1152 + 1 µM LPI; 1 µM NOSer; 10 µM Y-27632 
+ 1 µM NOSer; 100 nM H1152 + 1 µM NOSer.  Note the lipid-induced cytoskeletal 
reorganisation is prevented in hGPR55-HEK293 cells in the presence of the ROCK inhibitors.  
Scale bars = 20 µm; n = 3; arrow = lamellipodia; arrowheads = stress fibres. 
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Figure 4.39:  ROCK I and II are required for GPR55-mediated FA elongation.  The ROCK I 
and II inhibitor (Y-27632; 10 µM) or ROCK II inhibitor (H1152; 100 nM) was applied to 
hGPR55-HEK293 cells prior to co-application with either of the lipids.  A, representative 
confocal images of vinculin labelling illustrating the effect of: DMSO; 10 µM Y-27632; 100 nM 
H1152; 1 µM LPI; 10 µM Y-27632 + 1 µM LPI; 100 nM H1152 + 1 µM LPI; 1 µM NOSer; 10 
µM Y-27632 + 1 µM NOSer; 100 nM H1152 + 1 µM NOSer.  Scale bars = 20 µm; n = 2.  B, 
histogram of pooled data, highlighting effects on FA length in hGPR55-HEK293 cells.  Note the 
presence of either of the ROCK inhibitors decreases the lipid-induced FA elongation.  
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Furthermore it was observed that Y-27632 applied with either lipid formed fewer FAs per cell.   
* = data compared to vehicle control.  Data are the means ± SEM; n = 2.  One-way ANOVA 
with a Bonferroni post hoc test; ***P < 0.001; ##P < 0.01; ###P < 0.001. 
 
4.2.2.6. Role of Ca2+ signalling in GPR55 effects on the actin cytoskeleton and FA 
elongation in hGPR55-HEK293 cells.   
Next the role of Ca2+ signalling in GPR55-mediated FA lengthening was investigated. 
Firstly the role of PLC was evaluated.  Cells treated with the PLC inhibitor U73122 (1 
µM; 55 min) led to increased formation of filopodia but were in general flat and spread 
out (figure 4.40).  Treatment of hGPR55-HEK293 with U73122 cells for 30 min prior to 
co-application with either LPI or NOSer did not prevent the formation of lamellipodia 
or stress fibres, which were similar to the effects of either the lipid alone.  These data 
suggest that the inhibition of PLC had no effect on the lipid-induced cell rounding and 
lamellipodia formation mediated by GPR55 in hGPR55-HEK293 cells. 
 
Next the effects of the PLC inhibitor U73122 (1 µM), were studied in the GPR55 FA 
assay.  One-way ANOVA analysis highlighted significant differences between the 
groups tested (F(5,12) = 14.55; P < 0.0001).  Further analysis with a Bonferroni post hoc 
test revealed that treatment with U73122 did not affect FA length by itself, but 
significantly inhibited the effects of LPI by 78.0 ± 8.7% (figure 4.41A and B).  The PLC 
inhibitor also inhibited the NOSer on FA length by 63.3 ± 5.6% but was not significant.  
These data suggest that PLC activation is important for lipid-modulation of FAs in 
hGPR55-HEK293 cells treated with LPI and is likely to be required FA increases in 
cells challenged with NOSer.   
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Figure 4.40:  Cytoskeletal reorganisation mediated by GPR55 in hGPR55-HEK293 cells does 
not require PLC activation.  The PLC inhibitor (U73122; 1 µM) was applied to hGPR55-
HEK293 cells for 30 min prior to co-application with either LPI or NOSer for a further 25 min.  
The F-actin cytoskeleton was visualised with Alexa Fluor® 546 phalloidin.  Panels show 
representative confocal images of phalloidin labelling following treatment with: DMSO; 1 µM 
U73122; 1 µM LPI; 1 µM U73122 + 1 µM LPI; 1 µM NOSer; 1 µM U73122 + 1 µM NOSer.  
Scale bars = 20 µm; n = 2.  Filled arrowheads = stress fibres; arrows = lamellipodia; open 
arrowheads = filopodia. 
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1 µM NOSer
1 µM U73122
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Figure 4.41:  PLC is required for GPR55-mediated FA elongation.  The PLC inhibitor 
(U73122; 1 µM) was applied to hGPR55-HEK293 cells for 30 min prior to co-application with 
either LPI (1 µM) or NOSer (1 µM).  A, representative confocal images of vinculin labelling 
illustrating the effect of: DMSO; 1 µM LPI; 1 µM NOSer; 1 µM U73122; 1 µM U73122 + 1 
µM LPI; 1 µM U73122 + 1 µM NOSer.  Scale bars = 20 µm; n = 3.  B, histogram of pooled 
data, highlighting vinculin-containing FA length in hGPR55-HEK293 cells.  Note the presence 
of the PLC inhibitor decreases the lipid-induced FA length.   * = data compared to vehicle 
control.  Data are means ± SEM; n = 3.  One-way ANOVA with a Bonferroni post hoc test; **P 
< 0.01; ##P < 0.01; ns = not significant.  
 
4.2.2.7. MAPK influences FA length but does not affect the actin cytoskeleton in 
hGPR55-HEK293 cells. 
The role of MAPK signalling in GPR55-mediated cytoskeletal changes was investigated 
using MAPK inhibitors.   Application of PD98059 (25 µM) induced cell rounding with 
dense areas of peripheral actin labelling (figure 4.42).  However, this was not observed 
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with U0126 (5 µM), which did not affect the cell morphology and were similar to 
control cells. LPI or NOSer when applied at 1 µM in the presence of either of the 
MEK1/2 inhibitors promoted similar cytoskeletal features as had been observed with 
each lipid alone.  These results suggest that MAPK activation is not required for the 
lipid-induced reorganisation of the F-actin cytoskeleton in hGPR55-HEK293 cells.   
 
 
Figure 4.42:  MAPK is not required for GPR55-mediated cytoskeletal reorganisation.  Two 
structurally different MEK1/2 inhibitors; PD98059 (25 µM) and U0126 (5 µM) were applied to 
hGPR55-HEK293 cells for 30 min prior to the co-application of either LPI (1 µM) or NOSer (1 
µM).  The F-actin cytoskeleton was visualised with Alexa Fluor® 546 phalloidin.  Panels show 
representative confocal images of phalloidin labelling following treatment with:  DMSO; 25 µM 
PD98059; 5 µM U0126; 1 µM LPI; 25 µM PD98059 + 1 µM LPI; 5 µM U0126 + 1 µM LPI; 1 
µM NOSer; 25 µM PD98059 + 1 µM NOSer; 5 µM U0126 + 1 µM NOSer.  Note that the 
MEK1/2 inhibitors did not affect LPI or NOSer induced changes in cytoskeletal reorganisation.  
Scale bars = 20 µm; n = 3; arrows = lamellipodia; arrowheads = stress fibres.   
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1 µM NOSer
5 µM U012625 µM PD98059
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The MEK1/2 inhibitors; PD98059 (25 µM) and U0126 (5 µM) were also tested in the 
GPR55-vinculin assay.  Analysis with a one-way ANOVA highlighted that there were 
significant differences within the groups tested in the presence of the MEK1/2 inhibitors 
(F(8,18) = 8.227; P = 0.0001).  Furthermore post hoc analysis revealed that treatment with 
PD98059 or U0126 (55 min) did not affect FAs, having a similar length to control cells 
(DMSO = 2.37 ± 0.11 µm, PD98059 = 2.21 ± 0.08 µm, U0126 = 2.36 ± 0.2 µm, n = 3, 
one-way ANOVA with a Bonferroni post hoc test, P > 0.05, figure 4.43A and B).  
However, pre-treatment with either PD98059 or U0126 prior to co-application with 
either LPI or NOSer inhibited their actions on FA length in hGPR55-HEK293 cells.  
LPI was inhibited by 90.7 ± 1.4% and 85.3 ± 13.9% in the presence of PD98059 and 
U0126 respectively.  Furthermore NOSer in the presence of PD98059 and U0126 was 
inhibited by 86.7 ± 8.3% and 97.1 ± 3.1% respectively; (LPI = 3.45 ± 0.15 µm, 
PD98059 + LPI = 2.54 ± 0.07 µm, U0126 + LPI = 2.33 ± 0.24 µm, NOSer = 3.43 ± 
0.14 µm, PD98059 + NOSer = 2.69 ± 0.22 µm, U0126 + LPI = 2.46 ± 0.17 µm).   
 
An inactive analogue of U0126; U0124 (5 µM) was utilised to confirm that any effects 
were mediated through MAPK signalling.  One-way ANOVA highlighted that there 
were significant differences within the data set when an inactive MEK1/2 inhibitor 
(F(5,12) = 10.78; P = 0.0004).  Moreover a Bonferroni post hoc test revealed that the 
inactive MEK1/2 inhibitor, U0124, applied to the cells prior to co-application with 
either LPI or NOSer had no effect (LPI = 3.45 ± 0.15 µm, U0124 + LPI = 3.31 ± 0.11 
µm, NOSer = 3.43 ± 0.14 µm, U0124 + NOSer = 3.45 ± 0.15 µm, n = 3, P > 0.05, 
figure 4.43C and D).  These data suggest that the lipid-mediated increases in the length 
of the vinculin-containing FAs require the activation of MAPK in hGPR55-HEK293 
cells challenged with LPI.  Furthermore it is likely that MAPK activation is required for 
FA lengthening in hGPR55-HEK293 cells treated with NOSer. 
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Figure 4.43:  MAPK is required for GPR55-mediated increases in FA length.  Two 
structurally different MEK1/2 inhibitors (PD98059; 25 µM or U0126; 5 µM) or an inactive 
MEK1/2 inhibitor (U0124; 5 µM) were applied to hGPR55-HEK293 cells for 30 min prior to 
co-application of with either LPI (1 µM) or NOSer (1 µM).   A, representative confocal images 
of vinculin labelling illustrating the effect of the active MEK1/2 inhibitors: DMSO; 25 µM 
PD98059; 5 µM U0126; 1 µM LPI; 25 µM PD98059 + 1 µM LPI; 5 µM U0126 + 1 µM LPI; 1 
µM NOSer; 25 µM PD98059 + 1 µM NOSer; 5 µM U0126 + 1 µM NOSer.  B, histogram of 
pooled MEK1/2 inhibitor data, highlighting effects on vinculin-containing FA length in 
hGPR55-HEK293 cells.  Note that the presence of the active MEK1/2 inhibitors (PD98059 or 
U0126) leads to an inhibition of lipid-mediated responses.  C, representative confocal images of 
vinculin labelling highlighting the effect of the inactive MEK1/2 inhibitor:  DMSO; 1 µM LPI; 1 
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µM NOSer; 5 µM U0124; 5 µM U0124 + 1 µM LPI; 5 µM U0124 + 1 µM NOSer.  D, 
histogram of pooled inactive MEK1/2 inhibitor data, highlighting effects on vinculin-containing 
FA length in hGPR55-HEK293 cells.  Note the presence of 5 µM U0124 does not alter the FA 
length of lipid-mediated responses.  * = data compared to vehicle control.  Data are the means 
± SEM; n = 3.  One-way ANOVA with a Bonferroni post hoc test; *P < 0.05; **P < 0.01; # < 
0.05; ## < 0.01; ns = not significant.  
 
4.2.2.8. PI-3 kinase activation is not required for GPR55-mediated cytoskeletal 
reorganisation or differences in FA length. 
Next we investigated whether PI-3 kinase was involved in GPR55-mediated 
cytoskeletal reorganisation or differences in FA length.  Application of two structurally 
different PI-3 kinase inhibitors, LY294022 (3 µM) or wortmannin (50 nM), to hGPR55-
HEK293 cells did not affect cell morphology or actin cytoskeletal structure relative to 
control cells (figure 4.44).   In addition, PI-3 kinase inhibitors did not affect responses 
to LPI or NOSer, with a similar reorganisation of the cytoskeleton associated with the 
appearance of stress fibres and lamellipodia.  These data suggest that lipid-induced 
cytoskeletal reorganisation in hGPR55-HEK293 cells is not mediated through PI-3 
kinase activation. 
 
Next, the two structurally distinct PI-3 kinase inhibitors; LY294002 (3 µM) and 
wortmannin (50 nM) were studied in the GPR55-FA assay. One-way ANOVA 
highlighted significant differences between the PI3 kinase data set (F(8,18) = 5.834; P = 
0.0009).  Bonferroni post hoc analysis revealed that treatment of hGPR55-HEK293 with 
either LY294022 or wortmannin did not affect FAs, where they had similar length to the 
control cells (DMSO = 2.25 ± 0.05 µm, LY294002 = 2.18 ± 0.28 µm, wortmannin = 
2.34 ± 0.17 µm, n = 3, one-way ANOVA with a Bonferroni post hoc test, P > 0.05, 
figure 4.45A and B).  Treatment with either LY294002 or wortmannin prior to co-
application with LPI did not significantly affect LPI-induced changes in FA length (LPI 
= 3.37 ± 0.14 µm, LY294022 + LPI = 3.02 ± 0.25 µm, wortmannin + LPI = 2.95 ± 0.06 
µm).  Likewise with NOSer, there was no significant inhibition of responses (NOSer = 
3.34 ± 0.23 µm, LY294002 + NOSer = 3.04 ± 0.25 µm, wortmannin + NOSer = 3.21 ± 
0.18 µm).  These data suggest that activation of PI-3 kinase is not required for the lipid-
mediated increases in FA length in hGPR55-HEK293 cells. 
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Figure 4.44:  GPR55-mediated cytoskeletal reorganisation does not require PI-3 kinase 
activation.  Two structurally distinct PI-3 kinase inhibitors (LY294022; 3 µM and wortmannin; 
50 nM) were applied to hGPR55-HEK293 cells for 30 min prior to co-application with either of 
the lipids.  The F-actin cytoskeleton was visualised with Alexa Fluor® 546 phalloidin.  Panels 
show representative confocal images of phalloidin labelling following treatment with:  DMSO; 
3 µM LY294002; 50 nM wortmannin; 1 µM LPI; 3 µM LY294002 + 1 µM LPI; 50 nM 
wortmannin + 1 µM LPI; 1 µM NOSer; 3 µM LY294002 + 1 µM NOSer; 50 nM wortmannin + 
1 µM NOSer.  Note PI-3 kinase inhibitors did not affect lipid-mediated cell retraction and the 
formation of lamellipodia and stress fibres.  Scale bars = 20 µm; n = 3.  Arrows = 
lamellipodia; arrow heads = stress fibres. 
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Figure 4.45:  GPR55-mediated effects on FA length do not require PI-3 kinase.  Cells were 
treated for 30 min with PI-3-kinase inhibitors (LY294002; 3 µM or wortmannin; 50 nM) prior 
to co-application of inhibitor with a lipid.  A, representative confocal images of vinculin 
labelling illustrating the effect of: DMSO; 3 µM LY294002; 50 nM wortmannin; 1 µM LPI; 3 
µM LY294002 + 1 µM LPI; 50 nM wortmannin + 1 µM LPI; 1 µM NOSer; 3 µM LY294002 + 
A DMSO 1 µM LPI 1 µM NOSer
50 nM wortmannin
3 µM LY294002
50 nM wortmannin
+ 1 µM NOSer
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1 µM NOSer; 50 nM wortmannin + 1 µM NOSer.  Scale bars = 20 µm; n = 3.  B, histogram of 
pooled data depicting effects on the length of vinculin-containing FAs in hGPR55-HEK293 
cells.  Note that inhibiting PI-3 kinase did not influence lipid-induced FA elongation.  * = data 
compared to vehicle control.  Data are the means ± SEM; n = 3.  One-way ANOVA with a 
Bonferroni post hoc test; *P < 0.05; ns = not significant. 
 
4.3.  DISCUSSION 
4.3.1.  GPR55-mediated pCREB in hGPR55-HEK293 cells 
This study confirmed that GPR55 signals to CREB not only with previously tested 
GPR55 agonists; LPI and AM251 (Henstridge et al., 2010) but also with novel N-acyl 
amino acids.  To date only two or the N-acyl amino acids (NAS and NAG) have been 
studied in relation to GPR55 activation.   
 
In the present study NASer (300 nM - 10 µM) was observed to promote pCREB.  
Recent evidence has reported that NASer (10 nM - 30 µM) applied for 30 min can 
promote the phosphorylation of ERK1/2 (pERK), a protein located upstream of CREB, 
in HUVEC cells (Milman et al., 2006).  The authors also observed that this effect was 
mediated by a Gαi/o linked GPCR as PTX abolished the pERK responses.    NOSer has 
also been reported to activate a Gαi/o linked GPCR in an osteoblastic cell line (MC3T3 
E1) resulting in increased pERK1/2 at a similar time point (30 min) as used in the 
pCREB assay in this study  (Smoum et al., 2010).  Therefore, both of the Israeli studies 
would strongly suggest that their observations are not GPR55-mediated (Milman et al., 
2006; Smoum et al., 2010).    The present observations, taken together with previous 
studies, suggest the existence of at least two GPCRs that are sensitive to NASer and 
NOSer.   It is proposed that due to the sensitivity of GPR55 to NASer and NOSer - 
GPR55 is proposed to be as a novel candidate receptor for both these endogenous lipids. 
 
The pCREB assay utilised in this study also observed that NAGly–induced pCREB was 
GPR55-mediated.  NAGly is reported to activate several GPCRs; GPR18 (Kohno et al., 
2006; Yin et al., 2009; McHugh et al., 2010, 2012; Caldwell et al., 2013), GPR72 
(Hannedouche and Roy, 2010) and can act as a GPR92 partial agonist (Oh et al., 2008).  
However prior studies did not find GPR55-mediated migratory effects in a Boyden 
chamber assay using hGPR55-HEK293 cells treated with NAGly but it should be noted 
that these cells were not placed in serum free prior to experimentation (McHugh et al., 
2010).  In another study GPR55(-/-) mice were  found to lower the intraocular pressure in 
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the murine eye to the same extent as wild type mice suggesting that the NAGly-induced 
response was not GPR55-mediated (Caldwell et al., 2013).  Both these studies suggest 
that the NAGly effects are through activation of GPR18.  Interestingly, both GPR55 
(Johns et al., 2007) and GPR18 (McHugh et al., 2010) have been considered as the 
enigmatic abnormal cannabidiol receptor and have an overlapping pharmacology (Ross, 
2009).  Therefore it is feasible to suggest that the N-acyl amino acids in this study may 
act as agonists/partial agonists at both these GPCRs, however it remains to be 
determined if NASer, NOSer, NPSer, NOGly and NPGly can promote GPR18-mediated 
signalling. 
 
This study also highlighted that some of the N-acyl amino acids may display ligand bias 
in the hGPR55-HEK293 cells.    This is when an agonist has the ability to activate the 
receptor but exerts a preference as to which downstream signalling pathway is activated 
(Kenakin, 2011).  The responses in the Ca2+ mobilisation and pCREB assay differed in 
potency for LPI (vinculin FA > Ca2+ > pCREB assay), NOSer (vinculin FA = pCREB > 
Ca2+ assay) and NOG (Ca2+ > pCREB assay) suggesting that these lipids may be 
demonstrating ligand bias.  Previously Henstridge et al., 2010, also reported that LPI 
was more potent in the Ca2+ mobilisation (49 ± 4 nM) than in the pCREB assay (630 ± 
110 nM).  However it was also reported that AM251 was considerably less potent than 
LPI in a pCREB immunoblot assay; 430 ± 90 nM and 93 ± 10 nM respectively 
(Henstridge et al., 2010).  In contrast this study finds that AM251 was more equipotent 
than LPI in the pCREB assay.   
 
Ligand 
Ca2+ 
EC50 nM  
 
pCREB 
EC50 nM  
 
Vinculin FAs 
EC50 nM  
 
LPI 
 
 
183 ± 8 262 ± 54 72 ± 10 
NASer 256 ± 18 nd nt 
NOSer 253 ± 4 95 ± 29 65 ± 11 
NPSer 314 ± 12 nd nt 
NAGly 908 ± 63 848 ± 153 nt 
NOGly 347 ± 12 1085 ± 264 nt 
NPGly nd nd nt 
AM251 nt 256 ± 51 nt 
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Table 4.2:  Relative ligand potencies for different GPR55-mediated signalling pathways in 
hGPR55-HEK293 cells.  EC50 values for changes in Ca2+, pCREB and vinculin FA length.  
Both LPI and NOSer are more potent in the FA and pCREB assays.  nt = not tested;   nd   = not 
determined (the Emax was not achieved therefore the EC50 could not be calculated). EC50 values 
(95% confidence limits). 
 
4.3.1.1. GPR55-modulation of pCREB involves a Gα13-Rho-ROCK signalling axis 
in hGPR55-HEK293 cells. 
LPI and NOSer-mediated nuclear pCREB activity in hGPR55-HEK293 cells involves 
multiple signalling pathways (figure 4.46 and 4.47).  Gα13 is suggested to be a 
requirement for Ca2+ mobilisation in hGPR55-HEK293 cells (Henstridge et al., 2009).  
Consistent with this, transient transfection of hGPR55-HEK293 cells with a dominant 
negative Gα13 construct decreased nuclear pCREB labelling.  Gαq-dependent Ca2+ 
mobilisation has also been documented in hGRR55-HEK293 cells (Lauckner et al., 
2008).  However in this assay nuclear pCREB was found to be Gαq-independent as 
application of the Gαq inhibitor; YM-254890, did not block the nuclear pCREB 
response.  Gα13 is known to activate Rho through an interaction with the guanine 
exchange factor, p115RhoGEF, therefore linking Gα13 directly to Rho activation (Hart 
et al., 1998).  Interestingly cannabinoid ligand treatment of HEK293 cells transiently 
transfected with GPR55 promoted the activation of RhoA (Ryberg et al., 2007).  Recent 
evidence highlights that hGPR55-HEK293 cells transfected with dominant negative 
RhoA have abolished Ca2+ mobilisation (Lauckner et al., 2008; Henstridge et al., 2009).  
Indeed, use of the cell permeable C3 transferase, CT04, to inhibit Rho directly, also 
promote a general trend of inhibiting lipid-induced pCREB responses in hGPR55-
HEK293 cells, but was not significant within the number of experiments.  However 
increasing the ‘n’ number may reveal a significant inhibition of Rho.  GPR55 signalling 
via Rho-ROCK is thought to be required for Ca2+ mobilisation (Waldeck-Weiermair et 
al., 2008; Henstridge et al., 2009), ERK1/2 phosphorylation (Anavi-Goffer et al., 2012) 
and cytoskeletal reorganisation (Balenga et al., 2011).  Hence the cells were treated with 
inhibitors of ROCK I and II (Y-27632) or ROCK II (H1152).  Both ROCK inhibitors 
were found to lower the nuclear pCREB response to the lipid ligands, suggesting that 
the Gα13-Rho-ROCK signalling axis can promote nuclear pCREB in hGPR55-HEK293 
cells.  However whilst Y-27632 promoted a very highly significant inhibition of pCREB 
in hGPR55-HEK293 cells, H1152 was observed to promote a trend of lowering the 
lipid-mediated pCREB response but at present was not significant.  It is likely that 
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increasing the experimental data will lead to H1152 inhibition of nuclear pCREB in 
hGPR55-HEK293 cells.  These data at present suggest that ROCK I is more important 
than ROCK II in the signalling to promote pCREB in hGPR55-HEK293 cells 
challenged with the endogenous lipids. 
 
4.3.1.2. Ca2+ is important for pCREB in hGPR55-HEK293 cells treated with 
endogenous lipids. 
As Ca2+ mobilisation occurred with both these lipids in hGPR55-HEK293 cells and 
required ROCK activation, the effect of Ca2+ in promoting pCREB was studied.  Ca2+ is 
a known signalling mediator for the activation of CREB (Sheng et al., 1990).  Chelation 
of intracellular Ca2+ reduced pCREB responses to basal levels, furthermore extracellular 
Ca2+ was also important for lipid-mediated pCREB signalling in hGPR55-HEK293 
cells.  Following application of a PLC inhibitor, to inhibit the breakdown of PIP2 into 
IP3 and DAG, and therefore the subsequent increase in Ca2+ due to the release from the 
ER, GPR55-mediated pCREB responses were also inhibited, adding further credence to 
the idea that Ca2+ is necessary for pCREB.  Ca2+, DAG and the presence of 
phospholipids, in particular phosphatidylserine, act synergistically to activate PKC 
(Ganong et al., 1986).  Furthermore, fatty acids such as arachidonic or oleic acid may 
also activate PKC (Shinomura et al., 1991).  Applying a PKC inhibitor prior to co-
application with either LPI or NOSer to hGPR55-HEK293 cells reduced pCREB 
staining when compared to either lipid alone.  However, the effects were greater against 
LPI treated cells (68.4 ±7.2% inhibition) than seen with cells treated with NOSer (42.2 
±8.1% inhibition).  Whether NOSer can be metabolised, or how quickly, in these cells is 
not known at present. It could however be plausible for NOSer to breakdown into L-
serine and oleic acid with the possibility the latter could act on PKC (Shinomura et al., 
1991) and therefore may explain why the NOSer-induced response is decreased to a 
lesser extent than seen with LPI.   A downstream effector of PKC is CaMKII (Waxham 
and Aronowski, 1993) which is also activated by increases in cytosolic Ca2+ 
(Schwaninger et al., 1993).  In vitro, the signal produced by Ca2+ mobilisation is 
transferred to the nucleus by CaMKII allowing CREB phosphorylation to occur  
(Schwaninger et al., 1993).  CaMKII phosphorylates CREB at serine residue 133 (Sun 
et al., 1994) which is known to be important for CREB activation (Gonzalez and 
Montminy, 1989).  CaMKII was found to lower nuclear pCREB in hGPR55-HEK293 
cells treated with LPI or NOSer but was not significant.  However it is probable that 
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increasing the experimental data set will promote a significant inhibition by either of the 
endogenous lipids. 
 
4.3.1.3.  MAPK and PI-3-kinase are required phosphorylated in hGPR55-HEK293 
cells challenged with endogenous lipids.  
GPR55-mediated p44/42 MAPK (ERK1/2) signalling has been reported in several cell 
types such as hGPR55-HEK293 cells (Oka et al., 2007; Henstridge et al., 2010; Anavi-
Goffer et al., 2012); osteoclasts (Whyte et al., 2009); murine microglial cell line BV2 
treated with INFγ (Pietr et al., 2009); PC3 and DU145 prostate cancer cell lines and 
OVCAR3 ovarian cancer cell line (Piñeiro et al., 2011); EVSA-T breast cancer cell line, 
T98G neuroblastoma cell line and xenografted T98G tumours (Andradas et al., 2011); 
skin carcinogenesis in mice (Pérez-Gómez et al., 2013).  As ERK1/2 is upstream of 
pCREB and is implicated in GPR55 signalling, the effects of MEK1/2 inhibitors were 
investigated in hGPR55-HEK293 cells.  Application of MEK1/2 inhibitors (either 
PD98059 or U0126) decreased the LPI (significantly) and NOSer-induced (not 
significant) nuclear pCREB.  It is possible that increasing the experimental data NOSer 
would be likely to be required to promote nuclear pCREB in hGPR55-HEK293 cells.  
Furthermore these effects were further confirmed as an inactive MEK1/2 inhibitor 
(U0124) promoted nuclear pCREB labelling that was similar to endogenous lipids 
alone.   
 
Activation of PI-3 kinase has been associated with GPR55-mediated Ca2+ mobilisation 
in HUVEC cells (Waldeck-Weiermair et al., 2008; Ross, 2009).   Whereby PI-3 kinase 
acted on PLCγ to promote Ca2+ mobilisation (Waldeck-Weiermair et al., 2008).  PI-3 
kinase is also an important mediator of AKT phosphorylation (Dugourd et al., 2003; 
Fresno Vara et al., 2004; Steelman et al., 2011) and therefore potentially could 
influence pCREB through a phosphorylated AKT-dependent signalling pathway (Du 
and Montminy, 1998). GPR55-mediated AKT phosphorylation occurs in ovarian and 
prostate cancer cells challenged with LPI (Piñeiro et al., 2011) thus GPR55 could signal 
through PI-3 kinase and promote pCREB.  Therefore in this study two structurally 
different PI-3-kinase inhibitors were applied to hGPR55-HEK293 cells.  Inhibition of 
PI-3 kinase was found to lower nuclear pCREB labelling in hGPR55-HEK293 cells 
induced by the endogenous lipids. Whilst these effects were significant in NOSer 
challenged cells; LPI treated cells produced a general trend where pCREB responses 
were lower in the present of the PI-3 kinase inhibitors suggesting that this pathway is 
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likely to be important in LPI-mediated signalling.    Furthermore mTOR signalling was 
found to not be required in the lipid-induced nuclear pCREB signalling in hGPR55-
HEK293 cells.  These data suggest that PI-3-kinase activation plays a role in pCREB 
signalling in hGPR55-HEK293 cells, which may involve AKT phosphorylation.  It 
however, remains unknown whether AKT is phosphorylated downstream of GPR55 in 
hGPR55-HEK293 cells.   
 
4.3.1.4. Summary of GPR55 signalling pathways required to promote nuclear 
pCREB. 
 
Figure 4.46:  Proposed signalling pathways required to promote pCREB in hGPR55-HEK293 
cells when challenged with LPI.  Multiple signalling pathways can promote pCREB in LPI 
challenged hGPR55-HEK293 cells.  Potential cross-talk can occur between Ca2+ mobilisation, 
MAPK and PI-3 kinase signalling pathways.  LPI, L-α-lysophosphatidylinositol; NOSer, N-
oleoyl-L-serine; RhoA, Ras homolog gene, family member A; ROCK, Rho associated protein 
kinase; PLC, Phospholipase C; PIP2, phosphatidylinositol 4, 5-bisphosphate; DAG, 
diacylglycerol; IP3, inositol 1, 4, 5-triphosphate; ER, endoplasmic reticulum; PKC, protein 
kinase C; CAMKII, Ca2+/calmodulin dependent protein kinase II; mTOR = mammalian Target 
of Rapamycin; raf = proto-oncogene c-RAF; MEKK1 = mitogen activated protein kinase kinase 
1; MEK1 = mitogen activated protein kinase 1; ERK1/2 = extracellular signal-regulated 
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protein kinases 1 and 2; MSKs = mitogen- and stress-activated kinases.  Green arrows = Ca2+ 
signalling pathway; orange arrows = PI-3 kinase signalling pathway; pink arrows = MAPK 
signalling pathway. Solid arrows = signalling effectors; dashed arrows = suggested effectors.   
 
 
 
Figure 4.47:  Proposed signalling pathways required to promote pCREB in NOSer 
challenged hGPR55-HEK293 cells.  Multiple signalling pathways can promote pCREB in 
NOSer challenged hGPR55-HEK293 cells.  Potential cross-talk can occur between Ca2+ 
mobilisation, MAPK and PI-3 kinase signalling pathways.  LPI, L-α-lysophosphatidylinositol; 
NOSer, N-oleoyl-L-serine; RhoA, Ras homolog gene, family member A; ROCK, Rho associated 
protein kinase; PLC, Phospholipase C; PIP2, phosphatidylinositol 4, 5-bisphosphate; DAG, 
diacylglycerol; IP3, inositol 1, 4, 5-triphosphate; ER, endoplasmic reticulum; PKC, protein 
kinase C; CAMKII, Ca2+/calmodulin dependent protein kinase II; mTOR = mammalian Target 
of Rapamycin; raf = proto-oncogene c-RAF; MEKK1 = mitogen activated protein kinase kinase 
1; MEK1 = mitogen activated protein kinase 1; ERK1/2 = extracellular signal-regulated 
protein kinases 1 and 2; MSKs = mitogen- and stress-activated kinases.  Green arrows = Ca2+ 
signalling pathway; orange arrows = PI-3 kinase signalling pathway; pink arrows = MAPK 
signalling pathway. Solid arrows = signalling effectors; dashed arrows = suggested effectors.   
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4.3.2. The actin cytoskeleton and vinculin. 
4.3.2.1. Cytoskeletal reorganisation occurs in hGPR55-HEK293 cells challenged 
with endogenous lipids. 
In this study both LPI and NOSer promoted the formation of stress fibres, filopodia and 
lamellipodia in hGPR55-HEK293 cells (figure 4.48).  The formation of stress fibres and 
FAs requires the activation of Rho (Ridley and Hall, 1992; Katoh et al., 2007).  
However the formation of the sheet-like lamellipodia at the leading edge of a polarised 
cell is thought to be mediated by the activation of Rac1, whilst the formation of 
filopodia (the finger like protrusions) are mediated by cdc42 (Nobes and Hall, 1995).  
Interestingly, GPR55 can activate each of these small GTPases; RhoA, cdc42 and rac1 
(Ryberg et al., 2007).  In this study the Gα13-Rho-ROCK signalling axis was found to be 
required for cytoskeletal reorganisation in hGPR55-HEK293 cells treated with either 
LPI or NOSer. Previous studies have highlighted that the GPR55-activated small G-
proteins; RhoA, rac2 and cdc42 are  important in cytoskeletal reorganisation in 
neutrophil (HL60) cells (Balenga et al., 2011).   Using F-actin staining with phalloidin 
to observe cytoskeletal changes the authors applied LPI, AM251 or the 
endocannabinoid 2-AG and found that each could exert cytoskeletal changes in 
neutrophils (Balenga et al., 2011).  However they also noted that the migratory, 
elongated type response in HL60 cells was only observed when GPR55 and CB2 
agonists; LPI and 2-AG respectively, were applied together and suggest that CB2 and 
GPR55 may act synergistically (Balenga et al., 2011).  An alternative study highlighted 
that cytoskeletal changes were observed in MDA-MB-231 breast cancer cells treated 
with LPI where they become elongated, a phenotype associated with migration (Ford et 
al., 2010).  This study however was not directed at effects on cell polarity as the 
hGPR55-HEK293 cells were surrounded by the lipids in petri dishes, leading to an even 
concentration around the cells. This would explain why the lamellipodia and filopodia 
were observed in several directions in the hGPR55-HEK293 cells.   
 
4.3.2.2. Gα13-Rho-ROCK signalling axis is required for cytoskeletal reorganisation 
and changes in FA length via GPR55 in hGPR55-HEK293 cells. 
This is the first study demonstrating that vinculin-containing FAs can be modulated by 
GPR55, where LPI or NOSer induced increases in the length of the vinculin-containing 
FAs.  As observed with cytoskeletal reorganisation in hGPR55-HEK293 cells, effects 
on FAs were mediated by the Gα13-Rho-ROCK signalling axis.  hGPR55-HEK293 cells 
treated with Y-27632, a ROCK I and II inhibitor were found to have fewer mature FAs 
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than cells inhibited by ROCK II alone especially in NOSer challenged hGPR55-
HEK293 cells.  This suggests that ROCK I may be more important for the reduction of 
FAs in hGPR55-HEK293 cells in NOSer treated cells.  Whereas, inhibition of the lipid-
induced stress fibres occurred with either of the ROCK inhibitors.  Studies in fibroblasts 
where cells were transfected with siRNA for ROCK I were found to have a complete 
loss of stress fibres and vinculin whereas cells transfected with ROCK II siRNA do not 
lose the stress fibres or vinculin FAs.  Therefore the two ROCK isoforms have distinct 
roles in fibroblasts (Yoneda et al., 2005).  This may also be the case for the vinculin-
containing FAs in the hGPR55-HEK293 cells.  Further experiments with ROCK I and II 
siRNAs would help in understanding the differences these two proteins are exerting in 
hGPR55-HEK293 cells especially in relation to the FAs.    
 
4.3.2.3. Inhibition of cdc42 has no effect on the actin cytoskeleton or FAs in 
hGPR55-HEK293 cells. 
The Rho family G protein, cdc42, is thought to play a role in filopodia formation.  It 
was reported that microinjection of cdc42 into fibroblasts leads to the formation of 
filopodia and vinculin-containing FAs at the periphery of cells, where they are 
associated with filopodia (Nobes and Hall, 1995).  However, in this study the 
application of cdc42 did not affect the formation of filopodia induced by the lipids.  
There was also no effect on the length of the vinculin-containing FAs in hGPR55-
HEK293 cells whereby cdc42 had been inhibited.  This could be a cell type specific 
response where cdc42 is not required for cytoskeletal reorganisation in hGPR55-
HEK293 cells but is required in fibroblasts (Nobes and Hall, 1995). 
 
4.3.2.4. Ca2+ mobilisation is important for FA length but has no effect on 
cytoskeletal reorganisation. 
GPR55 is linked to the activation of PLC to induce both the mobilisation of Ca2+ and 
pCREB in hGPR55-HEK293 cells. Therefore any potential role involving PLC in 
cytoskeletal reorganisation or changes in FA length were studied through the 
application of U73122; a PLC inhibitor.  Previously PLC is reported to be important for 
the reorganisation of the cytoskeleton whereby application of U73122 (10 µM) or PLC 
siRNA to DU145 prostate cancer cells was found to inhibit the formation of 
lamellipodia and filopodia in response to serum (Jones et al., 2005).  This however is in 
contrast to the present study where the application of U73122 did not appear to affect 
the formation of stress fibres or lamellipodia in hGPR55-HEK293 cells treated with LPI 
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or NOSer, suggesting that Ca2+ is not involved in cytoskeletal reorganisation in 
hGPR55-HEK293 cells treated with either LPI or NOSer.  It may be that the U73122 
concentration in this study was not high enough to fully block PLC and all its 
downstream effects; however, higher concentrations of U73122 were found to have 
non-specific effects and therefore could not be tested.   
 
Both Ca2+ and PKC (both of which are downstream of PLC) have previously been 
implicated in vinculin phosphorylation (Werth and Pastan, 1984).  Also PLC has been 
reported to effect vinculin FA length in papillary renal cells treated with bradykinin 
(Márquez et al., 2008).  In this study vinculin-containing FAs were shorter when 
hGPR55-HEK293 cells were treated with U73122, a PLC inhibitor.  These data suggest 
that Ca2+ is important for changes in vinculin-containing FA length but has no effect on 
the cytoskeleton in hGPR55-HEK293 cells.  The activation of PLC is required for FA 
increases in length in hGPR55-HEK293 cells treated with LPI and is likely to be 
responsible for increases in FA length in NOSer challenged cells. 
 
4.3.2.5. MAPK is involved in GPR55-mediated effects on FA length, but not 
changes in the actin cytoskeleton in hGPR55-HEK293 cells. 
In this study MAPK signalling was found to be important for GPR55-mediated FA 
elongation.  A requirement for ERK1/2 in the formation of FAs is controversial as some 
studies find ERK1/2 is necessary for their formation (Fincham et al., 2000; Pullikuth 
and Catling, 2010) whilst others argue that ERK1/2 activation leads to their disassembly 
(Webb et al., 2004).  In the present study the GPR55-mediated FA elongation was 
inhibited by MEK1/2 blockers.  Moreover LPI was found to be more effectively 
blocked than NOSer challenged hGPR55-HEK293 cells.  Furthermore this pathway was 
not involved in actin cytoskeletal changes induced by LPI or NOSer in the hGPR55-
HEK293 cells.   
 
In conclusion, this study has highlighted that the N-acyl amino acids exert GPR55-
mediated effects on pCREB in hGPR55-HEK293 cells.  Furthermore multiple signalling 
pathways are required for GPR55-pCREB signalling, including Ca2+, MAPK and 
potentially AKT.  LPI and NOSer were further characterised in two other GPR55-
mediated assays; an F-actin cytoskeletal reorganisation assay and a novel FA assay 
studying the changes in length of vinculin-containing FAs.  Signalling through the Rho-
ROCK pathway was found to be important for both cytoskeletal reorganisation and 
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changes in FA length (figure 4.49 and 4.50).  However, Ca2+ and the MAPK pathways 
were also found to be important in changes in FA length but had little or no effect on 
cytoskeletal reorganisation in hGPR55-HEK293 cells.  Although some of the signalling 
pathways such as Ca2+, Rho-ROCK and MAPK are required for FA formation and 
pCREB (figure 4.48).  The two outcomes are thought to be separate as FA formation is 
likely to be by focal contacts translocating to peripheral regions and combining to form 
larger focal adhesions rather than being gene regulated.  The time scale of ligand 
treatment (25 min) is not long enough for gene regulation to play a role, if pCREB were 
to be involved, as this normally requires several hours for gene transcription to occur.  It 
remains to be determined if these GPR55-mediated N-acyl amino acid effects have a 
physiological role in a native system. Therefore having established that N-acyl amino 
acids can activate multiple GPR55-mediated signalling cascades in recombinant human 
GPR55 over-expressing cells, the next chapter shall explore the actions of N-acyl amino 
acids and LPI-induced in cells which endogenously expresses GPR55.   
 
4.3.2.6. Signalling pathways required for F-actin cytoskeletal reorganisation and 
FA formation in hGPR55-HEK293 cells. 
Figure 4.48:  Proposed signalling pathways required to promote F-actin reorganisation in 
hGPR55-HEK293 cells.  Lipid induced F-actin cytoskeletal reorganisation which promotes the 
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formation of stress fibres, lamellipodia and filopodia occur in hGPR55-HEK293 cells.  These 
effects are mediated through the Gα13-Rho-ROCK signalling axis.  
 
 
Figure 4.49:  Proposed signalling pathways required to promote the formation of LPI-
induced FAs in hGPR55-HEK293 cells.  LPI-induced vinculin-containing FAs require the 
activation of multiple signalling pathways.  Gα13 but not Gαq is required for the FA formation.  
Rho-ROCK signalling is important but in this study cdc42 did not promote the formation of 
FAs.  PLC activation is required which would lead to the subsequent release of Ca2+ from the 
ER.  Ca2+ is important for the formation of FAs.  Note the dashed line highlights possible 
interactions. 
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Figure 4.50:  Proposed signalling pathways required to promote the formation of FAs in 
hGPR55-HEK293 cells challenged with NOSer.  NOSer-induced vinculin-containing FAs 
require the activation of multiple signalling pathways.  Gα13 but not Gαq is required for the FA 
formation.  Rho-ROCK signalling is important but in this study cdc42 did not promote the 
formation of FAs.  PLC activation is likely to be required and would therefore lead to the 
subsequent release of Ca2+ from the ER.  Ca2+ is important for the formation of FAs.  Note the 
dashed line highlights possible interactions. 
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4.3.3.  Summary of individual pCREB signalling pathways in hGPR55-HEK293 
cells. 
 
 
Figure 4.51:  Proposed LPI-induced Ca2+ signalling cascade required for pCREB in 
hGPR55-HEK293 cells.  LPI was found to require Ca2+ mobilisation to induce nuclear pCREB.  
Endogenous lipid binding of GPR55 initiates the activation of Gα13 which in turn is likely to 
activate RhoA whereby ROCK I is phosphorylated.  Moreover is is likely that ROCK II is als 
required for pCREB.  Phosphorylation of PLC initiates the hydrolysis of PIP2 into DAG and 
IP3.  IP3 translocates to IP3 receptors on the ER allowing promoting the release of Ca2+.  DAG 
and/or Ca2+ activated PKC.  PKC and Ca2+ can act upon CAMKII which can then 
phosphorylate CREB.  LPI, L-α-lysophosphatidylinositol; RhoA, Ras homolog gene, family 
member A; ROCK, Rho associated protein kinase; PLC, Phospholipase C; PIP2, 
phosphatidylinositol 4, 5-bisphosphate; DAG, diacylglycerol; IP3, inositol 1, 4, 5-triphosphate; 
ER, endoplasmic reticulum; PKC, protein kinase C; CAMKII, Ca2+/calmodulin dependent 
protein kinase II. 
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Figure 4.52:  Proposed Ca2+ signalling cascade required for pCREB in NOSer challenged 
hGPR55-HEK293 cells.  NOSer was found to require Ca2+ mobilisation to induce nuclear 
pCREB.  Endogenous lipid binding of GPR55 is likely to initiate the activation of Gα13 which in 
turn is likely to activate RhoA whereby ROCK I is phosphorylated.  Phosphorylation of PLC 
initiates the hydrolysis of PIP2 into DAG and IP3.  IP3 translocates to IP3 receptors on the ER 
allowing promoting the release of Ca2+.  DAG and/or Ca2+ activated PKC.  It is also likely that 
PKC and Ca2+ can act upon CAMKII which can then phosphorylate CREB.  NOSer, N-oleoyl-L-
serine; RhoA, Ras homolog gene, family member A; ROCK, Rho associated protein kinase; 
PLC, Phospholipase C; PIP2, phosphatidylinositol 4, 5-bisphosphate; DAG, diacylglycerol; 
IP3, inositol 1, 4, 5-triphosphate; ER, endoplasmic reticulum; PKC, protein kinase C; CAMKII, 
Ca2+/calmodulin dependent protein kinase II. 
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Figure 4.53:  Proposed LPI-induced signalling cascades required promoting nuclear pCREB 
with MAPK and PI-3 kinase signalling pathways.  Gα13 acting on RhoA could lead to the 
phosphorylation of MEKK1 which in turn can phosphorylate MEK1/2.  MEK1/2 subsequently 
phosphorylates ERK1/2 which translocates into the nucleus to phosphorylate CREB.  
Alternatively Rho phosphorylates ROCK which then subsequently phosphorylates ERK1/2.  PI-3 
kinase could be activated by the βγ subunits of the Gα13 -protein which can then phosphorylate 
AKT and ultimately CREB.  Solid arrows = signalling effectors; dashed arrows = suggested 
effectors. Pink arrows = MAPK signalling pathway; orange arrows = PI-3 kinase signalling 
pathway. 
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Figure 4.54:  Proposed signalling cascades required to promote NOSer-induced nuclear 
pCREB with MAPK and PI-3 kinase signalling pathways.  Gα13 acting on RhoA could lead to 
the phosphorylation of MEKK1 which in turn can phosphorylate MEK1/2.  MEK1/2 
subsequently phosphorylates ERK1/2 which translocates into the nucleus to phosphorylate 
CREB.  Alternatively Rho phosphorylates ROCK which then subsequently phosphorylates 
ERK1/2.  PI-3 kinase could be activated by the βγ subunits of the Gα13 -protein which can then 
phosphorylate AKT and ultimately CREB.  Solid arrows = signalling effectors; dashed arrows 
= suggested effectors. Pink arrows = MAPK signalling pathway; orange arrows = PI-3 kinase 
signalling pathway. 
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CHAPTER FIVE 
 
Endogenous Lipid Mediated Effects in 
the Prostate Cancer Cell Line, DU145. 
A Potential Role for GPR55? 
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5.1. INTRODUCTION 
GPR55 is known to be expressed in metastatic cancer cells such as prostate cancer cells 
lines; PC3 and DU145 (Piñeiro et al., 2011).  In a study of two breast cancer cell lines; 
MCF-7 and MDA-MB-231 the authors observed higher GPR55 mRNA expression in 
the latter cells, which had a higher metastatic capability (Ford et al., 2010).  The MCF-7 
cells did not migrate towards serum in a Boyden chamber assay.  However the transient 
transfection of GPR55 cDNA into MCF-7 cells led to the development of a migratory 
phenotype, where the cells could now migrate towards the serum, suggesting GPR55 
may play a role migration (Ford et al., 2010).  GPR55 is also reported to be expressed at 
higher levels in aggressive cancer cells suggesting it may play a detrimental role in 
cancer (Andradas et al., 2011).  Indeed the authors found that the increased expression 
of GPR55 correlated with the patients who had the worst prognosis (Andradas et al., 
2011).  It was also noted that GPR55-mediated ERK1/2 signalling is necessary for 
carcinoma proliferation in both cell lines and xenograft studies using glioblastoma cells 
(Andradas et al., 2011).  Furthermore malignant cancer growth in skin carcinomas was 
found to be GPR55-mediated (Pérez-Gómez et al., 2013).  GPR55 was also involved in 
growth of prostate cancer PC3 cells in soft agar as GPR55 knockdown inhibited the 
effect (Piñeiro et al., 2011).  Another study however has reported that AEA exerted 
anti-proliferative effects in cholangiocarcinoma which was GPR55-mediated through 
Gα12 proteins (Huang et al., 2011).  These differences suggest that effects on cell growth 
may be cell type specific.   
 
GPR55 is reported to signal through the Gα12 family of heterotrimeric G proteins, whose 
members consist of Gα12 and Gα13, and are involved in many aspects of oncogenesis 
(Worzfeld et al., 2008).  Studies with prostate cancer cells have highlighted that there is 
an up-regulation of Gα12 in invasive prostate cancer cell lines including DU145 cells 
(Kelly et al., 2006).  Rho proteins which can be activated by either Gα12/13 or Gαq which 
are also required for prostate cancer growth (Dorsam and Gutkind, 2007).  Interestingly 
these proteins are associated with GPR55 (Lauckner et al., 2008; Henstridge et al., 
2009). 
 
The lysophospholipid, LPI had been found to increase in the extracellular medium of 
epithelial (Falasca and Corda, 1994) and fibroblast cells (Falasca et al., 1998) 
suggesting that LPI could act as an autocrine mediator on the cells that had released the 
lipid.  More recently LPI was found to be increased in the ascites fluid and plasma from 
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women with ovarian cancer compared to women with benign tumours or healthy 
volunteers (Xiao et al., 2001; Sutphen et al., 2004) suggesting LPI is present in the 
ascites surrounding the tumours.  Furthermore, LPI is generated in DU145 cells via 
cytosolic PLA2 whereby it can exit the cell through an ABCC1 transporter; allowing 
LPI to act in an autocrine manner on cells in the tumour microenvironment (Piñeiro et 
al., 2011).  Therefore both LPI and GPR55 appear to be important factors in some 
cancer pathophysiologies.   
 
This study was to characterise LPI and the novel, endogenous GPR55 ligand NOSer in a 
native GPR55-expressing prostate cancer cell line; DU145.  Firstly, GPR55-mediated 
Ca2+ mobilisation in the DU145 cells was studied.  LPI and NOSer were then evaluated 
using the pCREB assay; where several pharmacological inhibitors were used to 
elucidate the signalling pathways required to promote pCREB.  Finally the F-actin 
cytoskeleton and FAs were assessed using DU145 cells challenged with either LPI or 
NOSer.  To the best of our knowledge this is the first study to report NOSer effects in 
DU145 cells.  Also this is the first study to determine the effects of both LPI and 
NOSer-induced pCREB, F-actin and vinculin responses in these cells. 
 
5.2. RESULTS 
5.2.1. Endogenous lipids promote GPR55-mediated Ca2+ mobilisation in DU145 
prostate cancer cells. 
Recent evidence has highlighted GPR55-mediated Ca2+ mobilisation in DU145 cells 
challenged with 10 µM LPI (Piñeiro et al., 2011).  In this study DU145 cells treated 
with LPI (100 nM) had no effect on the mobilisation of Ca2+ (figure 5.1Ai).  Perfusion 
of LPI (3 µM), however, was found to promote a single Ca2+ transient in DU145 cells 
(figure 5.1Aii). Mean peak Ca2+ responses were concentration-dependent (figure 5.1B), 
however an EC50 could not be calculated as the responses did not reach Emax within the 
concentration range tested (100 nM - 10 µM; figure 5.1B).  LPI (1 µM) perfused over 
DU145 cells that were transiently transfected with mouse CB2-siRNA (69 hr) produced 
a single Ca2+ transient (figure 5.1Ci).  However DU145 cells that had been transiently 
transfected with human GPR55-siRNA (69 hr) and challenged with LPI (1 µM) 
produced a Ca2+ transient peak response that was reduced by 33.9 ± 19.4% compared 
with the CB2-siRNA treated cells (figure 5.1Cii).    DU145 cells treated with GPR55-
siRNA produced mean peak Ca2+ responses that were lower than seen with control 
CB2-siRNA treated cells (CB2-siRNA = 0.22 ± 0.03 ratio units, GPR55-siRNA = 0.134 
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± 0.02 ratio units, n = 45, Student’s unpaired two-tailed t-test, P < 0.05, figure 5.1D).  
These data suggests that LPI-induced Ca2+ mobilisation in DU145 cells are at least in 
part GPR55-mediated. 
 
Figure 5.1:  LPI-induced Ca2+ mobilisation in DU145 cells.  A, representative Ca2+ traces 
from DU145 cells treated with LPI at i, 100 nM; ii, 3 µM.  B, LPI concentration-response curve 
in DU145 cells.  Data are the mean peak response ± SEM derived from 30 cells from 3 
independent experiments.  C, representative Ca2+ trace from DU145 cells transiently 
transfected for 69 hr with i, CB2-siRNA; ii, GPR55-siRNA and then treated with 1 µM LPI.  D, 
histogram of pooled data, depicting mean Ca2+ peak responses from DU145 cells transiently 
transfected either CB2- or 55-siRNA and perfused with 1 µM LPI.   Note the mean Ca2+ 
response was significantly decreased in the GPR55-siRNA transfected cells when compared to 
control CB2-siRNA transfected cells.  Data are the mean, peak response ± SEM of 45 cells from 
2 independent experiments.  Student’s unpaired two-tailed t-test; *P < 0.05. 
 
Having confirmed that LPI promoted Ca2+ mobilisation in DU145 cells, the effects of 
NOSer were studied.  DU145 cells challenged with NOSer (1 µM) did not promote Ca2+ 
transients but were found to produce a small ‘bump’-like response (figure 5.2Ai).  
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Increasing the concentration of NOSer (10 µM) was observed to produce a single Ca2+ 
transient (figure 5.2Aii).  The augmentation of mean peak Ca2+ responses was observed 
as NOSer concentrations were increased (100 nM - 10 µM).  However an Emax was not 
reached in this concentration range therefore the EC50 could not be calculated (figure 
5.2B).  Mean, peak Ca2+ responses were also observed to be lower in comparison with 
LPI responses at equivalent concentrations.  DU145 cells transiently transfected with 
human CB2-siRNA (69 hr) challenged with NOSer (10 µM) promoted a single Ca2+ 
transient (figure 5.2Ci).  DU145 cells transiently transfected with human GPR55-siRNA 
(69 hr) and then challenged with NOSer (10 µM) were found to produce a single Ca2+ 
transient however, the mean peak Ca2+ responses were found to lower than the control 
CB2-siRNA treated DU145 cells (figure 5.2Cii).  NOSer (10 µM) perfused over DU145 
cells transiently transfected with GPR55-siRNA reduced the mean, peak Ca2+ transients 
by 58.1 ± 6.2% when compared to control CB2-siRNA transfected cells (CB2-siRNA = 
0.282 ± 0.04, GPR55-siRNA = 0.123 ± 0.024, n = 45 cells, Student’s unpaired two-
tailed t-test, P < 0.001, figure 5.2Ci, ii and D).  These data suggest that NOSer-induced 
Ca2+ peak responses are at least in part GPR55-mediated.   However, it is also observed 
that NOSer was not as efficacious as LPI at promoting Ca2+ mobilisation in DU145 cells 
suggesting ligand bias where signalling through Ca2+ is less effective when GPR55 is 
activated with NOSer.  
 
5.2.1.1. The GPR55 antagonist CBD partially lowers Ca2+ mobilisation in DU145 
cells.  
To further confirm that GPR55 was mediating the Ca2+ mobilisation occurring in 
DU145 cells the purported GPR55 antagonist CBD (1 µM) was utilised (Ryberg et al., 
2007; Whyte et al., 2009).  As LPI (3 µM) was found to produce a sub-maximal 
response in DU145 cells it was used for all subsequent inhibitor experiments.  LPI 
applied in the presence of CBD was observed to lower the mean peak Ca2+ response by 
28.98 ± 7.7% in DU145 cells when compared with LPI alone (LPI = 0.911 ± 0.028 ratio 
units, CBD + LPI = 0.668 ± 0.059 ratio units, n = 43 cells, P < 0.001, Student’s 
unpaired two-tailed t-test, figure 5.3B and C). 
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Figure 5.2:  NOSer promotes Ca2+ mobilisation in DU145 cells.  NOSer was perfused at a rate 
of 2 ml/min over DU145 cells.  A, representative Ca2+ traces from DU145 cells treated with 
NOSer at i, 1 µM; ii, 10 µM.  B, NOSer concentration-response curve in DU145 cells.  Data 
are the mean peak response ± SEM derived from 30 cells from 3 independent experiments.  C, 
representative Ca2+ trace from DU145 cells transiently transfected for 69 hr with i.  CB2-
siRNA; ii.  GPR55-siRNA and then treated with 10 µM NOSer.  D, histogram of pooled data, 
depicting mean Ca2+ peak responses from DU145 cells transiently transfected either CB2 or 55 
siRNA and perfused with 10 µM NOSer.   Note the mean Ca2+ response was significantly 
decreased in the GPR55-siRNA transfected cells when compared to control CB2-siRNA 
transfected cells.  Data are the mean peak response ± SEM of 45 cells from 2 independent 
experiments.  Student’s unpaired two-tailed t-test; *P < 0.05. 
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Figure 5.3:  CBD antagonises LPI-induced Ca2+ mobilisation in DU145 cells.  DU145 cells 
were perfused with 1 µM CBD (20 min) prior to co-application with 3 µM LPI (5 min).  A, 
representative Ca2+ trace from DU145 cells challenged with 3 µM LPI.  B, representative Ca2+ 
trace from DU145 cells treated with 1 µM CBD and 3 µM LPI.  C, histogram of pooled data, 
depicting mean peak Ca2+ responses from DU145 cells treated with either 3 µM LPI alone or in 
the presence of 1 µM CBD.  Analysis revealed that the presence of CBD significantly decreased 
the LPI-induced Ca2+ response.  Data are the mean peak response ± SEM of 43 cells from 2 
independent experiments.    Student’s unpaired two-tailed t-test followed by a Bonferroni post 
hoc test; ***P < 0.001. 
 
5.2.1.2.  LPI-induced Ca2+ transients require Gαq in DU145 cells. 
Previous studies have highlighted that Gαq can induce the mobilisation of Ca2+ through 
GPR55 activation in transiently transfected hGPR55-HEK293 cells (Lauckner et al., 
2008).  Therefore the Gαq inhibitor, YM-254890 (1 μM) was applied to DU145 cells in 
the presence of LPI (3 μM).  When LPI (3 µM) was co-applied with YM-254890 (1 
µM) responses were markedly reduced by 66.3 ± 11.6%. Only slight increases in Ca2+ 
ratio were observed, with a clear Ca2+ transient induced in just one cell (LPI = 1.096 ± 
0.092 ratio units, YM-254890 + LPI = 0.364 ± 0.04 ratio units, n = 58 cells, Student’s 
unpaired two-tailed t-test, P < 0.001, figure 5.4C).    These data suggest that LPI 
mediates the mobilisation of Ca2+ in DU145 cells via activation of the heterotrimeric G-
protein, Gαq.   
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Figure 5.4:  LPI-mediated Ca2+ signalling is through the activation of Gαq in DU145 cells.  
The Gαq inhibitor YM-254890 (1 μM) was perfused over the DU145 cells for 20 min prior to a 
five minute co-application with 3 μM LPI followed by a final 5 min application of YM-254890 
during washout.  A, representative Ca2+ trace from DU145 cells treated with 3 µM LPI.  B, 
representative Ca2+ trace of the responding DU145 cell treated with the co-application of 1 µM 
YM-254890 and 3 µM LPI.  C, histogram of pooled data depicting mean, peak Ca2+ response 
data whereby the presence of YM-254890 decreases the LPI-mediated Ca2+ response in DU145 
cells.   The analysis revealed a significant decrease in mean Ca2+ responses in DU145 cells 
when the Gαq inhibitor was present with LPI.  Data are the mean peak response ± SEM of 58 
cells from 3 independent experiments.  Student’s unpaired two-tailed t-test; ***P < 0.001. 
 
5.2.1.3.  ROCK signalling is not required for Ca2+ mobilisation in DU145 cells. 
Gαq along with activating PLCβ (Takashima et al., 2008) can activate RhoA (Vogt et 
al., 2003), which is known to exert many of its actions via ROCK (Fujisawa et al., 
1996; Matsui et al., 1996).   In the hGPR55-HEK293 cells we showed that both 
isoforms of ROCK are important for Ca2+ mobilisation.   Therefore the same two 
ROCK inhibitors; Y27632 (ROCK I and II inhibitor) and H1152 (ROCK II inhibitor), 
were tested in the DU145 cells.  Y-27632 (10 µM) applied to DU145 cells prior to co-
application with LPI (3 µM) had no effect on the mean, peak Ca2+ response (LPI = 
0.738 ± 0.044 ratio units, Y-27632 + LPI = 0.748 ±0.044 ratio units, n = 36 cells, 
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applied to DU145 cells prior to co-application with LPI did not alter the Ca2+ mean peak 
responses when compared to LPI alone (LPI = 0.862 ± 0.050, H1152 + LPI = 0.839 ± 
0.052, n = 46 cells, Student’s unpaired two-tailed t-test, P > 0.05, figure 5.5Ci, ii and 
D). 
 
Figure 5.5:  LPI-induced Ca2+ mobilisation does not require ROCK signalling. DU145 cells 
were treated with ROCK inhibitors for 20 min prior to co-appplication with LPI.  A, 
representative Ca2+ traces from DU145 cells challenged with either i, 3 µM LPI or ii, 3 µM LPI 
in the presence of 10 µM Y-27632.  B, histogram of pooled data depicting mean peak Ca2+ 
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response data from DU145 cells with either perfusion of LPI or LPI in the presence of Y-27632. 
Data are the mean, peak response ± SEM of 36 cells from 2 independent experiments.  C, 
representative Ca2+ trace from DU145 cells perfused with either i, 3 µM LPI or ii, 3 µM LPI in 
the presence of 1 µM H1152.  D, histogram of pooled data, highlighting the mean, peak Ca2+ 
response data of DU145 cells treated with either LPI alone or LPI in the presence of H1152. 
Data are the mean, peak response ± SEM of 46 cells from 3 independent experiments. Note that 
the mean peak Ca2+ response hGPR55-HEK293 cells was unaffected by the presence of either 
ROCK II inhibitor.  Student’s unpaired two-tailed t-test; ns = not significant.   
 
The effects of ROCK inhibitors were also tested against NOSer (10 µM). However, 
responses to NOSer in the presence of Y-27632 (10 µM) were similar in magnitude to 
NOSer alone (NOSer = 0.670 ± 0.035, Y-27632 + NOSer = 0.737 ± 0.051, n = 30 cells, 
Student’s unpaired two-tailed t-test, P > 0.05, figure 5.6Ai, ii, B).  Likewise, responses 
to NOSer in the presence of H1152 (1 µM) were similar in magnitude to NOSer alone 
(NOSer = 0.723 ± 0.045, H1152 + NOSer = 0.795 ± 0.043, n = 20 cells, Student’s 
unpaired two-tailed t-test, P > 0.05, figure 5.6Ci, ii, D).  These data are in agreement 
with Falasca’s group whereby ROCK signalling is not required for LPI-induced Ca2+ 
mobilisation in DU145 cells (Piñeiro et al., 2011). 
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Figure 5.6:  ROCK signalling is not required for NOSer-mediated Ca2+ mobilisation in 
DU145 cells.  ROCK inhibitors were applied to DU145 cells for 20 min prior to co-application 
with LPI.  A, representative Ca2+ trace from DU145 cells challenged with either i.  10 µM 
NOSer or ii.  10 µM NOSer in the presence of 10 µM Y-27632.  B,  histogram of pooled data, 
the mean peak Ca2+ response data of DU145 cells perfused with NOSer or NOSer in the 
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presence of Y-27632.  Data are the mean peak response ±SEM of 30 cells from 2 independent 
experiments.  C, representative Ca2+ trace from DU145 cells perfused with either i, 10 µM 
NOSer or ii,  10 µM NOSer in the presence of 1 µM H1152.  D, histogram of pooled data, 
depicting  mean peak Ca2+ response data of DU145 cells treated with either NOSer alone or 
NOSer in the presence of H1152.  Note there is no difference in the Ca2+ responses seen with 
NOSer in the presence of either ROCK inhibitor.  Data are the mean, peak response ± SEM of 
20 cells from 2 independent experiments. Student’s unpaired two-tailed t-test; ns = not 
significant. 
 
5.2.1.4. Role of intracellular Ca2+ stores in GPR55-mediated Ca2+ responses in 
DU145 cells. 
Gαq is also known to promote the mobilisation of Ca2+ through the activation of PLCβ 
(Takashima et al., 2008).  Also PLC is reported to be required for GPR55-mediated 
Ca2+ mobilisation (Lauckner et al., 2008; Henstridge et al., 2009).  Therefore, U73122 
(1 µM), a broad spectrum PLC inhibitor was applied to DU145 cells.  Responses to LPI 
when applied in the presence of U73122 were reduced by 41.9% when compared to 
treatment with LPI alone (LPI = 0.844 ± 0.077, U73122 + LPI = 0.490 ± 0.120, n = 17 
cells, Student’s unpaired two-tailed t-test, P < 0.05, figure 5.7Ai, ii and B).  Likewise, 
treatment with U73122 (20 min) also inhibited responses to NOSer by 48.2 ± 16.5%, 
relative to NOSer alone (NOSer = 0.470 ± 0.055, U73122 + NOSer = 0.233 ± 0.037, n = 
28 cells, Student’s unpaired two-tailed t-test, P < 0.001, figure 5.7Ci, ii, D).  These data 
suggest that Gαq-PLC signalling is important for LPI and NOSer-induced Ca2+ 
mobilisation.   
 
As PLC is required in Ca2+ signalling in DU145 cells the effect of inhibition of IP3 
receptors was studied.  PLC is the enzyme responsible for the hydrolysis of PIP2 into 
IP3 and DAG (Clapham, 2007).  IP3 can translocate from the cell membrane and act on 
IP3 receptors on the ER which promotes the release of Ca2+ through the opened IP3 
receptor (Clapham, 2007).  2-APB is an antagonist of IP3 receptors (Maruyama et al., 
1997) but can also interact with some TRP channels such as TRPV1-3 (Colton and Zhu, 
2007), TRPV6 (Kovacs et al., 2012) TRPM6 and TRPM7 (Li et al., 2006) at 
concentrations >100 µM.  Therefore 30 µM was used in an attempt to preferentially 
target IP3 receptors. Application of NOSer in the presence of 2-APB (30 µM) inhibited 
Ca2+ responses by 69.5% in comparison with those observed with NOSer alone (NOSer 
= 0.720 ± 0.042 ratio units, 2-APB + NOSer = 0.220 ± 0.052 ratio units, n = 22 cells, 
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Student’s unpaired two-tailed t-test, P < 0.001, figure 5.8A-C).  These data suggest that 
IP3 receptors may be required for the mobilisation of Ca2+ in DU145 cells.   
 
 
Figure 5.7:  Endogenous lipids signal through PLC to promote Ca2+ mobilisation in DU145 
cells.  The PLC inhibitor U73122 (1 µM) was applied to DU145 cells prior to the co-
application of the inhibitor with either LPI or NOSer.  A, representative Ca2+ trace from 
DU145 cells challenged with either i, 3 µM LPI or ii, 1 µM U73122 and 3 µM LPI.  B, 
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histogram of pooled data depicting the mean, peak Ca2+ response highlighting that the 
responses to LPI are decreased when the PLC inhibitor is present.  The analysis revealed a 
significant decrease in mean Ca2+ responses when the PLC inhibitor was present with LPI.  
Data are the mean, peak response ± SEM of 17 cells from 1 experiment.  C, representative Ca2+ 
trace from DU145 cells treated with 10 µM either i, NOSer or ii, 10 µM NOSer applied in the 
presence of 1 µM U73122.  D, histogram of pooled data, depicting the mean peak Ca2+ 
response data whereby NOSer applied in the presence of the PLC inhibitor produced mean 
peak Ca2+ responses that were decreased when compared to NOSer alone.  The analysis 
revealed a significant decrease in mean Ca2+ peak responses when the PLC inhibitor was 
present with NOSer.  Data are the mean, peak response ± SEM of 28 cells from 2 independent 
experiments.  Student’s unpaired two-tailed t-test; *P < 0.05; ***P < 0.001. 
 
 
Figure 5.8:  IP3 receptors play a role in Ca2+ mobilisation in DU145 cells.  Cells were treated 
with 2-APB (30 µM) for 20 min prior to co-application with NOSer (5 min).  A, representative 
Ca2+ traces from DU145 cells challenged with i, 10 µM NOSer or ii, 30 µM 2-APB co-applied 
with 10 µM NOSer.  B, histogram of pooled data, for the mean, peak Ca2+ response 
highlighting that responses to NOSer are significantly decreased when the lipid is applied with 
the IP3/TRP channel antagonist.  Data are the mean peak response ± SEM of 22 cells from 1 
experiment.   Student’s unpaired two-tailed t-test; ***P < 0.001. 
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5.2.2. Endogenous lipids, CREB phosphorylation and DU145 cells. 
The next sets of experiments were designed to study the effect LPI and NOSer had on 
pCREB in DU145 cells.  In hGPR55-HEK293 cells pCREB labelling increased and was 
localised to the nucleus when the cells were challenged with the GPR55 lipid ligands.  
The signalling pathways required for pCREB signalling in hGPR55-HEK293 cells were 
also studied in the DU145 cells. 
 
5.2.2.1.  LPI and NOSer induce nuclear pCREB in DU145 prostate cancer cells. 
LPI, as a natural ligand for GPR55 was applied to DU145 cells in the pCREB assay.  
Cells treated with DMSO (0.1%) were found to have low levels of pCREB but there 
was some nuclear labelling observed, suggesting a low level of constitutive activation 
(figure 5.9A).  In the presence of TPA (100 nM) there was a pronounced increase in 
nuclear pCREB labelling in all cells.  Low concentrations of LPI (10 nM and 30 nM) 
did not affect pCREB levels, being similar to DMSO control.  However, as the LPI 
concentration was increased (100 nM - 10 µM range) nuclear pCREB labelling 
increased along with an increase in the number of cells that responded, giving an EC50 
of 222 ± 45 nM (95% confidence limits) (figure 5.9B). 
 
Next the effects of NOSer were investigated in DU145 cells. Increasing NOSer 
concentrations (10 nM - 10 µM) promoted a corresponding increase in nuclear pCREB 
labelling with 10 µM producing pCREB responses that were similar to TPA (figure 
5.10A and B).  As a clear Emax was not observed within the concentration range (10 nM 
- 10 µM) the EC50 could not be calculated. 
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Figure 5.9:  LPI promotes concentration-dependent increases in nuclear pCREB in DU145 
cells.   Increasing concentrations of LPI were applied to the prostate cancer cell line, DU145 
for 25 min.  A, representative confocal images of nuclear pCREB in DU145 cells illustrating the 
effects of the following treatments: DMSO, vehicle control; 100 nM TPA, positive control; 10 
nM LPI; 30 nM LPI; 100 nM LPI; 300 nM LPI; 1 µM LPI; 3 µM LPI;  10 µM LPI.  Scale bars 
= 20 µm. n = 3.  B, concentration-response curve of nuclear pCREB in DU145 cells challenged 
with LPI. Fluorescence intensity was calculated as CTNF normalised relative to 1 µM LPI.  
Data are the means ± SEM; n = 3.    
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Figure 5.10:  NOSer treatment of DU145 prostate cells promotes the phosphorylation of 
nuclear CREB.  Increasing concentrations of NOSer were applied to the prostate cancer cell 
line, DU145 for 25 min.  A, representative confocal images of nuclear pCREB in DU145 cells 
illustrating the effects of the following treatments: DMSO, vehicle control; 100 nM TPA, 
positive control; 10 nM NOSer; 30 nM NOSer; 100 nM NOSer; 300 nM NOSer; 1 µM NOSer; 3 
µM NOSer;  10 µM NOSer.  Scale bars = 20 µm. n = 3.  B, concentration-response curve of 
nuclear pCREB labelling in DU145 cells challenged with increasing concentrations of NOSer.  
Fluorescence intensity was calculated as CTNF normalised relative to 1 µM LPI.  Data are the 
mean ± SEM; n = 3.   
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5.2.2.2.  A role for G13 and Gq in LPI and NOSer-mediated pCREB responses in 
DU145 cells. 
In the next series of experiments the effects of dominant negative Gα13(Q226L/D294N) 
on LPI and NOSer-mediated pCREB responses were evaluated.  One-way ANOVA 
analysis revealed that there was no significant difference across the experimental data 
(F(5,12) = 1.286; P = 0.03323).  DU145 cells transfected with Gα13(Q226L/D294N) 
showed elevated pCREB levels relative to control.  These data suggest that the transient 
transfection may have stressed the cells and promoted pCREB responses even in the 
absence of agonist treatment.  This may have masked the true inhibition of Gα13 in 
DU145 cells challenged with LPI or NOSer.  It is very difficult to interpret this due to 
pCREB induction with Gα13(Q226L/D294N) which is not significantly different to LPI 
or NOSer responses.   
 
Although Gαq was not required to promote pCREB staining in hGPR55-HEK293 cells it 
has been implicated in both GPR55-mediated Ca2+ signalling (Lauckner et al., 2008) 
and ERK1/2 phosphorylation (Obara et al., 2011).  Interestingly the present study 
suggests that GPR55-mediated Ca2+ mobilisation in DU145 cells involved Gαq 
activation.  Therefore the Gαq inhibitor YM-254890 (1 µM) was tested to elucidate if 
GPR55-mediated Gαq signalling can promote nuclear pCREB in DU145 cells. Analysis 
using a One-way ANOVA revealed that there were significant differences within the 
experimental data (F(5,12) =  13.49; P = 0.0001).  Responses to LPI or NOSer were 
inhibited by 97.7 ± 4.1% or 62.8 ± 15.5% respectively in the presence of YM-254890 
(figure 5.12A and B).  In control experiments, similar pCREB labelling was observed in 
DU145 cells treated with either DMSO or Gαq inhibitor alone.  These data suggest that 
Gαq is important for the promotion of pCREB in NOSer challenged DU145 cells and 
likely to be required in LPI treated cells.  
 
 
 
 
262 
 
 
Figure 5.11:  A role for Gα13 in promoting nuclear pCREB in DU145 cells.  Cells were treated 
with a dominant negative Gα13 (Q226L/D294N) cDNA for 18 hr prior to application of the 
lipids.  A, representative confocal images of nuclear pCREB in DU145 cells treated as follows 
DMSO; 1 µM LPI; 1 µM NOSer; Gα13(Q226L/D294N); Gα13(Q226L/D294N) + 1 µM LPI; 
Gα13(Q226L/D294N) + 1 µM NOSer. Scale bars = 20 µm, n = 3.  B, histogram of pooled data, 
showing the mean CTNF when DU145 cells were challenged with either 1 µM LPI or 1 µM 
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NOSer either with or without Gα13(Q226L/D294N).  These data are the mean CTNF normalised 
to 1 µM LPI.  Data are the means ± SEM; n = 3.  One-way ANOVA.   
 
 
Figure 5.12:  Gαq signalling is required for endogenous lipid induced nuclear pCREB in 
DU145 cells.   A, representative confocal images of nuclear pCREB labelling in DU145 cells 
are as follows DMSO; 1 µM LPI; 1 µM NOSer; 1 µM YM-254890; 1 µM YM-254890 + 1 µM 
LPI; 1 µM YM-254890 + 1 µM NOSer.  B, histogram of pooled data, showing the percentage 
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mean of nuclear pCREB fluorescence intensity when DU145 cells were challenged with either 1 
µM LPI or 1 µM NOSer either in the presence or absence of 1 µM YM-254890.  Analysis 
revealed that lipid challenge in the presence of the Gαq inhibitor promoted pCREB which was 
significantly decreased when compared to NOSer alone.  * = data compared to vehicle control.  
Data are the means ±SEM; n = 3.  One-way ANOVA followed by a Bonferroni post hoc test; 
***P < 0.001; #P < 0.05; ns = not significant. 
 
5.2.2.3.  Rho and ROCK are required to induce nuclear pCREB in DU145 cells. 
Both Gα13 and Gαq have been previously reported to activate RhoA (Chikumi et al., 
2002; Vogt et al., 2003).  Furthermore GPR55-mediated Rho activation is required for 
Ca2+ mobilisation (Henstridge et al., 2009) and, in the present study, for pCREB in 
hGPR55-HEK293 cells.  Therefore the effects of the cell permeable Rho inhibitor 
(CT04; 1 µg/ml) were tested on pCREB responses.  A one-way ANOVA highlighted 
significant differences within the CT04 experimental data (F(5,12) = 10.57; P = 0.0005).  
CT04 did not increase pCREB levels when compared to basal levels (5.13A and B).  
CT04 was applied to DU145 cells for 4 hr prior to lipid challenge was found to lower 
pCREB responses to both LPI and NOSer by 59.9 ± 16.0% and 71.5 ± 4.4% 
respectively.  These data suggest that Rho activation is required to promote pCREB 
labelling in DU145 cells when challenged with either LPI or NOSer. 
 
In the present study ROCK signalling was required to promote nuclear pCREB in the 
stably transfected hGPR55-HEK293 cells when they were challenged with either LPI or 
NOSer.  Therefore the ROCK inhibitors, Y-27632 (10 µM) and H1152 (100 nM), were 
tested in the DU145 cells with the same endogenous lipids. A one-way ANOVA 
highlighted significant differences within the Y-27632 data set (F(5,12) = 12.00; P = 
0.0002).  Furthermore a Bonferroni post hoc test revealed that treatment with Y-27632 
had no effect by itself (figure 5.14A and B).  However Y-27632 co-applied with 1 µM 
LPI markedly inhibited responses by 86.2 ± 8.2% and significantly decreased responses 
by 63.6 ± 16.6% when co-applied with 10 µM.     
 
H1152 was also tested with the DU145 cells.  Analysis with a one-way ANOVA 
revealed significant differences within the H1152 experimental data (F(5,12) = 11.29; P = 
0.0003).  A Bonferroni post hoc test highlighted that treatment with H1152 lowered 
pCREB responses to LPI and significantly inhibited responses to 10 µM NOSer by 
120.7 ± 5.5% and 66.5 ± 8.3% respectively.  However H1152 has no effect by itself 
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(figure 5.14D and E).  These data suggest that NOSer challenged DU145 cells require 
ROCK activation to promote pCREB.  Furthermore ROCK is likely to be required by 
DU145 cells challenged with LPI.  This highlights a difference in signalling as NOSer 
and LPI-mediated Ca2+ mobilisation did not require ROCK signalling in the DU145 
cells. 
 
Figure 5.13:  Signalling through Rho is required for LPI and NOSer-mediated pCREB 
responses in DU145 cells.  Cells were treated for 4 hr with a membrane permeant Rho inhibitor 
(1 µg/ml CT04) prior to treatment with lipid.  A, representative confocal images of nuclear 
pCREB in hGPR55-HEK293 cells are as follows: DMSO; 1 µM LPI; 1 µM NOSer; 1 µg/ml 
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CT04; 1 µg/ml CT04 + 1 µM LPI; 1 µg/ml CT04 + 1 µM NOSer. Scale bars = 20 µm; n = 3.  
B, histogram of pooled data displaying the mean nuclear pCREB fluorescence when DU145 
cells were challenged with either 1 µM LPI or 1 µM NOSer either in the presence of absence of 
the Rho inhibitor.  Analysis revealed that the presence of the Rho inhibitor significantly 
decreased the effects of lipid challenge in DU145 cells.  The data is CTNF normalised to 1 µM 
LPI.  Data are the means ± SEM; n = 3.  * = compared to vehicle control.   One-way ANOVA 
followed by a Bonferroni post hoc test; **P < 0.01; #P < 0.05.   
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Figure 5.14:  ROCK signalling is required to promote nuclear pCREB in DU145 cells.  A, 
representative confocal images of nuclear pCREB labelling are DMSO; 1 µM LPI; 1 µM 
NOSer; 10 µM Y-27632; 10 µM Y-27632 + 1 µM LPI; 10 µM Y-27632 + 1 µM NOSer.  Scale 
bars = 20 µm; n = 3.  B, histogram of pooled data, highlighting the CTNF of nuclear pCREB 
fluorescence when DU145 cells were challenged with either 1 µM LPI, 1 µM NOSer or the 
lipids in the presence of 10 µM Y-27632.  Analysis revealed the ROCK I and II inhibitor (Y-
27632; 10 µM) decreases the nuclear pCREB labelling in lipid challenged DU145 cells.   C, 
representative confocal images of nuclear pCREB labelling are DMSO; 1 µM LPI; 1 µM 
NOSer; 100 nM H1152; 100 nM H1152 + 1 µM LPI; 100 nM H1152 + 1 µM NOSer.  Scale 
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bars = 20 µm; n = 3.  D, histogram of pooled data showing the CTNF of nuclear pCREB in 
DU145s challenged with 1 µM LPI or 1 µM NOSer alone or co-applied with 100 nM H1152.  
Analysis revealed presence of the ROCK II inhibitor decreased the lipid-induced pCREB 
labelling in the DU145 cells.  * = data compared to vehicle control.  Data are means ± SEM; n 
= 3.  One-way ANOVA followed by a Bonferroni post hoc test.  *P < 0.05; **P < 0.01; ***P < 
0.001; #P < 0.05; ns = not significant.  
 
5.2.2.4.  The role of Ca2+ homeostasis in nuclear pCREB responses to endogenous 
lipids in DU145s.   
The next sets of experiments were to determine if increases in Ca2+ were a required for 
LPI and NOSer-mediated pCREB responses in DU145 cells.  This study previously 
demonstrated that in hGPR55-HEK293 cells, Ca2+ plays a role in promoting GPR55-
mediated pCREB labelling.  LPI can also promote Ca2+ mobilisation in DU145 cells 
however NOSer was much less effective at inducing Ca2+ mobilisation than seen with 
LPI.  Therefore the role of lipid-induced Ca2+ signalling in promoting pCREB in DU145 
cells was studied.  A one-way ANOVA highlighted significant differences in the 
BAPTA-AM experimental data set (F(5,12) = 6.69; P = 0.0034).  A Bonferroni post hoc 
test revealed that in the presence of BAPTA-AM, neither LPI nor NOSer was able to 
stimulate any additional increase in pCREB levels (figure 5.15A and B).  These data 
suggest that the chelation of intracellular Ca2+ may interfere with LPI and NOSer-
mediated pCREB.  However the direct effect of BAPTA-AM on pCREB levels masks 
this effect. 
 
Does the presence of extracellular Ca2+ effect pCREB responses in DU145s treated with 
exogenous lipids?  In order to address this, cells were placed in Ca2+ free HBS 
supplemented with 100 µM EDTA (CF-HBS) for 5 min prior to the addition of lipids in 
CF-HBS applied for 25 min.   Cells in CF-HBS had a tendency to retract, become 
rounded and in general have a less flattened morphology in CF-HBS.  A one-way 
ANOVA was performed but did not find any significant differences with the data set 
(F(5,6) = 4.664; P = 0.0438).  The pCREB responses to both LPI and NOSer in CF-HBS 
were lowered (figure 5.16A and B).  These data suggest that the extracellular Ca2+ is 
likely to be important for lipid promoted nuclear pCREB in DU145 cells. 
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Figure 5.15:  Effects of BAPTA-AM on LPI and NOSer-mediated nuclear pCREB signalling 
in DU145 cells.  A, representative confocal images of nuclear pCREB labelling in DU145 cells 
are as follows DMSO; 1 µM LPI; 1 µM NOSer; 50 µM BAPTA-AM; 50 µM BAPTA-AM + 1 
µM LPI; 50 µM BAPTA-AM + 1 µM NOSer.  B,  histogram of pooled data, showing the 
percentage mean of nuclear pCREB fluorescence intensity when DU145 cells were challenged 
with either 1 µM LPI or 1 µM NOSer either in the presence of 50 µM BAPTA-AM or alone.  
Analysis revealed that both LPI and NOSer-induced pCREB responses were not significantly 
decreased when Ca2+ was chelated.  However LPI-induced pCREB responses whilst they were 
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lower were not significantly different when the Ca2+ was chelated.  * = data compared to 
vehicle control.  Data are the means ± SEM; n = 3.  One-way ANOVA followed by a Bonferroni 
post hoc test; *P < 0.05; **P < 0.01; ns = not significant. 
 
 
Figure 5.16:  Ca2+ from extracellular media is required for LPI-mediated nuclear pCREB in 
DU145s.  Ca2+-free HBS supplemented with 100 µM EGTA (CF-HBS) was applied to DU145 
cells 5 min prior to the co-application of the respective lipid for a further 25 min.  A, 
representative confocal images of nuclear pCREB labelling in DU145 cells are as follows 
DMSO; 1 µM LPI; 1 µM NOSer; CF-HBS; Ca2+ free HBS + 1 µM LPI; Ca2+ free HBS + 1 µM 
NOSer.  Scale bars = 20 µM; n = 2.  B, histogram of pooled data, showing the percentage 
mean of nuclear pCREB fluorescence intensity when DU145 cells were challenged with either 1 
CF-HBS
+ 1 µM NOSer
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µM LPI or 1 µM NOSer either in the presence of Ca2+ free HBS or alone.  * = data compared 
to vehicle control.  Data are the means ± SEM; n = 2.  One-way ANOVA.   
 
DU145 cells were then tested with the PLC inhibitor, U73122 (1 µM).  Analysis using a 
one-way ANOVA highlighted significant differences within the PLC inhibitor 
experimental data set (F(5,12) = 15.98; P < 0.0001).  Responses to LPI were abolished in 
the presence of U73122 (1 µM), with pCREB labelling similar to DMSO controls 
(figure 5.17A and B).  In contrast, when U73122 was co-applied with NOSer, nuclear 
pCREB labelling that was similar to that observed in NOSer treated cells.  These data 
suggest that PLC is required for the promotion of nuclear pCREB in DU145 cells 
challenged with LPI but has no affect in NOSer challenged cells.   
 
PKC is a well-established kinase that can promote CREB phosphorylation (Zanassi et 
al., 2001).  In this PKC was also involved in promoting pCREB in hGPR55-HEK293 
cells treated with LPI or NOSer.  Using Gö6983 (1 µM), a broad spectrum cell 
permeable selective PKC inhibitor was tested to uncover the role of PKC in pCREB 
responses to LPI (1 µM) or NOSer (1 µM) in DU145 cells.  A one-way ANOVA 
revealed significant differences within the Gö6983 experimental data set (F(5,12) = 
10.61; P = 0.0004).  Moreover a Bonferroni post hoc test highlighted that treatment with 
Gö6983 alone did not effect pCREB levels (figure 5.18A and B). However when LPI 
was co-applied with Gö6983, pCREB responses to LPI were lowered.  Responses to 
NOSer were inhibited, to a lesser extent than seen with LPI.  These data suggest that 
PKC is likely to be involved in promoting pCREB in DU145 cells challenged with LPI 
but may not be so important in cells challenged with NOSer.   
 
CaMKII is another kinase implicated in GPR55-CREB signalling in hGPR55-HEK293 
cells, therefore KN-62 (2 µM), a CaMKII inhibitor was tested on the DU145 cells.  
One-way ANOVA analysis highlighted significant differences within the KN-62 data 
set (F(5,6) = 25.18; P = 0.0006).  Furthermore a Bonferroni post hoc test revealed that 
treatment with KN-62 alone did not affect basal levels of pCREB (figure 5.19A and B).  
However, when KN-62 was co-applied with LPI responses were markedly inhibited.  
Responses to NOSer were also slightly inhibited in the presence of KN-62 but were not 
significant.  These data suggest that CaMKII is involved in LPI-induced pCREB 
responses in DU145 cells.  However NOSer-induced pCREB in DU145 cells does not 
require the activation of CAMKII. 
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Figure 5.17:  A role for PLC in LPI, but not NOSer-mediated nuclear pCREB signalling in 
DU145s cells.  A, representative confocal images of nuclear pCREB labelling in DU145 cells 
are as follows DMSO; 1 µM LPI; 1 µM NOSer; 1 µM U73122; 1 µM U73122 + 1 µM LPI; 1 
µM U73122 + 1 µM NOSer.  Scale bars = 20 µm; n = 3.  B, histogram of pooled data; 
depicting the mean CTNF of nuclear pCREB in DU145 cells treated with either 1 µM LPI, 1 
µM NOSer or a lipid co-applied with 1 µM U73122.  Analysis revealed that inhibiting PLC 
significantly decreased the LPI-induced pCREB labelling in the DU145 cells however it had no 
effect on NOSer-induced pCREB.  * = data compared to vehicle control.  Data are the means ± 
SEM; n = 3.  One-way ANOVA followed by a Bonferroni post hoc test.  **P < 0.01; #P < 0.05; 
ns = not significant.   
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Figure 5.18:  PKC signalling is likely to be involved in nuclear pCREB signalling in DU145 
cells treated with endogenous lipids.  A, representative confocal images of nuclear pCREB 
labelling in DU145 cells are as follows DMSO; 1 µM LPI; 1 µM NOSer; 1 µM Gö6983; 1 µM 
Gö6983 + 1 µM LPI; 1 µM Gö6983 + 1 µM NOSer.  Scale bars = 20 µm; n = 3.  B, histogram 
of pooled data; depicting the mean CTNF normalised to 1 µM LPI of nuclear pCREB in DU145 
cells treated with either 1 µM LPI, 1 µM NOSer or a lipid co-applied with 1 µM Gö6983.  The 
analysis revealed that PKC inhibition decreased the pCREB labelling in DU145 cells 
challenged with either of the lipids however to a greater extent with LPI.  * = data compared to 
vehicle control.  Data are the means ± SEM; n = 3.  One-way ANOVA followed by a Bonferroni 
post hoc test.  *P < 0.05; **P < 0.01; ns = not significant.   
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Figure 5.19:  CaMKII is involved in GPR55-pCREB signalling in DU145 cells.  A, 
representative confocal images of nuclear pCREB labelling in DU145 cells are as follows 
DMSO; 1 µM LPI; 1 µM NOSer; 2 µM KN-62; 2 µM KN-62 + 1 µM LPI; 2 µM KN-62 + 1 µM 
NOSer.  Scale bars = 20 µm; n = 2.  B, histogram of pooled data; depicting the mean CTNF of 
nuclear pCREB in DU145 cells treated with either 1 µM LPI, 1 µM NOSer or a lipid co-applied 
with 2 µM KN-62.  Analysis revealed CaMKII inhibition significantly decreased the pCREB 
labelling in LPI challenged DU145 cells.  * = data compared to vehicle control.  Data are the 
means ± SEM; n = 2.  One-way ANOVA followed by a Bonferroni post hoc test.  *P < 0.05; **P 
< 0.01; ns = not significant.   
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5.2.2.5.  Do DU145 cells challenged with lipids signal through the MAP kinase 
pathway to induce nuclear pCREB? 
Previously LPI (1 µM) was reported to promote ERK1/2 phosphorylation in DU145 
cells.  The authors also observed that 100 nM LPI phosphorylated ERK1/2, albeit to a 
lesser extent (Piñeiro et al., 2011).  Therefore, PD98059 and U0126, two structurally 
different MEK1/2 inhibitors, were applied to DU145 cells.  One-way ANOVA revealed 
there were significant differences within the MEK1/2 inhibitor experimental data (F(8,18) 
= 37.12; P < 0.0001).  Furthermore a Bonferroni post hoc test highlighted that neither of 
these inhibitors (PD98059, 25 µM; U0126, 5 µM) effected basal pCREB (figure 5.20A 
and B).  However responses to LPI or NOSer were abolished in their presence.   
 
To further confirm the MEK inhibitors results, U0124 (5 µM), an inactive analogue of 
U0126 was employed.  One-way ANOVA revealed significant differences within the 
experimental data (F(5,12) = 20.86; P < 0.0001).  Moreover a Bonferroni post hoc test 
highlighted that treatment with U0124 did not affect responses to LPI (1 µM) or NOSer 
(1 µM) (figure 5.20C and D).  These data suggest that both LPI and NOSer require 
activation of MEK1/2 to promote nuclear pCREB labelling in DU145 cells. 
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Figure 5.20:  MAPK is required for GPR55-pCREB signalling in DU145 cells.  Cells were 
treated for 30 min with MEK1/2 inhibitors (25 µM PD98059 or 5 µM U0126) prior to co-
application of inhibitor with lipid.  A, representative confocal images of nuclear pCREB in 
DU145 cells treated with active MEK1/2 inhibitors were as follows DMSO; 25 µM PD98059; 5 
µM U0126; 1 µM LPI;  25 µM PD98059 + 1 µM LPI; 5 µM U0126 + 1 µM LPI; 1 µM NOSer; 
25 µM PD98059 + 1 µM NOSer; 5 µM U0126 + 1 µM NOSer.   Scale bars = 20 µm; n = 3.  B, 
histogram of pooled data, showing the mean CTNF in DU145 cells were challenged with either 
1 µM LPI or 1 µM NOSer either with or without MEK1/2 inhibitors; 25 µM PD98059 or 5 µM 
U0126.    Analysis revealed a significant decrease in lipid-induced pCREB labelling in DU145 
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cells where the MEK1/2 inhibitors were present.  Alternatively cells were treated for 30 min 
with an inactive form of MEK1/2 inhibitor (5 µM U0124) then the lipids were co-applied.  C, 
representative confocal images of DU145 cells were challenged as follows DMSO; 1 µM LPI; 1 
µM NOSer; 5 µM U0124; 5 µM U0124 + 1 µM LPI; 5 µM U0124 + 1 µM NOSer.  Scale bars 
= 20 µm; n=3.   D, histogram of pooled data, highlighting the mean CTNF of pCREB in DU145 
cells when treated with either LPI or NOSer either alone or in the presence of U0124.  Note 
there was no significant difference in lipid-induced pCREB labelling in DU145 cells when the 
inactive MEK1/2 inhibitor was present.  Fluorescent intensity is the mean CTNF normalised to 
1 µM LPI.  Data are means ± SEM; n = 3.  * = data compared to vehicle control.  One-way 
ANOVA followed by a Bonferroni post hoc test.  ***P < 0.001; ###P < 0.001; ns = not 
significant. 
 
5.2.2.6. PI-3-kinase is not required to promote pCREB in DU145 cells. 
LPI-induced AKT phosphorylation has been observed previously in DU145 cells 
(Piñeiro et al., 2011) and a substrate of PI-3-kinase/AKT pathway is CREB (Nicholson 
and Anderson, 2002).  Two structurally different PI-3-kinase inhibitors, LY294002 and 
wortmannin, were therefore used to assess the potential role PI-3-kinase exerts on 
GPR55-mediated CREB phosphorylation. An one-way ANOVA revealed significant 
differences across the LY294002 data set (F(5,12) = 5.236; P = 0.0088).  Furthermore a 
Bonferroni post hoc test highlighted treatment with LY294002 (3 µM) did not affect 
basal pCREB levels.  LPI (1 µM) was inhibited but not significantly whereas NOSer 
was not inhibited when LY294002 was present (figure 5.21A and B). 
 
Application of wortmannin (50 nM) to the DU145 cells was then studied.  An one-way 
ANOVA revealed significant differences across the wortmannin experimental data set 
(F(5,12) = 10.47; P = 0.0005).  Moreover a Bonferroni post hoc test highlighted that 
neither lipid was significantly lowered when the inhibitor was present. These data 
suggest that in DU145 cells LPI-induced pCREB is likely at least in part through the 
activation of PI-3 kinase, whereas NOSer does not involve PI-3 kinase activation. 
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5.21:  PI-3-kinase has a role in signalling to nuclear pCREB with LPI but is not required for 
NOSer responses in DU145s.  Cells were treated for 30 min with MEK1/2 inhibitors (3 µM 
LY294002 or 50 nM wortmannin) prior to co-application of inhibitor with lipid.  A, 
representative images of nuclear pCREB in DU145 cells treated with PI-3-kinase inhibitors 
were as follows DMSO; 1 µM LPI; 1 µM NOSer; 3 µM LY294002; 3 µM LY294002 + 1 µM 
LPI; 3 µM LY294002 + 1 µM NOSer.   Scale bars = 20 µm.  n = 3.  B, histogram of pooled 
data, showing the percentage mean of nuclear pCREB fluorescence when DU145 cells were 
challenged with either 1 µM LPI or 1 µM NOSer either with or without 3 µM LY294002.    C, 
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representative images of DU145 cells were challenged as DMSO; 1 µM LPI; 1 µM NOSer; 50 
nM wortmannin; 50 nM wortmannin + 1 µM LPI; 50 nM wortmannin + 1 µM NOSer.   Scale 
bars = 20 µm; n = 3.   D, histogram of pooled data, highlighting the fluorescence intensity of 
nuclear pCREB in hGPR55-HEK293 cells when treated with either 1 µM LPI or 1 µM NOSer 
either alone or in the presence of 50 nM wortmannin.  Analysis revealed LPI-induced pCREB 
labelling was decreased in DU145 cells treated with the PI-3-kinase inhibitors.  Fluorescent 
intensity is the mean CTNF normalised to 1 µM LPI.  Data are means ± SEM; n = 3.  * = data 
compared to vehicle control.  One-way ANOVA followed by a Bonferroni post hoc test.  *P < 
0.05; **P < 0.01; ns = not significant. 
 
5.2.2.7.  mTOR and pCREB in DU145 cells. 
Next the involvement of mTOR in pCREB responses was investigated as it is 
downstream of PI-3 kinase.  An one-way ANOVA revealed significant differences 
within the mTOR inhibitor experimental data (F(5,12) = 7.587; P = 0.0020).  Furthermore 
a Bonferroni post hoc test highlighted that treatment with the mTOR inhibitor 
rapamycin (50 nM) did not effect pCREB levels (figure 5.22A and B). However, this 
antagonist did not significantly affect responses to LPI or NOSer.  These data suggest 
that activated mTOR is not a key player in lipid-induced nuclear pCREB in DU145 
cells.   
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Figure 5.22:  mTOR is not required for LPI and NOSer-mediated pCREB signalling in 
DU145 cells.  A, representative confocal images of nuclear pCREB labelling in DU145 cells 
are as follows DMSO; 1 µM LPI; 1 µM NOSer; 50 nM rapamycin; 50 nM rapamycin + 1 µM 
LPI; 50 nM rapamycin + 1 µM NOSer.  Scale bars = 20 µm; n = 3.  B, histogram of pooled 
data; depicting the mean CTNF of nuclear pCREB in DU145 cells treated with either 1 µM LPI, 
1 µM NOSer or a lipid co-applied with 50 nM rapamycin.  Note there was no significant 
difference between rapamycin treated DU145 cells and lipid alone challenged cells. Data are 
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means ± SEM; n = 3. * = data compared to vehicle control. One-way ANOVA followed by a 
Bonferroni post hoc test.  *P < 0.05; **P < 0.01; ns = not significant.   
 
5.2.3. The actin cytoskeleton and vinculin, a focal adhesion protein. 
5.2.3.1. Changes in cytoskeletal reorganisation and focal adhesion length occur in 
DU145 cells treated with endogenous lipids. 
Both cytoskeletal reorganisation and changes in vinculin were observed in hGPR55-
HEK293 cells when challenged with LPI or NOSer.  Could similar effects also be seen 
in DU145 cells treated with the endogenous lipids and are these effects GPR55-
mediated?  Initially, the temporal-dependence (15, 25, 60, 120 min) of changes in the 
actin cytoskeleton was evaluated using LPI and NOSer   No effect of the lipids was 
observed at 15 min.  However, after 25 min treatment some stress fibres were observed.  
Likewise after 60 min and 120 min of lipid challenge, stress fibres were present but to a 
lesser extent (figure 5.23).     
 
Next, DU145 cells were challenged with either LPI or NOSer and changes in FA length 
were studied at similar time points as used in the cytoskeletal reorganisation study; 15, 
30, 60 or 120 min.  A two-way ANOVA revealed significant differences within the time 
points tested (F(3,24) = 11.32; P < 0.0001).  A Bonferroni post hoc test highlighted that 
LPI (3 µM; 15 min) and NOSer (3 µM; 15 min) treated DU145 cells were found to have 
FA lengths that were similar to control cells (DMSO = 2.02 ± 0.03 µm, LPI = 2.19 ± 
0.04 µm, NOSer = 2.15 ± 0.07 µm, n = 3, P > 0.05, figure 5.24A and B).  Note that the 
control cells have longer FAs than at other time points in the study.  This may be due to 
the technique of moving the cells thereby adding extra stress to them leading to 
increased FA activity.  Lipid treatment for 25 min promoted a clear increase in FA 
length compared to control cells (DMSO = 1.56 ± 0.03 µm, LPI = 2.17 ± 0.04 µm, 
NOSer = 2.16 ± 0.04 µm, n = 3, P < 0.01). Treatment of the cells for 60 min promoted a 
more robust increase in FA length (DMSO = 1.69 ± 0.03 µm, LPI = 2.48 ± 0.05 µm, 
NOSer = 2.42 ± 0.05 µm, n = 3, P < 0.01).  Finally when the cells were treated for 120 
min there was a smaller lipid-induced increase in FA length which were similar to 
vehicle control (DMSO = 1.60 ± 0.03 µm, LPI = 1.84 ± 0.03 µm, NOSer = 1.80 ± 0.03 
µm, n = 3, P > 0.05). These data highlight the dynamic nature of changes in vinculin-
containing focal adhesion length. 
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Figure 5.23:  Time-course study of the effect of LPI and NOSer on the F-actin cytoskeleton 
in DU145 cells.  Cells were treated with ligands for times as above.  Alexa-fluor® Phalloidin 
546 was applied for 20 min to allow visualisation of polymerised F-actin. Scale bars = 20 µm; 
n = 3. Note the DU145 cell morphology and cytoskeleton are similar to control cells at 15 min.  
From 25 min cytoskeletal reorganisation is observed in cells treated with the endogenous lipids.  
Arrows = lamellipodia; arrow heads = stress fibres.   
DMSO – 15 min 3 µM LPI – 15 min 3 µM NOSer – 15 min
DMSO – 120 min 3 µM LPI – 120 min 3 µM NOSer – 120 min
DMSO – 60 min 3 µM LPI – 60 min 3 µM NOSer – 60 min
DMSO – 25 min 3 µM LPI – 25 min 3 µM NOSer – 25 min
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Figure 5.24:  Focal adhesion length is dynamic in DU145 cells.  Cells were treated with the 
endogenous lipids for various times.  Vinculin was visualised using an anti-vinculin antibody 
followed by the appropriate Alexa fluor® 488 secondary antibody.  A, representative confocal 
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images of vinculin labelling in DU145s at various time points.  Scale bars = 20 µm; n = 3.  B, 
histogram of pooled focal adhesion (FA) length data at various time points; DMSO (black), 3 
µM LPI (white) and 3 µM NOSer (grey).  * = vehicle control compared to LPI; # = vehicle 
control compared to NOSer.  Data are means ± SEM; n = 3.  Two-way ANOVA with a 
Bonferroni post hoc test; **P < 0.01; ***P < 0.001; ##P < 0.01; ###P < 0.001; ns = not 
significant.   
 
5.2.3.2. Cytoskeletal reorganisation and increases in FA length are GPR55-
mediated in DU145 cells. 
In order to test for GPR55 involvement in cytoskeletal responses to NOSer and LPI, we 
investigated the effects of lowering GPR55 levels using siRNA techniques.  Initially 
GPR55 siRNA was evaluated in hGPR55-HEK293 cells, which have a triple HA-tag 
attached to the N-terminus of the receptor, which can be used to visualise GPR55 
expression using an antibody against HA.  Therefore, hGPR55-HEK293 cells were 
transiently transfected with either GPR30-siRNA (control) or GPR55-siRNA for 72 hr 
prior to the commencement of experiments.   A one-way ANOVA revealed significant 
differences within the siRNA data set (F(2,9) = 11.34; P = 0.0035).   Moreover a 
subsequent Bonferroni post hoc test highlighted that hGPR55-HEK293 cells that were 
either untreated or transfected with GPR30-siRNA had bright HA staining that was 
predominantly localised to the plasma membrane (Untreated = 1029000 ± 50990 units, 
GPR30-siRNA = 1139000 ± 89490 units, n = 4, one-way ANOVA, P > 0.05).   In 
contrast hGPR55-HEK293 cells transfected with GPR55-siRNA were observed to have 
HA staining that was lower than seen with untreated (39.5 ± 9.8%; n = 4, P < 0.05) or 
GPR30-siRNA (44.9 ± 8.9%; n = 4, P < 0.01, figure 5.25A and B). 
 
Having validated that the GPR55-siRNA was effective, we next evaluated it in DU145 
cells.   DU145 cells were transiently transfected with either GPR30-siRNA (control) or 
GPR55-siRNA for 72 hr prior to the commencement of experiments.  DU145 cells were 
then treated with either LPI (3 µM) or NOSer (3 µM; 60 min), fixed and permeablised 
then phalloidin was applied to visualise any cytoskeletal reorganisation.  DMSO applied 
to either untreated or siRNA transiently transfected cells were observed to have a flat, 
spread-out morphology and with little or no stress fibres.  However, LPI challenged 
control cells (untreated or GPR30-siRNA transfected cells) demonstrated a clear 
cytoskeletal reorganisation whereby stress fibres were observed in some of the untreated 
and GPR30-siRNA transfected cells.  The untreated cells were also found to have 
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increased lamellipodia formation following LPI treatment. GPR55-siRNA transfected 
cells were found to have a similar morphology to vehicle treated (DMSO) cells.  
However, when NOSer or LPI was applied to untreated or GPR30-siRNA transfected 
cells, cytoskeletal reorganisation was seen in the form of stress fibres and increased 
lamellipodia formation was also observed (figure 5.25C). These data suggest that the 
cytoskeletal reorganisation observed in DU145s challenged with the endogenous lipids 
is GPR55-mediated. 
 
Next the effect of GRP55 knockdown on FA length was assessed.  A two-way ANOVA 
revealed significant differences within the siRNA treatments (F(2,12) = 14.38; P = 
0.0007).  DU145 cells that were untreated or transfected with GPR30-siRNA had 
similar FA lengths in the presence of DMSO, however treatment with NOSer or LPI 
induced normal FA lengthening (Untreated + DMSO = 1.68 ± 0.03 µm, 30-siRNA + 
DMSO = 1.72 ± 0.03 µm, untreated + LPI = 2.21 ± 0.04 µm, 30-siRNA + LPI = 2.14 ± 
0.04 µm, untreated + NOSer = 2.07 ± 0.04 µm, 30-siRNA+NOSer = 2.10 ± 0.04 µm, n 
= 3, P > 0.05).  However, GPR55-siRNA treated DU145 cells had normal FA lengths at 
rest, but showed markedly reduced responses to LPI and NOSer  (30-siRNA + DMSO = 
1.72 ± 0.03 µm, 55-siRNA + DMSO = 1.77 ± 0.03 µm, 30-siRNA + LPI = 2.14 ± 0.04 
µm, 55-siRNA + LPI = 1.82 ± 0.03 µm, 30-siRNA + NOSer = 2.10 ± 0.04 µm, 55-
siRNA + NOSer = 1.75 ± 0.03 µm, n = 3, two-way ANOVA with a Bonferroni post hoc 
test, P < 0.001).  These data suggest that the increases in vinculin-containing FA length 
are GPR55-mediated.   
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Figure 5.25:  Cytoskeletal reorganisation is GPR55-mediated in DU145 cells.  To validate the 
siRNA; triple HA-tagged, hGPR55-HEK293 cells were transiently transfected with either 
untreated
30 siRNA
55 siRNA
A B
U
nt
re
at
ed
G
PR
30
-s
iR
N
A
G
PR
55
-s
iR
N
A
0
250000
500000
750000
1000000
1250000
ns
#
**
flu
or
es
ce
nc
e 
in
te
ns
ity
3 µM LPI – untreated 3 µM LPI – 30-siRNA 3 µM LPI – 55-siRNA
DMSO – untreated DMSO – 30-siRNA DMSO – 55-siRNA
3 µM NOSer – untreated 3 µM NOSer – 30-siRNA 3 µM NOSer – 55-siRNA
C
289 
 
GPR30-siRNA or GPR55-siRNA (72 hr).  The cells were fixed and then labelled with HA 
antibody and visualised with an Alexa fluor® 488 secondary antibody. A, representative 
confocal images of hGPR55-HEK293 cells either untreated or transiently transfected with 
GPR30-siRNA or GPR55-siRNA.  GPR55 expression was localised to the cell membrane.  
Decreased HA labelling was observed in GPR55-siRNA transfected cells when compared to the 
untreated and GPR30-siRNA transfected DU145 cells; n = 4.  B, histogram of pooled data; the 
HA-immunoreactivity corresponding to GPR55 expression in hGPR55-HEK293 cells.  Data are 
means ± SEM; n = 4.  One-way ANOVA with a Bonferroni post hoc test. **P < 0.01; #P < 
0.05; ns = not significant.  C, representative confocal images of DU145 cells stained with Alexa 
Fluor® 546 phalloidin to visualise the actin cytoskeleton; n = 3.  Arrows = lamellipodia; arrow 
heads = stress fibres. 
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Figure 5.26:  Increases in FA length are GPR55-mediated in DU145 cells.  Representative 
confocal images are A, hGPR55-HEK293 cells were either untreated or transfected with 
GPR30-siRNA or GPR55-siRNA; 72 hr.  Note cells that were untreated or transfected with 
GPR30-siRNA have bright HA labelling that is localised to the plasma membrane (this 
corresponds to the localisation of GPR55).  Cells treated with GPR55-siRNA exhibited 
decreased HA immunoreactivity therefore suggesting less GPR55 is present in these cells.  
Scale bars = 20 µm.  B, DU145 cells were either untreated or transfected with GPR30-siRNA 
or GPR55-siRNA; 72 hr.  The cells were then challenged with DMSO (vehicle control), LPI (3 
µM) or NOSer (3 µM) for 60 min.  Scale bars = 20 µm; n = 3.  C, histogram of pooled data, 
showing FA length (µm) in DU145 cells both untreated with siRNA or transiently transfected 
with either GPR30-siRNA or GPR55-siRNA and challenged with the endogenous lipids.  Note 
the DU145 cells treated with GPR55-siRNA were found to have shorter FAs lengths when 
compared to control cells.  Data are means ± SEM; n = 3.  # = untreated compared to GPR55-
siRNA treated DU145 cells; * = GPR30-siRNA compared to GPR55-siRNA treated DU145 
cells.  Two-way ANOVA with a post hoc Bonferroni test; **P < 0.01; ##P < 0.01; ###P < 
0.001.   
 
5.2.3.3. Cytoskeletal reorganisation and FA length are concentration-dependent in 
DU145 cells challenged with endogenous lipids. 
Marked changes in cytoskeletal structure are seen in DU145 cells treated for 60 min 
with LPI.  Next, the concentration-dependence of these effects on the actin cytoskeleton 
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was determined at a 60 min period.  Cells challenged with DMSO (0.1%) had a typical 
flattened morphology (figure 5.27).  Low concentrations of LPI (< 10 nM) did not have 
any clear effect on the cytoskeleton.  Higher concentrations of LPI (30 nM - 1 µM) 
induced some cytoskeletal reorganisation in DU145 cells, with some stress fibres 
observed along with formation of lamellipodia.  As the LPI concentration was further 
increased (3 - 10 µM) the cytoskeletal reorganisation became more pronounced.  The 
cells were also more rounded and lamellipodia had been induced. 
 
Having ascertained that LPI can increase GPR55-mediated vinculin-containing FA 
length in DU145 cells, the concentration-dependence of this effect was investigated.  
Low concentrations of LPI (<10 nM) did not effect FA lengths in comparison with 
control (DMSO) cells (figure 5.28A and B).  However higher concentrations of LPI 
increased FA lengths, with an EC50 =  106.3 ± 80.9 nM (95% confidence limits).   
 
The effects of varying concentrations of NOSer on the actin cytoskeleton in DU145 
cells were studied next. Treatment with NOSer (10 nM - 10 µM) promoted the 
formation of stress fibres in the DU145 cells and lamellipodia were also induced (figure 
5.29). 
 
The next series of experiments were designed to assess the effect on the length of 
vinculin-containing FAs challenged with various NOSer concentrations.  DMSO (0.1%) 
was applied as the vehicle control. NOSer (10 nM - 10 µM) applied to DU145 cells 
promoted an increase in the length of the vinculin-containing FAs (figure 5.30A and B).  
These increases were concentration-dependent, with an EC50 of 71.0 ± 63.5 nM (95% 
confidence limits).  Further experiments are required to clarify if 10 µM NOSer always 
promotes shorter FAs. 
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Figure 5.27:  Concentration-dependence of cytoskeletal reorganisation in DU145 cells 
challenged with LPI.  The actin cytoskeleton was visualised with Alexa Fluor 546® phalloidin 
which binds to the polymerised F-actin.  Representative confocal images of phalloidin labelling 
are illustrated for: DMSO; 10 nM LPI; 30 nM LPI; 100 nM LPI; 300 nM LPI; 1 µM LPI; 3 µM 
DMSO 10 nM LPI
30 nM LPI
300 nM LPI
3 µM LPI 10 µM LPI
1 µM LPI
100 nM LPI
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LPI; 10 µM LPI.  Scale bars = 20 µm; n = 1; note the arrow heads = stress fibres; arrows = 
lamellipodia. 
 
Figure 5.28:  LPI-mediated increases in FA length are concentration-dependant in DU145 
cells.  LPI was applied to DU145 cells for 60 min then vinculin-containing FA length was 
analysed.  A, representative confocal images are illustrated for the following treatments:  
DMSO; 10 nM LPI; 30 nM LPI; 100 nM LPI; 300 nM LPI; 1 µM LPI; 3 µM LPI; 10 µM LPI.  
Scale bars = 20 µm; n = 1.  B, concentration response curve for LPI-induced FA lengthening in 
DU145 cells.  Mean control (DMSO) lengths have been subtracted.  Data are means ± SEM; n 
= 1.   
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Figure 5.29:  NOSer-induced actin reorganisation in DU145 cells.  Various concentrations of 
NOSer (60 min) were applied to DU145 cells and the actin cytoskeleton was visualised using 
Alexa Fluor® 546 phalloidin.  Representative confocal images of DU145 cells are illustrated 
for cells treated with: DMSO; 10 nM NOSer; 30 nM NOSer; 100 nM NOSer; 300 nM NOSer; 1 
DMSO 10 nM NOSer
30 nM NOSer
300 nM NOSer
3 µM NOSer 10 µM NOSer
1 µM NOSer
100 nM NOSer
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µM NOSer; 3 µM NOSer; 10 µM NOSer.  Scale bars = 20 µm; n = 1; note the arrow heads = 
stress fibres; arrows = lamellipodia. 
 
 
Figure 5.30:  FA lengthening in DU145 cells challenged with NOSer.  Vinculin 
immunolabelling in DU145 cells treated with various concentrations of NOSer for 60 min.  A, 
representative confocal images are illustrated for the following treatments: DMSO; 10 nM 
NOSer; 30 nM NOSer; 100 nM NOSer; 300 nM NOSer; 1 µM NOSer; 3 µM NOSer; 10 µM 
NOSer.  Scale bars = 20 µm; n = 1.  B, concentration-response curve for FA lengthening in 
DMSO 10 nM NOSer
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DU145 cells challenged with varying concentrations of NOSer.  Mean DMSO value has been 
removed from each NOSer concentration.  Data are means ± SEM; n = 1.   
 
5.2.3.4. Signalling through ROCK is necessary for the formation of vinculin-
containing FAs and cytoskeletal reorganisation in DU145 cells. 
Cytoskeletal reorganisation in DU145 cells treated with the ROCK inhibitors; Y27632 
(10 µM) and H1152 (100 nM) was assessed by looking at changes in F-actin and 
vinculin-containing FAs.  Initially effects on F-actin were determined using phalloidin 
labelling.  Treatment of DU145 cells with Y-27632 induced some changes in the cell 
morphology compared to control cells with increased lamellipodia being observed 
(figure 5.31).  Cells treated with the ROCK II inhibitor H1152, had more staining in the 
centre of the cell than seen with Y-27632, ROCK I and II inhibitor with a few stress 
fibres being observed.   Pre-treatment of DU145 cells with either Y-27632 or H1152 
prior to co-application with LPI led to a loss of the stress fibres, but with normal 
lamellipodia formation in comparison with LPI alone. Likewise, NOSer-induced stress 
fibre formation was also inhibited following treatment with Y-27632 or H1152, such 
that they were more akin with control cells.  However lamellipodia formation was not 
effected. These data suggest that ROCK-mediated signalling is important for the 
formation of stress fibres but not lamellipodia in the DU145 cells treated with the 
endogenous lipids. 
 
DU145 cells were treated for 60 min with either LPI or NOSer alone or each lipid in the 
presence of either ROCK inhibitor; Y-27632 or H1152. Cells treated with either Y-
27632 (10 µM) or H1152 (100 nM) had very few vinculin-containing FAs with many 
cells completely lacking any vinculin-containing FAs (figure 5.32). Furthermore, no 
clear increase in vinculin-positive FAs was observed following treatment with LPI or 
NOSer in DU145 cells pre-treated for 30 min with either Y-27632 or H1152.  These 
data suggest that LPI and NOSer-induced vinculin-containing FAs require signalling 
through ROCK.   
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Figure 5.31: DU145 cells require ROCK signalling to promote cytoskeletal reorganisation 
following treatment with LPI and NOSer.   The actin cytoskeleton was visualised using Alexa 
Fluor® 546 phalloidin. Representative confocal images are illustrated for DU145 cells with the 
following treatments: DMSO; 10 µM Y-27632; 100 nM H1152; 3 µM LPI; 10 µM Y-27632 + 3 
µM LPI; 100 nM H1152 + 3 µM LPI; 3 µM NOSer; 10 µM Y-27632 + 3 µM NOSer; 100 nM 
H1152 + 3 µM NOSer.  Scale bars = 20 µm.  n = 2.  Note a loss of the lipid-induced stress 
fibres with cells pre-treated with either of the ROCK inhibitors. Arrows = lamellipodia; arrow 
heads = stress fibres.  
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Figure 5.32: Vinculin-containing FAs require signalling through ROCK in DU145 cells 
treated with endogenous lipids.  DU145 cells were pre-treated with either of the ROCK 
inhibitors; Y-27632 (10 µM) or H1152 (100 nM) for 30 min prior to co-application with either 
LPI (3 µM) or NOSer (3 µM).  Representative confocal images are illustrated for DU145 cells 
treated as follows DMSO; 10 µM Y-27632; 100 nM H1152; 3 µM LPI; 10 µM Y-27632 + 3  µM 
LPI; 100 nM H1152 + 3 µM LPI; 3 µM NOSer; 10 µM Y-27632 + 3 µM NOSer; 100 nM 
H1152 + 3 µM NOSer.  Scale bars = 20 µm.  n = 2.  Note the ROCK inhibitors decreased the 
number of vinculin-containing FAs and prevented their up-regulation with either of the 
endogenous lipids. 
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5.3. DISCUSSION 
5.3.1.  GPR55, lipid ligands and Ca2+ signalling in DU145 cells. 
This study was designed to consider GPR55-mediated signalling pathways required for 
Ca2+ mobilisation, nuclear pCREB, F-actin cytoskeletal reorganisation and changes in 
vinculin-containing FAs in the prostate cancer cell line, DU145.  Both LPI and NOSer 
were found to induce GRP55-mediated Ca2+ mobilisation in the DU145 cells.  LPI has 
previously been studied in DU145 cells whereby Ca2+ mobilisation, pERK1/2, pAKT 
and proliferation of the cells was observed (Piñeiro et al., 2011).  Studies with ovarian 
cancer have shown that micromolar concentrations of LPI are present (Sutphen et al., 
2004) and in this study similar low micromolar concentrations of LPI have led to the 
Ca2+ mobilisation, pCREB, F-actin cytoskeletal reorganisation and increases in FA 
length in the metastatic DU145 cells.  To date there are no reports of NOSer mediated 
signalling in relation to prostate cancer.   
 
Both LPI and NOSer were found to promote GPR55-mediated Ca2+ mobilisation in the 
DU145 cells.  LPI-induced effects were sensitive to CBD, a putative GPR55 antagonist.  
However the LPI-induced Ca2+ mobilisation was only partially decreased in DU145 
cells where inhibitors had been applied.  There is evidence that LPI can act on TRPV2 
channels in a metastatic prostate cancer cell line; PC3 (Monet et al., 2009) and TRPV2 
is also expressed in DU145 cells (Monet et al., 2010).  Therefore some of the Ca2+ 
mobilisation that is observed with LPI may be due to non-GPR55 specific effects such 
as LPI acting on TRP channels.   
 
In this study Gαq activation was required for the LPI-induced mobilisation of Ca2+ in the 
DU145 cells.  Previous research reported that GPR55-mediated Gαq activation was 
necessary for Ca2+ mobilisation in both hGPR55-HEK293 cells (Lauckner et al., 2008) 
and phaeochromocytoma PC12 cells (Obara et al., 2011).  Gαq can activate Rho 
(Chikumi et al., 2002) and Rho-ROCK activation is required for LPI-induced Ca2+ 
mobilisation in hGPR55-HEK293 cells (Henstridge et al., 2009).  However in DU145 
cells challenged with either LPI or NOSer, ROCK activation was not required for Ca2+ 
mobilisation.  These results are in agreement with a previous study whereby LPI-
induced Ca2+ mobilisation in DU145 cells was ROCK-independent (Piñeiro et al., 
2011).  Gαq directly activating PLCβ (Hubbard and Hepler, 2006) promotes the 
hydrolysis of PIP2 into IP3 and DAG, the former promoting Ca2+ mobilisation from the 
ER (Clapham, 2007).  In the DU145 cells PLC was required for the mobilisation of Ca2+ 
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adding credence that LPI challenge to DU145 cells initiates signalling through the Gαq-
PLC signalling axis; figure 5.33).  At present it remains unknown if NOSer activation of 
GPR55 recruits Gαq. Further experiments are required to determine if LPI and NOSer 
activate Gα13 to promote Ca2+ mobilisation in DU145 cells.  However NOSer does 
require the activation of PLC to promote Ca2+ mobilisation in DU145 cells.   
 
 
Figure 5.33:  Proposed GPR55-mediated Ca2+ cascade in LPI challenged DU145 cells.  
Agonist binding to GPR55 leads to the activation of Gαq the heterotrimeric G-protein which can 
then activate PLC.  PLC activation leads to the hydrolysis of PIP2 into IP3 and DAG.  IP3 then 
translocates and acts on IP3 receptors localised to the membrane of the ER.  The ER being the 
main Ca2+ store found in cells.  Subsequently Ca2+ is release which may then act on Ca2+ 
channels in the plasma membrane to allow them to open and allow the influx of Ca2+ from the 
extracellular media.  GPR55, G-protein coupled receptor 55; LPI, L-α-
lysophosphatidylinositol; PLC, Phospholipase C; PIP2, phosphatidylinositol 4, 5-bisphosphate; 
DAG, diacylglycerol; IP3, inositol 1, 4, 5-triphosphate; ER, endoplasmic reticulum. 
 
5.3.2.  GPR55 and pCREB signalling in DU145 cells. 
In this study pCREB labelling was increased in DU145 cells treated with either LPI or 
NOSer.  Two heterotrimeric G-proteins; Gα13 and Gαq, were tested for involvement in 
lipid-induced pCREB responses in these cell.  Further studies are required to understand 
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the role of Gα13 in nuclear pCREB signalling in DU145 cells.  However there was a 
trend to inhibit the lipid-induced responses suggesting that it is likely to be required   
(figure 5.34 and 5.35).  Interestingly both Gα13 (Kozasa et al., 2011) and Gαq (Chikumi 
et al., 2002) can regulate Rho. However there may be differences in the activation of 
Rho by these G-proteins.  In one study  investigating G-protein regulation of RhoA with 
thrombin, a 2-fold higher concentration of thrombin was required for Gαq-mediated 
activation of RhoA compared to concentrations required for Gα13-mediated activation 
(Vogt et al., 2003).  Another study described the activation of RhoA with Gαq and found 
the mechanism differed from Gα13-mediated regulation depending on which RhoGEF 
was present (Chikumi et al., 2002).  Therefore it could be possible for GPR55-mediated 
Gα13 or Gαq to regulate RhoA.   However further experiments would be required to 
investigate whether there are similar differences in G-protein signalling via GPR55 in 
DU145 cells.  This would also help to understand any GPR55-induced ligand bias that 
may be occurring at the level of these G-proteins.  Furthermore the Rho-ROCK 
signalling axis whilst not required for Ca2+ mobilisation was required to promote 
pCREB.  In this study both LPI and NOSer required ROCK activation to promote 
pCREB in DU145 cells.   
 
5.3.2.1.  GPR55 and MAPK signalling  in DU145 cells 
In the present investigation both LPI and NOSer required MAPK signalling to promote 
pCREB in the DU145 cells.  Indeed, the pCREB response promoted by either of the 
lipids was found to be abolished in the presence of the MEK1/2 inhibitors.  These 
results suggest that MAPK signalling may be the most important pathway to promote 
pCREB in DU145 cells challenged with either LPI or NOSer.  Several studies report 
GPR55 phosphorylation of ERK1/2 in hGRP55-HEK293 cells (Oka et al., 2007, 2009; 
Henstridge et al., 2010), osteoclasts (Whyte et al., 2009), in several different cancer 
cells (Andradas et al., 2011) including prostate cancer cells (Piñeiro et al., 2011).  The 
transcription factor CREB is located downstream of ERK1/2 and previously Rho-
ROCK signalling was reported for GPR55-mediated pERK1/2 in DU145 cells treated 
with LPI (Piñeiro et al., 2011).  Furthermore Rho and ROCK may be important 
mediators of MAPK signalling in DU145 cells.  Rho has previously been reported to 
activate MEKK1; which has p115RhoGAP bound to it in intact murine embryonic 
fibroblast (NIH 3T3), Madin-Darby Canine Kidney (MDCK) and HEK 293 cells 
(Christerson et al., 2002).   MEKK1 is the protein located upstream of MEK1/2, in 
HEK293 cells (Gallagher et al., 2004).  Also ROCK inhibition has been shown to 
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decrease pERK1/2 in a glioblastoma cells; LN-18 when treated with fibronectin or 
platelet derived growth factor (Zohrabian et al., 2009).  Therefore it is possible that LPI 
and NOSer promote pCREB in DU145 cells via a direct route from Rho and ROCK to 
MAPK signalling. 
 
5.3.2.2.  Differences between LPI and NOSer. 
LPI was found to be more efficacious and potent than NOSer in the Ca2+ mobilisation 
assay.  Extracellular Ca2+ was likely to be required for LPI-induced pCREB.  In 
addition, PLC, CaMKII, PKC and possibly PI-3 kinase were all found to be required for 
LPI-induced pCREB in DU145 cells (figure 5.38).  In contrast NOSer did not require 
PLC, CAMKII and PI-3 kinase to promote the formation of pCREB in the DU145 cells.  
However PKC may be likely for NOSer-induced pCREB in DU145 cells (figure 5.39).  
PKCε has been reported as a RhoA effector in a yeast 2-hybrid assay (Wheeler and 
Ridley, 2004).  Furthermore a study using the phospholipid LPA applied to NIH 3T3 
murine embryonic fibroblast cells found that Rho activation was required to activate 
both PKCα and PKCε to promote the activation of serum response element.  
Interestingly PKCε is a member of the Ca2+ independent PKC isoforms (Soh et al., 
1999).  Therefore it is possible that NOSer activates Gα13 or Gαq to activate RhoA 
leading to the subsequent phosphorylation of PKC in the DU145 cells which could be 
independent of Ca2+.  This study however did not differentiate between PKC isoforms.   
 
Only LPI is likely to involve activation of PI-3 kinase to promote pCREB in DU145 
cells.  The CREB phosphorylation may occur through the activation of AKT; recent 
research suggests that LPI induced phosphorylation of AKT can be GPR55 mediated in 
DU145 cells (Piñeiro et al., 2011).     
 
These data suggest NOSer may exert ligand bias with Ca2+ mobilisation being less 
favoured than pCREB in DU145 cells.  Both lipids promote pCREB in hGPR55-
HEK293 and DU145 cells however, NOSer was found to be more efficacious but less 
potent when compared to LPI with this pathway in the DU145 cells. 
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Figure 5.34:  Potential signalling pathways required for LPI-induced pCREB in DU145 cells.  
Multiple signalling pathways can promote pCREB in hGPR55-HEK293 cells.  Potential cross-
talk can occur between Ca2+ mobilisation, MAPK and PI-3 kinase signalling pathways.  LPI, L-
α-lysophosphatidylinositol; RhoA, Ras homolog gene, family member A; ROCK, Rho associated 
protein kinase; PLC, Phospholipase C; PIP2, phosphatidylinositol 4, 5-bisphosphate; DAG, 
diacylglycerol; IP3, inositol 1, 4, 5-triphosphate; PKC, protein kinase C; CaMKII, 
Ca2+/calmodulin dependent protein kinase II; PI-3K, phosphatidylinositide 3-kinase; mTOR = 
mammalian Target of Rapamycin; raf = proto-oncogene c-RAF; MEKK1 = mitogen activated 
protein kinase kinase 1; MEK1 = mitogen activated protein kinase 1; ERK1/2 = extracellular 
signal-regulated protein kinases 1 and 2; pCREB, phosphorylated cyclic AMP response element 
binding protein.  Green arrows = Ca2+ signalling pathway; purple arrows = PI-3 kinase 
signalling pathway; pink arrows = MAPK signalling pathway. Solid arrows = signalling 
effectors; dashed arrows = suggested effectors.    
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Figure 5.35:  Potential signalling pathways required for NOSer-induced pCREB in DU145 
cells.  Multiple signalling pathways can promote pCREB in hGPR55-HEK293 cells.  Potential 
cross-talk can occur between ROCK, MAPK and PKC signalling pathways.  NOSer, N-oleoyl-
L-serine; RhoA, Ras homolog gene, family member A; ROCK, Rho associated protein kinase; 
PKC, protein kinase C; CaMKII, Ca2+/calmodulin dependent protein kinase II; raf = proto-
oncogene c-RAF; MEKK1 = mitogen activated protein kinase kinase 1; MEK1 = mitogen 
activated protein kinase 1; ERK1/2 = extracellular signal-regulated protein kinases 1 and 2; 
pCREB, phosphorylated cyclic AMP response element binding protein.  Green arrows = ROCK 
signalling pathway; blue arrows = PKC signalling pathway; pink arrows = MAPK signalling 
pathway. Solid arrows = signalling effectors; dashed arrows = suggested effectors. 
 
5.3.3.  Cytoskeletal reorganisation and FAs in DU145 cells. 
Both LPI and NOSer promoted F-actin cytoskeletal reorganisation and increases in 
vinculin-containing FA length in the DU145 cells.  This is the first study to observe 
GPR55-mediated effects on FAs.  These have a dynamic nature, with co-ordinated 
assembly and disassembly, to allow the movement of cells (Carisey et al., 2013).  In 
DU145 cells as was also observed in hGPR55-HEK293 cells, the length of the FAs 
increased with time until 120 min, after which they became shorter suggesting that 
disassembly may be occurring.  The cells in this study were fixed at a time point (60 
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min) and the treatment was such that the cells would not have a directional polarity as 
the ligands were applied to a petri dish and the cells were bathed with a uniform 
concentration of lipid. 
 
Both LPI and NOSer promoted an increase in the stress fibres that was observed to be 
concentration-dependent.  Vinculin-containing FAs were also found to be LPI or NOSer 
concentration-dependent.    Changes in the actin cytoskeleton occur depending on which 
of the small Rho GTPase that has been activated.  Each small Rho GTPase has a 
specific role in actin cytoskeletal reorganisation.  Rho is also reported to be required for 
the formation of focal adhesion complexes (Ridley and Hall, 1992; Nobes and Hall, 
1995).  Rac plays a role in the formation of lamellipodia in cells whereas cdc42 
activation leads to the formation of filopodia  (Nobes and Hall, 1995).  Interestingly 
GPR55 can promote the activation of several small Rho GTPases; RhoA, Rac1 and 
cdc42 (Ryberg et al., 2007) and Rac2 (Balenga et al., 2011).  Lipid-induced 
lamellipodia were still present when the ROCK inhibitor had been applied to the DU145 
cells.  Both stress fibre and FA formation were ROCK dependent suggesting that LPI 
and NOSer induced effects are mediated through the Rho-ROCK signalling axis in the 
DU145 cells.   
 
In conclusion this study has revealed both LPI and NOSer can exert GPR55-mediated 
Ca2+ mobilisation, F-actin cytoskeletal reorganisation and FA elongation in the prostate 
cancer cell line; DU145.  It however remains to be determined if the LPI and NOSer 
pCREB responses are GPR55-mediated.  Problems with the siRNA assay suggest that 
more optimisation is required as pCREB was elevated in all cell treatments when using 
the described siRNA protocol.  Also transiently transfecting the cells with serum 
containing medium and leaving the siRNA-liposome complexes for 60 hr then 
transferring the cells into serum free medium led to a strange, non-specific labelling in 
the cells.   A potential way to resolve the issue could be to transfect the cells in serum 
free medium for 24 hr then remove the medium and replace with serum-containing 
medium and use the cells at 69 - 72 hr.  The cells would need to be put in serum free 
medium overnight prior to the start of the experiments.  This allows time for the siRNA-
liposome complexes time to enter the cells but does not stress the cells too long which 
occurs when they are serum starved for 72 hr.   
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It was also observed that there are subtle differences in the signalling pathways when 
the lipids were compared in DU145 cells in the pCREB assay.  NOSer induced Ca2+ 
mobilisation was not as efficacious as LPI induced responses in the DU145 cells.  As 
such Ca2+ mobilisation may not be important to promote pCREB in NOSer challenged 
DU145 cells.  However Ca2+ mobilisation was important for pCREB in LPI-challenged 
DU145 cells.  The use of the novel antagonists CID16020046 (Kargl et al., 2013) or 
ML193 (Yu et al., 2013) would also help to decipher GPR55’s role in these signalling 
assays when challenged with the endogenous lipids. 
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5.3.4. Breakdown of proposed LPI and NOSer-mediated signalling pathways to 
promote pCREB in DU145 cells. 
 
 
Figure 5.36:  Summary of Ca2+ cascade require for LPI-induced pCREB in DU145 cells.  LPI 
binding of GPR55is likely to initiate the activation of Gα13 or Gαq which in turn activates RhoA 
and ROCK.  This then leads to activation of PLC, which promotes the hydrolysis of PIP2 into 
DAG and IP3.  IP3 activates IP3 receptors on the ER promoting the release of Ca2+.  DAG 
and/or Ca2+ then lead to activation of PKC.  Both PKC and Ca2+ can activate CAMKII which 
can then phosphorylate CREB (at either serine 133; positive regulation or 142; negative 
regulation) Note the antibody in this study was specific for pCREB serine 133.  LPI, L-α-
lysophosphatidylinositol;; RhoA, Ras homolog gene, family member A; ROCK, Rho associated 
protein kinase; PLC, Phospholipase C; PIP2, phosphatidylinositol 4, 5-bisphosphate; DAG, 
diacylglycerol; IP3, inositol 1, 4, 5-triphosphate; PKC, protein kinase C; CaMKII, 
Ca2+/calmodulin dependent protein kinase II; pCREB, phosphorylated cyclic AMP response 
element binding protein.  Solid arrows = signalling effectors; dashed arrows = suggested 
effectors. 
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Figure 5.37:  Summary of proposed Ca2+ cascade require for NOSer-induced pCREB in 
DU145 cells.  NOSer binding of GPR55 initiates the activation of Gα13 or Gαq which in turn 
activates RhoA and ROCK.  This may lead to activation of PKC.  Both PKC and Ca2+ (from the 
cytosol) could activate CaMKII which can then phosphorylate CREB (at either serine 133; 
positive regulation or 142; negative regulation) Note the antibody in this study was specific for 
pCREB serine 133.  NOSer, N-oleoyl-L-serine; RhoA, Ras homolog gene, family member A; 
PKC, protein kinase C; CaMKII, Ca2+/calmodulin dependent protein kinase II; pCREB, 
phosphorylated cyclic AMP response element binding protein.   
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5.38:  Summary of the MAPK and PI-3-kinase signalling pathways required to promote LPI-
induced nuclear pCREB in DU145 cells.  Gα13 or Gαq acting on RhoA could lead to the 
phosphorylation of MEKK1 which in turn can phosphorylate MEK1/2.  MEK1/2 subsequently 
phosphorylates ERK1/2 which translocates into the nucleus to phosphorylate CREB.  
Alternatively Rho phosphorylates ROCK which then subsequently phosphorylates ERK1/2.  PI-3 
kinase could be activated by the Gαq which could then phosphorylate AKT which could then 
phosphorylate CREB.  GPR55, G-protein coupled receptor 55; LPI, L-α-
lysophosphatidylinositol; RhoA, Ras homolog gene, family member A; ROCK, Rho associated 
protein kinase; PI-3K, phosphatidylinositide 3-kinase; MEKK1, mitogen-activated protein 
kinase kinase kinase 1; MEK1, Mitogen-activated protein kinase kinase 1; ERK1/2, 
extracellular signal-regulated kinase 1/2; pCREB, phosphorylated cyclic AMP response 
element binding protein.  Solid arrows = signalling effectors; dashed arrows = suggested 
effectors.  Pink arrows = MAPK signalling pathway; purple arrows = PI-3 kinase signalling 
pathway. 
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5.39:  Summary of the MAPK signalling pathway required to promote NOSer-induced 
nuclear pCREB in DU145 cells.  Gα13 or Gαq acting on RhoA could lead to the 
phosphorylation of MEKK1 which in turn can phosphorylate MEK1/2.  MEK1/2 subsequently 
phosphorylates ERK1/2 which translocates into the nucleus to phosphorylate CREB.  
Alternatively Rho phosphorylates ROCK which then subsequently phosphorylates ERK1/2.    
GPR55, G-protein coupled receptor 55; NOSer, N-oleoyl-L-serine; RhoA, Ras homolog gene, 
family member A; ROCK, Rho associated protein kinase; MEKK1, mitogen-activated protein 
kinase kinase kinase 1; MEK1, Mitogen-activated protein kinase kinase 1; ERK1/2, 
extracellular signal-regulated kinase 1/2; pCREB, phosphorylated cyclic AMP response 
element binding protein.  Solid arrows = signalling effectors; dashed arrows = suggested 
effectors.   
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6.1.  INTRODUCTION 
GPR55 is recognised as a novel lipid sensing receptor where the general consensus is 
that the endogenous lipid LPI is the natural GPR55 ligand (Oka et al., 2007; Henstridge 
et al., 2009).  However the GPR55 cannabinoid pharmacology is controversial with 
some groups reporting that cannabinoid ligands can activate the receptor (Ryberg et al., 
2007; Lauckner et al., 2008; Henstridge et al., 2010; Sharir et al., 2012) with others 
contesting these claims (Henstridge et al., 2009; Oka et al., 2007).  Recently a family of 
lipid mediators,  the N-acyl amino acids, are gaining interest due to their structural 
similarity to the endocannabinoids (Bradshaw et al., 2009).  They are an intriguing 
group of endogenous lipids which have little or no affinity for either CB1 or CB2 
receptors.  Some of these lipids have shown biological activity but many remain orphan 
lipids where no known biological target has been elucidated (Bradshaw et al., 2009).   
Therefore this study was carried out to investigate potential effects of N-acyl amino 
acids upon the activation of GPR55. 
 
6.2.  SUMMARY OF RESEARCH FINDINGS 
6.2.1.  N-acyl amino acids induced activation of GPR55 promotes Ca2+ 
mobilisation. 
This study has highlighted for the first time that the N-acyl amino acids tested are 
GPR55 agonist/partial agonists. Using a Ca2+ assay in hGPR55-HEK293 cells, N-acyl 
serines were found to be more potent and efficacious when compared with N-acyl 
glycines with NASer and NOSer being the most active of these ligands.   However LPI 
remained the most potent and efficacious of all the lipids tested in this assay.  Previous 
research has highlighted that LPI activation of GPR55 requires Gα13-Rho-ROCK 
signalling followed by subsequent activation of PLC to promote a release of Ca2+ from 
internal stores (Lauckner et al., 2008; Henstridge et al., 2009).  In agreement this study 
found that NOSer also required ROCK, PLC activation and Ca2+ release from stores in 
hGPR55-HEK293 cells.  However in contrast the present study found that the DU145 
prostate cancer cell line, did not require ROCK activation to promote Ca2+ mobilisation 
which confirmed the findings of a previous study (Piñeiro et al., 2011).  In support of 
this, Gαq is suggested to be a downstream effector of GPR55 in hGPR55-HEK293 cells 
(Lauckner et al., 2008) and with phaeochromocytoma PC12 cells (Obara et al., 2011).  
This is also the first study to report that LPI induced Ca2+ mobilisation requires Gαq in 
DU145 cells.  Furthermore NOSer was less efficacious in the Ca2+ assay in DU145 cells 
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when compared to LPI.  These results suggest that GPR55 may exhibit ligand bias in 
Ca2+ mobilisation in DU145 cells. 
 
6.2.2.  CREB phosphorylation, N-acyl amino acids and GPR55. 
There were subtle differences when the effects of lipid ligands in hGPR55-HEK293 
cells were compared using pCREB and Ca2+ assays.  NOSer was now found to be the 
most potent and efficacious lipid tested.  Moreover, NOSer exhibited an efficacy which 
was similar to AM251, which was previously reported to be more efficacious than LPI 
in a pCREB immunolabelling assay (Henstridge et al., 2010).  NOGly was the least 
potent in the pCREB assay when tested on the hGPR55-HEK293 cells this is contrast to 
the Ca2+ mobilisation assay.  These data suggest that NOGly may exert ligand bias in 
the hGPR55-HEK293 cells with a preference for Ca2+ rather than pCREB signalling.  
Furthermore NASer exhibited ligand bias; certainly in the hGRP55-HEK293 cells as the 
potency of the lipid acting through GPR55 was different dependent on the assay used 
(Ca2+ > pCREB).   
 
Previously LPI has been shown to activate two kinases upstream of CREB; ERK1/2 and 
AKT (Piñeiro et al., 2011).  However this study is the first time that both LPI and 
NOSer induced CREB phosphorylation in DU145 cells has been reported.  Furthermore 
this study highlights that LPI requires signalling via Ca2+, MAPK and PI-3 kinase to 
promote pCREB.  In contrast Ca2+ is not required for pCREB in DU145 cells 
challenged with NOSer.   A probable reason being NOSer is less effective at promoting 
Ca2+ mobilisation in DU145 cells.  Moreover NOSer is less potent but more efficacious 
in promoting pCREB than LPI in these cells.   
 
6.2.3.  N-acyl amino acids promote actin cytoskeletal reorganisation and FA 
elongation. 
Previous studies highlighted that GPR55 can activate members of the Rho family of 
small GTPases ; RhoA, cdc42, rac1 (Ryberg et al., 2007) and rac2 (Balenga et al., 
2011).  These Rho GTPases are important for cytoskeletal reorganisation and the 
formation of FAs (Hall, 1998).  This is the first study to highlight that GPR55 can 
mediate the formation of FAs with either LPI or NOSer.  Moreover there was little 
difference in potency or efficacy for mediating changes in vinculin length in hGPR55-
HEK293 cells treated with either LPI or NOSer.  Of all the assays tested LPI was the 
most potent in the vinculin assay measuring FA elongation.  NOSer was found to have 
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an EC50 similar as seen in the pCREB assay in hGPR55-HEK293 cells.  GPR55-
mediated FA formation and actin cytoskeletal reorganisation has not been reported prior 
to this study in DU145 cells.  Stress fibres, filopodia and lamellipodia were all observed 
in DU145s and hGPR55-HEK293 cells when challenged with either LPI or NOSer.  
Actin cytoskeletal reorganisation required signalling via Rho and ROCK only in 
hGPR55-HEK293 cells.  The formation of FAs was found to require Rho-ROCK, 
MAPK and Ca2+ signalling in hGPR55-HEK293 cells (figure 6.1). 
 
Whilst the hGPR55-HEK293 cells allow GPR55 to be studied in detail the effects may 
differ from endogenous expression of the receptor.  Indeed the over-expression of 
GPR55 may mask some of the signalling by forcing signalling down a particular 
pathway where one G-protein has a higher affinity for the activated GPCR which may 
then mask other signalling that is occurring (Hermans, 2003).  This may be a reason 
behind the observed differences where hGPR55-HEK293 cells only signalled via Gα13 
where the DU145 cells activate both Gα13 and Gαq (figure 6.2).  Another explanation 
may be the levels of each G-protein could be different in differing cell types.  Therefore 
it could be that Gαq is expressed at a higher level in DU145 cells.  
  
6.2.4.  Potential interactions between the signalling outcomes in this study. 
Ca2+ is an important second messenger which influences CREB phosphorylation 
through the activation of Ca2+/CaMKII (Sheng et al., 1990; Impey et al., 1998).  
Interestingly Ca2+ requires an intact actin cytoskeleton to allow capacitance entry of 
Ca2+ in keratinocytes (Korkiamäki et al., 2003).  However this is not required for Ca2+ 
capacitance entry in NIH 3T3 cells but the authors report that the disrupted cytoskeleton 
may affect the spatial relationship between the IP3 receptors and PLC (Ribeiro et al., 
1997).  Moreover the actin cytoskeleton is also required for the regulation of 
interactions between STIM1 (the Ca2+ sensor on the ER) and Orai1 and TRPC1 the Ca2+ 
channels in the plasma membrane in HEK293 cells therefore playing a role in Ca2+ 
influx after store depletion (Galán et al., 2011).   
 
Although some of the signalling pathways such as Ca2+, Rho-ROCK and MAPK are 
required for FA formation and pCREB mediated by GPR55.  The two outcomes are 
thought to be separate as FA formation is likely to be by focal contacts translocating to 
peripheral regions and combining to form larger focal adhesions rather than being gene 
regulated.  The time scale of ligand treatment (25 min) is not long enough for gene 
316 
 
regulation to play a role, if pCREB were to be involved, as this normally requires 
several hours for gene transcription to occur.   
 
Vinculin is important adaptor protein allowing the binding of the vinculin head to talin 
an integrin associated protein and the F-actin cytoskeleton binds to the vinculin tail 
allowing an anchor to form in the cell (Chen et al., 2006).  This anchoring of the cell 
generates force to allow the cytoskeleton the ability to make the cell contract 
(Dumbauld et al., 2010).  GPR55 is known to signal via Rho (Henstridge et al., 2009).  
Rho activation of actin filaments can promote vinculin activation leading to the 
strengthening of vinculin containing adhesions which could then have an effect on cell 
contractility, migration and shape (Chen et al., 2006). 
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Figure 6.1:  Summary of endogenous lipid mediated GPR55 signalling.  A, LPI and B, NOSer 
mediated signalling pathways in hGPR55-HEK293 cells required to promote pCREB, Ca2+ 
mobilisation, changes in vinculin and actin cytoskeletal reorganisation. Note Gα13 is activated 
in hGPR55-HEK293 cells with either LPI or NOSer.  Signalling effectors that were activated 
were similar for both the lipids.   Dashed arrows = putative signalling; solid arrows = 
confirmed signalling (from this study). 
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Figure 6.2:  Summary of endogenous lipid induced GPR55 signalling in DU145 cells.  LPI 
promotes signalling to allow pCREB, Ca2+ mobilisation, changes in vinculin and actin 
cytoskeletal reorganisation.  Signalling pathways in DU145 cells challenged with A, LPI or B, 
NOSer.  Note both Gα13 and Gαq are recruited in the DU145 cells challenged with either LPI or 
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NOSer.  Dashed arrows = putative signalling; solid arrows = confirmed signalling (from this 
study). 
 
6.2.5.  Potential physiological roles of NOSer effects mediated by GPR55. 
Whist the physiological role of NOSer remains elusive at the present time interactions 
with GPR55 in a physiological setting are plausible.  For example both NOSer and 
GPR55 are localised to bone (Whyte et al., 2009; Smoum et al., 2010).  NOSer acting 
on GPR55 in bone may have a detrimental effect leading to increased bone loss as was 
observed GPR55(+/+) mice treated with LPI or O-1602 an effect that was absent in 
GPR55(-/-) mice (Whyte et al., 2009).  Prostate cancer is known as one of the cancers to 
commonly metastasise to bone (Tantivejkul et al., 2004).  Therefore if levels of NOSer 
were to be increased in the microenvironment surrounding bone this could potentially 
act upon GPR55 in prostate cancer cells and encourage their migration to the region.  
Furthermore NOSer could then act on GPR55 present in the prostate cancer cells to 
allow them to proliferate. 
 
Also NOSer is found in brain and spleen of mice (Smoum et al., 2010), it is interesting 
to note that these are areas where GPR55 is expressed (Ryberg et al., 2007).  The role of 
GPR55 in the brain is still in its infancy but mEPSCs occur in CA1 pyramidal neurons 
when the cells were treated with LPI and were sensitive to CBD.  It remains to be 
determined if NOSer is present in the hippocampal region of the brain but if this were to 
be so then NOSer could exert effects upon the pyramidal neurons.   Furthermore GPR55 
has been associated with neurotransmitter release that is dependent on Ca2+ mobilisation 
(Sylantyev et al., 2013).  The presence of NOSer in the brain may also contribute to 
effects on microglia (the macrophages of the brain).  GPR55 is also localised in 
microglia and is increased in the murine microglial BV2 cell line when the cells are 
‘primed’ with INFγ.  These cells were found to have increases in ERK1/2 
phosphorylation when challenged with LPI (Pietr et al., 2009).  Therefore it would be 
possible for NOSer to induce a similar effect.   
 
Until there is knowledge of where NOSer is localised, how it is synthesised and released 
into plasma or microenvironments a physiological role can only be speculated.  
However, understanding the localisation of GPR55 and NOSer in a physiological 
system will help to elucidate the role of NOSer signalling via GPR55. 
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6.2.6.  Limitations within this study. 
To improve this study the use of either quantitative polymerase chain reaction (qPCR) 
or western blotting techniques would be required.  This would allow a quantification of 
GPR55 expression in the endogenously expressing DU145 prostate cancer cell line and 
in the overexpressing hGPR55-HEK293 cell line.  Furthermore these techniques would 
confirm GPR55 knockdown in cells treated with siRNA.   
 
Time course studies using western blots would allow an insight into GPR55-mediated 
activation of pCREB.  Also increasing the ‘n’ number of the pCREB experimental data 
would be advantageous as many of the inhibitor experiments whilst highlighting a 
general trend of inhibition do not highlight significant differences.   
 
The selectivity of protein kinase inhibitors should also be considered.  Kinase inhibitors 
are known to be promiscuous in nature (Davies et al., 2000; Bain et al., 2007).  
Therefore validation of the kinase inhibitors would further improve the conclusions in 
this study.  To further validate the kinase inhibitors in this study the use of two 
structurally unrelated inhibitors would be advantageous.   In this study two structurally 
unrelated MEK1/2 and PI-3 kinase inhibitors were used.  Furthermore using inactive 
analogues of the inhibitor of interest would help confirm the effect of the inhibitor.  To 
allow this and inactive analogue (U0124) of the MEK1/2 inhibitor (U0126) was tested.  
Also, confirming the effects of the inhibitors on targets that are known to be activated in 
cells.  Applying the inhibitor of interest (eg MEK1/2 inhibitor) to HEK293 cells prior to 
then applying epidermal growth factor to initiate ERK1/2 signalling and run a Western 
blot.  Untreated cells should produce the relevant phosphoERK1/2 band whereas those 
treated with the inhibitor should not have a corresponding band.  Furthermore data from 
the International Centre for Kinase Profiling (http://www.kinase-screen.mrc.ac.uk/) 
based in the Protein Phosphorylation and Ubiquitylation Unit at the University of 
Dundee allows comparisons of many enzymes to allow the specificity of kinase 
inhibitors to be evaluated (Cohen, 2010). 
 
6.3.  FUTURE DIRECTIONS 
6.3.1.  GPR55 mediated signalling – other considerations. 
This study did not look into the effects of the β-arrestins.  These proteins are now 
known to be important signalling mediators in their own right.  Interestingly β-arrestins 
can play a roles in stress fibre formation (Barnes et al., 2005), ERK1/2 activation (Coffa 
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et al., 2011) and gene transcription (DeWire et al., 2008).  It is not known if GPR55 
signalling requires the activation of β-arrestins, although GPR55 exhibits agonist-
induced internalization which is likely to be β-arrestin-mediated (Henstridge et al., 
2010).  Use of siRNA against β-arrestin isoforms could determine if these proteins are 
important for the lipid mediated GPR55 signalling.  Furthermore previous research 
observed that thrombin concentrations need to be 2 fold higher than that required for 
Gα12/13 to elicit Gαq-mediated Rho activation of the thromboxane A2 receptor (Vogt et 
al., 2003).  Therefore it could be possible for GPR55-mediated Gα13 or Gαq activation to 
activate RhoA.   However further experiments would be required to optimise the LPI or 
NOSer concentration which promotes signalling through each of the G-proteins as this 
study just utilised a sub-maximal concentration for each lipid.  These sets of 
experiments would help to elucidate any ligand bias whether G-protein dependent or 
independent. 
 
To improve our understanding of the signalling pathway data in the DU145 cells, 
further experiments would help to clarify the exact position of the proteins in the 
signalling pathway.  It is known that AKT can be activated by LPI in DU145 cells 
(Piñeiro et al., 2011).  This kinase can  phosphorylate CREB (Du and Montminy, 1998; 
Das et al., 2005).  However NOSer has not been studied in relation to either ERK1/2 or 
AKT activation.  It would be interesting to study where these kinases are in relation to 
each other and ROCK in the CREB signalling pathways. Further work is required to 
determine if LPI or NOSer activation of CREB actually induces transcription of genes 
in DU145 cells.  CREB phosphorylation leads to the transcription of genes such as c-
FOS in breast cancer cells which is GPR55-mediated (Andradas et al., 2011).  CREB 
mediated gene transcription is temporal in nature and this needs to be confirmed in the 
DU145 cells.  Previous work has highlighted that 25min is the optimal timing for 
pCREB signalling in hGPR55-HEK293 cells however gene transcription was not 
studied (Henstridge et al., 2010). 
 
6.3.2.  Are there other potential NOSer targets? 
A general point to note are that lipids can exert effects on many different targets 
therefore some care must be taken when evaluated the results.  Whilst this study 
highlights that the lipids act on GPR55 when in hGPR55-HEK293 cells, other targets 
for LPI or NOSer may exist.  Little is known about the NOSer targets within cells 
however it is documented that NOSer can promote ERK1/2 activation in osteoblasts via 
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a Gαi/o linked GPCR (Smoum et al., 2010).  The Abn-CBD receptor, GPR18 is known 
to activate a Gαi/o GPCR (McHugh et al., 2010) and is reported to have some overlap in 
pharmacology with GPR55 (Ross, 2009).  Furthermore GPR18 expression is increased 
in metastatic melanoma however it remains to be determined if this is the case for 
prostate cancer (Qin et al., 2011).  Another N-acyl amino acid, NAGly, is a GPR18 
agonist highlighting this receptor has some sensitivity to this family of proteins (Kohno 
et al., 2006; McHugh et al., 2012).  Therefore application of NOSer to GPR18 would be 
of interest.   
 
LPI is known to have effects on other GPCRs such as GPR119 (Soga et al., 2005), and 
certain ion channels such as potassium channels; BKCa (Bondarenko et al., 2011), 
TREK and TRAAK (Blondeau et al., 2002) and TRPV2 (Monet et al., 2009).  Therefore 
it is feasible that NOSer will also have additional binding targets.  Interestingly oleic 
acid is able to bind and activate GPR119 (Hansen et al., 2012) also OEA is a GPR119 
ligand (Overton et al., 2006).  Therefore NOSer may be able to activate GPR119.  Also 
endocannabinoids have the ability to bind and activate members of the PPAR family of 
nuclear receptors.  Furthermore oleic acid is also known to activate PPAR-α therefore 
compounds with an oleic fatty acid present may be potential ligands for this receptor as 
was observed with OEA (Fu et al., 2003).  It is not known at present if NOSer has 
affinity for these receptors but could be feasible due to the presence of the oleic fatty 
acid moiety.  Prior application of the antagonists that are available for these receptors 
(MK886 – PPARα, GW9662 - PPARγ and GSK0660 – PPARδ) would help to 
determine if NOSer is acting on these receptors (Scuderi et al., 2012; Paterniti et al., 
2013).  Other GPCRs of interest would be the FFA receptors especially GPR40 which is 
activated by medium to long chain fatty acids such as oleic acid  (Briscoe et al., 2003).  
Therefore NOSer should be tested as a potential FFA receptor ligand. 
 
6.3.3.  Use of novel antagonists. 
Application of the novel GPR55 antagonists would allow the validation that the effects 
in the DU145 cells are GPR55-mediated.  Originally CBD was an antagonist for GPR55  
however this ligand has several targets such as Abn-CBD (Járai et al., 1999), TRPV1 
(Costa et al., 2004) and PPAR-γ (O’Sullivan and Kendall, 2010).  Therefore there has 
been a requirement for a more GPR55-specific antagonist.  Recently two novel 
antagonist;  ML193 (Kotsikorou et al., 2013) and CID16020046 (Kargl et al., 2013) 
have been reported as being GPR55 specific.  In this study the use of siRNA in the 
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DU145 cells to assess GPR55-mediated CREB signalling remains undetermined.  The 
protocol was found to affect pCREB levels in all the cell treatments therefore a 
comparison with DMSO control cells was not determined.  A possible way to reveal the 
influence of GPR55 in mediating pCREB in the DU145 cells would be to use these 
novel GPR55 specific antagonists.   
 
6.3.4.  Migration studies and DU145 cells. 
Migration of cells is important in cancer metastasis (Ridley et al., 2003).  Cytoskeletal 
reorganisation and formation of FAs are important in cell migration particularly to 
promote directionality on the migrating cell (Machesky and Hall, 1997; Zaidel-Bar et 
al., 2003).  It should also be noted that the presence of stress fibres does not 
automatically correlate with the migratory ability of cells.  For example 
polymorphonuclear leukocytes do not contain stress fibres but are highly motile cells 
(Valerius et al., 1981).  Therefore future experiments studying migration would be 
required to understand the effects that cytoskeletal reorganisation and changes in FAs 
would have in DU145 cells.  GPR55 has previously been reported as inducing a 
migratory phenotype in breast cancer lines where the cells exhibited a directed polarity 
(Ford et al., 2010).  The use of wound assays would allow the migration of cells to be 
recorded when challenged with either LPI or NOSer.  Application of antagonists or 
siRNA would also help to determine the influence of GPR55 on cell migration.  Further 
studies to understand the signalling effectors required for FA elongation and 
cytoskeletal reorganisation in the DU145 cells are required.   
 
6.3.5.  Physiological properties of NOSer 
Physiological concentrations are unknown at present are as the synthesising and 
degradation processes that are involved with the NOSer. This makes it difficult to 
understand the physiological role of NOSer when acting on GPR55.  For example is 
NOSer synthesising and degrading enzymes localised in the same regions as GPR55?  
Furthermore the concentration of NOSer in tissues is in its infancy and further evidence 
will enhance the field in gaining a better understanding of the concentration and where 
NOSer is localised.   
 
6.4.  CONCLUDING REMARKS 
This study adds a further level of complexity to the GPR55-cannabinoid sensitivity 
debate and further confirms that GPR55 is a novel lipid sensing receptor.  This study 
324 
 
has highlighted that the putative cannabinoid receptor; GPR55 is a novel target for a 
sub-set of N-acyl amino acids.   It is the first study to suggest GPR55 as a novel GPCR 
target for NOSer; in both a recombinant over-expressing hGPR55-HEK293 cell line and 
in endogenously expressing prostate cancer cell line; DU145.   It also demonstrates that 
NASer is a GPR55 agonist however; results in efficacy and potency are affected by the 
assay being studied.  This therefore emphasises the importance of using different 
signalling assays to assess effects of novel ligands.  Finally there is an importance in 
having the knowledge of endogenous lipids and the receptors that they target for the 
development of novel therapeutics.  Without an understanding of the effects 
endogenous lipids exert then assessment of drug interactions is more difficult to predict.   
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